NZ617388B2 - Partially saturated tricyclic compounds and methods of making and using same - Google Patents
Partially saturated tricyclic compounds and methods of making and using same Download PDFInfo
- Publication number
- NZ617388B2 NZ617388B2 NZ617388A NZ61738812A NZ617388B2 NZ 617388 B2 NZ617388 B2 NZ 617388B2 NZ 617388 A NZ617388 A NZ 617388A NZ 61738812 A NZ61738812 A NZ 61738812A NZ 617388 B2 NZ617388 B2 NZ 617388B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- group
- acid
- alkoxy
- chromenecarboxylic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 251
- 208000008589 Obesity Diseases 0.000 claims abstract description 28
- 235000020824 obesity Nutrition 0.000 claims abstract description 27
- -1 R R N- Chemical group 0.000 claims description 279
- 125000000217 alkyl group Chemical group 0.000 claims description 236
- 239000000203 mixture Substances 0.000 claims description 232
- 229910052739 hydrogen Inorganic materials 0.000 claims description 153
- 239000001257 hydrogen Substances 0.000 claims description 146
- 239000002253 acid Substances 0.000 claims description 145
- 125000001424 substituent group Chemical group 0.000 claims description 126
- 125000003545 alkoxy group Chemical group 0.000 claims description 122
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 122
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims description 118
- 125000000623 heterocyclic group Chemical group 0.000 claims description 105
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 97
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 96
- 235000019000 fluorine Nutrition 0.000 claims description 91
- 125000001153 fluoro group Chemical group F* 0.000 claims description 90
- 229910052757 nitrogen Inorganic materials 0.000 claims description 84
- 229910052731 fluorine Inorganic materials 0.000 claims description 81
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 79
- 239000011737 fluorine Substances 0.000 claims description 74
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 71
- 125000003342 alkenyl group Chemical group 0.000 claims description 55
- 229910052760 oxygen Inorganic materials 0.000 claims description 52
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 48
- 125000000304 alkynyl group Chemical group 0.000 claims description 45
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 40
- 239000011780 sodium chloride Substances 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000004043 oxo group Chemical group O=* 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 23
- 125000005842 heteroatoms Chemical group 0.000 claims description 23
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 21
- 125000002837 carbocyclic group Chemical group 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 17
- 125000004429 atoms Chemical group 0.000 claims description 15
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 15
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 15
- 230000004580 weight loss Effects 0.000 claims description 14
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 12
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 229940094937 Thioredoxin Drugs 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 230000003579 anti-obesity Effects 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims description 2
- BVJSHQWNXSXIBK-UHFFFAOYSA-N di(ethyl)azanide Chemical group [CH2]C[N-]C[CH2+] BVJSHQWNXSXIBK-UHFFFAOYSA-N 0.000 claims description 2
- 230000003834 intracellular Effects 0.000 claims description 2
- 210000000056 organs Anatomy 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 102000002933 thioredoxin family Human genes 0.000 claims description 2
- 108060008226 thioredoxin family Proteins 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- AANWSSRODWFWAH-DOMZBBRYSA-N (3aR,9bR)-7-(benzenesulfonamido)-2,3a,4,9b-tetrahydro-1H-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C([C@@H]1OCC[C@@H]1C=1C=C2)OC=1C(C(=O)O)=C2NS(=O)(=O)C1=CC=CC=C1 AANWSSRODWFWAH-DOMZBBRYSA-N 0.000 abstract 2
- 102100016477 METAP2 Human genes 0.000 abstract 1
- 101710012506 METAP2 Proteins 0.000 abstract 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 141
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 132
- 239000002904 solvent Substances 0.000 description 130
- 239000000543 intermediate Substances 0.000 description 118
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 88
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 82
- 239000007787 solid Substances 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 71
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- 239000002585 base Substances 0.000 description 51
- 235000019253 formic acid Nutrition 0.000 description 47
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 45
- 238000001816 cooling Methods 0.000 description 43
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 43
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 42
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 41
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 40
- 206010033307 Overweight Diseases 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 40
- 235000020825 overweight Nutrition 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 40
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 235000019441 ethanol Nutrition 0.000 description 33
- 239000000706 filtrate Substances 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 32
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 30
- HMXJOWDZAJWLTF-UHFFFAOYSA-M 2H-chromene-2-carboxylate Chemical compound C1=CC=C2C=CC(C(=O)[O-])OC2=C1 HMXJOWDZAJWLTF-UHFFFAOYSA-M 0.000 description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 28
- 241000282619 Hylobates lar Species 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 239000003054 catalyst Substances 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000004587 chromatography analysis Methods 0.000 description 22
- 238000010992 reflux Methods 0.000 description 22
- 238000000926 separation method Methods 0.000 description 22
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000007792 addition Methods 0.000 description 19
- 238000002953 preparative HPLC Methods 0.000 description 19
- 230000001603 reducing Effects 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 239000002775 capsule Substances 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 238000010438 heat treatment Methods 0.000 description 17
- 229910052763 palladium Inorganic materials 0.000 description 16
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000006722 reduction reaction Methods 0.000 description 15
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 239000001184 potassium carbonate Substances 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 210000000577 Adipose Tissue Anatomy 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrugs Drugs 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 229960000583 Acetic Acid Drugs 0.000 description 9
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 230000000875 corresponding Effects 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000000051 modifying Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000011369 resultant mixture Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 210000001624 Hip Anatomy 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 150000001345 alkine derivatives Chemical group 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 239000002876 beta blocker Substances 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000001033 ether group Chemical group 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000006011 modification reaction Methods 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003039 volatile agent Substances 0.000 description 6
- 208000006673 Asthma Diseases 0.000 description 5
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 5
- 208000000509 Infertility Diseases 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 230000002378 acidificating Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 150000003973 alkyl amines Chemical class 0.000 description 5
- 125000005233 alkylalcohol group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 239000012024 dehydrating agents Substances 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 150000008282 halocarbons Chemical class 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-Dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 4
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 4
- 206010002855 Anxiety Diseases 0.000 description 4
- 206010057666 Anxiety disease Diseases 0.000 description 4
- 208000005846 Cardiomyopathy Diseases 0.000 description 4
- 229920002301 Cellulose acetate Polymers 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 206010058108 Dyslipidaemia Diseases 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 210000001503 Joints Anatomy 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- 206010061227 Lipid metabolism disease Diseases 0.000 description 4
- 208000003067 Myocardial Ischemia Diseases 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N N,N'-Diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 description 4
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 4
- 208000002815 Pulmonary Hypertension Diseases 0.000 description 4
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 4
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 4
- 150000001336 alkenes Chemical group 0.000 description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 125000005621 boronate group Chemical group 0.000 description 4
- 201000008031 cardiomyopathy Diseases 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 229920000591 gum Polymers 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 230000000968 intestinal Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000002474 noradrenergic Effects 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 4
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 4
- 239000003638 reducing agent Substances 0.000 description 4
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000000707 stereoselective Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 206010006334 Breathing abnormality Diseases 0.000 description 3
- 229960005069 Calcium Drugs 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 206010007541 Cardiac disease Diseases 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 3
- 229960003608 Clomifene Drugs 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M Copper(I) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 208000008466 Metabolic Disease Diseases 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 208000001797 Obstructive Sleep Apnea Diseases 0.000 description 3
- JQPTYAILLJKUCY-UHFFFAOYSA-N Palladium(II) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010037175 Psychiatric disease Diseases 0.000 description 3
- 206010038683 Respiratory disease Diseases 0.000 description 3
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 3
- 210000002784 Stomach Anatomy 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 3
- 230000002730 additional Effects 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 125000005418 aryl aryl group Chemical group 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- 229910000090 borane Inorganic materials 0.000 description 3
- 125000005620 boronic acid group Chemical group 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 230000001808 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical group B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- KONIYTHNVWYBMP-UHFFFAOYSA-N ethylcyclohexane Chemical compound [CH2-]C[C+]1CCCCC1 KONIYTHNVWYBMP-UHFFFAOYSA-N 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 239000000727 fraction Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000008079 hexane Substances 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 201000009673 liver disease Diseases 0.000 description 3
- 229960001252 methamphetamine Drugs 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001850 reproductive Effects 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 201000001880 sexual dysfunction Diseases 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 229960000103 thrombolytic agents Drugs 0.000 description 3
- 229960004394 topiramate Drugs 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- 230000000261 vasodilator Effects 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- ZWRMSOMIVOVMQX-UHFFFAOYSA-M 2-(2-aminoethyldisulfanyl)ethanamine;palladium(2+);chloride Chemical compound [Cl-].[Pd+2].NCCSSCCN ZWRMSOMIVOVMQX-UHFFFAOYSA-M 0.000 description 2
- SEYURSMOEWBZSA-MRVPVSSYSA-N 2-[(2R)-1-ethylpyrrolidin-2-yl]ethanamine Chemical compound CCN1CCC[C@@H]1CCN SEYURSMOEWBZSA-MRVPVSSYSA-N 0.000 description 2
- SEYURSMOEWBZSA-QMMMGPOBSA-N 2-[(2S)-1-ethylpyrrolidin-2-yl]ethanamine Chemical compound CCN1CCC[C@H]1CCN SEYURSMOEWBZSA-QMMMGPOBSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- DKKJNZYHGRUXBS-BQYQJAHWSA-N 5,6-Dehydrokawain Chemical compound O1C(=O)C=C(OC)C=C1\C=C\C1=CC=CC=C1 DKKJNZYHGRUXBS-BQYQJAHWSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N Amfepramone Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N Arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 229940092705 Beclomethasone Drugs 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N Benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960002802 Bromocriptine Drugs 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- 229960001058 Bupropion Drugs 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- KRVSOGSZCMJSLX-UHFFFAOYSA-L Chromic acid Chemical compound O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 2
- 229940107775 Clomiphene Drugs 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229940097362 Cyclodextrins Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229940030606 DIURETICS Drugs 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 210000001198 Duodenum Anatomy 0.000 description 2
- 206010014698 Endocrine disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 229960003883 Furosemide Drugs 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 description 2
- 210000003405 Ileum Anatomy 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 229940036543 Ionamin Drugs 0.000 description 2
- 210000001630 Jejunum Anatomy 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 229940040461 Lipase Drugs 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M Lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 229940041655 Meperidine Drugs 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 229960003105 Metformin Drugs 0.000 description 2
- GCOWZPRIMFGIDQ-UHFFFAOYSA-N N',N'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCCCN GCOWZPRIMFGIDQ-UHFFFAOYSA-N 0.000 description 2
- 102000012301 Neuropeptide Y receptors Human genes 0.000 description 2
- 108050002826 Neuropeptide Y receptors Proteins 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 Nifedipine Drugs 0.000 description 2
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
- 229960000436 Phendimetrazine Drugs 0.000 description 2
- 229960003562 Phentermine Drugs 0.000 description 2
- 206010035004 Pickwickian syndrome Diseases 0.000 description 2
- 229960005095 Pioglitazone Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 2
- 229960004063 Propylene glycol Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 101710026013 SPCC1281.06c Proteins 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000004003 Subcutaneous Fat Anatomy 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L Tin(II) chloride Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N Trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal Effects 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 239000002160 alpha blocker Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 230000001396 anti-anti-diuretic Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000975 bioactive Effects 0.000 description 2
- 239000011942 biocatalyst Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960004890 diethylpropion Drugs 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000004041 inotropic agent Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 102000004882 lipase Human genes 0.000 description 2
- 108090001060 lipase Proteins 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 239000004050 mood stabilizer Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 101700066061 scd1 Proteins 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 230000002295 serotoninergic Effects 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 235000016804 zinc Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- JEPWLORERBTIOD-UHFFFAOYSA-N (1-ethylazetidin-3-yl)methanamine Chemical compound CCN1CC(CN)C1 JEPWLORERBTIOD-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
- IGNPOXGBNFMJHE-SSDOTTSWSA-N (2R)-1-azabicyclo[2.2.2]octan-2-amine Chemical compound C1CN2[C@@H](N)CC1CC2 IGNPOXGBNFMJHE-SSDOTTSWSA-N 0.000 description 1
- YGULWPYYGQCFMP-NPHUUBOGSA-N (2R,3S)-2,3-dihydroxybutanedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 YGULWPYYGQCFMP-NPHUUBOGSA-N 0.000 description 1
- HKQOBOMRSSHSTC-DIBAFDJWSA-N (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;[(2R,3R,4S,5R,6S)-4,5,6-triacetyloxy-3-[(2S,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate;[( Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O.CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1.CCC(=O)OC[C@H]1O[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@@H]1O[C@H]1[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](COC(=O)CC)O1 HKQOBOMRSSHSTC-DIBAFDJWSA-N 0.000 description 1
- SYOKIDBDQMKNDQ-HHUWHTLVSA-N (2S)-1-[2-[[(5S,7R)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C[C@H](C2)CC(C1)(C1)O)C21NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-HHUWHTLVSA-N 0.000 description 1
- IGNPOXGBNFMJHE-ZETCQYMHSA-N (2S)-1-azabicyclo[2.2.2]octan-2-amine Chemical compound C1CN2[C@H](N)CC1CC2 IGNPOXGBNFMJHE-ZETCQYMHSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- LJIZUXQINHXGAO-ITWZMISCSA-N (4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 LJIZUXQINHXGAO-ITWZMISCSA-N 0.000 description 1
- VDSBXXDKCUBMQC-VUOWKATKSA-N (4S,6R)-6-[(E)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@@H]2OC(=O)C[C@@H](O)C2)=C1 VDSBXXDKCUBMQC-VUOWKATKSA-N 0.000 description 1
- NOFOWWRHEPHDCY-DAUURJMHSA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 NOFOWWRHEPHDCY-DAUURJMHSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- BPZSYCZIITTYBL-ORAYPTAESA-N (S,S)-formoterol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-ORAYPTAESA-N 0.000 description 1
- SECXUXOCDLQOBI-MKFZHGHUSA-N (Z)-8aH-phthalazin-1-ylidenehydrazine;hydrochloride Chemical compound Cl.C1=CC=CC2C(=N/N)/N=NC=C21 SECXUXOCDLQOBI-MKFZHGHUSA-N 0.000 description 1
- IUFVBLNYWMTPOB-UHFFFAOYSA-N 1,1,3-trioxo-4H-1$l^{6},2,4-benzothiadiazine-7-carboxylic acid Chemical compound N1C(=O)NS(=O)(=O)C2=CC(C(=O)O)=CC=C21 IUFVBLNYWMTPOB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OSZYHTJPTLLICF-UHFFFAOYSA-N 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol;hydron;chloride Chemical compound Cl.COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 OSZYHTJPTLLICF-UHFFFAOYSA-N 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- KTXVDQNRHZQBOR-UHFFFAOYSA-N 1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)COC1=CC=CC=C1C1CCCC1 KTXVDQNRHZQBOR-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-Ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N 10-oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- NMPVEAUIHMEAQP-UHFFFAOYSA-N 2-Bromoacetaldehyde Chemical compound BrCC=O NMPVEAUIHMEAQP-UHFFFAOYSA-N 0.000 description 1
- VPSRQEHTHIMDQM-FDOHDBATSA-N 2-[(3R)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid;hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FDOHDBATSA-N 0.000 description 1
- GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- OJCZPLDERGDQRJ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 OJCZPLDERGDQRJ-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- FQAWBGAIOYWONH-UHFFFAOYSA-N 3-chloroperoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OOCl)=C1 FQAWBGAIOYWONH-UHFFFAOYSA-N 0.000 description 1
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- FYBXRCFPOTXTJF-RFVHGSKJSA-N 5-[(2R)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one;hydrochloride Chemical compound Cl.N1C(=O)CCC2=C1C=CC=C2OC[C@H](O)CNC(C)(C)C FYBXRCFPOTXTJF-RFVHGSKJSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N Acarbose Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N Acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 Acebutolol Drugs 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 102000005922 Amidases Human genes 0.000 description 1
- 108020003076 Amidases Proteins 0.000 description 1
- 229960004104 Amiloride Hydrochloride Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N Amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 Amiodarone Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N Amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960004005 Amlodipine Besylate Drugs 0.000 description 1
- 229960002519 Amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N Amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940025084 Amphetamine Drugs 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 229960000983 Anistreplase Drugs 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- 210000000617 Arm Anatomy 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229960002274 Atenolol Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N BAY 38-9456 Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 229960003619 Benazepril hydrochloride Drugs 0.000 description 1
- KXDROGADUISDGY-UHFFFAOYSA-N Benzamil hydrochloride Chemical compound C=1C=CC=CC=1CN=C(N)NC(=O)C1=NC(Cl)=C(N)N=C1N KXDROGADUISDGY-UHFFFAOYSA-N 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N Betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 229960005400 Bisoprolol Fumarate Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N Bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- DIKBFYAXUHHXCS-UHFFFAOYSA-N Bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N Bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960001050 Bupivacaine Hydrochloride Drugs 0.000 description 1
- 241001608519 Bursera fagaroides Species 0.000 description 1
- 210000001217 Buttocks Anatomy 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N Butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N CHEMBL3185877 Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N Cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 Cannabidiol Drugs 0.000 description 1
- QHMBSVQNZZTUGM-MSOLQXFVSA-N Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-MSOLQXFVSA-N 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 229960002165 Carteolol Hydrochloride Drugs 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- WZNRVWBKYDHTKI-UHFFFAOYSA-N Cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
- 229960001761 Chlorpropamide Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N Chlortalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 229940107084 Chlorthalidone Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 229940046989 Clomiphene Citrate Drugs 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960002925 Clonidine Hydrochloride Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 Clopidogrel Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000004859 Copal Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229950002753 Crilvastatin Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QGJUIPDUBHWZPV-YQBUGCKMSA-N DB07465 Chemical compound C([C@@H](C1)C2)[C@@H](C3)C[C@@]1(O)C[C@]23[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-YQBUGCKMSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229950003040 Dalvastatin Drugs 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229940119750 Dextroamphetamine Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical group CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N Diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N Digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N Diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960005316 Diltiazem Hydrochloride Drugs 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N Dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N Dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 Dipyridamole Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N Disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229940028937 Divalproex Sodium Drugs 0.000 description 1
- 229960000220 Doxazosin Mesylate Drugs 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 102000002148 EC 2.3.1.20 Human genes 0.000 description 1
- 108010001348 EC 2.3.1.20 Proteins 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960000309 Enalapril Maleate Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N Etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960002541 Ethacrynic Acid Drugs 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 229960003580 Felodipine Drugs 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N Fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N Fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 229960002907 Follitropin beta Drugs 0.000 description 1
- 229960001880 Fosinopril Sodium Drugs 0.000 description 1
- 101710042131 GCG Proteins 0.000 description 1
- 102100003818 GCG Human genes 0.000 description 1
- 101700010630 GHRL Proteins 0.000 description 1
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 229950000806 Glenvastatin Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-SPZCMYQFSA-N Glucosamine Chemical compound N[C@H]1C(O)OC(CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-SPZCMYQFSA-N 0.000 description 1
- 229960002849 Glucosamine Sulfate Drugs 0.000 description 1
- 229940014653 Glyburide Drugs 0.000 description 1
- 102000006602 Glyceraldehyde-3-Phosphate Dehydrogenases Human genes 0.000 description 1
- 108020004445 Glyceraldehyde-3-Phosphate Dehydrogenases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940094892 Gonadotropins Drugs 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- 229960003050 Guanabenz Acetate Drugs 0.000 description 1
- 229960004746 Guanfacine Hydrochloride Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 229960005384 Hydralazine Hydrochloride Drugs 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N Indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 Indapamide Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940030980 Inova Drugs 0.000 description 1
- 206010022489 Insulin resistance Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 210000001596 Intra-Abdominal Fat Anatomy 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N Iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- GGECDTUJZOXAAR-UHFFFAOYSA-N Iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L Iron(II) chloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- 229960000201 Isosorbide Dinitrate Drugs 0.000 description 1
- 229960003827 Isosorbide Mononitrate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N Isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N Isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N Labetalol Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 229960003091 Labetalol hydrochloride Drugs 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N Lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229940063711 Lasix Drugs 0.000 description 1
- 208000001921 Latent Autoimmune Diabetes in Adults Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 229960002394 Lisinopril Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 229940008015 Lithium Carbonate Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N Lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Loniten Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N Lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960000519 Losartan Potassium Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960005170 MOEXIPRIL Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N Methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N Methyldopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 229960000615 Methyldopa Drugs 0.000 description 1
- 229940045385 Methylergonovine Maleate Drugs 0.000 description 1
- 229960001344 Methylphenidate Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N Metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960001300 Metoprolol Tartrate Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N Mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 Mevastatin Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 229960003632 Minoxidil Drugs 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N Modafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 208000001022 Morbid Obesity Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- QOHMWDJIBGVPIF-UHFFFAOYSA-N N',N'-diethylpropane-1,3-diamine Chemical compound CCN(CC)CCCN QOHMWDJIBGVPIF-UHFFFAOYSA-N 0.000 description 1
- ZQEQANWXEQSAGL-UHFFFAOYSA-N N',N'-dimethylpentane-1,5-diamine Chemical compound CN(C)CCCCCN ZQEQANWXEQSAGL-UHFFFAOYSA-N 0.000 description 1
- UOTKNWSJLVKOJR-UHFFFAOYSA-N N,N',N'-trimethylbutane-1,4-diamine Chemical compound CNCCCCN(C)C UOTKNWSJLVKOJR-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N N,N-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- DGFYECXYGUIODH-UHFFFAOYSA-N N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydron;chloride Chemical compound Cl.NC(N)=NC(=O)CC1=C(Cl)C=CC=C1Cl DGFYECXYGUIODH-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 102100016788 NDST1 Human genes 0.000 description 1
- 101700000542 NDST1 Proteins 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N NMM N-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N Nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 Nadolol Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N Nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 Nalbuphine Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N Nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 Nateglinide Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229960003057 Nialamide Drugs 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N Nialamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 229960001783 Nicardipine Drugs 0.000 description 1
- 229960000227 Nisoldipine Drugs 0.000 description 1
- 229940085033 Nolvadex Drugs 0.000 description 1
- 229960001158 Nortriptyline Drugs 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- USDOYYUAZAHPNN-UHFFFAOYSA-N OBO.O=CC1=CC=CO1 Chemical compound OBO.O=CC1=CC=CO1 USDOYYUAZAHPNN-UHFFFAOYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 101710008205 OXT Proteins 0.000 description 1
- 102100017240 OXT Human genes 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- YNZFUWZUGRBMHL-UHFFFAOYSA-N Opipramol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 Oxytocin Drugs 0.000 description 1
- 229940097241 POTASSIUM-SPARING DIURETICS Drugs 0.000 description 1
- 102100018344 PRPF3 Human genes 0.000 description 1
- 101700055558 PRPF3 Proteins 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 229960004493 Penbutolol Sulfate Drugs 0.000 description 1
- 229960000964 Phenelzine Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002386 Prazosin hydrochloride Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229960004604 Propranolol Hydrochloride Drugs 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N Prostacyclin Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N Protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960003042 Quinapril hydrochloride Drugs 0.000 description 1
- 101710005260 RPL6A Proteins 0.000 description 1
- 101710005264 RPL6B Proteins 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N Ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 Ramipril Drugs 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N Rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229940086526 Renin-inhibitors Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N Reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 Risperidone Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N Ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229960001634 Ritodrine Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N Ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- 229960001549 Ropivacaine Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960004937 Saxagliptin Drugs 0.000 description 1
- 229960004499 Scopolamine Hydrobromide Drugs 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 Sertraline Drugs 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 229960002639 Sildenafil citrate Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N Sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 description 1
- 206010040979 Sleep apnoea syndrome Diseases 0.000 description 1
- 229940084026 Sodium Valproate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 229960001204 Sufentanil Citrate Drugs 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940034173 Symbyax Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N Tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229960000216 Tenecteplase Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 229960000195 Terbutaline Drugs 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229960005333 Tetrabenazine Drugs 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N Tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229960005001 Ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N Ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N Tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 229960005221 Timolol Maleate Drugs 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J Tin(IV) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N Toloxatone Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
- 229940035305 Topamax Drugs 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001288 Triamterene Drugs 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N Tributyltin hydride Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M Trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triurene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N Valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 229960000881 Verapamil hydrochloride Drugs 0.000 description 1
- 229940061637 Xopenex Drugs 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 229960004764 Zafirlukast Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940093612 Zein Drugs 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- UAYWVJHJZHQCIE-UHFFFAOYSA-L Zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N Ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- FXAAOALUHHXBSO-AXFHLTTASA-N [(1R,5R)-3,3,5-trimethylcyclohexyl] (2S)-5-oxopyrrolidine-2-carboxylate Chemical compound C1C(C)(C)C[C@@H](C)C[C@H]1OC(=O)[C@H]1NC(=O)CC1 FXAAOALUHHXBSO-AXFHLTTASA-N 0.000 description 1
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1S,4aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2S)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 1
- DQEFEBPAPFSJLV-WLTGXWPBSA-N [(2R,3R,4S,5R,6S)-4,5,6-tri(propanoyloxy)-3-[(2S,3R,4S,5R,6R)-3,4,5-tri(propanoyloxy)-6-(propanoyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl propanoate Chemical compound CCC(=O)OC[C@H]1O[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@@H]1O[C@H]1[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](COC(=O)CC)O1 DQEFEBPAPFSJLV-WLTGXWPBSA-N 0.000 description 1
- IWSWDOUXSCRCKW-UHFFFAOYSA-N [6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-yl]azanium;chloride Chemical compound Cl.N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 IWSWDOUXSCRCKW-UHFFFAOYSA-N 0.000 description 1
- IVPKEUMTZCSLMM-UHFFFAOYSA-O [methoxy(methylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CNC(OC)=[N+](C)C IVPKEUMTZCSLMM-UHFFFAOYSA-O 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-L acetate;chloride Chemical compound [Cl-].CC([O-])=O WJGAPUXHSQQWQF-UHFFFAOYSA-L 0.000 description 1
- UTKBLLDLHPDWDU-ODZAUARKSA-N acetic acid;(Z)-but-2-enedioic acid Chemical compound CC(O)=O.OC(=O)\C=C/C(O)=O UTKBLLDLHPDWDU-ODZAUARKSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 description 1
- AEMQUICCWRPKDB-UHFFFAOYSA-N acetic acid;cyclohexane-1,2-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1CCCCC1C(O)=O AEMQUICCWRPKDB-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 229960002734 amfetamine Drugs 0.000 description 1
- ACHKKGDWZVCSNH-UHFFFAOYSA-N amiloride hydrochloride Chemical compound Cl.NC(N)=NC(=O)C1=NC(Cl)=C(N)N=C1N ACHKKGDWZVCSNH-UHFFFAOYSA-N 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229940058933 biguanide antimalarials Drugs 0.000 description 1
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- VMDFASMUILANOL-WXXKFALUSA-N bisoprolol fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VMDFASMUILANOL-WXXKFALUSA-N 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 229940090127 blood glucose lowering Alpha glucosidase inhibitors Drugs 0.000 description 1
- 229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- CROBTXVXNQNKKO-UHFFFAOYSA-N borohydride Chemical compound [BH4-] CROBTXVXNQNKKO-UHFFFAOYSA-N 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229950005228 bromoform Drugs 0.000 description 1
- 230000003182 bronchodilatating Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- HUCIWBPMHXGLFM-UHFFFAOYSA-N bupivacaine hydrochloride hydrate Chemical compound O.[Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C HUCIWBPMHXGLFM-UHFFFAOYSA-N 0.000 description 1
- YIYSEJAAJSSNNS-UHFFFAOYSA-N but-1-en-1-one Chemical group [CH2]CC=C=O YIYSEJAAJSSNNS-UHFFFAOYSA-N 0.000 description 1
- FQFTUKDNONXKLN-UHFFFAOYSA-N but-1-yn-1-olate Chemical group [CH2+]CC#C[O-] FQFTUKDNONXKLN-UHFFFAOYSA-N 0.000 description 1
- WPTMDNDUQTZHIC-UHFFFAOYSA-N but-1-yne Chemical group [CH2-]CC#[C+] WPTMDNDUQTZHIC-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 229940082638 cardiac stimulant Phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agents Methyldopa Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NCBFTYFOPLPRBX-UHFFFAOYSA-N dimethyl azodicarboxylate Substances COC(=O)N=NC(=O)OC NCBFTYFOPLPRBX-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OPCPRUQQEJNFIV-UHFFFAOYSA-N disodium;cyanoboron(1-) Chemical compound [Na+].[Na+].[B-]C#N.[B-]C#N OPCPRUQQEJNFIV-UHFFFAOYSA-N 0.000 description 1
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002196 ecbolic Effects 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- YREISLCRUMOYAY-IIPCNOPRSA-N ergometrine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 YREISLCRUMOYAY-IIPCNOPRSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960005210 follitropin alfa Drugs 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- WHGLQYBALPTZNJ-UHFFFAOYSA-N furan;oxolane Chemical compound C1CCOC1.C=1C=COC=1 WHGLQYBALPTZNJ-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- VENHFCZBHVZHMO-UHFFFAOYSA-N gold;triphenylphosphane Chemical compound [Au].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VENHFCZBHVZHMO-UHFFFAOYSA-N 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 229940121381 gonadotrophin releasing hormone (GnRH) antagonists Drugs 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960002844 iprindole Drugs 0.000 description 1
- 229960002589 iproclozide Drugs 0.000 description 1
- 229960003049 iproniazid Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- MLGUXXSGWWCJQW-KBPBESRZSA-N kavapyrone Chemical compound O1C(=O)C=C(OC)C=C1[C@H]1[C@H](C=2C=CC=CC=2)O1 MLGUXXSGWWCJQW-KBPBESRZSA-N 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-L lithium;dihydroxide Chemical compound [Li+].[OH-].[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-L 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- NCBFTYFOPLPRBX-AATRIKPKSA-N methyl (NE)-N-methoxycarbonyliminocarbamate Chemical compound COC(=O)\N=N\C(=O)OC NCBFTYFOPLPRBX-AATRIKPKSA-N 0.000 description 1
- HTEAGOMAXMOFFS-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C HTEAGOMAXMOFFS-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- BVSLKGYNCICXIH-UHFFFAOYSA-N methyl 6-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-(2-formylfuran-3-yl)-2-(4-methylphenyl)sulfonyloxybenzoate Chemical compound C=1C=C(C)C=CC=1S(=O)(=O)OC=1C(C(=O)OC)=C(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C=CC=1C=1C=COC=1C=O BVSLKGYNCICXIH-UHFFFAOYSA-N 0.000 description 1
- POOUESKYPHSXSK-UHFFFAOYSA-N methyl 6-amino-3-(2-formylfuran-3-yl)-2-hydroxybenzoate Chemical compound COC(=O)C1=C(N)C=CC(C2=C(OC=C2)C=O)=C1O POOUESKYPHSXSK-UHFFFAOYSA-N 0.000 description 1
- MYSWGNHLJGOCPT-UHFFFAOYSA-N methyl prop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C=C MYSWGNHLJGOCPT-UHFFFAOYSA-N 0.000 description 1
- 229960000328 methylergometrine Drugs 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 229960000939 metoprolol succinate Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 201000000090 microsporidiosis Diseases 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960005290 opipramol Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 101700057139 oxyT Proteins 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229940021222 peritoneal dialysis Isotonic solutions Drugs 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- XQGZJPMNGZVHQC-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanolate Chemical compound [K+].CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 XQGZJPMNGZVHQC-UHFFFAOYSA-N 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- TVTJZMHAIQQZTL-LVCDZQEYSA-M sodium;(2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-LVCDZQEYSA-M 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 230000000153 supplemental Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001909 terazosin hydrochloride Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ODGCEQLVLXJUCC-UHFFFAOYSA-N tetrafluoroborate Chemical compound F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000005636 thioacylation reaction Methods 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910000083 tin tetrahydride Inorganic materials 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229960002309 toloxatone Drugs 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229960002070 torsemide Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- YTJUCJAUJCXFTN-UHFFFAOYSA-O tritert-butylphosphanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CC(C)(C)[PH+](C(C)(C)C)C(C)(C)C YTJUCJAUJCXFTN-UHFFFAOYSA-O 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
Provided herein are tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. In one embodiment the compound is cis-(3aRS,9bRS)-7-(benzenesulfonylamino)-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid. compound is cis-(3aRS,9bRS)-7-(benzenesulfonylamino)-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene-6-carboxylic acid.
Description
PARTIALLY SATURATED TRICYCLIC COMPOUNDS
AND METHODS OF MAKING AND USING SAME
CROSS REFERENCE TO RELATED APPLICATION
This application claims priority to U.S. Provisional Patent Application
61/559,856 filed November 15, 2011, and U.S. Provisional Patent Application 61/483,257 filed
May 6, 2011, both of which are hereby incorporated by reference in their entirety.
BACKGROUND
[0001a] Any discussion of the prior art throughout the specification should in no way be
considered as an admission that such prior art is widely known or forms part of common
general knowledge in the field.
Over 1.1 billion people worldwide are reported to be overweight. Obesity is
estimated to affect over 90 million people in the United States alone. Twenty-five percent of
the population in the United States over the age of twenty is considered clinically obese. While
being overweight or obese presents problems (for example restriction of mobility, discomfort in
tight spaces such as theater or airplane seats, social difficulties, etc.), these conditions, in
particular clinical obesity, affect other aspects of health, i.e., diseases and other adverse health
conditions associated with, exacerbated by, or precipitated by being overweight or obese. The
estimated mortality from obesity-related conditions in the United States is over 300,000
annually (O’Brien et al. Amer J Surgery (2002) 184:4S-8S; and Hill et al. (1998) Science,
280:1371).
There is no curative treatment for being overweight or obese. Traditional
pharmacotherapies for treating an overweight or obese subject, such as serotonin and
noradrenergic re-uptake inhibitors, noradrenergic re-uptake inhibitors, selective serotonin re-
uptake inhibitors, intestinal lipase inhibitors, or surgeries such as stomach stapling or gastric
banding, have been shown to provide minimal short-term benefits or significant rates of
relapse, and have further shown harmful side-effects to patients.
MetAP2 encodes a protein that functions at least in part by enzymatically
removing the amino terminal methionine residue from certain newly translated proteins such as
glyceraldehydephosphate dehydrogenase (Warder et al. (2008) J Proteome Res 7:4807).
Increased expression of the MetAP2 gene has been historically associated with various forms
of cancer. Molecules inhibiting the enzymatic activity of MetAP2 have been identified and
have been explored for their utility in the treatment of various tumor types (Wang et al. (2003)
Cancer Res. 63:7861) and infectious diseases such as microsporidiosis, leishmaniasis, and
malaria (Zhang et al. (2002) J. Biomed. Sci. 9:34). Notably, inhibition of MetAP2 activity in
obese and obese-diabetic animals leads to a reduction in body weight in part by increasing the
oxidation of fat and in part by reducing the consumption of food (Rupnick et al. (2002) Proc.
Natl. Acad. Sci. USA 99:10730).
Such MetAP2 inhibitors may be useful as well for patients with excess adiposity
and conditions related to adiposity including type 2 diabetes, hepatic steatosis, and
cardiovascular disease (via e.g. ameliorating insulin resistance, reducing hepatic lipid content,
and reducing cardiac workload). Accordingly, compounds capable of modulating MetAP2 are
needed to address the treatment of obesity and related diseases as well as other ailments
favorably responsive to MetAP2 modulator treatment.
[0005a] It is an object of the present invention to overcome or ameliorate at least one of
the disadvantages of the prior art, or to provide a useful alternative.
SUMMARY
[0005b] According to a first aspect, the present invention provides a tricyclic
compound represented by:
# B1
A2 B
A2 B
R O O
O O 2
A1 A N
A1 A N
(R ) (R )
CO H CO H
Formula I or Formula II
wherein:
B is a 3-6 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
B is a 3-6 membered saturated heterocyclic or carbocyclic ring;
wherein the ring B or B is optionally substituted by one or more fluorine atoms on any
of the available carbon atoms;
D is a 5-7 membered heterocyclic, carbocyclic, heteroaromatic or aromatic ring;
D is a 5-7 membered heterocyclic or carbocyclic ring;
1 1 1 1
wherein B is fused to D such that the two atoms shared by B and D are both carbon
2 2 2 2
and B is fused to D such that the two atoms shared by B and D are both carbon; and wherein
for Formula I the bond common to both the B and D rings is a single or double bond;
- 2a -
1 + D1 D2 + 1 + D1 D2
X is selected from the group consisting of: -C(R R )-*, -W -*, -C(R R )-
D5 D6 + C1 C2 + 2 D5 D6 + 2 + D1 D2 4 +
C(R R )-*, -C(R )=C(R )-*, -W -C(R R )-*, -W -C(O)-*, -C(R R )-W -*, -
C2 + C1 + D1 D2 D3 D4 D5 D6 + 2 D3 D4
N=C(R )-*, -C(R )=N-*, -C(R R )-C(R R )-C(R R )-*, -W -C(R R )-
D5 D6 + 2 D5 D6 + D1 D2 3 D5 D6 + D1 D2 3
C(R R )-*, -W -C(O)-C(R R )-*, -C(R R )-W -C(R R )-*, -C(R R )-W -C(O)-
+ D1 D2 D3 D4 4 + D1 D2 4 +
*, -C(R R )-C(R R )-W -* and -C(R R )-C(O)-W -*; wherein the and * indicate the
attachment points of X as indicated in Formula I;
2 + D1 D2 + 1 + D1 D2
X is selected from the group consisting of: -C(R R )-*, -W -*, -C(R R )-
D5 D6 + 2 D5 D6 + 2 + D1 D2 4 + D1 D2 D3 D4
C(R R )-*, -W -C(R R )-*, -W -C(O)-*, -C(R R )-W -*, -C(R R )-C(R R )-
D5 D6 + 2 D3 D4 D5 D6 + 2 D5 D6 + D1 D2 3
C(R R )-*, -W -C(R R )-C(R R )-*, -W -C(O)-C(R R )-*, -C(R R )-W -
D5 D6 + D1 D2 3 + D1 D2 D3 D4 4 + D1 D2
C(R R )-*, -C(R R )-W -C(O)-*, -C(R R )-C(R R )-W -* and -C(R R )-C(O)-
4 + 2
W -*; wherein the and * indicate the attachment points of X as indicated in Formula II;
# # #
Y is selected from the group consisting of: a bond, *-CH - , *-O- , *-CH -CH - , *-O-
2 2 2
# # # # # #
CH - , *-CH -O- , *-CH -CH -CH - , *-O-CH -CH - and *-CH -O-CH - ; wherein the * and
2 2 2 2 2 2 2 2 2
indicate the attachment points of Y as indicated in Formula I or Formula II;
1 N1
W is selected from the group consisting of O, S or N(R );
2 N2
W is selected from the group consisting of O or N(R );
3 N3
W is selected from the group consisting of O or N(R );
4 N4
W is selected from the group consisting of O or N(R );
A is a ring selected from the group consisting of phenyl, a 5-6 membered heteroaryl
having 1, 2 or 3 heteroatoms each selected from S, N or O, and a 4-7 membered heterocycle
having 1, 2 or 3 heteroatoms each selected from N or O;
B1 B2
R and R are independently selected from the group consisting of H, F, OH, CN,
C alkoxy or C alkyl; wherein C alkyl and C alkoxy are optionally substituted by a group
1-2 1-3 1-3 1-2
selected from OH, C alkoxy, CN or one or more fluorine atoms;
R is selected, independently for each occurrence, from the group consisting of
hydrogen, hydroxyl, cyano, halogen, C alkyl or C alkoxy; wherein C alkyl, or C alkoxy
1-4 1-3 1-4 1-3
may be optionally substituted by oneor more fluorines;
n is 0, 1, or 2;
A2 i j
R is selected from the group consisting of hydrogen, R R N-, heterocyclyl,
heterocyclyloxy and heterocyclyl-(NR )-; wherein said heterocyclyl may optionally be
substituted by one or more substituents selected from R and wherein if said heterocyclyl
- 2b -
contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R ;
R is selected from the group consisting of: C alkyl, C alkenyl, C alkynyl, C
1-6 2-6 2-6 3-
cycloalkyl, C alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) -
6 1-6 3-6 3-6 3-6 1-6 w
a a a
(wherein w is 0, 1 or 2), C alkyl-N(R )-, C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-,
1-6 1-6 1-6
a a a a
C alkyl-N(R )-carbonyl-N(R )-, C alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C
1-6 1-6 2 1-6 2 1-
a a a
alkoxycarbonyl-N(R )-, C alkylcarbonyl-N(R )-C alkyl-, C alkyl-N(R )-carbonyl-C
6 1-6 1-6 1-6 1-
alkyl-, C alkoxyC alkyl-; wherein C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C
6 1-6 1-6 1-6 2-6 2-6 3-6 1-
alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) -, C alkyl-N(R )-,
6 3-6 3-6 3-6 1-6 w 1-6
a a a a
C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-, C alkyl-N(R )-carbonyl-N(R )-, C
1-6 1-6 1-6 1-
a a a
alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C alkoxycarbonyl-N(R )-, C alkylcarbonyl-
6 2 1-6 2 1-6 1-6
N(R )C alkyl-, C alkyl-N(R )-carbonyl-C alkyl-, C alkoxy-C alkyl may optionally be
1-6 1-6 1-6 1-6 1-6
substituted by R , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR )-, heterocyclyl,
heterocyclyloxy or heterocyclyl-N(R )-; and wherein said heteroaryl or phenyl may optionally
be substituted with one or more substituents selected from R ; and wherein said heterocyclyl
may optionally be substituted by one or more substituents selected from R ; and wherein if said
heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more
groups R ;
D1 D2
R and R are each independently selected from the group consisting of hydrogen,
fluorine, hydroxyl, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may
1-2 1-2 1-2 1-2
optionally be substituted by one or more fluorine atoms or a group selected from cyano or
hydroxyl;
D3 D4
R and R are each independently selected from the group consisting of hydrogen,
fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may
1-3 1-3 1-3 1-3
optionally be substituted by one or more fluorine atoms or a group selected from cyano,
hydroxyl or N(R R );
D5 D6
R and R are each independently selected from the group consisting of hydrogen,
fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may
1-2 1-2 1-2 1-2
optionally be substituted by a substituent or substituents selected from the group consisting of:
one or more fluorine atoms,cyano, hydroxyl or N(R R );
R is selected from the group consisting of hydrogen, halogen, C alkyl or C alkoxy;
1-2 1-2
wherein the C alkyl or C alkoxy may optionally be substituted by one or more fluorine
1-2 1-2
atoms;
- 2c -
R is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C
alkyl or C alkoxy; wherein the C alkyl and C alkoxy may optionally be substituted by one
2 1-2 1-2 1-2
or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R );
R is selected from the group consisting of hydrogen or C alkyl;
R is selected from the group consisting of hydrogen or C alkyl;
R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl;
1-3 1-2
wherein the C alkyl and C alkylcarbonyl may optionally be substituted by a substituent or
1-3 1-2
substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or
N(R R );
R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl;
1-3 1-2
wherein the C alkyl and C alkylcarbonyl may optionally be substituted by a substituent or
1-3 1-2
substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or
N(R R );
R and R are independently selected, for each occurrence, from the group consisting of
hydrogen and C alkyl; wherein C alkyl may optionally be substituted by one or more
1-3 1-3
substituents selected from fluorine, cyano, oxo and hydroxyl;
or R and R , together with the nitrogen to which they are attached, may form a 4-6
membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or
N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more
substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl;
R is independently selected, for each occurrence, from the group consisting of R ,
hydrogen, C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -,
1-6 3-6 2-6 2-6 1-6 1-6 w
(wherein wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-;
1-6 1-6
wherein C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -, C
1-6 3-6 2-6 2-6 1-6 1-6 w 1-
alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or
6 1-6
more substituents selected from R ;
R is independently selected for each occurrence from the group consisting of R ,
hydrogen, oxo, C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -,
1-6 2-6 2-6 3-6 1-6 1-6 w
(wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-; wherein C
1-6 1-6 1-
alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -, C
6 2-6 2-6 3-6 1-6 1-6 w 1-
alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or
6 1-6
more substituents selected from R ;
- 2d -
R is independently selected for each occurrence from the group consisting of hydrogen,
C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) -, C alkoxycarbonyl-,
1-6 3-6 3-6 3-6 1-6 2 1-6
i j i j
R R N-carbonyl- and R R N-SO -; wherein C alkyl, C alkenyl, C alkynyl C cycloalkyl
2 1-6 3-6 3-6 3-6
and C alkyl-S(O) -, C alkylcarbonyl- may optionally be substituted by one or more
1-6 2 1-6
substituents selected from R ;
R and R are selected independently for each occurrence from the group consisting of
hydrogen, C alkyl C cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein C alkyl
1-4 3-6 1-4
and C cycloalkyl may be optionally substituted by one or more substituents selected from
a b a b
fluorine, hydroxyl, cyano, R R N-, R R N-carbonyl- and C alkoxy and wherein heterocyclyl
and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected
from C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, halo-C -alkyl, hydroxyl-
1-6 2-6 2-6 3-6 1-6 1-6
C -alkyl, R R N-C alkyl- and C -alkoxy-C -alkyl group; and wherein if said heterocyclyl
1-6 1-6 1-6 1-6
or heterocyclylcarbonyl contains a –NH moiety that nitrogen may optionally be substituted by
one or more groups C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) - and C
1-6 3-6 3-6 3-6 1-6 2 1alkylcarbonyl; or R and R taken together with the nitrogen to which they are attached form a
4-7 membered heterocyclic ring, which may have an additional heteroatom selected from O, S,
or N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by
one or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano,
a b a b a b
C alkyl, C alkoxy, R R N-, R R N-SO - and R R N-carbonyl-; wherein said C alkyl or C
1-6 1-6 2 1-6 1-
alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7
membered heterocyclic ring may be optionally substituted on nitrogen by one or more
substituents selected from the group consisting of C alkyl and R R N-carbonyl-; and wherein
said C alkyl may be optionally substituted by one or more substituents selected from the
group consisting of fluorine, hydroxyl, cyano;
R is independently selected, for each occurrence, from the group consisting of halogen,
i j i j i j i j a
hydroxyl, cyano, C alkoxy, R R N-, R R N-carbonyl-, R R N-SO - and R R N-carbonyl-N(R )-;
1-6 2
and pharmaceutically acceptable salts, stereoisomers and esters thereof.
[0005c] According to a second aspect, the present invention provides a pharmaceutically
acceptable composition comprising a compound of the invention and a pharmaceutically
acceptable excipient.
[0005d] According to a third aspect, the present invention provides a method of treating
and/or controlling obesity, comprising administering to a non-human patient in need thereof an
effective amount of a compound of the invention.
- 2e -
[0005e] According to a fourth aspect, the present invention provides a method of
inducing weight loss in a non-human patient in need thereof, comprising administering to said
patient an effective amount of a compound of the invention.
[0005f] According to a fifth aspect, the present invention provides the use of a
compound of the invention in the manufacture of a medicament for treating or preventing
obesity.
[0005g] According to a sixth aspect, the present invention provides the use of a
compound of the invention in the manufacture of a medicament for inducing weight loss.
[0005h] Unless the context clearly requires otherwise, throughout the description and the
claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive
sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including,
but not limited to”.
The invention provides, for example, compounds which may be modulators of
MetAP2, and their use as medicinal agents, processes for their preparation, and pharmaceutical
compositions containing them as an active ingredient both alone or in combination with other
agents, as well as provides for their use as medicaments and/or in the manufacture of
medicaments for the inhibition of MetAP2 activity in warm-blooded animals such as humans.
In particular this invention relates to compounds useful for the treatment of obesity, type 2
diabetes, and other obesity-associated conditions. Also provided are pharmaceutical
compositions comprising at least one disclosed compound and a pharmaceutically acceptable
carrier.
In an embodiment, provided herein are compounds represented by formula I and
# B1
A2 B
A2 B
O O 1 R
O O 2
S 2 R
A1 A N
A1 A N
(R ) (R )
n n H
CO H CO H
Formula I or Formula II
or pharmaceutically acceptable salts, stereoisomers, esters or prodrugs thereof, where A, B ,
2 1 2 A1 A2 B1 B2 1 2
B , D , D , R , R , R , R , Y, X , X , and n are as defined herein.
DETAILED DESCRIPTION
The features and other details of the disclosure will now be more particularly
described. Before further description of the present invention, certain terms employed in the
specification, examples and appended claims are collected here. These definitions should be
read in light of the remainder of the disclosure and as understood by a person of skill in the art.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning
as commonly understood by a person of ordinary skill in the art.
Definitions
"Treating" includes any effect, e.g., lessening, reducing, modulating, or
eliminating, that results in the improvement of the condition, disease, disorder and the like.
The term "alkenyl" as used herein refers to an unsaturated straight or branched
hydrocarbon having at least one carbon-carbon double bond. Exemplary alkenyl groups
include, but are not limited to, a straight or branched group of 2-6 or 3-4 carbon atoms, referred
to herein as C2- alkenyl, and C3_4alkenyl, respectively. Exemplary alkenyl groups include, but
are not limited to, vinyl, allyl, butenyl, pentenyl, etc.
The term "alkoxy" as used herein refers to a straight or branched alkyl group
attached to oxygen (alkyl-O-). Exemplary alkoxy groups include, but are not limited to,
alkoxy groups of 1-6 or 2-6 carbon atoms, referred to herein as Ci_alkoxy, and C2_6alkoxy,
respectively. Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy,
isopropoxy, etc.
The term "alkoxyalkyl" as used herein refers to a straight or branched alkyl
group attached to oxygen, attached to a second straight or branched alkyl group (alkyl-O-alkyl-
). Exemplary alkoxyalkyl groups include, but are not limited to, alkoxyalkyl groups in which
each of the alkyl groups independently contains 1-6 carbon atoms, referred to herein as Ci_
6alkoxy-Ci_6alkyl. Exemplary alkoxyalkyl groups include, but are not limited to
methoxymethyl, 2-methoxyethyl, 1-methoxyethyl, 2-methoxypropyl, ethoxymethyl, 2-
isopropoxyethyl etc.
The term "alkyoxycarbonyl" as used herein refers to a straight or branched alkyl
group attached to oxygen, attached to a carbonyl group (alkyl-O -C(O)-). Exemplary
alkoxycarbonyl groups include, but are not limited to, alkoxycarbonyl groups of 1-6 carbon
atoms, referred to herein as C^alkoxycarbonyl. Exemplary alkoxycarbonyl groups include, but
are not limited to, methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, etc.
The term "alkenyloxy" used herein refers to a straight or branched alkenyl group
attached to oxygen (alkenyl-O-). Exemplary alkenyloxy groups include, but are not limited to,
groups with an alkenyl group of 3-6 carbon atoms, referred to herein as _alkenyloxy.
Exemplary "alkenyloxy" groups include, but are not limited to allyloxy, butenyloxy, etc.
The term "alkynyloxy" used herein refers to a straight or branched alkynyl
group attached to oxygen (alkynyl-O). Exemplary alkynyloxy groups include, but are not
limited to, groups with an alkynyl group of 3-6 carbon atoms, referred to herein as
Exemplary alkynyloxy groups include, but are not limited to, propynyloxy,
6alkynyloxy.
butynyloxy, etc.
The term "alkyl" as used herein refers to a saturated straight or branched
hydrocarbon. Exemplary alkyl groups include, but are not limited to, straight or branched
hydrocarbons of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as Ci-ealkyl, and Ci_
respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl,
3alkyl,
propyl, isopropyl, 2-methyl-l -butyl, 3-methylbutyl, 2-methyl-l-pentyl, 3-methyl-l-pentyl,
4-methyl-l-pentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,2-dimethyl-l-
butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl,
neopentyl, hexyl, etc.
The term "alkylcarbonyl" as used herein refers to a straight or branched alkyl
group attached to a carbonyl group (alkyl-C(O)-). Exemplary alkylcarbonyl groups include, but
are not limited to, alkylcarbonyl groups of 1-6 atoms, referred to herein as C^alkylcarbonyl
groups. Exemplary alkylcarbonyl groups include, but are not limited to, acetyl, propanoyl,
isopropanoyl, butanoyl, etc.
The term "alkynyl" as used herein refers to an unsaturated straight or branched
hydrocarbon having at least one carbon-carbon triple bond. Exemplary alkynyl groups include,
but are not limited to, straight or branched groups of 2-6, or 3-6 carbon atoms, referred to
herein as and respectively. Exemplary alkynyl groups include, but are
C2- alkynyl, C3_6alkynyl,
not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, etc.
The term "carbonyl" as used herein refers to the radical -C(O)-.
The term "cyano" as used herein refers to the radical -CN.
The term "cycloalkoxy" as used herein refers to a cycloalkyl group attached to
oxygen (cycloalkyl-O-). Exemplary cycloalkoxy groups include, but are not limited to,
cycloalkoxy groups of 3-6 carbon atoms, referred to herein as groups.
C 3_ cycloalkoxy
Exemplary cycloalkoxy groups include, but are not limited to, cyclopropoxy, cyclobutoxy,
cyclohexyloxy, etc
The terms "cycloalkyl" or a "carbocyclic group" as used herein refers to a
saturated or partially unsaturated hydrocarbon group of, for example, 3-6, or 4-6 carbons,
referred to herein as _cycloalkyl or C^cycloalkyl, respectively. Exemplary cycloalkyl
groups include, but are not limited to, cyclohexyl, cyclopentyl, cyclopentenyl, cyclobutyl or
cyclopropyl.
The terms "halo" or "halogen" as used herein refer to F, CI, Br, or I.
The terms "heteroaryl" or "heteroaromatic group" as used herein refers to a
monocyclic aromatic 5-6 membered ring system containing one or more heteroatoms, for
example one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, said
heteroaryl ring may be linked to the adjacent radical though carbon or nitrogen. Examples of
heteroaryl rings include but are not limited to furan, thiophene, pyrrole, thiazole, oxazole,
isothiazole, isoxazole, imidazole, pyrazole, triazole, pyridine or pyrimidine etc.
The terms "heterocyclyl" or "heterocyclic group" are art-recognized and refer to
saturated or partially unsaturated, 4-10 membered ring structures, including bridged or fused
rings, and whose ring structures include one to three heteroatoms, such as nitrogen, oxygen,
and sulfur. Where possible, heterocyclyl rings may be linked to the adjacent radical through
carbon or nitrogen. Examples of heterocyclyl groups include, but are not limited to,
pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, oxetane, azetidine,
tetrahydrofuran or dihydrofuran etc.
The term "heterocyclyloxy" as used herein refers to a heterocyclyl group
attached to oxygen (heterocyclyl-O-).
The term "heteroaryloxy" as used herein refers to a heteroaryl group attached to
oxygen (heteroaryl-O-).
The terms "hydroxy" and "hydroxyl" as used herein refers to the radical -OH.
The term "oxo" as used herein refers to the radical =0.
"Pharmaceutically or pharmacologically acceptable" include molecular entities
and compositions that do not produce an adverse, allergic or other untoward reaction when
administered to an animal, or a human, as appropriate. For human administration, preparations
should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA
Office of Biologies standards.
The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable
excipient" as used herein refers to any and all solvents, dispersion media, coatings, isotonic and
absorption delaying agents, and the like, that are compatible with pharmaceutical
administration. The use of such media and agents for pharmaceutically active substances is
well known in the art. The compositions may also contain other active compounds providing
supplemental, additional, or enhanced therapeutic functions.
The term "pharmaceutical composition" as used herein refers to a composition
comprising at least one compound as disclosed herein formulated together with one or more
pharmaceutically acceptable carriers.
"Individual," "patient," or "subject" are used interchangeably and include any
animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine,
cattle, sheep, horses, or primates, and most preferably humans. The compounds of the
invention can be administered to a mammal, such as a human, but can also be administered to
other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g.,
dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and
laboratory animals (e.g., rats, mice, guinea pigs, and the like). The mammal treated in the
methods of the invention is desirably a mammal in which treatment of obesity or weight loss is
desired. "Modulation" includes antagonism (e.g., inhibition), agonism, partial antagonism
and/or partial agonism.
In the present specification, the term "therapeutically effective amount" means
the amount of the subject compound that will elicit the biological or medical response of a
tissue, system or animal, (e.g. mammal or human) that is being sought by the researcher,
veterinarian, medical doctor or other clinician. The compounds of the invention are
administered in therapeutically effective amounts to treat a disease. Alternatively, a
therapeutically effective amount of a compound is the quantity required to achieve a desired
therapeutic and/or prophylactic effect, such as an amount which results in weight loss.
The term "pharmaceutically acceptable salt(s)" as used herein refers to salts of
acidic or basic groups that may be present in compounds used in the compositions.
Compounds included in the present compositions that are basic in nature are capable of forming
a wide variety of salts with various inorganic and organic acids. The acids that may be used to
prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that
form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions,
including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate,
bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate,
oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate,
gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate,
ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., l ,l'-methylene-£>«-(2-
hydroxynaphthoate)) salts. Compounds included in the present compositions that are acidic
in nature are capable of forming base salts with various pharmacologically acceptable cations.
Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium,
magnesium, sodium, lithium, zinc, potassium, and iron salts. Compounds included in the
present compositions that include a basic or acidic moiety may also form pharmaceutically
acceptable salts with various amino acids. The compounds of the disclosure may contain both
acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case,
the compound can exist as an acid addition salt, a zwitterion, or a base salt.
The compounds of the disclosure may contain one or more chiral centers and,
therefore, exist as stereoisomers. The term "stereoisomers" when used herein consist of all
enantiomers or diastereomers. These compounds may be designated by the symbols "(+)," "(-
)," "R" or "S," depending on the configuration of substituents around the stereogenic carbon
atom, but the skilled artisan will recognize that a structure may denote a chiral center
implicitly. The present invention encompasses various stereoisomers of these compounds and
mixtures thereof. Mixtures of enantiomers or diastereomers may be designated "(+)" in
nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center
implicitly.
The compounds of the disclosure may contain one or more double bonds and,
therefore, exist as geometric isomers resulting from the arrangement of substituents around a
carbon-carbon double bond. The symbol denotes a bond that may be a single, double or triple
bond as described herein. Substituents around a carbon-carbon double bond are designated as
being in the "Z" or "E" configuration wherein the terms "Z" and "E" are used in accordance
with IUPAC standards. Unless otherwise specified, structures depicting double bonds
encompass both the "E" and "Z" isomers. Substituents around a carbon-carbon double bond
alternatively can be referred to as "cis" or "trans," where "cis" represents substituents on the
same side of the double bond and "trans" represents substituents on opposite sides of the
double bond.
Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and
therefore, exist as geometric isomers resulting from the arrangement of substituents around the
ring. The arrangement of substituents around a carbocyclic or heterocyclic ring are designated
as being in the "Z" or "E" configuration wherein the terms "Z" and "E" are used in
accordance with IUPAC standards. Unless otherwise specified, structures depicting carbocyclic
or heterocyclic rings encompass both "Z" and "E" isomers. Substituents around a carbocyclic
or heterocyclic rings may also be referred to as "cis" or "trans", where the term "cis" represents
substituents on the same side of the plane of the ring and the term "trans" represents
substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the
substituents are disposed on both the same and opposite sides of plane of the ring are
designated "cis/trans."
Individual enantiomers and diasteriomers of compounds of the present invention
can be prepared synthetically from commercially available starting materials that contain
asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by
resolution methods well known to those of ordinary skill in the art. These methods of
resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary,
separation of the resulting mixture of diastereomers by recrystallization or chromatography and
liberation of the optically pure product from the auxiliary, (2) salt formation employing an
optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on
chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical
or enzymatic reagents. Racemic mixtures can also be resolved into their component
enantiomers by well known methods, such as chiral-phase liquid chromatography or
crystallizing the compound in a chiral solvent. Stereoselective syntheses, a chemical or
enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during
the creation of a new stereocenter or during the transformation of a pre-existing one, are well
known in the art. Stereoselective syntheses encompass both enantio- and diastereoselective
transformations, and may involve the use of chiral auxiliaries. For examples, see Carreira and
Kvaerno, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.
The compounds disclosed herein can exist in solvated as well as unsolvated
forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is
intended that the invention embrace both solvated and unsolvated forms. In one embodiment,
the compound is amorphous. In one embodiment, the compound is a single polymorph. In
another embodiment, the compound is a mixture of polymorphs. In another embodiment, the
compound is in a crystalline form.
The invention also embraces isotopically labeled compounds of the invention
which are identical to those recited herein, except that one or more atoms are replaced by an
atom having an atomic mass or mass number different from the atomic mass or mass number
usually found in nature. Examples of isotopes that can be incorporated into compounds of the
invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine
1 14 1 1 17 1 1
and chlorine, such as ¾ H, C, C, N, 0 , 0 , P, P, S, F, and C1, respectively.
For example, a compound of the invention may have one or more H atom replaced with
deuterium.
[0042] Certain isotopically-labeled disclosed compounds (e.g., those labeled with H
and C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., H)
and carbon- 14 (i.e., C) isotopes are particularly preferred for their ease of preparation and
detectability. Further, substitution with heavier isotopes such as deuterium (i.e., H) may afford
certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo
half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
Isotopically labeled compounds of the invention can generally be prepared by following
procedures analogous to those disclosed in the examples herein by substituting an isotopically
labeled reagent for a non-isotopically labeled reagent.
The term "prodrug" refers to compounds that are transformed in vivo to yield a
disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound.
The transformation may occur by various mechanisms (such as by esterase, amidase,
phosphatase, oxidative and or reductive metabolism) in various locations (such as in the
intestinal lumen or upon transit of the intestine, blood or liver). Prodrugs are well known in the
art (for example, see Rautio, Kumpulainen, et al, Nature Reviews Drug Discovery 2008, 7,
255). For example, if a compound of the invention or a pharmaceutically acceptable salt,
hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can
comprise an ester formed by the replacement of the hydrogen atom of the acid group with a
group such as (Ci.g)alkyl, )alkylcarbonyloxymethyl, l-(alkylcarbonyloxy)ethyl having
(C2-i2
from 4 to 9 carbon atoms, l-methyl-l-(alkylcarbonyloxy)-ethyl having from 5 to 10 carbon
atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-
(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-l-
(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl
having from 3 to 9 carbon atoms, l-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10
carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolactonyl, di-N,N-(Ci_
(such as b -dimethylaminoethyl), carbamoyl-(Ci_2)alkyl, N,N-di(Ci.
2)alkylamino(C2-3)alkyl
and piperidino-, pyrrolidine- or morpholino(C2-3)alkyl.
2)alkylcarbamoyl-(Ci_2)alkyl
Similarly, if a compound of the invention contains an alcohol functional group, a
prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a
group such as (Ci_ )alkylcarbonyloxymethyl, l-((Ci_6)alkylcarbonyloxy)ethyl, l-methyl-l-((Ci_
)alkylcarbonyloxy)ethyl (Ci_6)alkoxycarbonyloxymethyl, N-(Ci_
)alkoxycarbonylaminomethyl, succinoyl, (Ci_ )alkylcarbonyl, <x-amino(Ci_4)alkylcarbonyl,
arylalkylcarbonyl and a-aminoalkylcarbonyl, or a-aminoalkylcarbonyl-a-aminoalkylcarbonyl,
where each a-aminoalkylcarbonyl group is independently selected from the naturally occurring
L-amino acids, P(0)(OH)2, -P(0)(0(Ci_6)alkyl)2 or glycosyl (the radical resulting from the
removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
If a compound of the invention incorporates an amine functional group, a
prodrug can be formed, for example, by creation of an amide or carbamate, an N-
alkylcarbonyloxyalkyl derivative, an (oxodioxolenyl)methyl derivative, an N-Mannich base,
imine or enamine. In addition, a secondary amine can be metabolically cleaved to generate a
bioactive primary amine, or a tertiary amine can metabolically cleaved to generate a bioactive
primary or secondary amine. For examples, see Simplicio, et at, Molecules 2008, 13, 5 19 and
references therein.
I. Tricyclic Compounds
In certain embodiments, the present invention provides compounds of Formula I
or Formula II:
Formula II
wherein
B may be a 3-6 membered saturated or partially unsaturated heterocyclic or carbocyclic
ring;
B may be a 3-6 membered saturated heterocyclic or carbocyclic ring;
wherein the ring B or B may optionally be substituted by one or more fluorine atoms
on any of the available carbon atoms
D may be a 5-7 membered heterocyclic, carbocyclic, heteroaromatic or aromatic ring;
D may be a 5-7 membered heterocyclic or carbocyclic ring;
1 1 1 1
wherein B is fused to D such that the two atoms shared by B and D are both carbon
2 2 2 2
and B is fused to D such that the two atoms shared by B and D are both carbon; and wherein
for Formula I the bond common to both the B and D rings may be a single or double bond;
1 + 1 2 + + 1 2
X may be selected from the group consisting of: -C(R R )-*, -W'-*, -C(R R )-
6 + 1 2 + 6 + + 1 4 +
C(R R )-*, -C(R )=C(R )-*, -W -C(R R )-*, -W -C(0)-*, -C(R R )-W -*, -
2 + 1 + 1 4 6 + 4
N=C(R )-*, -C(R )=N-*, -C(R R )-C(R R )-C(R R )-*, -W -C(R R )-
6 + 6 + 1 6 + 1
C(R R )-*, -W -C(0)-C(R R )-*, -C(R R )-W -C(R R )-*, -C(R R )-W -C(0)-
+ 1 4 4 + 1 4 +
*, -C(R R )-C(R R )-W -* and -C(R R )-C(0)-W -*; wherein the and * indicate the
attachment points of X as indicated in Formula I;
2 + 1 2 + + 1 2
X may be selected from the group consisting of: -C(R R )-*, -W'-*, -C(R R )-
6 + 6 + + 1 4 + 1 4
C(R R )-*, -W -C(R R )-*, -W -C(0)-*, -C(R R )-W -*, -C(R R )-C(R R )-
6 + 4 6 + 6 + 1 3
C(R R )-*, -W -C(R R )-C(R R )-*, -W -C(0)-C(R R )-*, -C(R R )-W -
6 + 1 + 1 4 4 + 1
C(R R )-*, -C(R R )-W -C(0)-*, -C(R R )-C(R R )-W -* and -C(R R )-C(0)-
4 + 2
W -*; wherein the and * indicate the attachment points of X as indicated in Formula II;
Y may be selected from the group consisting of: a bond, *-CH - , * , *-CH -CH - ,
*CH - , *-CH , *-CH -CH -CH - , *CH -CH - and *-CH CH - ;wherein the *
2 2 2 2 2 2 2 2 2
and *indicate the attachment points of Y as indicated in Formula I or Formula II;
1 N 1
W may be selected from the group consisting of O, S, or N(R );
2 N2
W may be selected from the group consisting of O or N(R );
3 N3
W may be selected from the group consisting of O or N(R );
4 N4
W may be selected from the group consisting of O or N(R );
A may be a ring selected from the group consisting of phenyl, a membered
1, 2 3 4-7
heteroaryl having or heteroatoms each selected from S, N or O, and a membered
1, 2 3
heterocycle having or heteroatoms each selected from N or O ;
B 1 B2
R and R are independently selected from the group consisting of H , F, OH, CN,
are optionally substituted by a group
Ci_2alkoxy,
selected from OH, CN or one or more fluorine atoms;
may be selected, independently for each occurrence, from the group consisting of
Ci_4alkyl
hydrogen, hydroxyl, cyano, halogen, or Cualkoxy; wherein C^alkyl, or C^alkoxy
may be optionally substituted by one or more fluorines;
1 2;
n may be or
may be selected from the group consisting of hydrogen, R'R N-, heterocyclyl,
heterocyclyloxy and heterocyclyl-(NR )-; wherein said heterocyclyl may optionally be
substituted by one or more substituents selected from R and wherein if said heterocyclyl
contains a -NH moiety that nitrogen may optionally be substituted by one or more groups R ;
Ci_6alkyl,
may be selected from the group consisting of: C2- alkenyl, C2-6alkynyl,
Ci_ -
C3_6cycloalkyl, alkoxy, C3_6alkenyloxy, C3_6alkynyloxy, C3_6cycloalkoxy, d-6alkyl-S(0)
a a a
0, 1 2), Ci. Ci. Ci.
(wherein w is or alkyl-N(R )-, alkyl-N(R )-carbonyl-, alkylcarbonyl-N(R )-,
a a a
Ci. Ci. )-S0 -, Ci.
alkyl-N(R )-carbonyl-N(R )-, alkyl-N(R alkyl-S0 -N(R )-, _
6 6 2 2
alkoxycarbonyl-N(R )-, d - alkylcarbonyl-N(R )-d-6alkyl-, d-6alkyl-N(R )-carbonyl-d-
Ci.6alkoxyCi. Ci. Ci
6alkyl-, alkyl-; wherein alkyl, C2-6alkenyl, C2-6alkynyl, d - cycloalkyl,
Ci. -, Ci.
6alkoxy, C3.6alkenyloxy, C3.6alkynyloxy, d - cycloalkoxy, alkyl-S(0) alkyl-N(R )-,
a a a
Ci. Ci. Ci. Ci
alkyl-N(R )-carbonyl-, alkylcarbonyl-N(R )-, alkyl-N(R )-carbonyl-N(R )-,
)-S0 -,
alkyl-N(R d . alkyl-S0 -N(R )-, d . alkoxycarbonyl-N(R )-, d _alkylcarbonyl-
6 2 2 6 6
)Ci. Ci. Ci.
N(R alkyl-, alkyl-N(R )-carbonyl-Ci. alkyl-, alkoxy-Ci. alkyl may optionally be
6 6 6
substituted by R , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR )-, heterocyclyl,
heterocyclyloxy or heterocyclyl-N(R )-; and wherein said heteroaryl or phenyl may optionally
be substituted with one or more substituents selected from R ; and wherein said heterocyclyl
may optionally be substituted by one or more substituents selected from R ; and wherein if said
heterocyclyl contains a -NH moiety that nitrogen may optionally be substituted by one or more
groups R ;
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl,
may optionally be substituted by one or more fluorine atoms or a group selected from cyano or
hydroxyl;
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl, cyano, Cualkyl or Cualkoxy; wherein the C alkyl and
alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from
cyano, hydroxyl or N(R R );
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl, cyano, and Ci_
may optionally be substituted by one or more fluorine atoms or a group selected from
2alkoxy
cyano, hydroxyl or N(R R );
R may be selected from the group consisting of hydrogen, halogen, C^alkyl or Ci_
wherein the may optionally be substituted by one or more
2alkoxy;
fluorine atoms;
R may be selected from the group consisting of hydrogen, halogen, hydroxyl, cyano,
wherein the and Cualkoxy may optionally be substituted by
one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R );
R may be selected from the group consisting of hydrogen or C^alkyl;
R may be selected from the group consisting of hydrogen or C^alkyl;
R may be selected from the group consisting of hydrogen, Ci alkyl or Ci_
wherein the Ci alkyl and C^alkylcarbonyl may optionally be substituted by
2alkylcarbonyl;
one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R );
R may be selected from the group consisting of hydrogen, Ci alkyl or Ci_
wherein the Ci alkyl and may optionally be substituted by
2alkylcarbonyl;
one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R );
R and R may be independently selected, for each occurrence, from the group
consisting of hydrogen and Cualkyl; wherein Ci alkyl may optionally be substituted by one or
more substituents selected from fluorine, cyano, oxo and hydroxyl;
or R and R , together with the nitrogen to which they are attached, may form a 4-6
membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or
N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more
substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl;
R may be independently selected, for each occurrence, from the group consisting of R ,
hydrogen, Ci-ealkyl, Ci_6alkoxy, Ci_6alkyl-S(0) -,
C3_6cycloalkyl, C2- alkenyl, C2- alkynyl,
6 6 w
(wherein wherein w is 0, 1 or 2), Ci_6alkylcarbonyl-N(R )- and Ci_ alkoxycarbonyl-N(R )-;
wherein Ci-ealkyl, Ci.6alkoxy, Ci. -, Ci.
C3. cycloalkyl, C2-6alkenyl, C2- alkynyl, alkyl-S(0)
6 6 6 w
)-, Ci_ alkoxycarbonyl-N(R )- may be optionally substituted by one or
6alkylcarbonyl-N(R
more substituents selected from R ;
R may be independently selected for each occurrence from the group consisting of R ,
hydrogen, oxo, Ci_ alkyl, Ci_ alkoxy, Ci_6alkyl-S(0) -,
C2-6alkenyl, C2- alkynyl, C3_6cycloalkyl,
(wherein w is 0, 1 or 2), Ci_ alkylcarbonyl-N(R )- and Ci_6alkoxycarbonyl-N(R )-; wherein Ci_
ealkyl, _cycloalkyl, Ci_6alkyl-S(0) -, Ci
C2- alkenyl, C2-6alkynyl, C 3
)-, Ci_ alkoxycarbonyl-N(R )- may be optionally substituted by one or
6alkylcarbonyl-N(R
more substituents selected from R ;
R may be independently selected for each occurrence from the group consisting of
hydrogen, Ci-ealkyl, Ci.6alkyl-S(0)2-, Ci.
C3_6alkenyl, C3_6alkynyl, C3_ cycloalkyl,
R'R N-carbonyl- and R'R N-S02-; wherein Ci-ealkyl,
6alkoxycarbonyl-, C3. alkenyl, C3_6alkynyl
and Ci_ alkyl-S(0)2-, may optionally be substituted by one or
C3_6cycloalkyl
more substituents selected from R ;
R and R may be selected independently for each occurrence from the group consisting
of hydrogen, _cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein Ci_4alkyl
and _cycloalkyl may be optionally substituted by one or more substituents selected from
fluorine, hydroxyl, cyano, R R N-, R R N-carbonyl- and Cualkoxy and wherein heterocyclyl
and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected
from Ci-ealkyl, Ci-ealkoxy, halo-Ci -alkyl, hydroxyl-
C2-6alkenyl, C2- alkynyl, C3_ cycloalkyl, .6
Ci -alkyl, R R N-Ci_ and Ci.6-alkoxy-Ci.6-alkyl group; and wherein if said heterocyclyl
.6 alkyl-
or heterocyclylcarbonyl contains a -NH moiety that nitrogen may optionally be substituted by
one or more groups Ci_ alkyl, Ci_ alkyl-S(0)2- and
C3_6alkenyl, C3_6alkynyl, C3_6cycloalkyl,
6-alkylcarbonyl;
or R and R taken together with the nitrogen to which they are attached may form a 4-7
membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or
N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one
or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, Ci_
alkyl, . alkoxy, R R N-, R R N-S0 - and R R N-carbonyl-; wherein said Ci. alkyl or d _
6 2 6
alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7
membered heterocyclic ring may be optionally substituted on nitrogen by one or more
substituents selected from the group consisting of Ci_ alkyl and R R N-carbonyl-; and wherein
said Ci_ alkyl may be optionally substituted by fluorine, hydroxyl, cyano;
R may be independently selected, for each occurrence, from the group consisting of
halogen, hydroxyl, cyano, Ci. alkoxy, R¾ N-, R'RN-carbonyl-, - and R¾ N-
R'^N-SOZ
carbonyl-N(R )-;
and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.
In some embodiments, X may be selected from the group consisting of: *,
+ N 1 + 1 6 + 1 2 + 6
-N(R )-*, -C(R R )-C(R R )-*, -C(R )=C(R )-*, C(R R )-*,
+ N 6 + + N + 2
-N(R )-C(R R )-*, C(0)-*, -N(R )-C(0)-*, -N=C(R )-* and
+ 4 6 + 1
C(R R )-C(R R )-*; wherein the and * indicate the attachment points of X as
indicated in Formula I. Exemplary X moities may be selected from the group consisting of: -
+ + + + +
NH-*, CH -*, -NH-CH -*, -N=CH-* and -CH=CH-*; wherein the and * indicate the
attachment points of X as indicated in Formula I.
In some embodiments X may be selected from the group consisting of *,
+ N 1 + 1 6 + 6 + N 6 +
-N(R )-*, -C(R R )-C(R R )-*, C(R R )-*, -N(R )-C(R R )-*, C(0)-*,
+ N + 4 6 +
-N(R )-C(0)-*, and C(R R )-C(R R )-*; wherein the and * indicate the attachment
points of X as indicated in Formula II. Exemplary X moities may be selected from the group
+ + +
consisting of: C¾-* and -NH-CI¾-*; wherein the and * indicate the attachment points
of X as indicated in Formula P .
1 2 1 N 1 N2
In one embodiment, R , R , R , R and R may be independently selected
for each occurrence from the group consisting of hydrogen and methyl. For example, R , R ,
1 N 1 N2
R , R and R may be hydrogen.
4 5 6
In certain embodiments, R , R , R and R may be independently selected
for each occurrence from the group consisting of hydrogen, fluorine, cyano and C^alkyl. For
4 5 6
example, R , R , R and R may be hydrogen.
In an embodiment, R may be selected from the group consisting of hydrogen,
halogen, cyano and C^alkyl. For example, R may be hydrogen.
In certain embodiments, R of the tricyclic compound of Formula II may be
selected from the group consisting of H, F or C^alkyl. For example, R may be H or methyl.
In another embodiment, R of the tricyclic compound of Formula P may be
hydrogen.
In certain embodiments, ring D may be selected from the group consisting of:
wherein the *, # and + indicate the points of attachment to the phenyl ring and the B ring as
indicated in Formula I. Exemplary D rings that may form part of the contemplated tricyclic
core may include those selected from the group consisting of:
In certain embodiments, ring D may be selected from the group consisting of:
wherein the *, # and + indicate the points of attachment to the phenyl ring and the B ring as
indicated in Formula P .
In some embodiments, Y may be selected from the group consisting of a bond,
* - and *- -0 - I ¾- ; wherein the * and # indicate the points of attachment to Y as
indicated in Formula I or Formula II. For example, Y may be a bond or * - ; wherein
the * and # indicate the points of attachment to Y as indicated in Formula I or Formula P .
For example, ring B or B may, in certain embodiments, be selected from the
group consisting of:
wherein the * and # indicate the points of attachment to Y as indicated in Formula I and II.
Exemplary B and B rings that may form part of the contemplated tricyclic core may include
Provided herein, for example, are tricyclic compounds represented by formulas
la lb, Ic, Id, Ie, If and lg:
In certain embodiments, A may be phenyl.
Also provided herein is a compound represented by Formula I P :
wherein:
B may be a 3-6 membered saturated or partially unsaturated heterocyclic or carbocyclic
ring; wherein the ring B may optionally be substituted by one or more fluorine atoms on any
of the available carbon atoms;
D may be a 5-7 membered heterocyclic, carbocyclic, heteroaromatic or aromatic ring;
1 1 1 1
wherein B is fused to D such that the two atoms shared by B and D are both carbon; and
wherein the bond common to both the B and D rings may be a single or double bond;
1 + 1 2 + + 1 2
X may be selected from the group consisting of: -C(R R )-*, -W'-*, -C(R R )-
6 + 1 2 + 6 + + 1 4 +
C(R R )-*, -C(R )=C(R )-*, -W -C(R R )-*, -W -C(0)-*, -C(R R )-W -*, -
2 + 1 + 1 4 6 + 4
N=C(R )-*, -C(R )=N-*, -C(R R )-C(R R )-C(R R )-*, -W -C(R R )-
6 + 6 + 1 6 + 1
C(R R )-*, -W -C(0)-C(R R )-*, -C(R R )-W -C(R R )-*, -C(R R )-W -C(0)-
+ 1 4 4 + 1 4 +
*, -C(R R )-C(R R )-W -* and -C(R R )-C(0)-W -*; wherein the and * indicate the
attachment points of X as indicated in Formula III;
Y may be selected from the group consisting of: a bond, *-CH - , * , *-CH -CH - ,
*CH - , *-CH , *-CH -CH -CH - , *CH -CH - and *-CH CH - ;wherein the *
2 2 2 2 2 2 2 2 2
and *indicate the attachment points of Y as indicated in Formula III;
1 N 1
W may be selected from the group consisting of O, S or N(R );
2 N2
W may be selected from the group consisting of O or N(R );
3 N3
W may be selected from the group consisting of O or N(R );
4 N4
W may be selected from the group consisting of O or N(R );
may be selected, independently for each occurrence, from the group consisting of
hydrogen, hydroxyl, cyano, halogen, Ci_ alkyl or Cualkoxy; wherein Ci_ alkyl, or Cualkoxy
may be optionally substituted by one or more fluorines;
n may be 0, 1, or 2;
may be selected from the group consisting of hydrogen, R'R N-, heterocyclyl,
heterocyclyloxy and heterocyclyl-(NR )-; wherein said heterocyclyl may optionally be
substituted by one or more substituents selected from R and wherein if said heterocyclyl
contains a -NH moiety that nitrogen may optionally be substituted by one or more groups R ;
may be selected from the group consisting of: Cusalkyl,
C2- alkenyl, C2-6alkynyl,
Ci_ alkoxy, d-6cycloalkoxy, d-6alkyl-S(0) -
C3_6cycloalkyl, C3_6alkenyloxy, C3.6alkynyloxy,
a a a
(wherein w is 0, 1 or 2), Ci. alkyl-N(R )-, . alkyl-N(R )-carbonyl-, Ci. alkylcarbonyl-N(R )-,
a a a
Ci. alkyl-N(R )-carbonyl-N(R )-, Ci. alkyl-N(R )-S0 -, Ci. alkyl-S0 -N(R )-, d _
6 6 2 2
alkoxycarbonyl-N(R )-, d - )-d-6alkyl-, d-6alkyl-N(R )-carbonyl-d-
alkylcarbonyl-N(R
ealkyl-, Ci.6alkoxyCi. wherein Ci. alkyl, d - Ci
alkyl-; C2-6alkenyl, C2-6alkynyl, cycloalkyl,
d - Ci. alkyl-S(0) -, Ci. alkyl-N(R )-,
6alkoxy, C3.6alkenyloxy, C3_6alkynyloxy, cycloalkoxy,
a a a
Ci. alkyl-N(R )-carbonyl-, Ci_ alkylcarbonyl-N(R )-, Ci. alkyl-N(R )-carbonyl-N(R )-, d -
alkyl-N(R )-S0 -, Ci. alkyl-S0 -N( )-, Ci. alkoxycarbonyl-N(R )-, d . alkylcarbonyl-
6 2 2 6
N(R )Ci. alkyl-, Ci. alkyl-N(R )-carbonyl-Ci. alkyl-, Ci. alkoxy-Ci. alkyl may optionally be
6 6 6
substituted by R , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR )-, heterocyclyl,
heterocyclyloxy or heterocyclyl-N(R )-; and wherein said heteroaryl or phenyl may optionally
be substituted with one or more substituents selected from R ; and wherein said heterocyclyl
may optionally be substituted by one or more substituents selected from R ;and wherein if said
heterocyclyl contains a -NH moiety that nitrogen may optionally be substituted by one or more
groups R ;
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl, wherein the
may optionally be substituted by one or more fluorine atoms or a group selected from cyano or
hydroxyl;
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl, cyano, Cualkyl or Cualkoxy; wherein the d alkyl and d
alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from
cyano, hydroxyl or N(R R );
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl, cyano, wherein the and d -
alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from
cyano, hydroxyl or N(R R );
R Ci_
may be selected from the group consisting of hydrogen, halogen, C^alkyl or
2alkoxy; wherein the may optionally be substituted by one or more
fluorine atoms;
may be selected from the group consisting of hydrogen, halogen, hydroxyl, cyano,
and Cualkoxy may optionally be substituted by
N(R R );
one or more fluorine atoms or a group selected from cyano, hydroxyl or
may be selected from the group consisting of hydrogen or C^alkyl;
may be selected from the group consisting of hydrogen or C^alkyl;
R Ci_
may be selected from the group consisting of hydrogen, Cijalkyl or
2alkylcarbonyl; wherein the Cijalkyl and C^alkylcarbonyl may optionally be substituted by
N(R R );
one or more fluorine atoms or a group selected from cyano, hydroxyl or
R Ci_
may be selected from the group consisting of hydrogen, Cijalkyl or
2alkylcarbonyl; wherein the Cualkyl and Cualkylcarbonyl may optionally be substituted by
N(R R );
one or more fluorine atoms or a group selected from cyano, hydroxyl or
and may be independently selected, for each occurrence, from the group
consisting of hydrogen and Cualkyl; wherein Cualkyl may optionally be substituted by one or
more substituents selected from fluorine, cyano, oxo and hydroxyl;
R R , 4-6
or and together with the nitrogen to which they are attached, may form a
membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or
N ; wherein the membered heterocyclic ring may optionally be substituted by one or more
substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl;
R R ,
may be independently selected, for each occurrence, from the group consisting of
Ci_ Ci_6alkyl-S(0) -,
hydrogen, alkyl, C3_6cycloalkyl, C2- alkenyl, C2- alkynyl,
0, 1 2), Ci_6alkylcarbonyl-N(R )- Ci_ )-;
(wherein wherein w is or and alkoxycarbonyl-N(R
Ci_6alkoxy, Ci_ -, Ci_
wherein Cusalkyl, C3_ cycloalkyl, C2-6alkenyl, C2- alkynyl, alkyl-S(0)
6 6 6 w
)-, Ci_ )-
6alkylcarbonyl-N(R alkoxycarbonyl-N(R may be optionally substituted by one or
more substituents selected from
R R ,
may be independently selected for each occurrence from the group consisting of
Ci_ Ci_ Ci_6alkyl-S(0) -,
hydrogen, oxo, alkyl, C2-6alkenyl, C2- alkynyl, C3_6cycloalkyl, alkoxy,
0, 1 2), Ci_ )- Ci_6alkoxycarbonyl-N(R )-; Ci_
(wherein w is or alkylcarbonyl-N(R and wherein
Ci_6alkyl-S(0) -, Ci
ealkyl, C2- alkenyl, C2-6alkynyl, C3_ cycloalkyl,
6alkylcarbonyl-N(R )-, alkoxycarbonyl-N(R )- may be optionally substituted by one or
more substituents selected from R ;
R may be independently selected for each occurrence from the group consisting of
Ci.6alkyl-S(0)2-, Ci.
hydrogen, d - alkyl, C3_6alkenyl, C3_6alkynyl, C3_ cycloalkyl,
6alkoxycarbonyl-, R'R N-carbonyl- and R'R N-S02-; wherein alkyl, d - alkenyl, C3.6alkynyl
Ci_ Ci.6alkylcarbonyl-
C3.6cycloalkyl and alkyl-S(0)2-, may optionally be substituted by one or
more substituents selected from R ;
R and R may be selected independently for each occurrence from the group consisting
Ci_4alkyl
of hydrogen, d - cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein
and d - cycloalkyl may be optionally substituted by one or more substituents selected from
fluorine, hydroxyl, cyano, R R N-, R R N-carbonyl- and C^alkoxy and wherein heterocyclyl
and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected
from alkyl, C2-6alkenyl, C2- alkynyl, d - cycloalkyl, C^alkoxy, halo-d- -alkyl, hydroxyl-
Ci.6-alkyl, Ci.6-alkoxy-Ci.6-alkyl
R R N-Ci. alkyl- and group; and wherein if said heterocyclyl
or heterocyclylcarbonyl contains a -NH moiety that nitrogen may optionally be substituted by
Ci. Ci.
one or more groups d - alkyl, C3_6alkenyl, C3_6alkynyl, C3_6cycloalkyl, alkyl-S(0)2- and
6-alkylcarbonyl;
or R and R taken together with the nitrogen to which they are attached may form a 4-7
membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or
N ; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one
or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano,
alkyl, . alkoxy, R R N-, R R N-S0 - and R R N-carbonyl-; wherein said d _ alkyl or d -
6 2 6
6alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7
membered heterocyclic ring may be optionally substituted on nitrogen by one or more
substituents selected from the group consisting of d_6alkyl and R R N-carbonyl-; and wherein
said d_6alkyl may be optionally substituted by fluorine, hydroxyl, cyano;
R may be independently selected, for each occurrence, from the group consisting of
halogen, hydroxyl, cyano, d _ alkoxy, R¾ N-, R'RN-carbonyl-, R'^N-SOZ- and R¾ N-
carbonyl-N(R )-;
and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.
In certain embodiments, R of the tricyclic compound of Formula III may be
selected from the group consisting of hydrogen, halogen, wherein d -
2alkyl may optionally be substituted by one or more fluorines. For example, may be
hydrogen or fluorine.
In another embodiment, of the tricyclic compound of Formula III may be
R'R N, Ci-ealkyl,
selected from the group consisting of hydrogen, heterocyclyl, C3_ alkenyl, C3.
6cycloalkyl, C^alkoxy; wherein said heterocyclyl may optionally be substituted by one or
more groups and wherein if said heterocyclyl contains a -NH moiety, that nitrogen may
optionally be substituted by on or more groups and wherein said C^alkyl, C3_ alkenyl, C3.
Ci_ R .
6cycloalkyl and alkoxy may optionally be substituted by one or more groups For
R 3-(N,N-diethylamino)propyl, 3-
example, may be selected from the group consisting of
1-enyl, 1-enyl
(pyrrolidin- l-yl)propyl, (Z)(N,N-diethylamino)prop- (Z)(azetidin- l-yl)prop-
1-enyl.
and (Z)(pyrrolidin- l-yl)prop-
Also provided herein is a compound represented by Formula IV:
D 5-7
may be a membered partially unsaturated heterocyclic or carbocyclic ring;
2 + 1 2 +
X -C(R R )-*, -W'-*,
may be selected from the group consisting of:
+ 1 6 + 6 + + 1 4 + 1 2
-C(R R )-C(R R )-*, -W -C(R R )-*, -W -C(0)-*, -C(R R )-W -*, -C(R R )-
4 6 + 4 6 + 6 +
C(R R )-C(R R )-*, -W -C(R R )-C(R R )-*, -W -C(0)-C(R R )-*, -
1 6 + 1 + 1 4 4 +
C(R R )-W -C(R R )-*, -C(R R )-W -C(0)-*, -C(R R )-C(R R )-W -*
and -
1 4 + 2
C(R R )-C(0)-W -*; X
wherein the and * indicate the attachment points of as indicated in
Formula IV;
1 N 1
W O, S N(R );
may be selected from the group consisting of or
2 N2
W O N(R );
may be selected from the group consisting of or
3 N3
W O N(R );
may be selected from the group consisting of or
4 N4
W O N(R );
may be selected from the group consisting of or
R H, OH, CN, Ci_2alkoxy Ci_
may be selected from the group consisting of F, or
3alkyl; wherein are optionally substituted by a group selected from
OH, CN
or one or more fluorine atoms;
R may be selected, independently for each occurrence, from the group consisting of
hydrogen, hydroxyl, cyano, halogen, Ci_4alkyl or Cualkoxy; wherein C^alkyl, or C^alkoxy
may be optionally substituted by one or more fluorines;
n may be 0, 1, or 2;
R may be selected from the group consisting of hydrogen, R'R N-, heterocyclyl,
heterocyclyloxy and heterocyclyl-(NR )-; wherein said heterocyclyl may optionally be
substituted by one or more substituents selected from R and wherein if said heterocyclyl
contains a -NH moiety that nitrogen may optionally be substituted by one or more groups R ;
R may be selected from the group consisting of:
C2- alkenyl, C2-6alkynyl,
Ci_ alkoxy, Ci_6alkyl-S(0) -
C3_6cycloalkyl, C3_6alkenyloxy, C3_6alkynyloxy, C3_6cycloalkoxy,
a a a
(wherein w is 0, 1 or 2), Ci. alkyl-N(R )-, Ci. alkyl-N(R )-carbonyl-, Ci. alkylcarbonyl-N(R )-,
a a a
Ci. alkyl-N(R )-carbonyl-N(R )-, Ci. alkyl-N(R )-S0 -, Ci. alkyl-S0 -N(R )-, Ci
6 6 2 2
alkoxycarbonyl-N(R )-, Ci. alkylcarbonyl-N(R )-Ci. alkyl-, Ci. alkyl-N(R )-carbonyl-Ci.
6 6 6
Ci.6alkoxyCi. wherein Ci-ealkyl, Ci.
6alkyl-, alkyl-; C2-6alkenyl, C2-6alkynyl, C3. cycloalkyl,
Ci. -, Ci. )-,
6alkoxy, C3_6alkenyloxy, C3.6alkynyloxy, C3. cycloalkoxy, alkyl-S(0) alkyl-N(R
6 6 w 6
a a a
Ci. alkyl-N(R )-carbonyl-, Ci. alkylcarbonyl-N(R )-, Ci. alkyl-N(R )-carbonyl-N(R )-, Ci.
alkyl-N(R )-S0 -, Ci_ alkyl-S0 -N( )-, Ci. alkoxycarbonyl-N(R )-, . alkylcarbonyl-
6 2 2 6
N(R )Ci. alkyl-, Ci. alkyl-N(R )-carbonyl-Ci. alkyl-, Ci. alkoxy-Ci. alkyl may optionally be
6 6 6
substituted by R , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR )-, heterocyclyl,
heterocyclyloxy or heterocyclyl-N(R )-; and wherein said heteroaryl or phenyl may optionally
be substituted with one or more substituents selected from R ; and wherein said heterocyclyl
may optionally be substituted by one or more substituents selected from R ;and wherein if said
heterocyclyl contains a -NH moiety that nitrogen may optionally be substituted by one or more
groups R ;
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl, Ci_ alkyl or Ci_ alkoxy; wherein the Ci_ alkyl and Ci_ alkoxy
2 2 2 2
may optionally be substituted by one or more fluorine atoms or a group selected from cyano or
hydroxyl;
R and R may be each independently selected from the group consisting of
hydrogen, fluorine, hydroxyl, cyano, Cualkyl or Cualkoxy; wherein the C alkyl and C
alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from
N(R R );
cyano, hydroxyl or
and may be each independently selected from the group consisting of
Ci_2alkyl Ci_2alkyl Ci_
hydrogen, fluorine, hydroxyl, cyano, or wherein the and
2alkoxy may optionally be substituted by a substituent or substituents selected from the group
N(R R );
consisting of: one or more fluorine atoms,cyano, hydroxyl or
R Ci_
may be selected from the group consisting of hydrogen, halogen, C^alkyl or
2alkoxy; wherein the may optionally be substituted by one or more
fluorine atoms;
may be selected from the group consisting of hydrogen, halogen, hydroxyl, cyano,
wherein the Cualkyl and Cualkoxy may optionally be substituted by
N(R R );
one or more fluorine atoms or a group selected from cyano, hydroxyl or
may be selected from the group consisting of hydrogen or C^alkyl;
R Ci_2alkyl;
may be selected from the group consisting of hydrogen or
R Ci_
may be selected from the group consisting of hydrogen, Cijalkyl or
Ci_2alkylcarbonyl
2alkylcarbonyl; wherein the Cualkyl and may optionally be substituted by a
substituent or substituents selected from the group consisting of: one or more fluorines, cyano,
N(R R );
hydroxyl or
R Ci_
may be selected from the group consisting of hydrogen, Cualkyl or
2alkylcarbonyl; wherein the Cualkyl and C^alkylcarbonyl may optionally be substituted by a
substituent or substituents selected from the group consisting of: one or more fluorines, cyano,
N(R R );
hydroxyl or
and may be independently selected, for each occurrence, from the group
consisting of hydrogen and Cualkyl; wherein Cualkyl may optionally be substituted by one or
more substituents selected from fluorine, cyano, oxo and hydroxyl;
R R , 4-6
or and together with the nitrogen to which they are attached, may form a
membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or
N ; wherein the membered heterocyclic ring may optionally be substituted by one or more
substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl;
R R ,
may be independently selected, for each occurrence, from the group consisting of
Ci_ Ci_6alkyl-S(0) -,
hydrogen, alkyl, C3_6cycloalkyl, C2- alkenyl, C2- alkynyl,
(wherein wherein w is 0, 1 or 2), Ci_6alkylcarbonyl-N(R )- and Ci_ alkoxycarbonyl-N(R )-;
wherein Ci_ alkyl, _cycloalkyl, C C Ci_ alkyl-S(0) -,
C 3 -6alkenyl, - alkynyl,
2 2 w
)-, Ci. )- may be optionally substituted by one or
6alkylcarbonyl-N(R alkoxycarbonyl-N(R
more substituents selected from R ;
R may be independently selected for each occurrence from the group consisting of R ,
hydrogen, oxo, Ci_ C C Ci. Ci.6alkyl-S(0) -,
alkyl, -6alkenyl, - alkynyl, C 3_6cycloalkyl, alkoxy,
6 6 6
2 2 w
(wherein w is 0, 1 or 2), Ci_ alkylcarbonyl-N(R )- and Ci_6alkoxycarbonyl-N(R )-; wherein Ci_
C C _cycloalkyl, Ci_6alkyl-S(0) -, Ci
6alkyl, - alkenyl, -6alkynyl, C 3
2 2 w
)-, Ci_ alkoxycarbonyl-N(R )- may be optionally substituted by one or
6alkylcarbonyl-N(R
more substituents selected from R ;
R may be independently selected for each occurrence from the group consisting of
hydrogen, Ci_ alkyl, _cycloalkyl, Ci_6alkyl-S(0) -, Ci
C 3_6alkenyl, C 3_6alkynyl, C 3
R'R N-carbonyl- and R'R N-S0 -; wherein Ci_ alkyl, _alkenyl,
6alkoxycarbonyl-, C 3 C 3.6alkynyl
and Ci. -, Ci_6alkylcarbonyl- may optionally be substituted by one or
C 3.6cycloalkyl alkyl-S(0)
more substituents selected from R ;
R and R may be selected independently for each occurrence from the group consisting
of hydrogen, heterocyclyl and heterocyclylcarbonyl; wherein Ci_4alkyl
C 3_ cycloalkyl,
and _cycloalkyl may be optionally substituted by one or more substituents selected from
fluorine, hydroxyl, cyano, R R N-, R R N-carbonyl- and C^alkoxy and wherein heterocyclyl
and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected
from Ci_ alkyl, C C _cycloalkyl, C^alkoxy, halo-Ci_ -alkyl, hydroxyl-
-6alkenyl, - alkynyl, C 3
Ci_6-alkyl, R R N-Ci_ alkyl- and Ci.6-alkoxy-Ci.6-alkyl group; and wherein if said heterocyclyl
or heterocyclylcarbonyl contains a -NH moiety that nitrogen may optionally be substituted by
one or more groups Ci-ealkyl, Ci. and Ci.
C 3_6alkenyl, C 3_6alkynyl, C 3_6cycloalkyl, alkyl-S(0)2-
6-alkylcarbonyl;
or R and R taken together with the nitrogen to which they are attached may form a 4-7
membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or
N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one
or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, Ci_
alkyl, Ci_ alkoxy, R R N-, R R N-S0 - and R R N-carbonyl-; wherein said _alkyl or Ci
6 2 6
may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7
6alkoxy
membered heterocyclic ring may be optionally substituted on nitrogen by one or more
substituents selected from the group consisting of Ci_ alkyl and R R N-carbonyl-; and wherein
said C^alkyl may be optionally substituted by one or more substituents selected from the
group consisting of fluorine, hydroxyl, cyano;
R may be independently selected, for each occurrence, from the group consisting of
halogen, hydroxyl, cyano, Ci_ alkoxy, R¾ N-, R'RN-carbonyl-, - and R¾ N-
R'^N-SOZ
carbonyl-N(R )-;
and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.
In certain embodiments, R of the tricyclic compound of Formula IV may be
hydrogen or fluorine.
In another embodiment, R of the tricyclic compound of Formula IV may be
selected from the group consisting of hydrogen, R'R N, heterocyclyl, C^alkyl, _alkenyl,
C3 C3.
cycloalkyl, C^alkoxy, heterocyclyl-NR -carbonyl-Ci_ alkyl and heterocyclyl-carbonyl-NR -
Ci_ealkyl; wherein said heterocyclyl may optionally be substituted by one or more groups R ;
and wherein if said heterocyclyl contains a -NH moiety, that nitrogen may optionally be
substituted by on or more groups R ; and wherein said Ci-ealkyl, _alkenyl, _cycloalkyl
C3 C3
and Ci-ealkoxy may optionally be substituted by one or more groups R .
Also provided herein are compounds that may be selected from the group
consisting of: cis-(3aRS,9bRS)(benzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenecarboxylic acid; cis-(3aRS,9bRS)[2-(3-diethylaminopropyl)
fluorobenzenesulfonyl-amino]- 1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic
acid; cis-(3aRS,9bRS)[2-(3-{pyrrolidin-l-yl}propyl)fluorobenzenesulfonylamino]-
l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid; cis-(3aRS,9bRS)[2-((Z)
diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenecarboxylic acid; cis-(3aR,9bR)[2-((Z)diethylaminoprop- l-enyl)fluoro-
benzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid; cis-
(3aS,9bS)[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-l,3a,4,9b-
tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid; 7-[2-((Z)diethylaminoprop- 1-enyl)-
4-fluorobenzenesulfonylamino]- 1,2-dihydrofuro[2,3-c]quinolinecarboxylic acid formate
salt; 7-(benzenesulfonylamino))-l,2-dihydrofuro[2,3-c]quinolinecarboxylic acid formate
salt; cis-(3aRS,9bRS)[2-((Z)diethylaminoprop- l-enyl)fluorobenzenesulfonylamino]-
l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinolinecarboxylic acid; (laRS,7bSR)[2-((Z)
diethylaminoprop- 1-enyl)fluorobenzenesulfonylamino] -1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laR,7bS)[2-((Z)diethylaminoprop-
l-enyl)fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid; (laS,7bR)[2-((Z)diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecaiboxylic acid;
(laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-7b-
methyl-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-((E)-
3-diethylaminoprop- 1-enyl)fluorobenzenesulfonylamino]-7b-methyl- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; cis-(3aRS,9bRS)[2-(4-dimethylamino-
butylamino)-benzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene
carboxylic acid; (laR,7bS)[2-(3-diethylaminopropyl)fluorobenzenesulfonyl-amino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-((Z)
diethylaminoprop- l-enyl)fluorobenzene-sulfonylamino]- 1, 1-difluoro- 1, la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laR,7bS)[2-((Z)diethylaminoprop-
l-enyl)fluorobenzene-sulfonylamino]- 1, 1-difluoro- 1, la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laS,7bR)[2-((Z)diethylaminoprop-
l-enyl)fluorobenzene-sulfonylamino]- 1, 1-difluoro- 1, la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2((Z)ethylaminoprop-
1-enyl)fluoro-benzenesulfonylamino]- 1,1a,2,7b-tetrahydrocyclopropa- [c]chromene
carboxylic acid; (laR,7bS)[2((Z)ethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid;
(laS JbR)[2((Z)ethylaminoprop-l-enyl)fluorobenzene-sulfonylamino]-l,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2[(Z)(pyrrolidin-l-
yl)prop-l-enyl]fluorobenzenesulfonylamino}-l,la,2,7b-tetrahydro-cyclopropa[c]chromene-
4-carboxylic acid; (laR,7bS){2[(Z)(pyrrolidin-l-yl)prop-l-enyl]
fluorobenzenesulfonyl-amino }-1,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid;
(laS,7bR) {2[(Z)(pyrrolidin- l-yl)prop- l-enyl]fluorobenzenesulfonylamino }-1,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-(3-
dimethylaminopropylamino)-benzenesulfonylamino] -1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laR,7bS)[2-(3-
dimethylaminopropylamino)benzene-sulfonylamino] -1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laS,7bR)[2-(3-dimethylaminopropyl-
amino)benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid;
(laRS,7bSR)[2-(4-dimethylaminobutylamino)benzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laR,7bS)[2-(4-dimethylamino-
butylamino)benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic
acid; (laS,7bR)[2-(4-dimethylaminobutylamino)benzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-(5-dimethylamino-
pentylamino)benzene-sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid; (laRS,7bSR){2[(Z)(propanyl)aminoprop-l-enyl]
fluorobenzenesulfonyl-amino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecaiboxylic acid;
(laRS,7bSR){2[(Z)((S)hydroxypyrrolidin-l-yl)aminoprop-l-enyl]
fluorobenzenesulfonylamino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid;
(laRS,7bSR){2[(Z)((R)hydroxypyrrolidin-l-yl)aminoprop-l-enyl]fluorobenzene-
sulfonylamino}-l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)-
-[2((Z)diethylaminobut- 1-enyl)fluorobenzenesulfonyl-amino]- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laR,7bS)[2((Z)diethylaminobut-l-
enyl)fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid; (laS,7bR)[2((Z)diethylaminobut-l-enyl)fluorobenzenesulfonyl-
amino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2-[2-
(4-ethylpiperazin- 1-yl)-ethyl]fluorobenzenesulfonylamino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2[(Z)(azetidin-l-
yl)prop-l-enyl]fluorobenzene-sulfonylamino}- l,la,2,7b-tetrahydro-cyclopropa[c]chromene-
4-carboxylic acid; (laRS,7bSR){2[(Z)(3-hydroxy-azetidin-l-yl)prop-l-enyl]
fluorobenzene-sulfonylamino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid;
(1aRS,7bSR) {2[(Z)(azetidin- 1-yl)propyl]fluorobenzenesulfonylamino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2((Z)
diethylaminobutyl)fluorobenzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2-[N-(4-
dimethylaminobutyl)-N-methylamino]-benzenesulfonyl-amino }-1,1a,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid; (laRS,7bSR){2-[((S)-l-
ethylpyrrolidinylcarbamoyl)-methyl]fluoro-benzenesulfonyl-amino}- l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid; (laRS,7bSR)[2-(l-ethylazetidinyl)-
4-fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic
acid; (laRS,7bSR) {2-[((R)-l-ethylpyrrolidinylcarbamoyl)methyl]
fluorobenzenesulfonyl-amino }-1,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid;
(laRS,7bSR) {2-[2-(pyrrolidin- l-yl)-ethyl]fluorobenzenesulfonylamino }-1,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-((R)-l-ethylpyrrolidin-
3-ylmethyl)fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromene
carboxylic acid; (laS,7bR)[2-((R)-l-ethylpyrrolidinylmethyl)fluorobenzenesulfonyl-
amino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (laR,7bS)[2-((R)-l-
ethylpyrrolidinylmethyl)fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2-[((S)-l-ethylpyrrolidin
yl)cabonyl-aminomethyl]fluorobenzene-sulfonylamino }-1,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-(4-
dimethylaminobutyrylamino)fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid; (laRS,7bSR)[2-((S)-l-ethyl-pyrrolidinylmethyl)
fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid;
(laRS,7bSR)[2-(3-dimethylaminopropylcarbamoyl)benzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)(2-{ [N-((S)-l-ethyl-
pyrrolidinyl)-N-methylcarbamoyl]methyl}fluoro-benzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid; (laRS,7bSR)(2-{ [N-((R)-l-ethyl-
pyrrolidinyl)-N-methylcarbamoyl]methyl}fluoro-benzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid; (laRS,7bSR){2-[2-((S)-l-
ethylpyrrolidinyl)ethylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid; (laRS,7bSR){2-[2-((R)-l-ethylpyrrolidinyl)ethylamino]-
benzenesulfonyl-amino}- l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid;
(laRS,7bSR)[2-(3-N,N,-diethylaminopropylamino)benzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)(2-{ [((R)-l-
ethylpyrrolidineyl)carbonyl-amino]methyl}fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2-[(l-ethylazetidin
ylmethyl)amino]benzene-sulfonylamino }-1,1a,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid; (laS,7bR)[2-((Z)diethylaminoprop-l-enyl)benzenesulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (laR,7bS)[2-((Z)
diethylaminoprop-l-enyl)benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene-
4-carboxylic acid; (laRS,7bSR)(2-{N-[((R)-l-ethylpyrrolidineyl)carbonyl]-N-methyl-
aminomethyl}fluorobenzenesulfonylamino)-l, la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid; (laRS,7bSR)(2-{N-[((S)-l-ethylpyrrolidineyl)carbonyl]-N-
methylamino-methyl }iluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-(4-
dimethylaminobutylamino)iluorobenzenesulfonyl-amino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2-[((R)-l-
ethylpyrrolidinylmethyl)amino]-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid; (laRS,7bSR){2-[((S)-l-ethylpyrrolidinylmethyl)amino]-
benzenesulfonylamino}- l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid;
(laRS,7bSR)[2-(4-ethyloxopiperazin-l-ylmethyl)fluorobenzene-sulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-(l-
ethylpiperidinylmethyl)fluoro-benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid; (laRS,7bSR){2-[2-(l-ethylazetidinyl)ethyl]fluoro-
benzenesulfonyl-amino}- l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid;
(laRS,7bSR){2-[((S)- l-azabicyclo[2.2.2]octyl)amino]benzenesulfonyl-amino}-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2-[((R)-l-azabicyclo-
[2.2.2]octyl)amino]benzenesulfonyl-amino}-l, la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid; (laRS,7bSR)(2-{ [((S)-l-ethylpyrrolidinecarbonyl)amino]methyl}
iluoro-benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid;
(laRS,7bSR){2-[2-((R)-l-ethylpyrrolidinylamino)ethyl]fluoro-
benzenesulfonylamino}- l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid;
(laRS JbSR){2-[((R)- l-ethylpyrrolidinyl)amino]-benzenesulfonylamino}-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid; (laRS,7bSR){2-[((S)-l-
ethylpyrrolidinyl)amino]-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid; (laRS,7bSR)(2-{ [((R)-l-ethylpyrrolidine
carbonyl)amino]-methyl}fluoro-benzenesulfonylamino)- 1,1a,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylic acid; (laRS,7bSR)[2-((Z)diethylamino
methylprop- l-enyl)fluorobenzene-sulfonylamino]- 1, la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid; (laRS,7bSR){2-[2-((R)-l-
ethylpyrrolidinyl)ethylamino]-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid; (laRS,7bSR){2-[2-((S)-l-ethylpyrrolidinyl)ethylamino]-
benzenesulfonyl-amino}- l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid;
(laRJbS)[2-((S)-l-ethylpyrrolidinyloxymethyl)fluoro-benzenesulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (laR,7bS)[2-((R)-l-
ethylpyrrolidinyloxymethyl)iluoro-benzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid; (laR,7bS) [2-(l-ethylpiperidin
ylmethyl)fluorobenzene-sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid; (1aR,7bS) {2-[2-((R)- 1-ethylpyrrolidinyl)ethyl]iluorobenzenesulfonyl-
amino }-l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; and pharmaceutically
acceptable salts, stereoisomers, esters and prodrugs thereof.
Procedures for making compounds described herein are provided below with
reference to Schemes 1-3. In the reactions described below, it may be necessary to protect
reactive functional groups (such as hydroxyl, amino, thio or carboxyl groups) to avoid their
unwanted participation in the reactions. The incorporation of such groups, and the methods
required to introduce and remove them are known to those skilled in the art (for example, see
Greene, Wuts, Protective Groups in Organic Synthesis. 2nd Ed. (1999)). The deprotection step
may be the final step in the synthesis such that the removal of protecting groups affords
compounds of Formula I, as disclosed herein, or as exemplified in, for example, General
Formula I, below. Starting materials used in the following schemes can be purchased or
prepared by methods described in the chemical literature, or by adaptations thereof, using
methods known by those skilled in the art. The order in which the steps are performed can vary
depending on the groups introduced and the reagents used, but would be apparent to those
skilled in the art.
The general synthetic strategy used to prepare the tricyclic compounds of
General Formula I is depicted in Scheme 1. The tricyclic system may be assembled in a variety
of ways, starting from an appropriately substituted and protected phenyl ring 1A. The group G'
is a suitably protected carboxylic acid, such as a methyl- or t-butyl carboxylate or is a
functional group that may be readily converted into a carboxylic acid, such as a nitrile or
aldehyde. The group G is a sulfonamide group, or a functional group that may be subsequently
converted into a sulfonamide group such as a suitably protected aniline. The B'-ring can be
directly attached to the substituted phenyl ring to give intermediate IB, and then the D'-ring
can be formed by an intra-molecular reaction to give intermediate IE. Alternatively, the B'-ring
can be attached to the substituted phenyl ring 1A via a linker, X', to give intermediate 1C, and
then the D'-ring can be formed by an intra-molecular reaction to give intermediate IE.
Alternatively, the D'-ring can be built up onto the substituted phenyl ring to give intermediate
ID, and then the B'-ring assembled to give intermediate IE. Modifications to the B' and D'
rings may be necessary to provide the required saturated or partially unsaturated ring systems
and this may be carried out prior to the formation of the tricyclic core or after it. For example,
if the B' ring is a dihydro- or tetrahydrofuran it may be prepared from a corresponding furan
compound by hydrogenation in the presence of a metal catalyst (for example palladium or
palladium hydroxide on a solid support such as carbon) in a solvent (such as ethyl acetate,
ethanol or dioxane) optionally in the presence of an acid (such as acetic acid). The
hydrogenation may be carried out at any stage during the synthesis of the compounds either
before or after the formation of the tricyclic core. Compounds of Formula I can be prepared
from intermediate IE by removal of any protecting groups. Alternatively, further modifications
may be made to IE, such as modifications at G, before the removal of any protecting groups to
give compounds of General Formula I. Specific steps in the synthetic process are described in
more detail below.
In Scheme 1, Step (i), compounds of structure 1A may be coupled under a range
of conditions to compounds of structure IB', where B' is an appropriate ring to afford
compounds of the type IB. The introduction of the B' ring may require a number of steps and
the preparation of a number of intermediates. Protecting groups may also be required. If R is a
suitable group (such as a halide or triflate), IB' can be converted to IB by formation of a
carbon-carbon bond. The carbon-carbon bond can be formed by reacting compounds of
structure IB' where R is a borane, boronate or boronic acid group (such as a 2-formylfuran
boronate) in the presence of a palladium catalyst (such as palladium chloride dppf or tris-
(dibenzylideneacetone)-dipalladium), in the presence of a base (such as cesium carbonate) and
a suitable reagent (such as a phosphine, for example, tri-ferf-butyl-phosphonium
tetrafluoroborate or triphenylphosphine) in an appropriate solvent (such as dioxane, water or
tetrahydrofuran, or mixtures thereof) and under appropriate conditions (such as heating, for
example heating at 80-120°C for 1-2 hours or microwave irradiation at 120-160°C for 10
minutes to 1 hour) to afford IB. A wide range of appropriate reagents and conditions are
known to those skilled in the art to couple organoboranes, boronates and boronic acids to
compounds such as 1A. [For example, see Miyaura, Suzuki, Chem. Rev. 1995, 95, 2457;
Suzuki, Modern Arene Chemistry 2002, 53-106].
Alternatively the carbon-carbon bond in Scheme 1, Step (i) can be formed by
coupling compounds of structure IB' in which B' is an appropriate ring and where R is a
trialkylstannane (such as a tri-n-butylstannane) with compounds of structure 1A where R is a
suitable group (such as a halide of triflate) in the presence of a palladium catalyst (such as
palladium chloride dppf), in an appropriate solvent (such as dimethoxyethane or
tetrahydrofuran) and under appropriate conditions (such as heating, at 80-120°C for 1-2 hours
or by microwave irradiation at 120-160°C for 10 minutes to 1 hour) to afford IB. A wide range
of appropriate reagents and conditions are known to those skilled in the art to couple stannanes
to aryl halides such as 1A. [For example, see Smith, March, March's Advanced Organic
Chemistry, 5 Edition, Wiley: New York, 2001, pp.931-932; De Souza, Current Organic
Synthesis 2006, 3(3), 313-326.].
Alternatively compounds of structure 1A, where R is a suitable group (such as a
halide or triflate), can be treated with, for example, a diboronate (such as bis-
pinacolatodiboron) in the presence of a palladium catalyst (such as palladium chloride dppf)
and a base (such as potassium acetate or diisopropylamine) in an appropriate solvent (such as a
mixture of dioxane and water) and under appropriate conditions (such as heating, for example
at 80-120°C for 1-2 hours or by microwave irradiation at 120-160°C for 10 minutes to 1 hour)
to give a compound of structure 1A, where R is a boronate. A wide range of appropriate
reagents and conditions are known to those skilled in the art to convert an aryl halide (or aryl
triflate) to an arylboronate (or an arylborane) [for example, see Marshall Chemtracts 2000,
13(4), 219-222]. The arylboronate (or arylborane) thus formed, can then be treated with
compounds of structure IB' (where R is a halogen or triflate) in the presence of suitable
reagents such as a phosphine (for example tri-tert-butyl-phosphonium tetrafluoroborate), a base
(such as cesium carbonate) and a catalyst (such as frw-(dibenzylideneacetone)-dipalladium) in
an appropriate solvent (such as a mixture of water and dioxane) under appropriate conditions
(such as heating at 80-120°C for 1-2 hours or by microwave irradiation at 120-160°C for 10
minutes to 1 hour) to afford compounds of structure IB.
In Scheme 1, Step (iv), the groups R and R of compound IB can be coupled
together to give the group X', which forms the D'-ring. R or R may have been masked by
protecting groups during Step (i), and may require deprotection before the group X' can be
formed. Alternatively, R or R may require chemical modification before the group X' can be
formed. For example if R or R is a nitro group, that group may be reduced, for example using
hydrogen in the presence of a suitable catalyst (such as palladium on a solid support, such as
carbon); or by treatment with an inorganic reducing agent (such as tin (II) chloride in DMF) to
give an amino group. For example, if R or R is a hydroxyalkyl group, that group may be
treated with an oxidising agent (such as Jones reagent or manganese dioxide) to give an
aldehyde; or with a different oxidising agent (such as potassium permanganate) to give a
carboxyhc acid. For example, if R or R is an aldehyde, that group may be treated with an
oxidising agent (such as potassium permanganate) to give a carboxyhc acid or with a reducing
agent (such as sodium borohydride) to give an alcohol. For example, if R or R is a ketone,
that group may be treated with a reducing agent (such as sodium borohydride) to give a
secondary alcohol. For example, if R or R is a carboxyhc acid or ester, that group may be
treated with a reducing agent (such as lithium aluminium hydride) to give an alcohol. For
example, if R or R is an alkene group, that group may be treated with a borane (such as 9-
borobicyclononane) and converted to a primary or secondary alcohol.
Formation of the linker X' may be carried out in a number of ways known to
those skilled in the art. For example, if one of the two groups R and R is a hydroxyl and the
other is a substituted alkylalcohol then IB can be treated with a dehydrating agent (such as
diisopropyl azodicarboxylate) in the presence of a phosphine, (such as triphenylphosphine) to
give IE, where X' is an ether. Alternatively, if one of the two groups R orR is a hydroxyl and
the other group is an alkyl group substituted with a leaving group (such as a halogen, tosylate
or triflate) IB can be treated with a base (such as diisopropylethylamine, potassium carbonate
or sodium hydride) to form IE, where X' is an ether.
Alternatively, if one of the groups R or R is a carboxyhc acid and the other
group is an alkyl halide or sulfonate, then IB can be treated with a base such as
diisopropylethylamine, potassium carbonate or sodium hydride to form IE, where X' is an
ester.
Alternatively, if one of the two groups R or R is a hydroxyl, or substituted
alkylalcohol and the other group is a carboxyhc acid or carboxyhc ester, then IB can be treated
with an acid (such as hydrochloric acid) or dehydrating agent (such as
dicyclohexylcarbodiimide or acetic anhydride) to form IE, where X' is an ester.
Alternatively, if one of the two groups R or R on IB is a hydroxyl or
substituted alkylalcohol and the other group is a carboxylic acid, then the carboxylic acid can
first be converted to a mixed anhydride (for example by treatment with 2,4,6-trichlorobenzoyl
chloride) or to an activated ester (for example by treatment with HATU in the presence of a
base such as diisopropylethylamine or pyridine), and the resulting mixed anhydride or activated
ester can be further treated with a base (such as diisopropylethylamine, pyridine or potassium
carbonate) to form IE, where X' is an ester.
Alternatively, if one of the groups R or R on IB is an amine or a substituted
alkylamine and the other group is a carboxylic acid, the carboxylic acid can be converted to an
activated ester (for example by treatment with HATU and a base such as diisopropylethylamine
or pyridine or TBTU in the presence of N-methylmorpholine), and the resulting activated ester
can be further treated with a base to form IE where X' is an amide.
Alternatively, if one of the two groups R or R on IB is an amine, or a
substituted alkylamine and the other group is a carboxylic acid, then IB can then be treated
with a dehydrating agent (such as such as diisopropylcarbodiimide) to form IE, where X' is an
amide.
Alternatively, if one of the two groups R or R is an amine, or substituted
alkylamine and the other group is an alkyl group substituted with a leaving group (such as a
halogen, tosylate or triflate) then IB can be treated with a base (such as diisopropylethylamine,
pyridine or potassium carbonate) to form IE, where X' is a substituted amine.
Alternatively, if one of the two groups R or R is an aldehyde, and the other
group is a phosphorane (such as an alkyl triphenylphosphorane) or an alkyl phosphonate (such
as an alkyl phosphonic acid diethyl ester) then IB can be treated with a base (such as
diisopropylethylamine, potassium carbonate or sodium hexamethyldisilazide) to form IE,
where X' is an alkene which may, or may not be further substituted.
Alternatively, if one of the two groups R or R is an amine and the other group
is an aldehyde then IB can be treated with an acid (such as p-toluenesulfoniic acid) or a Lewis
acid (such as tin tetrachloride) to give IE, where X' is -CR=N- or -N=CR-.
In Scheme 1, Step (ii), compounds of the structure 1A can be reacted with IC
to form the linker X' and give compounds of the structure IC. The formation of the linker X' in
compounds with the structure 1C may require a number of steps and the preparation of a
number of intermediates, and the use of protecting groups may also be required.
For example, if one of the two groups R or R is a hydroxyl group and the other
group is a substituted alkylalcohol then 1A and 1C can be treated with a dehydrating agent
(such as diisopropyl azodicarboxylate) in the presence of a phosphine, (such as
triphenylphosphine) to give 1C, where X' is an ether. Alternatively, if one of the two groups R
or R is a hydroxyl and the other group is an alkyl group substituted with a leaving group (such
as a halogen, or a mesylate) 1A and 1C can be treated with a base (such as
diisopropylethylamine, potassium carbonate or sodium hydride) to form 1C, where X' is an
ether.
Alternatively, in Scheme 1, Step (ii), if one of the two groups R or R is a
hydroxyl, or alkylalcohol and the other group is a carboxyhc acid, then the carboxyhc acid can
be converted to an acyl halide (for example by treatment with thionyl chloride or oxalyl
chloride), or to a mixed anhydride (for example by treatment with 2,4,6-trichlorobenzoyl
chloride in the presence of a base such as diisopropylethylamine) or to an activated ester (for
example by treatment with HATU in the presence of a base such as diisopropylethylamine or
pyridine, or treatment with diisopropylcarbodiimide in the presence of HOBT), then 1A and
1C can be combined to form 1C, where X' is an ester.
Alternatively, if one of the two groups R or R is an amine, or alkylamine and
the other group is a carboxyhc acid, then the carboxyhc acid can be converted to an acyl halide
(for example by treatment with thionyl chloride or oxalyl chloride), or to a mixed anhydride
(for example by treatment with 2,4,6-trichlorobenzoyl chloride in the presence of a base such as
diisopropylethylamine), or to an activated ester (for example by treatment with HATU in the
presence of disopropylethylamine or pyridine, or treatment with diisopropylcarbodiimide in the
presence of HOBT), then 1A and 1C can be combined to form 1C, where X' is an amide.
Alternatively, if one of the two groups R or R is an amine, or substituted
alkylamine and the other group is an alkyl group substituted with a leaving group (such as a
halogen, or a triflate) then 1A and 1C can be treated with a base (such as
diisopropylethylamine, pyridine or potassium carbonate) to form 1C, where X' is a substituted
amine.
Alternatively, if one of the two groups R or R is an aldehyde, and the other
group is a phosphorane (such as an alkyltriphenylphosphorane) or an alkylphosphonate (such as
an alkylphosphonic acid diethyl ester) then 1A and 1C can be treated with a base (such as
diisopropylethylamine or potassium carbonate or sodium hexamethyldisilazide) to form 1C,
where X' is an alkene which may, or may not be further substituted.
In Scheme 1, Step (v), compounds of structure IE may be prepared from
compounds of structure 1C by reaction of the groups R and R under a range of conditions to
form a carbon-carbon bond. If one of the groups R orR is a suitable group (such as a halide
or triflate), and the other group is a borane, boronate or boronic acid then, in the presence of a
palladium catalyst (such as palladium chloride dppf), and in the presence of a base (such as
cesium carbonate), in an appropriate solvent (such as dioxane, water or tetrahydrofuran or
mixtures thereof) and under appropriate conditions (such as heating, for example heating at 80-
120°C for 1-2 hours or microwave irradiation at 120-160°C for 10 minutes to 1 hour), 1C can
be converted into IE. A wide range of appropriate reagents and conditions are known to those
skilled in the art to couple organoboranes, boronates and boronic acids to give compounds of
the type IE.
Alternatively, if one of the groups R or R is a suitable group (such as a halide
or triflate), and the other group is a trialkylstannane, the carbon-carbon bond can be formed in
the presence of a palladium catalyst (such as palladium chloride dppf), in an appropriate
solvent (such as dimethoxyethane or tetrahydrofuran) and under appropriate conditions (such as
heating, at 80-120°C for 1-2 hours or by microwave irradiation at 120-160°C for 10 minutes to
1 hour) to afford IE. A wide range of appropriate reagents and conditions are known to those
skilled in the art to couple aryl or heteroaryl stannanes to aryl or heteroaryl halides.
In Scheme 1, Step (iii), compounds of structure 1A may be reacted under a
range of conditions with intermediates of the type ID' to give compounds of structure ID
where D' is a six- or seven-membered fused heterocyclic ring and R and R are suitable
functional groups that may be used to form the B'-ring. The groups R and R may be reacted
together to form a carbon-carbon bond, and the groups R and R may be reacted together to
form the group X'. Methods to form bicyclic compounds of structure ID from substituted
phenyl rings of structure 1A are well known to those skilled in the art (see Comprehensive
Heterocyclic Chemistry Ed.: Katritzky, Ramsden, Scriven, and Taylor, Elsevier, 2008).
For example, a compound of structure 1A, where R is a hydroxyl group and R
is hydrogen, can be treated with a suitably protected and substituted 3-halo-propanoic acid or
ester in an appropriate solvent (such as tetrahydrofuran or dimethylformamide) and in the
presence of a base (such as sodium carbonate or diisopropylethylamine) at a temperature
between room temperature and the reflux temperature of the solvent to give a compound of the
type 1A, where R is a substituted oxypropanoic acid or ester. This intermediate may be treated
with a suitable reagent (such as a strong acid, for example triflic acid) to give ID where R is
oxo, R is hydrogen and X' is -OCH -.
Alternatively, a compound of structure 1A, where R is a hydroxyl and R is
hydrogen, can be treated with a propargyl halide or tosylate in the presence of a base (such as
potassium carbonate or cesium carbonate) in a solvent (such as acetone) at a temperature
between room temperature and the reflux temperature of the solvent to give a compound of
type 1A in which R is a propargyloxyl group. This intermediate may be heated to ~200°C or
treated with an appropriate catalyst (such as a gold catalyst, for example triphenylphosphine
gold triflamide) in an appropriate solvent (such as toluene) at a temperature between 80°C and
the reflux temperature of the solvent to give a compound of structure ID wherein X' is -OCH -,
R and R are H and the bond between is a double bond (i.e. a chromene).
Further modification of the intermediates of structure ID having a double bond
between the carbons that R and R are attached to (such as a chromene) may be achieved, for
example, by treatment with a hydroborating agent (such as borane-THF complex) followed by
oxidation with, for example, hydrogen peroxide to give a mixture of compounds of structure
ID wherein X' is OCH , R is H and R is a hydroxyl group and wherein X' is -OCH -, R is a
hydroxyl and R is H which may be separated by chromatography.
Further modification of an intermediate of structure ID in which one of R and
R is H and the other is a hydroxyl may be carried out. For example, the intermediate may be
oxidized by treatment with an oxidizing agent (such as Dess Martin periodinane) to give a
compound of structure ID in which one ofR and R is H the other is oxo.
Alternatively, a compound of structure 1A in which R is an appropriate group
(such as a halogen, for example bromine or iodine, or a triflate) and R is a protected amine
(such as an acetamide or a trifluoroacetamide) may be coupled with a terminal alkyne in the
presence of a palladium catalyst (such as tetrakis(triphenylphosphine) palladium (0)) optionally
in the presence of an additional copper catalyst (such as copper (I) iodide) in the presence of a
base or salt (such as triethylamine or potassium acetate), in a solvent (such as tetrahydrofuran
or dimethylformamide) at a temperature between room temperature and the reflux temperature
of the solvent or by irradiation in the microwave at a temperature between 100°C and 160°C to
give a compound of structure 1A in which R is a substituted alkyne and R is a protected
amine (such as an acetamide or a trifluoroacetamide). Alternatively, a compound of structure
1A in which R is an appropriate group (such as a halogen, for example bromine or iodine, or a
triflate) and R is a protected amine (such as an acetamide or a trifluoroacetamide) may be
coupled with an acetylenic stannane in the presence of a palladium catalyst (such as palladium
chloride dppf) in an appropriate solvent (such as dioxane, dimethoxyethane or tetrahydrofuran)
at a temperature between room temperature and the reflux temperature of the solvent or
alternatively by irradiation in the microwave at a temperature between 100°C and 160°C to give
a compound of structure 1A in which R is an alkyne and R is a protected amine (such as an
acetamide or a trifluoroacetamide).
In Scheme 1, Step (iii), a compound of structure 1A in which R is an
appropriately substituted alkyne and R is a protected amine (such as an acetamide of a
trifluoroacetamide) may be treated with a base (such as potassium carbonate or sodium
methoxide) in an appropriate solvent (such as acetone, DMF or methanol) at a temperature
between room temperature and the reflux temperature of the solvent to give a compound of
structure ID in which X' is NH. Alternatively, a compound of structure 1A in which R is an
appropriately substituted alkyne and R is a protected amine (such as an acetamide of a
trifluoroacetamide) may be treated with a palladium catalyst (such as bis-
(triphenylphosphine)palladium chloride) in the presence of a base (such as triethylamine) and
an appropriate catalyst (such as copper(I) iodide) in a solvent (such as dimethylformamide) at a
temperature between room temperature and the reflux temperature of the solvent to give a
compound of structure ID in which X' is NH.
The general synthetic strategy to elaborate ID is shown in Scheme 2.
In Scheme 2, compounds of structure ID may be converted to a variety of
compounds of structure IE using reactions known to those skilled in the art. In some cases
modifications to the groups R and R in ID may be required in order to be able to generate
the require ring systems. One skilled in the art will recognize that it may be necessary for
various functional groups to be protected prior to reaction. Specific steps in the synthetic
procedures are described in more detail below.
In Scheme 2, Step (i), ID in which R and R are both H and the bond between
the carbon atoms is a double bond, may be treated with diethyl zinc and di-iodomethane
optionally in the presence of additional reagents (such as trifluoroacetic acid or zinc iodide) in a
solvent (such as 1,2-dichloroethane) at a temperature between -78°C and room temperature to
give compounds of structure 2A in which the B' ring is a cyclopropyl ring. Alternatively,
9 10
compounds of structure ID in which R and R are both H and the bond between the carbon
atoms is a double bond, may be treated with trimethyl sulfoxonium iodide or trimethyl
sulphonium iodide in the presence of a base (such as sodium hydride) in a solvent (such as
dimethyl sulfoxide) at a temperature between room temperature and 100°C. Alternatively,
9 10
compounds of structure ID in which R and R are both H and the bond between the carbon
atoms is a double bond, may be treated with diazomethane in the presence of a catalyst (such as
palladium acetate) in a solvent such as diethyl ether at a temperature between 0°C and room
temperature.
Alternatively, compounds of structure 2A may be prepared in a two step
9 10
procedure. For example, in Scheme 2, Step (ii), ID in which R and R are both H and the
bond between the carbon atoms is a double bond, may be treated with trimethylsilyl
diazomethane in the presence of a catalyst (such as palladium acetate) in a solvent (such as
diethyl ether) at a temperature between 0°C and room temperature to give the intermediate 2A'
in which J is H and J' is a trimethyl silyl group. In Scheme 2, Step (iii), intermediates 2A' in
which J is H and J' is a trimethyl silyl group may be converted to compounds of structure 2A
by treatment with a source of fluoride, (for example tetrabutyl ammonium fluoride) in a solvent
(such as tetrahydrofuran) at a temperature between 0°C and room temperature.
Alternatively in Scheme 2, Step (ii), ID in which R and R are both H and the
bond between the carbon atoms is a double bond, may be treated with a haloform (such as
chloroform or bromoform) in the presence of a base such as sodium hydroxide or potassium t-
butoxide in the presence of a catalyst (such as triethylbenzylammonium chloride or tetrabutyl
ammonium bromide) in a mixture of water and a halogenated solvent (such as dicloromethane
or dichloroethane) or alternatively in excess of the haloform at a temperature between room
temperature and 80°C to give the intermediate 2A' in which J and J' are both chlorine or
bromine. In Scheme 2, Step (iii), the intermediates 2A' in which J and J' are both chlorine or
bromine may be converted to compounds of structure 2A by treatment with a base (such as
sodium methoxide or sodium t-butoxide) in a solvent (such as tetrahydrofuran) at a temperature
between room temperature and the reflux temperature of the solvent. Alternatively, the
intermediates 2A' in which J and J' are both chlorine or bromine may be converted to
compounds of structure 2A by reduction; for example, by treatment with lithium aluminium
hydride in a solvent (such as tetrahydrofuran) at a temperature between 0°C and the reflux
temperature of the solvent or alternatively, for example by hydrogenation using a catalyst (such
as palladium on carbon) in a solvent (such as methanol or ethanol), optionally in the presence
of a base (such as triethylamine). Alternatively, the intermediates 2A' in which J and J' are
both chlorine or bromine may be converted to compounds of structure 2A under radical
conditions; for example, by treatment with a tin hydride (such as tributyl tin hydride) optionally
in the presence of a radical initiator (such as azo-£>w-isobutyronitrile) in a solvent (such as
toluene) at a temperature between room temperature and the reflux temperature of the solvent.
In Scheme 2, Step (iv), ID in which X' includes a carbonyl (for example where
X' is -O-C(O)-) and R and R are both H and the bond between the carbon atoms is a double
bond, may be converted to the corresponding compounds 2B by treatment with ethylene in a
solvent (such as dichloromethane) under photochemical conditions.
Alternatively compounds of structure 2B may be prepared in a multi-step
9 10
procedure. For example, in Scheme 2, Step (v), ID in which both R and R are both H and the
bond between the two carbon atoms is a double bond may be treated with an acrylate (such as
ethyl acrylate) in a solvent (such as acetonitrile) under photochemical conditions to give an
intermediate 2B' in which J" is an ester group (such as an ethyl ester). The ester may be
hydrolysed by, for example, treatment with sodium hydroxide or lithium hydroxide in a solvent
such as aqueous ethanol or aqueous dioxane at a temperature between room temperature and
the reflux temperature of the solvent to give an intermediate of structure 2B' in which J" is a
carboxylic acid. In Scheme 2, Step (vi), the acid may be removed for example by heating in, for
example, quinoline optionally in the presence of a catalyst (such as copper) to around 200°C.
In Scheme 2, Step (vii), ID in which R is a hydroxyl and R is a group CH OH
may be treated with a sulfonyl chloride (such as 4-toluenesulfonyl chloride or methanesulfonyl
chloride) in the presence of a base (such as triethylamine), optionally in the presence of 4-
dimethylaminopyridine, in a solvent (such as dichloromethane or toluene) at a temperature
between room temperature and the reflux temperature of the solvent. The product may be
treated with a base (such as triethylamine, diisopropylethylamine or sodium hydride) in an
appropriate solvent (such as dichloromethane, tetrahydrofuran or DMF) to give a compound of
structure 2C.
In Scheme 2, Step(viii), ID in which R is CH CH OH and R is C¾OH may
be converted to compounds 2D. One of the hydroxyl groups may need to be protected and the
other is treated with a sulfonyl chloride (such as 4-toluenesulfonyl chloride or methanesulfonyl
chloride) in the presence of a base (such as triethylamine) optionally in the presence of 4-
dimethylaminopyridine, in a solvent (such as dichloromethane or toluene) at a temperature
between room temperature and the reflux temperature of the solvent. After deprotection of the
remaining hydroxyl group, the intermediate may be treated with a base (such as triethylamine,
diisopropylethylamine or sodium hydride) in a solvent (such as dichloromethane,
tetrahydrofuran or dimethylformamide at a temperature between room temperature and the
reflux temperature of the solvent to give a compound of structure 2D.
Alternatively, compounds of structure 2D may be prepared in a 2 step
9 10
procedure. For example, in Scheme 2, Step (ix), ID in which R is (¾H and R is
CH OH may be converted to compounds of structure 2D'. The carboxylic acid may be
converted to an acid chloride (by treatment with, for example, thionyl chloride or oxalyl
chloride, optionally in the presence of a catalytic amount of DMF in a solvent such as
dichloromethane or toluene) or to a mixed anhydride (for example by treatment with 2,4,6-
trichlorobenzoyl chloride in the presence of a base such as diisopropylethylamine) or to an
activated ester (for example by treatment with HATU in the presence of a base such as
diisopropylethylamine or pyridine, or treatment with diisopropylcarbodiimide in the presence
of HOBT). The acid chloride, mixed anhydride or activated ester may then be treated with a
base (such as triethylamine or pyridine), in a solvent (such dichloromethane or toluene) to give
the compound of structure 2D'. In Scheme 2, Step (x), compounds of structure 2D' may be
converted to compounds of structure 2D by reduction, for example, by treatment with lithium
aluminium hydride, sodium diisobutylaluminium hydride or borane-dimethyl sulfide complex,
in an appropriate solvent (such as tetrahydrofuran) at a temperature between -78°C and room
temperature.
In Scheme 2, Step (xi), ID in which R is CH CH OH and R is a hydroxyl
may be treated with a sulfonyl chloride (such as 4-toluenesulfonyl chloride or methanesulfonyl
chloride) in the presence of a base (such as triethylamine), optionally in the presence of 4-
dimethylaminopyridine, in a solvent (such as dichloromethane or toluene) at a temperature
between room temperature and the reflux temperature of the solvent, followed by treatment
with a base (such as triethylamine, diisopropylethylamine or sodium hydride) in an appropriate
solvent (such as dichloromethane, tetrahydrofuran or DMF) at a temperature between room
temperature and the reflux temperature of the solvent to give a compound of structure 2E.
Alternatively, compounds of structure 2E may be prepared in a 2 step procedure.
In Scheme 2, Step (xii), ID in which R is H and R is oxo may be converted to compounds of
structure 2E' by treatment with chloroacetaldehyde or bromoacetaldehyde in the presence of an
aqueous base (such as sodium bicarbonate or sodium hydroxide in water) at a temperature
between 0°C and room temperature, followed by treatment with an acid (such as concentrated
sulfuric acid) in a mixture of water and an organic solvent (such as ethyl acetate).
In Scheme 2, Step (xiii), compounds of structure 2E may be prepared from
compounds of structure 2E' by hydrogenation in the presence of a metal catalyst (such as
palladium or palladium hydroxide on a solid support such as carbon) in a solvent (such as an
ether, for example tetrahydrofuran or dioxane, or an alcohol, such as methanol or ethanol),
optionally in the presence of an acid (such as acetic acid). Depending upon the nature of the
linker X', the bond between the two rings may be reduced or not to give either a
tetrahydrofuran or a dihydrofuran. For example, if X' is -N=C- then the B' ring in 2E will be a
dihydrofuran whereas if X' is then the B' ring will be a tetrahydrofuran.
In Scheme 1, Step (vii), compounds of general structure IE may be converted to
compounds of General Formula I by the conversion of the group G' to a carboxylic acid. If the
group G' is a carboxylic ester (such as a methyl, ferf-butyl or benzyl ester) then a variety of
reagents and conditions can be used to convert IE into a compound of the General Formula I.
For example, if G' is a methyl, ethyl or benzyl ester, it may be converted to a carboxylic acid
by treatment with an inorganic base (such as lithium hydroxide or sodium hydroxide) in a
solvent (such as methanol, dioxane or water, or mixtures thereof) at a temperature between
room temperature and the reflux temperature of the solvent, or alternatively by microwave
irradiation at 120-180°C for 10 minutes to 1hour. Alternatively if G' is a benzyl ester it may be
converted to a carboxylic acid by hydrogenation in the presence of a catalyst (such as
palladium on a solid support such as carbon) in a solvent (such as dioxane or ethyl acetate).
Alternatively if G' is a ferf-butyl ester, it may be converted to a carboxylic acid by treatment
with an acid (such as trifluoromethanesulfonic acid or hydrogen chloride) in a solvent (such as
dichloromethane or dioxane).
Alternatively, if the group G' is a nitrile, it may be converted into a carboxylic
acid by treatment with aqueous acid (such as a mineral acid, for example hydrochloric acid)
under appropriate conditions (such as heating, for example to reflux); or by treatment with
aqueous base (such as an aqueous hydroxide, for example aqueous sodium hydroxide) under
appropriate conditions (such as heating, for example to reflux).
Alternatively, if the group G' is an aldehyde (CHO) or a hydroxymethyl
(CH OH) moiety then it may be converted into a carboxylic acid by treatment with a suitable
oxidising reagent (such as potassium permanganate or chromic acid).
The general synthetic strategy to modify the group G is depicted in Scheme 3.
The G group may be introduced and/or modified either before, during or after the assembly of
the tricyclic ring system. Specific steps used to assemble sulfonamide are described in more
detail below.
SCHEME 3
3A 3B 3C
In Scheme 3, the asterisks denote either the presence of the groups R and R (as
shown in Scheme 1) or the presence of the D' and B' rings, or intermediates towards the
preparation of the rings (as shown in Schemes 1 and 2).
In Scheme 3, Step (i), compounds of structure 3A in which G is a nitro group
may be converted to compounds 3B by reduction, for example by catalytic hydrogenation in
the presence of a metal catalyst (such as palladium on a solid support such as carbon) in a
solvent (such as an ether, for example tetrahydrofuran, or an alcohol, for example methanol or
ethanol). Alternatively, compounds of structure 3A in which G is a nitro group may be
converted to compounds of structure 3B by chemical reduction. For example, the reduction
may be achieved using a metal or metal salt (such as iron, zinc or tin (II) chloride) in the
presence of an acid (such as hydrochloric acid or acetic acid).
In Scheme 3, Step (i), compounds of structure 3A in which G is a protected
amino group may be converted to compounds of structure 3B by removal of the protecting
groups. Protecting groups for amino groups are well known to those skilled in the art and
methods for their removal are equally well known [for example, see Greene, Wuts, Protective
Groups in Organic Synthesis. 2nd Ed. (1999)]. For example, compounds of structure 3A in
which F is an amino group protected with one or two Boc groups may be converted to
compounds of structure 3B by treatment with an acid (such as trifluoroacetic acid, formic acid
or hydrogen chloride) in a solvent (such as dichloromethane or dioxane).
Alternatively, in Scheme 3, Step (i), compounds of structure 3A in which G is a
pivaloyl protected aniline may be converted to compounds of structure 3B by treatment with an
acid (such as concentrated sulfuric acid) in a solvent (such as methanol) at a temperature
between room temperature and the reflux temperature of the solvent.
In Scheme 3, Step (ii), compounds of structure 3B may be converted to
compounds of structure 3C by treatment with an appropriate sulfonyl chloride (such as a
substituted or unsubstituted benzene sulfonyl chloride) or an activated sulfonate ester (such as a
pentafluorophenyl sulfonate ester) in the presence of a suitable base (such as pyridine,
diisopropylethylamine or cesium carbonate) in a suitable solvent (such as dichloromethane or
dimethylformamide) at a temperature between room temperature and the reflux temperature of
the solvent.
Intermediates towards the preparation of compounds of Formula 1 or, for
example, General Formula 1 may require reduction of an aromatic ring system to give the
saturated ring system required in the compounds of Formula 1. This hydrogenation may be
carried out by hydrogenation of the intermediates in the presence of a metal catalyst (for
example palladium or palladium hydroxide on a solid support, such as carbon) in a solvent
(such as ethanol, ethyl acetate or dioxane) optionally in the presence of an acid (such as acetic
acid). The reduction of the aromatic rings may be carried out before the formation of the
tricyclic ring system or after it or at any stage during the synsthesis as will be recognized by
those skilled in the art.
Compounds of any of Formula I, Formula P or, for example, General Formula I
as depicted above, or any of the intermediates described in the schemes above, can be further
derivatised by using one or more standard synthetic methods known to those skilled in the art.
Such methods can involve substitution, oxidation or reduction reactions. These methods can
also be used to obtain or modify compounds of General Formula I or any preceding
intermediates by modifying, introducing or removing appropriate functional groups. Particular
substitution approaches include alkylation, arylation, heteroarylation, acylation, thioacylation,
halogenation, sulfonylation, nitration, formylation, hydrolysis and coupling procedures. These
procedures can be used to introduce a functional group onto the parent molecule (such as the
nitration or sulfonylation of aromatic rings) or to couple two molecules together (for example
to couple an amine to a carboxylic acid to afford an amide; or to form a carbon-carbon bond
between two heterocycles). For example, alcohol or phenol groups can be converted to ether
groups by coupling a phenol with an alcohol in a solvent (such as tetrahydrofuran) in the
presence of a phosphine (such as triphenylphosphine) and a dehydrating agent (such as diethyl,
diisopropyl or dimethyl azodicarboxylate). Alternatively, ether groups can be prepared by
deprotonation of an alcohol, using a suitable base (such as sodium hydride) followed by the
addition of an alkylating agent (such as an alkyl halide or an alkyl sulfonate).
In another example, a primary or secondary amine can be alkylated using a
reductive alkylation procedure. For example, the amine can be treated with an aldehyde and a
borohydride (such as sodium triacetoxyborohydride, or sodium cyanoborohydride in a solvent
(such as a halogenated hydrocarbon, for example dichloromethane, or an alcohol, for example
ethanol) and, where necessary, in the presence of an acid (such as acetic acid).
In another example, hydroxy groups (including phenolic OH groups) can be
converted into leaving groups, such as halogen atoms or sulfonyloxy groups (such as
alkylsulfonyloxy, for example trifluoromethanesulfonyloxy, or aryl suphonyloxy, for example
p-toluenesulfonyloxy) using conditions known to those skilled in the art. For example, an
aliphatic alcohol can be reacted with thionyl chloride in a halogenated hydrocarbon (such as
dichloromethane) to afford the corresponding alkyl chloride. A base (such as triethylamine) can
also be used in the reaction.
In another example, ester groups can be converted to the corresponding
carboxylic acid by acid- or base-catalysed hydrolysis depending on the nature of the ester
group. Acid catalysed hydrolysis can be achieved by treatment with an organic or inorganic
acid (such as trifluoroacetic acid in an aqueous solvent, or a mineral acid such as hydrochloric
acid in a solvent such as dioxane). Base catalysed hydrolysis can be achieved by treatment with
an alkali metal hydroxide (such as lithium hydroxide in an aqueous alcohol, for example
methanol).
In another example, aromatic halogen substituents in the compounds may be
subjected to halogen-metal exchange by treatment with a base (such as a lithium base, for
example n-butyl or t-butyl lithium) optionally at a low temperature (such as -78°C) in a solvent
(such as tetrahydrofuran) and the mixture may then be quenched with an electrophile to
introduce a desired substituent. Thus, for example, a formyl group can be introduced by using
dimethylformamide as the electrophile. Aromatic halogen substituents can also be subjected to
palladium catalysed reactions to introduce groups such as carboxylic acids, esters, cyano or
amino substituents.
In another example, an aryl, or heteroaryl ring substituted with an appropriate
leaving group (such as a halogen or sulfonyl ester, for example a triflate) can undergo a
palladium catalysed coupling reaction with a wide variety of substrates to form a caibon-carbon
bond. For example, a Heck reaction can be used to couple such a ring system to an alkene
(which may, or may not, be further substituted) by treatment with an organopalladium complex
(such as tetrakis(triphenylphosphine)palladium(0), palladium (P ) acetate or palladium (II)
chloride) in the presence of a ligand (such as a phosphine, for example triphenylphosphine) in
the presence of a base (such as potassium carbonate or a tertiary amine, for example,
triethylamine), in an appropriate solvent (such as tetrahydrofuran or DMF), under appropriate
conditions (such as heating to, for example, 50-120°C). In another example, a Sonogashira
reaction can be used to couple such a ring system to an alkyne (which may, or may not be
further substituted) by treatment with a palladium complex (such as
tetrakis(triphenylphosphine)palladium(0)) and a halide salt of copper (I) (such as copper (I)
iodide), in the presence of a base (such as a potassium carbonate or a tertiary amine, for
example, triethylamine), in an appropriate solvent (such as tetrahydrofuran or
dimethylformamide), under appropriate conditions (such as heating to, for example, 50-120°C).
In another example, a Stille reaction can be used to couple such a ring system to an alkene, by
treatment with an organotin compound (such as an alkynyltin or alkenyltin reagent, for example
an alkenyltributylstannane) in the presence of a palladium complex (such as
tetrakis(triphenylphosphine)palladium(0)), with, or without the presence of a salt (such as a
copper (I) halide), in an appropriate solvent (such as dioxane or dimethylformamide), under
appropriate conditions (such as heating to, for example, 50-120°C).
Particular oxidation approaches include dehydrogenations and aromatisation,
decarboxylation and the addition of oxygen to certain functional groups. For example,
aldehyde groups can be prepared by oxidation of the corresponding alcohol using conditions
well known to those skilled in the art. For example, an alcohol can be treated with an oxidising
agent (such as Dess-Martin periodinane) in a solvent (such as a halogenated hydrocarbon, for
example dichloromethane). Alternative oxidising conditions can be used, such as treatment
with oxalyl chloride and an activating amount of dimethylsulfoxide and subsequent quenching
by the addition of an amine (such as triethylamine). Such a reaction can be carried out in an
appropriate solvent (such as a halogenated hydrocarbon, for example dichloromethane) and
under appropriate conditions (such as cooling below room temperature, for example to -78°C
followed by warming to room temperature). In another example, sulfur atoms can be oxidised
to the corresponding sulfoxide or sulfone using an oxidising agent (such as a peroxy acid, for
example 3-chloroperoxybenzoic acid) in an inert solvent (such as a halogenated hydrocarbon,
for example dichloromethane) at around ambient temperature.
Particular reduction approaches include the removal of oxygen atoms from
particular functional groups or saturation (or partial saturation) of unsaturated compounds
including aromatic or heteroaromatic rings. For example, primary alcohols can be generated
from the corresponding ester or aldehyde by reduction, using a metal hydride (such as lithium
aluminium hydride or sodium borohydride in a solvent such as methanol). Alternatively,
CH OH groups can be generated from the corresponding carboxylic acid by reduction, using a
metal hydride (such as lithium aluminium hydride in a solvent such as tetrahydrofuran). In
another example, a nitro group may be reduced to an amine by catalytic hydrogenation in the
presence of a metal catalyst (such as palladium on a solid support such as carbon) in a solvent
(such as an ether, for example tetrahydrofuran, or an alcohol, such as methanol), or by chemical
reduction using a metal (such as zinc, tin or iron) in the presence of an acid (such as acetic acid
or hydrochloric acid). In a further example an amine can be obtained by reduction of a nitrile,
for example by catalytic hydrogenation in the presence of a metal catalyst (such as palladium
on a solid support such as carbon), or Raney nickel in a solvent (such as tetrahydrofuran) and
under suitable conditions (such as cooling to below room temperature, for example to -78°C, or
heating, for example to reflux).
Salts of compounds of General Formula I can be prepared by the reaction of a
compound of General Formula I with an appropriate acid or base in a suitable solvent, or
mixture of solvents (such as an ether, for example, diethyl ether, or an alcohol, for example
ethanol, or an aqueous solvent) using conventional procedures. Salts of compound of General
Formula I can be exchanged for other salts by treatment using conventional ion-exchange
chromatography procedures.
Where it is desired to obtain a particular enantiomer of a compound of General
Formula I, this may be produced from a corresponding mixture of enantiomers by employing
any suitable conventional procedure for resolving enantiomers. For example, diastereomeric
derivatives (such as salts) can be produced by reaction of a mixture of enantiomers of a
compound of General Formula I (such a racemate) and an appropriate chiral compound (such
as a chiral base). The diastereomers can then be separated by any conventional means such as
crystallisation, and the desired enantiomer recovered (such as by treatment with an acid in the
instance where the diastereomer is a salt). Alternatively, a racemic mixture of esters can be
resolved by kinetic hydrolysis using a variety of biocatalysts (for example, see Patel
Steroselective Biocatalysts, Marcel Decker; New York 2000).
In another resolution process a racemate of compounds of General Formula I
can be separated using chiral High Performance Liquid Chromatography. Alternatively, a
particular enantiomer can be obtained by using an appropriate chiral intermediate in one of the
processes described above. Chromatography, recrystallisation and other conventional
separation procedures may also be used with intermediates or final products where it is desired
to obtain a particular geometric isomer of the invention.
II. Methods
Another aspect of the invention provides methods of modulating the activity of
MetAP2. Such methods comprise exposing said receptor to a compound described herein. In
some embodiments, the compound utilized by one or more of the foregoing methods is one of
the generic, subgeneric, or specific compounds described herein, such as a compound of
Formula I, la, lb, Ic, Id, Ie, If, II, P I or IV. The ability of compounds described herein to
modulate or inhibit MetAP2 can be evaluated by procedures known in the art and/or described
herein. Another aspect of the invention provides methods of treating a disease associated with
expression or activity of MetAP2 in a patient. For example, a contemplated method includes
administering a disclosed compound in an amount sufficient to establish inhibition of
intracellular MetAP2 effective to increase thioredoxin production in the patient and to induce
multi organ stimulation of anti-obesity processes in the subject, for example, by administering a
disclosed compound in an amount insufficient to reduce angiogenesis in the patient.
In certain embodiments, the invention provides a method of treating and or
ameliorating obesity in a patient by administering an effective amount of a disclosed
compound. Also provided herein are methods for inducing weight loss in a patient in need
thereof. Contemplated patients include not only humans, but other animals such as companion
animals (e.g., dogs, cats).
Other contemplated methods of treatment include method of treating or
ameliorating an obesity-related condition or co-morbidity, by administering a compound
disclosed herein to a subject. For example, contemplated herein are methods for treating type 2
diabetes in a patient in need thereof.
Exemplary co-morbidities include cardiac disorders, endocrine disorders,
respiratory disorders, hepatic disorders, skeletal disorders, psychiatric disorders, metabolic
disorders, and reproductive disorders.
Exemplary cardiac disorders include hypertension, dyslipidemia, ischemic
heart disease, cardiomyopathy, cardiac infarction, stroke, venous thromboembolic disease and
pulmonary hypertension. Exemplary endocrine disorders include type 2 diabetes and latent
autoimmune diabetes in adults. Exemplary respiratory disorders include obesity-
hypoventilation syndrome, asthma, and obstructive sleep apnea. An exemplary hepatic
disorder is nonalcoholic fatty liver disease. Exemplary skeletal disorders include back pain and
osteoarthritis of weight-bearing joints. Exemplary metabolic disorders include Prader-Willi
Syndrome and polycystic ovary syndrome. Exemplary reproductive disorders include sexual
dysfunction, erectile dysfunction, infertility, obstetric complications, and fetal abnormalities.
Exemplary psychiatric disorders include weight-associated depression and anxiety.
In particular, in certain embodiments, the invention provides a method of
treating the above medical indications comprising administering to a subject in need thereof a
therapeutically effective amount of a compound described herein, such as a compound of
Formula I, la, lb, Ic, Id, Ie, If, II, P I or IV.
Obesity or reference to "overweight" refers to an excess of fat in proportion to
lean body mass. Excess fat accumulation is associated with increase in size (hypertrophy) as
well as number (hyperplasia) of adipose tissue cells. Obesity is variously measured in terms of
absolute weight, weight:height ratio, distribution of subcutaneous fat, and societal and esthetic
norms. A common measure of body fat is Body Mass Index (BMI). The BMI refers to the
ratio of body weight (expressed in kilograms) to the square of height (expressed in meters).
Body mass index may be accurately calculated using either of the formulas: weight(kg) /
2 2 2
height (m ) (SI) or 703 X weight(lb) / heighten ) (US).
In accordance with the U.S. Centers for Disease Control and Prevention (CDC),
an overweight adult has a BMI of 25 kg/m to 29.9 kg/m , and an obese adult has a BMI of 30
kg/m or greater. A BMI of 40 kg/m or greater is indicative of morbid obesity or extreme
obesity. Obesity can also refer to patients with a waist circumference of about 102 cm for
males and about 88 cm for females. For children, the definitions of overweight and obese take
into account age and gender effects on body fat. Patients with differing genetic background
may be considered "obese" at a level differing from the general guidelines, above.
The compounds of the present invention also are useful for reducing the risk of
secondary outcomes of obesity, such as reducing the risk of left ventricular hypertrophy.
Methods for treating patients at risk of obesity, such as those patients who are overweight, but
not obese, e.g. with a BMI of between about 25 and 30 kg/m , are also contemplated. In certain
embodiments, a patient is a human.
BMI does not account for the fact that excess adipose can occur selectively in
different parts of the body, and development of adipose tissue can be more dangerous to health
in some parts of the body rather than in other parts of the body. For example, "central obesity",
typically associated with an "apple-shaped" body, results from excess adiposity especially in
the abdominal region, including belly fat and visceral fat, and carries higher risk of co-
morbidity than "peripheral obesity", which is typically associated with a "pear-shaped" body
resulting from excess adiposity especially on the hips. Measurement of waist/hip circumference
ratio (WHR) can be used as an indicator of central obesity. A minimum WHR indicative of
central obesity has been variously set, and a centrally obese adult typically has a WHR of about
0.85 or greater if female and about 0.9 or greater if male.
Methods of determining whether a subject is overweight or obese that account
for the ratio of excess adipose tissue to lean body mass involve obtaining a body composition
of the subject. Body composition can be obtained by measuring the thickness of subcutaneous
fat in multiple places on the body, such as the abdominal area, the subscapular region, arms,
buttocks and thighs. These measurements are then used to estimate total body fat with a margin
of error of approximately four percentage points. Another method is bioelectrical impedance
analysis (BIA), which uses the resistance of electrical flow through the body to estimate body
fat. Another method is using a large tank of water to measure body buoyancy. Increased body
fat will result in greater buoyancy, while greater muscle mass will result in a tendency to sink.
In another aspect, the invention provides methods for treating an overweight or
obese subject involving determining a level of at least one biomarker related to being
overweight or obese in the subject, and administering an effective amount of a disclosed
compound to achieve a target level in the subject. Exemplary biomarkers include body weight,
Body Mass Index (BMI), Waist/Hip ratio WHR, plasma adipokines, and a combination of two
or more thereof.
In certain embodiments, the compound utilized by one or more of the foregoing
methods is one of the generic, subgeneric, or specific compounds described herein, such as a
compound of Formula I, la, lb, Ic, Id, Ie, If, P , III or IV.
The compounds of the invention may be administered to patients (animals and
humans) in need of such treatment in dosages that will provide optimal pharmaceutical
efficacy. It will be appreciated that the dose required for use in any particular application will
vary from patient to patient, not only with the particular compound or composition selected, but
also with the route of administration, the nature of the condition being treated, the age and
condition of the patient, concurrent medication or special diets then being followed by the
patient, and other factors which those skilled in the art will recognize, with the appropriate
dosage ultimately being at the discretion of the attendant physician. For treating clinical
conditions and diseases noted above, a compound of this invention may be administered orally,
subcutaneously, topically, parenterally, by inhalation spray or rectally in dosage unit
formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants
and vehicles. Parenteral administration may include subcutaneous injections, intravenous or
intramuscular injections or infusion techniques.
Treatment can be continued for as long or as short a period as desired. The
compositions may be administered on a regimen of, for example, one to four or more times per
day. A suitable treatment period can be, for example, at least about one week, at least about
two weeks, at least about one month, at least about six months, at least about 1 year, or
indefinitely. A treatment period can terminate when a desired result, for example a weight loss
target, is achieved. A treatment regimen can include a corrective phase, during which dose
sufficient to provide reduction of weight is administered, and can be followed by a maintenance
phase, during which a e.g. a lower dose sufficient to prevent weight gain is administered. A
suitable maintenance dose is likely to be found in the lower parts of the dose ranges provided
herein, but corrective and maintenance doses can readily be established for individual subjects
by those of skill in the art without undue experimentation, based on the disclosure herein.
Maintenance doses can be employed to maintain body weight in subjects whose body weight
has been previously controlled by other means, including diet and exercise, bariatric procedures
such as bypass or banding surgeries, or treatments employing other pharmacological agents.
III. Pharmaceutical Compositions and Kits
Another aspect of the invention provides pharmaceutical compositions
comprising compounds as disclosed herein formulated together with a pharmaceutically
acceptable carrier. In particular, the present disclosure provides pharmaceutical compositions
comprising compounds as disclosed herein formulated together with one or more
pharmaceutically acceptable carriers. These formulations include those suitable for oral, rectal,
topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous)
rectal, vaginal, or aerosol administration, although the most suitable form of administration in
any given case will depend on the degree and severity of the condition being treated and on the
nature of the particular compound being used. For example, disclosed compositions may be
formulated as a unit dose, and/or may be formulated for oral or subcutaneous administration.
Exemplary pharmaceutical compositions of this invention may be used in the
form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which
contains one or more of the compound of the invention, as an active ingredient, in admixture
with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral
applications. The active ingredient may be compounded, for example, with the usual non
toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories,
solutions, emulsions, suspensions, and any other form suitable for use. The active object
compound is included in the pharmaceutical composition in an amount sufficient to produce the
desired effect upon the process or condition of the disease.
For preparing solid compositions such as tablets, the principal active ingredient
may be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as
corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium
phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid
preformulation composition containing a homogeneous mixture of a compound of the
invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these
preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed
evenly throughout the composition so that the composition may be readily subdivided into
equally effective unit dosage forms such as tablets, pills and capsules.
In solid dosage forms for oral administration (capsules, tablets, pills, dragees,
powders, granules and the like), the subject composition is mixed with one or more
pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any
of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol,
and/or silicic acid; (2) binders, such as, for example, caiboxymethylcellulose, alginates, gelatin,
polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4)
disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic
acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6)
absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as,
for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and
bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid
polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In
the case of capsules, tablets and pills, the compositions may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled
gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular
weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more
accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin
or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for
example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-
active or dispersing agent. Molded tablets may be made by molding in a suitable machine a
mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other
solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or
prepared with coatings and shells, such as enteric coatings and other coatings well known in the
pharmaceutical-formulating art.
Compositions for inhalation or insufflation include solutions and suspensions in
pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject
composition, the liquid dosage forms may contain inert diluents commonly used in the art, such
as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ,
olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty
acid esters of sorbitan, cyclodextrins and mixtures thereof.
Suspensions, in addition to the subject composition, may contain suspending
agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan
esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and
tragacanth, and mixtures thereof.
Formulations for rectal or vaginal administration may be presented as a
suppository, which may be prepared by mixing a subject composition with one or more suitable
non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol,
a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body
temperature and, therefore, will melt in the body cavity and release the active agent.
Dosage forms for transdermal administration of a subject composition include
powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The
active component may be mixed under sterile conditions with a pharmaceutically acceptable
carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to a subject
composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc
and zinc oxide, or mixtures thereof.
Powders and sprays may contain, in addition to a subject composition,
excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and
polyamide powder, or mixtures of these substances. Sprays may additionally contain
customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted
hydrocarbons, such as butane and propane.
Compositions and compounds of the present invention may alternatively be
administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal
preparation or solid particles containing the compound. A non-aqueous (e.g., fluorocarbon
propellant) suspension could be used. Sonic nebulizers may be used because they minimize
exposing the agent to shear, which may result in degradation of the compounds contained in the
subject compositions. Ordinarily, an aqueous aerosol is made by formulating an aqueous
solution or suspension of a subject composition together with conventional pharmaceutically
acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of
the particular subject composition, but typically include non-ionic surfactants (Tweens,
Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic
acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols
generally are prepared from isotonic solutions.
Pharmaceutical compositions of this invention suitable for parenteral
administration comprise a subject composition in combination with one or more
pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions,
suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable
solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats,
solutes which render the formulation isotonic with the blood of the intended recipient or
suspending or thickening agents.
Examples of suitable aqueous and non-aqueous carriers which may be employed
in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as
glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof,
vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and
cyclodextrins. Proper fluidity may be maintained, for example, by the use of coating materials,
such as lecithin, by the maintenance of the required particle size in the case of dispersions, and
by the use of surfactants
In another aspect, the invention provides enteral pharmaceutical formulations
including a disclosed compound and an enteric material; and a pharmaceutically acceptable
carrier or excipient thereof. Enteric materials refer to polymers that are substantially insoluble
in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids
at specific pHs. The small intestine is the part of the gastrointestinal tract (gut) between the
stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of
the duodenum is about 5.5, the pH of the jejunum is about 6.5 and the pH of the distal ileum is
about 7.5. Accordingly, enteric materials are not soluble, for example, until a pH of about 5.0,
of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of
about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of
about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of
about 9.4, of about 9.6, of about 9.8, or of about 10.0. Exemplary enteric materials include
cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP),
polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate
(HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose
acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate,
cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of
methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate,
methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic
anhydride (Gantrez ES series), ethyl methyacrylate-methylmethacrylate-
chlorotrimethylammonium ethyl acrylate copolymer, natural resins such as zein, shellac and
copal collophorium, and several commercially available enteric dispersion systems (e. g. ,
Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D,
Estacryl 30D, Coateric, and Aquateric). The solubility of each of the above materials is either
known or is readily determinable in vitro. The foregoing is a list of possible materials, but one
of skill in the art with the benefit of the disclosure would recognize that it is not comprehensive
and that there are other enteric materials that would meet the objectives of the present
invention.
Advantageously, the invention also provides kits for use by a e.g. a consumer in
need of weight loss. Such kits include a suitable dosage form such as those described above
and instructions describing the method of using such dosage form to mediate, reduce or prevent
inflammation. The instructions would direct the consumer or medical personnel to administer
the dosage form according to administration modes known to those skilled in the art. Such kits
could advantageously be packaged and sold in single or multiple kit units. An example of such
a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are
being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules,
and the like). Blister packs generally consist of a sheet of relatively stiff material covered with
a foil of a preferably transparent plastic material. During the packaging process recesses are
formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be
packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff
material is sealed against the plastic foil at the face of the foil which is opposite from the
direction in which the recesses were formed. As a result, the tablets or capsules are sealed in
the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such
that the tablets or capsules can be removed from the blister pack by manually applying pressure
on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet
or capsule can then be removed via said opening.
It may be desirable to provide a memory aid on the kit, e.g., in the form of
numbers next to the tablets or capsules whereby the numbers correspond with the days of the
regimen which the tablets or capsules so specified should be ingested. Another example of
such a memory aid is a calendar printed on the card, e.g., as follows "First Week, Monday,
Tuesday, . . . etc. . . . Second Week, Monday, Tuesday, . . . " etc. Other variations of memory
aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several pills or
capsules to be taken on a given day. Also, a daily dose of a first compound can consist of one
tablet or capsule while a daily dose of the second compound can consist of several tablets or
capsules and vice versa. The memory aid should reflect this.
Also contemplated herein are methods and compositions that include a second
active agent, or administering a second active agent. For example, in addition to being
overweight or obese, a subject or patient can further have overweight- or obesity-related co
morbidities, i.e., diseases and other adverse health conditions associated with, exacerbated by,
or precipitated by being overweight or obese. Contemplated herein are disclosed compounds in
combination with at least one other agent that has previously been shown to treat these
overweight- or obesity-related conditions.
For example, Type II diabetes has been associated with obesity. Certain
complications of Type II diabetes, e.g., disability and premature death, can be prevented,
ameliorated, or eliminated by sustained weight loss (Astrup, A. Pub Health Nutr (2001) 4:499-5
). Agents administered to treat Type II diabetes include sulfonylureas (e.g., Chlorpropamide,
Glipizide, Glyburide, Glimepiride); meglitinides (e.g., Repaglinide and Nateglinide);
biguanides (e.g., Metformin); thiazolidinediones (Rosiglitazone, Troglitazone, and
Pioglitazone); dipeptidylpeptidase-4 inhibitors (e.g., Sitagliptin, Vildagliptin, and Saxagliptin);
glucagon-like peptide- 1 mimetics (e.g., Exenatide and Liraglutide); and alpha-glucosidase
inhibitors (e.g., Acarbose and Miglitol.
Cardiac disorders and conditions, for example hypertension, dyslipidemia,
ischemic heart disease, cardiomyopathy, cardiac infarction, stroke, venous thromboembolic
disease and pulmonary hypertension, have been linked to overweight or obesity. For example,
hypertension has been linked to obesity because excess adipose tissue secretes substances that
are acted on by the kidneys, resulting in hypertension. Additionally, with obesity there are
generally higher amounts of insulin produced (because of the excess adipose tissue) and this
excess insulin also elevates blood pressure. A major treatment option of hypertension is weight
loss. Agents administered to treat hypertension include Chlorthalidone; Hydrochlorothiazide;
Indapamide, Metolazone; loop diuretics (e.g., Bumetanide, Ethacrynic acid, Furosemide, Lasix,
Torsemide); potassium-sparing agents (e.g., Amiloride hydrochloride, benzamil,
Spironolactone, and Triamterene); peripheral agents (e.g., Reserpine); central alpha-agonists
(e.g., Clonidine hydrochloride, Guanabenz acetate, Guanfacine hydrochloride, and
Methyldopa); alpha-blockers (e.g., Doxazosin mesylate, Prazosin hydrochloride, and Terazosin
hydrochloride); beta-blockers (e.g., Acebutolol, Atenolol, Betaxolol, Bisoprolol fumarate,
Carteolol hydrochloride, Metoprolol tartrate, Metoprolol succinate, Nadolol, Penbutolol sulfate,
Pindolol, Propranolol hydrochloride, and Timolol maleate); combined alpha- and beta-blockers
(e.g., Carvedilol and Labetalol hydrochloride); direct vasodilators (e.g., Hydralazine
hydrochloride and Minoxidil); calcium antagonists (e.g., Diltiazem hydrochloride and
Verapamil hydrochloride); dihydropyridines (e.g., Amlodipine besylate, Felodipine, Isradipine,
Nicardipine, Nifedipine, and Nisoldipine); ACE inhibitors (benazepril hydrochloride,
Captopril, Enalapril maleate, Fosinopril sodium, Lisinopril, Moexipril, Quinapril
hydrochloride, Ramipril, Trandolapril); Angiotensin P receptor blockers (e.g., Losartan
potassium, Valsartan, and Irbesartan); Renin inhibitors (e.g., Aliskiren); and combinations
thereof. These compounds are administered in regimens and at dosages known in the art.
Carr et al. (The Journal of Clinical Endocrinology & Metabolism (2004) Vol.
89, No. 6 2601-2607) discusses a link between being overweight or obese and dyslipidemia.
Dyslipidemia is typically treated with statins. Statins, HMG-CoA reductase inhibitors, slow
down production of cholesterol in a subject and/or remove cholesterol buildup from arteries.
Statins include mevastatin, lovastatin, pravastatin, simvastatin, velostatin, dihydrocompactin,
fluvastatin, atorvastatin, dalvastatin, carvastatin, crilvastatin, bevastatin, cefvastatin,
rosuvastatin, pitavastatin, and glenvastatin. These compounds are administered in regimens
and at dosages known in the art. Eckel (Circulation (1997) 96:3248-3250) discusses a link
between being overweight or obese and ischemic heart disease. Agents administered to treat
ischemic heart disease include statins, nitrates (e.g., Isosorbide Dinitrate and Isosorbide
Mononitrate), beta-blockers, and calcium channel antagonists. These compounds are
administered in regimens and at dosages known in the art.
Wong et al. (Nature Clinical Practice Cardiovascular Medicine (2007) 4:436-
443) discusses a link between being overweight or obese and cardiomyopathy. Agents
administered to treat cardiomyopathy include inotropic agents (e.g., Digoxin), diuretics (e.g.,
Furosemide), ACE inhibitors, calcium antagonists, anti-arrhythmic agents (e.g., Sotolol,
Amiodarone and Disopyramide), and beta-blockers. These compounds are administered in
regimens and at dosages known in the art. Yusef et al. (Lancet (2005) 366(9497): 1640- 1649)
discusses a link between being overweight or obese and cardiac infarction. Agents
administered to treat cardiac infarction include ACE inhibitors, Angiotensin II receptor
blockers, direct vasodilators, beta blockers, anti-arrhythmic agents and thrombolytic agents
(e.g., Alteplase, Retaplase, Tenecteplase, Anistreplase, and Urokinase). These compounds are
administered in regimens and at dosages known in the art.
Suk et al. (Stroke (2003) 34: 1586-1592) discusses a link between being
overweight or obese and strokes. Agents administered to treat strokes include anti-platelet
agents (e.g., Aspirin, Clopidogrel, Dipyridamole, and Ticlopidine), anticoagulant agents (e.g.,
Heparin), and thrombolytic agents. Stein et al. (The American Journal of Medicine (2005)
18(9):978-980) discusses a link between being overweight or obese and venous
thromboembolic disease. Agents administered to treat venous thromboembolic disease include
anti-platelet agents, anticoagulant agents, and thrombolytic agents. Sztrymf et al. (Rev
Pneumol Clin (2002) 58(2): 104-10) discusses a link between being overweight or obese and
pulmonary hypertension. Agents administered to treat pulmonary hypertension include
inotropic agents, anticoagulant agents, diuretics, potassium (e.g., K-dur), vasodilators (e.g.,
Nifedipine and Diltiazem), Bosentan, Epoprostenol, and Sildenafil. Respiratory disorders and
conditions such as obesity-hypoventilation syndrome, asthma, and obstructive sleep apnea,
have been linked to being overweight or obese. Elamin (Chest (2004) 125:1972- 1974)
discusses a link between being overweight or obese and asthma. Agents administered to treat
asthma include bronchodilators, anti-inflammatory agents, leukotriene blockers, and anti-Ige
agents. Particular asthma agents include Zafirlukast, Flunisolide, Triamcinolone,
Beclomethasone, Terbutaline, Fluticasone, Formoterol, Beclomethasone, Salmeterol,
Theophylline, and Xopenex.
Kessler et al. (Eur Respir J (1996) 9:787-794) discusses a link between being
overweight or obese and obstructive sleep apnea. Agents administered to treat sleep apnea
include Modafinil and amphetamines.
Hepatic disorders and conditions, such as nonalcoholic fatty liver disease, have
been linked to being overweight or obese. Tolman et al. (Ther Clin Risk Manag (2007) 6:1153-
1163) discusses a link between being overweight or obese and nonalcoholic fatty liver disease.
Agents administered to treat nonalcoholic fatty liver disease include antioxidants (e.g.,
Vitamins E and C), insulin sensitizers (Metformin, Pioglitazone, Rosiglitazone, and Betaine),
hepatoprotectants, and lipid-lowering agents.
Skeletal disorders and conditions, such as, back pain and osteoarthritis of
weight-bearing joints, have been linked to being overweight or obese van Saase (J Rheumatol
(1988) 15(7): 1152-1 158) discusses a link between being overweight or obese and osteoarthritis
of weight-bearing joints. Agents administered to treat osteoarthritis of weight-bearing joints
include Acetaminophen, non-steroidal anti-inflammatory agents (e.g., Ibuprofen, Etodolac,
Oxaprozin, Naproxen, Diclofenac, and Nabumetone), COX-2 inhibitors (e.g., Celecoxib),
steroids, supplements (e.g. glucosamine and chondroitin sulfate), and artificial joint fluid.
Metabolic disorders and conditions, for example, Prader-Willi Syndrome and
polycystic ovary syndrome, have been linked to being overweight or obese. Cassidy (Journal
of Medical Genetics (1997) 34:917-923) discusses a link between being overweight or obese
and Prader-Willi Syndrome. Agents administered to treat Prader-Willi Syndrome include
human growth hormone (HGH), somatropin, and weight loss agents (e.g., Orlistat, Sibutramine,
Methamphetamine, Ionamin, Phentermine, Bupropion, Diethylpropion, Phendimetrazine,
Benzphetermine, and Topamax).
Hoeger (Obstetrics and Gynecology Clinics of North America (2001) 28(1):85-
97) discusses a link between being overweight or obese and polycystic ovary syndrome.
Agents administered to treat polycystic ovary syndrome include insulin-sensitizers,
combinations of synthetic estrogen and progesterone, Spironolactone, Eflornithine, and
Clomiphene. Reproductive disorders and conditions such as sexual dysfunction, erectile
dysfunction, infertility, obstetric complications, and fetal abnormalities, have been linked to
being overweight or obese. Larsen et al. (Int J Obes (Lond) (2007) 8:1189-1 198) discusses a
link between being overweight or obese and sexual dysfunction. Chung et al. (Eur Urol (1999)
36(l):68-70) discusses a link between being overweight or obese and erectile dysfunction.
Agents administered to treat erectile dysfunction include phosphodiesterase inhibitors (e.g.,
Tadalafil, Sildenafil citrate, and Vardenafil), prostaglandin E analogs (e.g., Alprostadil),
alkaloids (e.g., Yohimbine), and testosterone. Pasquali et al. (Hum Reprod (1997) 1:82-87)
discusses a link between being overweight or obese and infertility. Agents administered to
treat infertility include Clomiphene, Clomiphene citrate, Bromocriptine, Gonadotropin-
releasing Hormone (GnRH), GnRH agonist, GnRH antagonist, Tamoxifen/nolvadex,
gonadotropins, Human Chorionic Gonadotropin (HCG), Human Menopausal Gonadotropin
(HmG), progesterone, recombinant follicle stimulating hormone (FSH), UrofoUitropin, Heparin,
Follitropin alfa, and Follitropin beta.
Weiss et al. (American Journal of Obstetrics and Gynecology (2004)
190(4): 109 1-1097) discusses a link between being overweight or obese and obstetric
complications. Agents administered to treat obstetric complications include Bupivacaine
hydrochloride, Dinoprostone PGE2, Meperidine HC1, Ferro-folic-500/iberet-folic-500,
Meperidine, Methylergonovine maleate, Ropivacaine HC1, Nalbuphine HC1, Oxymorphone
HC1, Oxytocin, Dinoprostone, Ritodrine, Scopolamine hydrobromide, Sufentanil citrate, and
Oxytocic.
Psychiatric disorders and conditions, for example, weight-associated depression
and anxiety, have been linked to being overweight or obese. Dixson et al. (Arch Intern Med
(2003) 163:2058-2065) discusses a link between being overweight or obese and depression.
Agents administered to treat depression include serotonin reuptake inhibitors (e.g., Fluoxetine,
Escitalopram, Citalopram, Paroxetine, Sertraline, and Venlafaxine); tricyclic antidepressants
(e.g., Amitriptyline, Amoxapine, Clomipramine, Desipramine, Dosulepin hydrochloride,
Doxepin, Imipramine, Iprindole, Lofepramine, Nortriptyline, Opipramol, Protriptyline, and
Trimipramine); monoamine oxidase inhibitors (e.g., Isocarboxazid, Moclobemide, Phenelzine,
Tranylcypromine, Selegiline, Rasagiline, Nialamide, Iproniazid, Iproclozide, Toloxatone,
Linezolid, Dienolide kavapyrone desmethoxyyangonin, and Dextroamphetamine);
psychostimulants (e.g., Amphetamine, Methamphetamine, Methylphenidate, and Arecoline);
antipsychotics (e.g., Butyrophenones, Phenothiazines, Thioxanthenes, Clozapine, Olanzapine,
Risperidone, Quetiapine, Ziprasidone, Amisulpride, Paliperidone, Symbyax, Tetrabenazine,
and Cannabidiol); and mood stabilizers (e.g., Lithium carbonate, Valproic acid, Divalproex
sodium, Sodium valproate, Lamotrigine, Carbamazepine, Gabapentin, Oxcarbazepine, and
Topiramate).
Simon et al. (Archives of General Psychiatry (2006) 63(7):824-830) discusses a
link between being overweight or obese and anxiety. Agents administered to treat anxiety
include serotonin reuptake inhibitors, mood stabilizers, benzodiazepines (e.g., Alprazolam,
Clonazepam, Diazepam, and Lorazepam), tricyclic antidepressants, monoamine oxidase
inhibitors, and beta-blockers.
Another aspect of the invention provides methods for facilitating and
maintaining weight loss in a subject involving administering to the subject an amount of a
disclosed compound effective to result in weight loss in the subject; and administering a
therapeutically effective amount of a different weight loss agent to maintain a reduced weight
in the subject. Weight loss agents include serotonin and noradrenergic re-uptake inhibitors;
noradrenergic re-uptake inhibitors; selective serotonin re-uptake inhibitors; and intestinal lipase
inhibitors. Particular weight loss agents include orlistat, sibutramine, methamphetamine,
ionamin, phentermine, bupropion, diethylpropion, phendimetrazine, benzphetermine,
bromocriptine, lorcaserin, topiramate, or agents acting to modulate food intake by blocking
ghrelin action, inhibiting diacylglycerol acyltransferase 1 (DGATl) activity, inhibiting stearoyl
CoA desaturase 1 (SCD1) activity, inhibiting neuropeptide Y receptor 1 function, activating
neuropeptide Y receptor 2 or 4 function, or inhibiting activity of sodium-glucose cotransporters
1 or 2. These compounds are administered in regimens and at dosages known in the art.
EXAMPLES
The compounds described herein can be prepared in a number of ways based on
the teachings contained herein and synthetic procedures known in the art. In the description of
the synthetic methods described below, it is to be understood that all proposed reaction
conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of
the experiment and workup procedures, can be chosen to be the conditions standard for that
reaction, unless otherwise indicated. It is understood by one skilled in the art of organic
synthesis that the functionality present on various portions of the molecule should be
compatible with the reagents and reactions proposed. Substituents not compatible with the
reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore
indicated. The starting materials for the examples are either commercially available or are
readily prepared by standard methods from known materials.
At least some of the compounds identified as "Intermediates" herein are
contemplated as compounds of the invention.
¾ NMR spectra were recorded at ambient temperature using a Varian Unity
Inova (400MHz) spectrometer with a triple resonance 5mm probe for Example compounds, and
either a Bruker Avance DRX (400MHz) spectrometer or a Bruker Avance DPX (300MHz)
spectrometer for Intermediate compounds. Chemical shifts are expressed in ppm relative to
tetramethylsilane. The following abbreviations have been used: br = broad signal, s = singlet, d
= doublet, dd = double doublet, ddd = double double doublet, dt = double triplet, t = triplet, td =
triple doublet, q = quartet, m = multiplet.
Mass Spectrometry (LCMS) experiments to determine retention times and
associated mass ions were performed using the following methods:
Method A : Experiments were performed on a Waters ZMD LC quadrapole mass
spectrometer linked to a Waters 1525 LC system with a diode array detector. The spectrometer
has an electrospray source operating in positive and negative ion mode. Additional detection
was achieved using a Sedex 85 evaporative light scattering detector. LC was carried out using a
Luna 3micron 30 x 4.6mm C18 column and a 2mL/minute flow rate. The initial solvent system
was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1%
formic acid (solvent B) for the first 0.5 minute followed by a gradient up to 5% solvent A and
95% solvent B over the next 4 minutes. The final solvent system was held constant for a further
1 minute.
Method B : Experiments were performed on a Waters V G Platform quadrupole
spectrometer linked to a Hewlett Packard 1050 LC system with a diode array detector. The
spectrometer has an electrospray source operating in positive and negative ion mode.
Additional detection was achieved using a Sedex 85 evaporative light scattering detector. LC
was carried out using a Luna 3micron 30 x 4.6mm C18 column and a 2mL/minute flow rate.
The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5%
acetonitrile containing 0.1% formic acid (solvent B) for the first 0.3 minute followed by a
gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. The final solvent
system was held constant for a further 1 minute.
Method C : Experiments were performed on a Waters Micromass ZQ2000
quadrapole mass spectrometer linked to a Waters Acquity UPLC system with a PDA UV
detector. The spectrometer has an electrospray source operating in positive and negative ion
mode. LC was carried out using an Acquity BEH 1.7micron C18 column, an Acquity BEH
Shield 1.7micron RP18 column or an Acquity HSST 1.8micron column. Each column has
dimensions of 100 x 2.1mm and was maintained at 40°C with a flow rate of 0.4mL/minute. The
initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5%
acetonitrile containing 0.1% formic acid (solvent B) for the first 0.4 minute followed by a
gradient up to 5% solvent A and 95% solvent B over the next 6 minutes. The final solvent
system was held constant for a further 0.8 minutes.
Method D : Experiments were performed on a Shimadzu LCMS-2020
spectrometer with an electrospray source operating in positive ion mode. LC was carried out
using a Shimadzu Shim-pack XR-ODS 2.2 micron 50x3.0mm column. The initial solvent
system was 95% water containing 0.05% trifluoroacetic acid (solvent A) and 5% acetonitrile
(solvent B) for the first 0.01 minute then a gradient up to 100% solvent B over the next 1.3
minutes. The final solvent syt=stem was held constant for a further 1 minute.
Method E : Experiments were performed on a Waters ZMD LC quadrapole mass
spectrometer linked to a Hewlett Packard HD 1100 system with a diode array detector. The
spectrometer has an electrospray source operating in positive and negative ion mode. LC was
carried out using a Luna 3micron 30 x 4.6mm C18 column and a 2mL/minute flow rate. The
initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5%
acetonitrile containing 0.1% formic acid (solvent B) for the first 0.5 minute followed by a
gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. The final solvent
system was held constant for a further 1 minute.
Method F : Experiments were performed on a Waters V G Platform quadrupole
spectrometer linked to a Hewlett Packard 1050 LC system with a diode array detector. The
spectrometer has an electrospray source operating in positive and negative ion mode.
Additional detection was achieved using a Sedex 85 evaporative light scattering detector. LC
was carried out using a Luna 3micron 30 x 4.6mm C18 column and a 2mL/minute flow rate.
The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5%
acetonitrile containing 0.1% formic acid (solvent B) for the first 0.3 minute followed by a
gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. The final solvent
system was held constant for a further 1 minute.Microwave experiments were carried out using
a Biotage Initiator™, which uses a single-mode resonator and dynamic field tuning.
Temperatures from 40-250 °C can be achieved, and pressures of up to 20 bars can be reached.
A facility exists to apply air cooling during the irradiation.
Preparative HPLC purification was carried out using either a C18-reverse-phase
column from Genesis (CI 8) or a C6-phenyl column from Phenomenex (C6- phenyl) (100 x
22.5 mm i.d. with 7 micron particle size, UV detection at 230 or 254 nm, flow 5-15mL/min),
eluting with gradients from 100-0 to 0-100 % water/acetonitrile or water/methanol containing
0.1% formic acid.. Fractions containing the required product (identified by LCMS analysis)
were pooled, the organic fraction removed by evaporation, and the remaining aqueous fraction
lyophilised, to give the product.
Compounds which required column chromatography were purified manually or
fully automatically using either a Biotage SP1™ Flash Purification system with Touch Logic
Control™ or a Combiflash Companion® with pre-packed silica gel Isolute® SPE cartridge,
Biotage SNAP cartridge or Redisep® Rf cartridge respectively.
Compounds have been named using Autonom2000 within ISISDraw.
Abbreviations:
DCM Dichloromethane
IMS Industrial methylated spirits
DMF N,N-Dimethylformamide
DMAP 4-Dimethylaminopyridine
THF Tetrahydrofuran
DMSO Dimethylsulfoxide
NMP N-methylpyrrolidinone
DCE 1,2-Dichloroethane
HATU 7-Azabenzotriazol-l-yl-N,N,N\N\tetramethyluronium
hexafluorophosphate
EDAC N-(3-Dimethylaminopropyl)-N'ethylcarbodiimide hydrochloride
IMS Industrial methylated spirit
NMM N-methylmorpholine
DBU l,8-Diazabicyclo[5.4.0]undecene
Example 1: Cis-(3aRS,9bRS)(Benzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromeneca
Mixture of cis enantiomers
Lithium hydroxide (0.048g) was added to a solution of methyl cis-(3aRS,9bRS)-
7-(benzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate
(Intermediate 1, 0.08g) in a mixture of dioxane (lOmL) and water (5mL) and the resultant
mixture was irradiated in the microwave at 110°C with air cooling for 20 minutes. Further
lithium hydroxide (0.2g) was added and the mixture was irradiated in the microwave at 110°C
with air cooling for a total of 80 minutes. After cooling, the solution was acidified by addition
of aqueous formic acid solution (10%) and the resultant mixture was extracted with ethyl
acetate, dried (MgSCU) and filtered. The filtrate was evaporated to dryness. The residue was
dissolved in a mixture of methanol (lOmL) and water (5mL) and treated with lithium hydroxide
(0.2g) then irradiated in the microwave at 110°C with air cooling for 40 minutes. After cooling,
the solution was acidified by addition of formic acid (10%) and the resultant mixture was
extracted with ethyl acetate, dried (MgSC^) and filtered. The filtrate was evaporated to dryness
and the residue was purified by preparative HPLC (CI 8) eluting with a mixture of acetonitrile
and water, containing 0.1% formic acid, with a gradient of 30-50% to give cis-(3aRS,9bRS)
(benzenesulfonylamino)- 1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid
(0.0 19g) as a white solid.
¾ NMR (CD OD) d : 7.71 (2H, d), 7.54 (1H, t), 7.44 (2H, t), 7.24 (1H, d), 7.12
(1H, d), 4.24 (1H, m), 4.09 (1H, dd), 3.92 (1H, dd), 3.8-3.65 (2H, m), 3.47 (1H, m), 2.45 (1H,
m), 1.83 (1H, m).
LCMS (Method C) r/t 3.79 (M-H) 374.
Example 2: Cis-(3aRS,9bRS)[2-(3-Diethylaminopropyl)fluorobenzenesulfonyl-amino]-
1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid
Mixture of cis enantiomers
A solution of 7-[2-((Z)diethylaminoprop- l-enyl)
fluorobenzenesulfonylamino]-4H-furo[2,3-c]chromenecarboxylic acid (Intermediate 8, O.lg)
in a mixture of IMS (2mL) and glacial acetic acid (3mL) was treated, under an atmosphere of
nitrogen, with palladium hydroxide on carbon (10%, 0.02g). The nitrogen was replaced by
hydrogen and the mixture was stirred under an atmosphere of hydrogen for 100 minutes. The
mixture was filtered through Celite and the filtrate was evaporated to dryness. The residue was
dissolved in toluene and the solution was re-evaporated. The residue was triturated with ether
and the solid was collected by filtration and purified by preparative HPLC (C6-phenyl) eluting
with a mixture of acetonitrile and water, containing 0.1% formic acid, with a gradient of 20-
40% to give cis-(3aRS,9bRS)[2-(3-diethylaminopropylfluorobenzenesulfonyl-amino]-
l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid (O.lg) as a white solid.
¾ NMR (CD OD) d : 7.94 (IH, dd), 7.18 (IH, d), 7.17 (IH, m), 7.06 (IH, d),
6.99 (IH, dt), 4.21 (IH, m), 3.98 (IH, dd), 3.88 (IH, dd), 3.72 (2H, m), 3.42 (IH, m), 3.23 (6H,
m), 3.10 (2H, m), 2.42 (IH, m), 1.98 (2H, m), 1.81 (IH, m), 1.31 (6H, t).
LCMS (Method C) r/t 3. 10 (M+H) 507.
Example 3: Cis-(3aRS,9bRS)[2-(3-{Pyrrolidin-l-yl}propyl)fluorobenzene-
sulfonylamino]- 1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid
Mixture of cis enantiomers
Lithium hydroxide (0.028g) was added to a solution of methyl cis-(3aRS,9bRS)-
7-[2-(3- {pyrrolidin- 1-yl }propyl)fluorobenzenesulfonylamino]- 1,3a,4,9b-tetrahydro-2H-
furo[2,3-c]chromenecarboxylate (Intermediate 14, 0.06g) in dioxane (2mL) and water (ImL)
and the mixture was stirred and heated at 80°C for 8 hours. After cooling, the mixture was
acidified by addition of aqueous formic acid solution (10%) and extracted with DCM. The
organic layer was dried (MgSCU) and filtered. The filtrate was evaporated to dryness and the
residue was purified by chromatography on silica eluting with a mixture of ammonia in
methanol (2M) and DCM with a gradient of 1-10%. The isolated solid was triturated with a
mixture of ether and cyclohexane (50%) and the solid was collected by filtration. The solid was
purified by preparative HPLC (CI 8) eluting with a mixture of acetonitrile and water, containing
0.1% formic acid, with a gradient of 10-95%. The isolated product was triturated with ether and
the solid was collected by filtration to give cis-(3aRS,9bRS)[2-(3-{pyrrolidin-l-yl}propyl)-
4-fluorobenzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic
acid (0.006g) as a white solid.
¾ NMR (CD OD) d : 7.93 (IH, dd), 7.21 (IH, d), 7.14 (IH, dd), 7.08 (IH, d),
6.99 (IH, dt), 4.21 (IH, m), 3.98 (IH, dd), 3.88 (IH, dd), 3.72 (2H, m), 3.43 (2H, m), 3.30 (4H,
m), 3.13 (3H, m), 2.42 (IH, m), 2.07 (4H, m), 2.0 (2H, m), 1.81 (IH, m).
LCMS (Method C) r/t 3. 11 (M+H) 505.
Example 4: Cis-(3aRS,9bRS)[2-((Z)Diethylaminoprop- l-enyl)fluoro-
benzenesulfonyl [2,3-c]chromenecarboxylic acid
Mixture of cis enantiomers
Prepared by proceeding in a similar manner to Example 3, starting from methyl
cis-(3aRS,9bRS)[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-
l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate (Intermediate 17) and heating at
80°C overnight.
¾ NMR (DMSO-d ) d : 7.65 (IH, dd), 7.30 (IH, d), 7.19 (2H, m), 7.02 (IH, d),
6.92 (IH, d), 6.10 (IH, m), 4.09 (IH, m), 3.82-3.64 (4H, m), 3.63-3.30 (3H, m), 3.03 (4H, q),
2.35 (IH, m), 1.68 (IH, m), 1.07 (6H, t).
LCMS (Method C) r/t 3.05 (M+H) 505.
Examples 5 and 6: Separation of enantiomers from Example 4.
Sample from Example 4 was subjected to chiral separation using a ChiralPak IC
column, 4.6mm x 250mm, particle size 5micron. Injection solvent DCE : absolute ethanol 1: 1,
injection concentration lmg/100 m , injection volume 120m . Eluting solvent absolute ethanol,
flow rate 0.55mL/minute, temperature 21°C.
Example 5: First eluting enantiomer: retention time on above column: 34.96 minutes, 93% de.
¾ NMR (DMSO-d ) d : 7.64 (IH, dd), 7.29 (IH, d), 7.18 (2H, m), 7.01 (IH, d),
6.92 (IH, d), 6.08 (IH, m), 4.09 (IH, m), 3.75 (2H, m), 3.59 (2H, m), 3.33 (3H, m), 3.03 (4H,
br), 2.34 (IH, m), 1.68 (IH, m), 1.06 (6H, t).
LCMS (Method C) r/t 3.07 (M+H) 505.
Example 6: Second eluting enantiomer: retention time on above column 40.97 minutes, 65%
¾ NMR (DMSO-d ) d : 7.64 (IH, dd), 7.29 (IH, d), 7.18 (2H, m), 7.01 (IH, d),
6.92 (IH, d), 6.08 (IH, m), 4.09 (IH, m), 3.75 (2H, m), 3.59 (2H, m), 3.33 (3H, m), 3.03 (4H,
br), 2.34 (IH, m), 1.68 (IH, m), 1.06 (6H, t).
LCMS (Method C) r/t 3.06 (M+H) 505.
Example 7: 7-[2-((Z)Diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-l,2-
dihydrofuro[2,3- acid formate salt
Prepared by proceeding in a similar manner to Example 1, starting from methyl
7-[N-{2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonyl}-N-(methoxy-
carbonyl)amino]-l,2-dihydrofuro[2,3-c]quinolinecarboxylate (Intermediate 20) as a yellow
solid.
¾ NMR (CD OD) d : 8.50 (IH, s), 8.47 (2H, s), 7.96 (IH, m), 7.91 (IH, d), 7.79
(IH, d), 7.45 (IH, d), 7.1 1 (2H, m), 6.13 (IH, m), 3.79 (2H, d), 3.59 (2H, t), 3.10 (6H, m), 1.16
(6H, m).
LCMS (Method C) r/t 2.84 (M+H) 500.
Example 8: 7-(Benzenesulfonylamino)-l,2-dihydrofuro[2,3-c]quinolinecarboxylic acid
formate salt
Prepared by proceeding in a similar manner to Example 1, starting from methyl
7-(benzenesulfonylamino)- 1,2-dihydrofuro[2,3-c]quinolinecarboxylate (Intermediate 26).
¾ NMR (DMSO-d ) d : 8.54 (1H, s), 8.25 (1H, s), 7.78 (3H, m), 7.66 (1H, d),
7.44 (3H, m), 4.69 (2H, t), 3.46 (2H, t).
LCMS (Method C) r/t 3.66 (M+H) 37 1.
Example 9: Cis-(3aRS,9bRS)[2-((Z)Diethylaminoprop- l-enyl)
fluorobenzenesul rofuro[2,3-c]quinolinecarboxylic acid
Lithium hydroxide (0.09g) was added to a solution of methyl cis-(3aRS,9bRS)-
-acetyl[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-l,2,3a,4,5,9b-
hexahydrofuro[2,3-c]quinolinecarboxylate (Intermediate 27, 0.06g) in a mixture of dioxane
(5mL) and water (ImL) and the mixture was stirred and heated at 80°C overnight. The mixture
was then irradiated in the microwave at 150°C for 30 minutes and then at 180°C for 30 minutes.
After cooling, the mixture was filtered and the filtrate was acidified by addition of formic acid
(ImL) and then evaporated to dryness. The residue was purified by preparative HPLC (C18)
eluting with a mixture of acetonitrile and water, containing 0.1% formic acid, with a gradient of
-98%. The isolated product was dissolved in DCM and evaporated to dryness then dissolved
in ether and evaporated to dryness to give cis-(3aRS,9bRS)[2-((Z)diethylaminoprop-l-
enyl)fluorobenzenesulfonylamino]-l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinoline
carboxylic acid (0.005g) as a white solid.
¾ NMR (CDC1 ) d : 8.54 (1H, br s), 7.99 (1H, br s), 7.48 (1H, d), 7.04 (1H, m),
6.90 (1H, d), 6.76 (1H, d), 6.62 (1H, m), 6.1 1 (1H, m), 4.17 (1H, m), 3.82 (1H, m), 3.78-3.59
(2H, m), 3.32-3.10 (4H, m), 3.04-2.86 (3H, m), 2.35 (1H, m), 1.79 (1H, m), 1.15 (6H, t).
LCMS (Method C) r/t 3.31 (M+H) 504
Example 10: (laRS,7bSR)[2-((Z)Diethylaminoprop-l-enyl)
f l uorobenzenesul clopropa[c]chromenecarboxylic acid
Methyl (laRS,7bSR) [2-((Z)diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 40, 0.185g) and lithium hydroxide monohydrate (0.159g) were suspended in
dioxane (4mL) and water (lmL). The reaction mixture was irradiated in the microwave at
135°C for 30 minutes. After cooling, the mixture was acidified to pH4 with formic acid, then
ethanol and toluene were added and the mixture concentrated in vacuo. The residue was
triturated with a mixture of methanol and DCM (10%) and the solid was filtered off and
washed with a mixture of methanol and DCM. The filtrate was concentrated in vacuo and the
residue was purified by chromatography on silica, eluting with a mixture of methanol and
DCM with a gradient of 0-8%. The resultant product was triturated with ethyl acetate and dried
in vacuo at 50°C to give (laRS,7bSR)[2-((Z)diethylaminoprop- l-enyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(0.066g) as a white solid.
¾ NMR (DMSO-d ) d : 7.64 (IH, dd), 7.35 (IH, d), 7.27-7.19 (2H, m), 7.10
(IH, d), 6.93 (IH, d), 6.20-6.10 (IH, m), 4.17 (IH, d), 3.76 (2H, br, s), 3.57 (IH, d), 3.10 (4H,
br, q), 1.92 (IH, td), 1.75-1.69 (IH, m), 1.13 (6H, t), 0.94 (IH, td), 0.74 (IH, m).
LCMS (Method C) r/t 3.32 (M+H) 475
Examples 11 and 12: Separation of enantiomers from Example 10.
Sample from Example 10 was subjected to chiral separation using a ChiralPak
IC column, 10mm x 250mm, particle size 5micron. Eluting solvent ferf-butyl methyl ether :
isopropanol : DCM (16:20:64).
Example 11: First eluting enantiomer: r/t on analytical column (4.6mm x 250mm): 21.8
minutes >99% ee: (laS,7bR)[2-((Z)Diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
¾ NMR (CDC1 ) d : 7.63 (IH, d), 7.43 (IH, m), 7.15-7.08 (2H, m), 6.85 (IH,
dt), 6.72 (IH, dd), 5.93 (IH, m), 4.27 (IH, d), 3.98 (IH, br m), 3.68 (IH, m), 3.58 (IH, br),
3.27-3.06 (4H, m), 1.87 (IH, m), 1.63 (IH, m), 1.23 (6H, t), 1.04 (IH, m), 0.91 (IH, m).
LCMS (Method C) r/t 3.30 (M+H) 475
Example 12: Second eluting enantiomer: r/t on analytical column (4.6mm x 250mm): 27.5
minutes, >99 ee: (laR,7bS)[2-((Z)Diethylaminoprop-l-enyl)fluorobenzenesulfonyl-
amino] -1,1a,2,7b-tetrahydro acid
¾ NMR (CDC1 ) d : 7.63 (IH, d), 7.43 (IH, m), 7.15-7.08 (2H, m), 6.85 (IH,
dt), 6.72 (IH, dd), 5.93 (IH, m), 4.27 (IH, d), 3.98 (IH, br m), 3.68 (IH, m), 3.58 (IH, br),
3.27-3.06 (4H, m), 1.87 (IH, m), 1.63 (IH, m), 1.23 (6H, t), 1.04 (IH, m), 0.91 (IH, m).
LCMS (Method C) r/t 3.32 (M+H) 475.
Absolute configuration of Examples 11 and 12 determined by X-ray crystal analysis of
Example 12 with MetAP2.
Example 13: (laRS,7bSR)[2-((Z)Diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-7b-methyl-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
Prepared by proceeding in a similar manner to Example 3, starting from methyl
(laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-7b-
methyl-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermeidate 48).
¾ NMR (CDCI ) d : 9.8-9.2 (IH, br s), 7.65 (IH, d), 7.39 (IH, m), 7.24 (IH, d), 7.18 (IH, d),
6.83 (IH, dt), 6.72 (IH, dd), 5.91 (IH, m), 4.21 (IH, d), 3.98 (IH, br t), 3.71 (IH, d), 3.61 (IH,
br s), 3.28-3.06 (4H, m), 1.41 (3H, s), 1.37 (IH, m), 1.24 (6H, t), 1.14 (IH, t), 0.74 (IH, dd).
LCMS (Method C) r/t 3.55 (M+H) 489.
Example 14: (laRS,7bSR)[2-((E)Diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-7b-methyl-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
Isolated as a minor by-product by preparative HPLC from the preparation of
Example 13.
¾ NMR (CDCI ) d : 11.9 (IH, br s), 7.93 (IH, dd), 7.70 (IH, d), 7.25 (IH, d), 7.10 (IH, d),
7.06 (IH, dd), 6.90 (IH, dt), 6.19 (IH, m), 4.23 (IH, d), 3.76 (IH, d), 3.68 (2H, m), 3.29 (4H,
q), 1.36 (6H, t), 1.35 (3H, s), 1.31 (IH, m), 1.10 (IH, t), 1.67 (IH, dd).
LCMS (Method C) r/t 3.66 (M+H) 489.
Example 15: Cis-(3aRS,9bRS)[2-(4-dimethylaminobutylamino)benzenesulfonylamino]-
1,3a,4,9b-tetrahydro-2H-furo[2, acid
4-Dimethylaminobutylamine (0.348g) and triethylamine (0.2ml) were added to a
suspension of cis-(3aRS,9bRS)(2-fluorobenzenesulfonylamino)- 1,3a,4,9b-tetrahydro-2H-
furo[2,3-c]chromenecarboxylic acid (Intermediate 57, 0.15g) in acetonitrile (1.5mL) and the
mixture was heated at 130°C in a sealed tube for 36 hours. The mixture was then diluted with
water (2mL) and the solution was purified by preparative HPLC (C6-phenyl) eluting with a
mixture of methanol and water, containing 0.1% formic acid, with a gradient of 5-98%. The
isolated product was further purified by chromatography on silica eluting with a mixture of
methanol and DCM with a gradient of 0-15% to give cis-(3aRS,9bRS)[2-(4-
dimethylaminobutylamino)-benzenesulfonylamino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenecarboxylic acid (0.062g) as a glass foam.
¾ NMR (CDC1 ) d : 11.21 (IH, br s), 7.72 (IH, dd), 7.37 (IH, d), 7.26 (IH, m), 7.02 (IH, d),
6.59 (IH, d), 6.56 (IH, t), 5.85 (IH, t), 4.29 (IH, dt), 4.05 (IH, dd), 3.85 (IH, m), 3.77 (2H, m),
3.34 (IH, q), 3.21 (2H, m), 2.98 (2H, t), 2.80 (6H, s), 2.41 (IH, m), 2.05 (IH, m), 1.83 (IH, m),
1.71 (2H, m).
LCMS (Method C) r/t 3. 18 (M+H) 490
Eaxmple 16: (laR,7bS)[2-(3-Diethylaminopropyl)fluorobenzenesulfonyl-
l ,l a,2,7b-tetrahydrocyclopro acid
Prepared by proceeding in a similar manner to Example 2, starting from
(laR,7bS)[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]-chromenecarboxylic acid (Example 12)
¾ NMR (CDCI ) d : 7.81 (IH, dd), 7.31 (IH, d), 7.07 (IH, d), 6.82 (2H, m), 4.32 (IH, d), 3.74
(IH, d), 3.42-3.32 (IH, m), 3.18 (4H, m), 3.14-2.94 (3H, m), 2.00 (2H, m), 1.84 (IH, m), 1.62
(IH, m), 1.31 (6H, t), 1.04 (IH, m), 0.88 (IH, m).
LCMS (Method C) r/t 3.36 (M+H) 477.
Example 17: (laRS,7bSR)[2-((Z)Diethylaminoprop-l-enyl)fluorobenzene-
sulfonylamino]- l ,l -difluoro- 4-carboxylic acid
Prepared by proceeding in a similar manner to Example 10, starting from methyl
(laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-l,l-
difluoro-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 59) as a
white solid.
¾ NMR (CDC1 ) d : 10.0-9.6 (IH, br s), 7.64 (IH, d), 7.47 (IH, dd), 7.21 (IH, d), 7.13 (IH, d),
6.87 (IH, dt), 6.73 (IH, dd), 5.95 (IH, m), 4.28 (IH, d), 3.96 (IH, m), 3.92-3.79 (IH, br s),
3.78-3.67 (IH, br s), 3.17 (4H, q), 2.64 (IH, t), 2.23 (IH, m), 1.24 (6H, t).
LCMS (Method C) r/t 3.38 (M+H) 5 11.
Examples 18 and 19: Separation of enantiomers from Example 17.
Sample from Example 17 was subjected to chiral separation using a ChiralPak
IA column, 20mm x 250mm, particle size 5micron. Eluting solvent methanol : ethanol :
heptane (12.5: 12.5:75).
Example 18: First eluting enantiomer: r/t on analytical column (4.6mm x 250mm): 14.7
minutes >95 ee.
¾ NMR (DMSO-d ) d : 7.83 (IH, t), 7.27-7.17 (3H, m), 7.09 (IH, d), 6.85 (IH,
d), 5.98 (IH, m), 4.27 (IH, d), 3.76 (IH, m), 3.56 (IH, t), 2.90 (IH, t), 2.85 (IH, t), 2.77 (4H,
br s), 2.55 (IH, s), 0.97 (6H, br t).
LCMS (Method C) r/t 3.39 (M+H) 5 11
Example 19: Second eluting enantiomer: r/t on analytical column 19.0 minutes, >95 ee.
¾ NMR (DMSO-d ) d : 7.72 (IH, dd), 7.36 (IH, d), 7.26 (IH, dt), 7.21 (IH,
dd), 7.18 (IH, d), 6.99 (IH, d), 6.13 (IH, m), 4.29 (IH, d), 3.87-3.70 (3H, m), 3.10 (4H, m),
2.96 (IH, t), 2.56 (IH, m), 1.1 1 (6H, t).
LCMS (Method C) r/t 3.39 (M+H) 5 11.
Example 20: (laRS,7bSR)[2((Z)Ethylaminoprop-l-enyl)fluorobenzenesulfonyl-
amino] -1,1a,2,7b-tetrahydrocy acid
A mixture of methyl (laRS,7bSR)[2((Z)ethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 63, 0.09g) and lithium hydroxide monohydrate (0.047g) in a mixture of dioxane
(lOmL) and water (5mL) was stirred and heated at 120°C for 32 hours. After cooling, the
mixture was concentrated under vacuum and the residue was acidified to pH4 with formic acid.
The resultant solid was collected by filtration and washed with water to give (laRS,7bSR)
[2((Z)ethylaminoprop-l-enyl)fluorobenzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (0.029g) as a grey solid.
¾ NMR (DMSO-d ) d : 10.4-9.95 (IH, br s), 7.5 1 (IH, dd), 7.21 (IH, d), 7.17 (IH, dt), 7.1 1
(IH, dd), 7.07 (IH, d), 6.99 (IH, d), 5.93 (IH, m), 4.1 1 (IH, d), 3.60 (2H, m), 3.5 1 (IH, d),
2.92 (2H, q), 1.87 (IH, m), 1.67 (IH, m), 1.12 (3H, t), 0.89 (IH, m), 0.69 (IH, m).
LCMS (Method C) r/t 3.32 (M+H) 447.
Examples 21 and 22: Separation of enantiomers from Example 20.
Sample from Example 20 was subjected to chiral separation using a ChiralPak
IC column, 10mm x 250mm, particle size 5micron. Eluting solvent ferf-butyl methyl ether :
isopropanol : DCM (15:20:65).
Example 21: First eluting enantiomer: r/t on analytical column (4.6mm x
250mm): 14.3 minutes >99 ee.
¾ NMR (DMSO-d ) d : 10.16 (2H, br s), 7.56 (IH, dd), 7.26 (IH, d), 7.22 (IH,
dt), 7.17 (IH, dd), 7.12 (IH, d), 7.05 (IH, d), 5.99 (IH, m), 4.16 (IH, d), 3.65 (2H, m), 3.57
(IH, d), 2.98 (2H, q), 1.93 (IH, m), 1.73 (IH, m), 1.17 (3H, t), 0.94 (IH, m), 0.78 (IH, q).
LCMS (Method C) r/t 3.27(M+H) 447.
Example 22: Second eluting enantiomer: r/t on analytical column 20.6 minutes, >99 ee.
¾ NMR (DMSO-d ) d : 10.16 (2H, br s), 7.56 (IH, dd), 7.26 (IH, d), 7.22 (IH,
dt), 7.17 (IH, dd), 7.12 (IH, d), 7.05 (IH, d), 5.99 (IH, m), 4.16 (IH, d), 3.65 (2H, m), 3.57
(IH, d), 2.98 (2H, q), 1.93 (IH, dt), 1.73 (IH, m), 1.17 (3H, t), 0.94 (IH, dt), 0.75 (IH, q).
LCMS (Method C) r/t 3.26(M+H) 447.
Example 23: ( 1aRS,7bSR) {2[(Z)(Pyrrolidin- l-yl)prop- l-enyl]fluorobenzene-
sulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 20, starting from methyl (laRS,7bSR)-
-{2[(Z)(pyrrolidin- l-yl)prop- l-enyl]fluorobenzene-sulfonylamino }- 1,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 66) as a white solid.
¾ NMR (DMSO-d ) d : 12.2-1 1.6 (IH, br s), 7.49 (IH, dd), 7.30 (IH, d), 7.21-7.12 (2H, m),
7.09 (IH, m), 6.97 (IH, d), 6.10 (IH, m), 4.12 (IH, d), 3.80 (2H, d), 3.5 1 (IH, d), 3.28 (4H, m),
1.89 (IH, m), 1.85 (4H, m), 1.68 (IH, m), 0.90 (IH, m), 0.69 (IH, m).
LCMS (Method C) r/t 3.39 (M+H) 473
Examples 24 and 25: Separation of enantiomers from Example 23.
Sample from Example 23 was subjected to chiral separation using a ChiralPak
IC column, 10mm x 250mm, particle size 5micron. Eluting solvent ferf-butyl methyl ether :
ethanol (75:25).
Example 24: First eluting enantiomer: r/t on analytical column (4.6mm x
250mm): 17.5 minutes >99 ee
¾ NMR (DMSO-d ) d : 7.55 (IH, dd), 7.35 (IH, d), 7.22 (2H, m), 7.14 (IH, d),
7.02 (IH, d), 6.14 (IH, m), 4.17 (IH, d), 3.84 (2H, br d), 3.57 (IH, d), 3.30 (4H, br), 1.97-1.85
(5H, br m), 1.73 (IH, m), 0.95 (IH, dt), 0.74 (IH, q).
LCMS (Method C) r/t 3.33(M+H) 473
Example 25: Second eluting enantiomer: r/t on analytical column 21.4 minutes, >98 ee.
¾ NMR (DMSO-d ) d : 7.55 (IH, dd), 7.34 (IH, d), 7.24 (IH, dd), 7.19 (IH,
dd), 7.14 (IH, d), 7.02 (IH, d), 6.14 (IH, dt), 4.17 (IH, d), 3.84 (2H, br d), 3.57 (IH, d), 3.29
(4H, br), 1.97-1.85 (5H, br m), 1.73 (IH, m), 0.95 (IH, dt), 0.74 (IH, q).
LCMS (Method C) r/t 3.34(M+H) 473.
Example 26: (laRS,7bSR)[2-(3-Dimethylaminopropylamino)benzenesulfonyl-amino]-
l ,l a,2,7b-tetrahydrocycloprop acid
A mixture of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 67, 0.15g), 3-
dimethylaminopropylamine (1.26g) and triethylamine (0.62g) in NMP (6mL) was stirred and
heated at 140°C for 48 hours. After cooling, the mixture was concentrated under vacuum and
the residue was purified by chromatography on silica, eluting with a mixture of methanol and
DCM with a gradient of 5-10%. The resultant product was repurified by preparative TLC,
eluting with a mixture of methanol and DCM (10%) to give (laRS,7bSR)[2-(3-
dimethylaminopropylamino)-benzenesulfonylamino] -1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.08g) as an off white solid.
¾ NMR (DMSO-d ) d : 7.36 (IH, dd), 7.22 (IH, dt),7.02 (2H, s), 6.68 (IH, d), 6.44 (IH, t),
6.24 (IH, br s), 4.1 1 (IH, d), 3.5 1 (IH, d), 3.30-3.10 (4H, m), 2.68 (6H, s), 1.83 (IH, m), 1.72-
1.52 (3H, m), 0.85 (IH, m), 0.65 (IH, m).
LCMS (Method C) r/t 3.31 (M+H) 446.
Examples 27 and 28: Separation of enantiomers from Example 26.
Sample from Example 26 was subjected to chiral separation using a ChiralPak
IB column 20mm x 250mm, particle size 5 micron. Eluting solvent hexane : ethanol :
diethylamine (49.8:50:0.2).
Example 27: First eluting enantiomer: r/t on analytical column (4.6mm x 250mm) 14.61
minutes (>98% ee).
¾ NMR (DMSO-d ) d : 7.37 (IH, dd), 7.23 (IH, dt),7.02 (2H, s), 6.68 (IH, d),
6.45 (IH, t), 6.24 (IH, br s), 4.11 (IH, d), 3.52 (IH, d), 3.35-3.02 (4H, m), 2.67 (6H, s), 1.84
(IH, m), 1.74-1.52 (3H, m), 0.85 (IH, m), 0.66 (IH, m).
LCMS (Method C) r/t 3.21 (M+H) 446.
Example 28: Second eluting enantiomer: r/t on analytical column (4.6mm x 250mm) 18.16
minutes (>98% ee).
¾ NMR (DMSO-d ) d : 7.37 (IH, dd), 7.23 (IH, dt),7.02 (2H, s), 6.68 (IH, d),
6.44 (lH, t), 6.25 (IH, br s), 4.1 1 (IH, d), 3.5 1 (IH, d), 3.41-3.05 (4H, m), 2.69 (6H, s), 1.84
(IH, m), 1.74-1.52 (3H, m), 0.85 (IH, m), 0.66 (IH, m).
LCMS (Method C) r/t 3.20 (M+H) 446.
Example 29: (laRS,7bSR)[2-(4-Dimethylaminobutylamino)benzenesulfonyl-amino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 26, starting from (laRS,7bSR)(2-
fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(Intermediate 67) and 4-dimethylaminobutylamine.
¾ NMR (DMSO-d ) d : 13.0-12.0 (1H, br s), 7.58 (1H, dd), 7.28 (1H, dt), 7.02 (2H, s), 6.69
(1H, d), 6.55 (1H, t), 5.70 (1H, m),4.14 (1H, d), 3.53 (1H, d), 3.15 (2H, m), 2.91 (2H, m), 2.67
(6H, s), 1.83 (1H, m), 1.76 (2H, m), 1.66 (1H, m), 1.53 (2H, m), 0.84 (1H, m), 0.67 (1H, m).
LCMS (Method C) r/t 3.43 (M+H) 460.
Examples 30 and 31: Separation of enantiomers from Example 29.
Sample from Example 29 was subjected to chiral separation using a ChiralPak IB column
20mm x 250mm, particle size 5 micron. Eluting solvent hexane : ethanol : diethylamine
(49.8:50:0.2).
Example 30: First eluting enantiomer: r/t on analytical column (4.6mm x 250mm) 12.69
minutes (>98 ee).
¾ NMR (DMSO-d ) d : 13.0-12.2 (1H, br s), 7.58 (1H, dd), 7.28 (1H, dt), 7.02 (2H, m), 6.69
(1H, d), 6.55 (1H, t), 5.71 (1H, m), 4.14 (1H, d), 3.53 (1H, d), 3.15 (2H, m), 2.89 (2H, m), 2.67
(6H, s), 1.83 (1H, m), 1.76 (2H, m), 1.66 (1H, m), 1.54 (2H, m), 0.85 (1H, m), 0.68 (1H, m).
LCMS (Method C) r/t 3.33 (M+H) 460.
Example 31: Second eluting enantiomer: r/t on analytical column (4.6mm x 250mm) 16.82
minutes (>98 ee).
¾ NMR (DMSO-d ) d : 12.9-12.1 (1H, br s), 7.58 (1H, dd), 7.28 (1H, dt), 7.02 (2H, s), 6.70
(1H, d), 6.55 (1H, t), 5.71 (1H, m), 4.14 (1H, d), 3.53 (1H, d), 3.15 (2H, m), 2.91 (2H, m), 2.68
(6H, s), 1.83 (1H, m), 1.77 (2H, m), 1.66 (1H, m), 1.54 (2H, m), 0.85 (1H, m), 0.68 (1H, m).
LCMS (Method C) r/t 3.33 (M+H) 460.
Example 32: (laRS,7bSR)[2-(5-Dimethylaminopentylamino)benzenesulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 26, starting from
(laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene-
4-carboxylic acid (Intermediate 67) and 5-dimethylaminopentylamine.
¾ NMR (DMSO-d ) d : 12.8-12.2(1H, br s), 7.67 (IH, dd), 7.30 (IH, dt), 6.98 (IH, d), 6.85
(IH, d), 6.68 (IH, d), 6.60 (IH, t), 5.54 (IH, m), 4.14 (IH, d), 3.54 (IH, d), 3.05 (4H, m), 2.66
(6H, s), 1.81 (IH, m), 1.63 (5H, m), 1.5 1 (2H, m), 0.83 (IH, m), 0.67 (IH, m).
LCMS (Method C) r/t 3.55 (M+H) 474.
Example 33: (laRS,7bSR){2[(Z)(Propanyl)aminoprop-l-enyl]fluorobenzene-
sulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A mixture of methyl (laRS,7bSR){2[(Z)(propanyl)aminoprop-l-enyl]-
4-fluorobenzenesulfonylamino }-1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylate
(Intermediate 69, 0.12g) and lithium hydroxide monohydrate (O.lg) in a mixture of dioxane
(lOmL) and water (5mL) was stirred and heated at 100°C overnight. After cooling, the mixture
was concentrated under vacuum and the residue was acidified to pH4 with formic acid then
extracted with a mixture of ethyl acetate and THF (1: 1). The organic phase was dried
(Na2SC 4)
and filtered. The filtrate was evaporated to dryness and the rsidue was dissolved in ethyl acetate
(2mL) and hexane was added (lOmL). The solid was collected by filtration and washed with
ether to give (laRS,7bSR){2[(Z)(propanyl)aminoprop-l-enyl]fluorobenzene-
sulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid (0.04g) as an off
white solid.
¾ NMR (DMSO-d ) d : 10.5-9.8 (IH, br s), 7.54 (IH, dd), 7.23-7.08 (3H, m), 7.04 (IH, d),
6.96 (IH, d), 5.91 (IH, m), 4.09 (IH, d), 3.63 (2H, m), 3.53 (IH, m), 3.49 (IH, d), 1.85 (IH,
m), 1.67 (IH, m), 1.16 (6H, d), 0.86 (IH, m), 0.67 (IH, m).
LCMS (Method C) r/t 3.37 (M+H) 461.
Example 34: (laRS,7bSR){2[(Z)((S)Hydroxypyrrolidin-l-yl)aminoprop-l-enyl]
f l uorobenzenesulfonyl 4-carboxylic acid
Prepared by proceeding in a similar manner to Example 33, starting from methyl
(laRS,7bSR){2[(Z)((S)hydroxypyrrolidin-l-yl)aminoprop-l-enyl]
fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 70).
¾ NMR (DMSO-d ) d : 12.5-1 1.3 (IH, br s), 7.62 (IH, m), 7.32 (IH, d), 7.22 (2H, m), 7.13
(IH, d), 6.98 (IH, d), 6.12 (IH, m), 5.26 (IH, m), 4.37 (IH, m), 4.19 (IH, d), 3.79 (2H, m),
3.59 (IH, dd), 3.20-3.00 (3H, br s), 2.05 (IH, m), 1.94 (IH, m), 1.77 (2H, m), 0.96 (IH, m),
0.76 (IH, m).
LCMS (Method C) r/t 3. 15 (M+H) 489.
Example 35: (laRS,7bSR){2[(Z)((R)Hydroxypyrrolidin-l-yl)aminoprop-l-enyl]
fluorobenzenesulfonylamino chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 33, starting from methyl
(laRS,7bSR){2[(Z)((R)hydroxypyrrolidin-l-yl)aminoprop-l-enyl]fluorobenzene-
sulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 71).
¾ NMR (DMSO-d ) d : 12.5-1 1.4 (IH, br s), 7.62 (IH, m), 7.33 (IH, d), 7.22 (2H, m), 7.13
(IH, d), 6.98 (IH, d), 6.14 (IH, m), 5.26 (IH, m), 4.37 (IH, m), 4.19 (IH, d), 3.79 (2H, m),
3.59 (IH, dd), 3.20-3.00 (3H, br s), 2.05 (IH, m), 1.94 (IH, m), 1.77 (2H, m), 0.96 (IH, m),
0.76 (IH, m).
LCMS (Method C) r/t 3. 14 (M+H) 489.
Example 36: (laRS,7bSR)[2((Z)Diethylaminobut-l-enyl)fluorobenzenesulfonyl-
amino] -1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a manner similar to Example 33, starting from methyl
(laRS,7bSR){N-(methoxycarbonyl)-N-[2((Z)diethylaminobut-l-enyl)
fluorobenzenesulfonyl]amino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 72).
¾ NMR (DMSO-d ) d : 12.8-1 1.4 (IH, br s), 7.54 (IH, dd), 7.14-7.02 (4H, m), 6.83 (IH, d),
.66 (IH, m), 4.09 (IH, d), 3.5 1 (IH, d), 3.13 (2H, m), 2.92 (4H, m), 2.34 (2H, m), 1.84 (IH,
m), 1.66 (IH, m), 1.06 (6H, t), 0.86 (IH, m), 0.67 (IH, m).
LCMS (Method C) r/t 3.35 (M+H) 489.
Examples 37 and 38: Separation of enantiomers from Example 36.
Sample from Example 37 was subjected to chiral separation using a ChiralPak
IC column, 10mm x 250mm, particle size 5micron. Eluting solvent ferf-butyl methyl ether:
isopropanol : DCM (16:20:64).
Example 37 : First eluting enantiomer: r/t on analytical column (4.6mm x 250mm): 25.8
minutes >98 ee
¾ NMR (DMSO-d ) d : 7.61 (IH, dd), 7.20-7.09 (4H, m), 6.90 (IH, d), 5.74
(IH, m), 4.16 (IH, d), 3.58 (IH, d), 3.22-3.1 1 (2H, m), 2.99 (4H, m), 2.50 (2H, m), 1.92 (IH,
dt), 1.72 (IH, m), 1.15 (6H, t), 0.93 (IH, m), 0.75 (IH, m).
LCMS (Method C) r/t 3.36(M+H) 489
Example 38: Second eluting enantiomer: r/t on analytical column 44.0 minutes, >98 ee.
¾ NMR (DMSO-d ) d : 7.61 (IH, dd), 7.20-7.10 (4H, m), 6.90 (IH, d), 5.74
(IH, m), 4.16 (IH, d), 3.58 (IH, d), 3.23-3.10 (2H, m), 2.99 (4H, q), 2.5 1 (2H, m), 1.92 (IH,
dt), 1.72 (IH, m), 1.15 (6H, t), 0.93 (IH, m), 0.75 (IH, m).
LCMS (Method C) r/t 3.36 (M+H) 489
Example 39: (laRS,7bSR){2-[2-(4-Ethylpiperazin-l-yl)-ethyl]fluorobenzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylic acid
A solution of (laRS,7bSR)(4-Fluorovinylbenzenesulfonylamino)-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid (Intermediate 74, 0.035g) and 3
drops of N-ethyl piperazine in isopropanol (0.5mL) was irradiated in the microwave at 160 °C
for 15 minutes then again at 170°C for 15minutes. After cooling, the mixture was purified by
preparative HPLC (CI 8) eluting with a mixture of methanol and water, containing 0.1% formic
acid, with a gradient of 20-60%. The isolated product was further purified by chromatography
on silica eluting with a mixture of methanol and DCM with a gradient of 0-10% to give
(1aS,7bR) {2-[2-(4-ethylpiperazin- 1-yl)-ethyl] fluorobenzenesulfonylamino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.018g) as an off white solid.
¾ NMR (CDC1 ) d : 7.95 (IH, dd), 7.07 (2H, s), 6.95 (IH, dd), 6.91 (IH, dt), 4.38 (IH, d), 3.79
(IH, d), 3.42 (2H, q), 3.35 (2H, q), 3.21-3.05 (4H, m), 3.04-2.88 (4H, m), 2.79 (2H, m), 1.86
(IH, dt), 1.66 (IH, m), 1.22 (3H, t), 1.06 (IH, q), 0.93 (IH, m).
LCMS (Method C) r/t 2.95 (M+H) 504
Example 40: (laRS,7bSR){2[(Z)(Azetidin-l-yl)prop-l-enyl]fluorobenzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydrocy chromenecarboxylic acid
Prepared by proceeding in a manner similar to Example 33, starting from methyl
(laRS,7bSR){2-[(Z)(azetidin-l-yl)prop-l-enyl]fluorobenzenesulfonyl-amino}-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 76).
¾ NMR (DMSO-d ) d : 12.8-1 1.1 (IH, br s), 7.5 1 (IH, dd), 7.26 (IH, d), 7.17 (IH, dt), 7.10
(2H, m), 7.00 (IH, d), 5.90 (IH, m), 4.12 (IH, d), 3.96 (4H, m), 3.74 (2H, m), 3.52 (IH, d),
2.27 (2H, m), 1.89 (IH, m), 1.69 (IH, m), 0.90 (IH, m), 0.69 (IH, m).
LCMS (Method C) r/t 3.26 (M+H) 459.
Example 41: (laRS,7bSR){2[(Z)(3-Hydroxyazetidin-l-yl)prop-l-enyl]fluorobenzene-
sulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a manner similar to Example 33, starting from methyl
(laRS,7bSR){2-[(Z)(3-hydroxyazetidin-l-yl)prop-l-enyl]fluorobenzene-
sulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 77).
¾ NMR (DMSO-d ) d : 12.8-1 1.2 (IH, br s), 7.53 (IH, m), 7.22 (IH, d), 7.17 (IH, dt), 7.09
(2H, m), 6.97 (IH, d), 5.90 (IH, m), 4.40 (IH, m), 4.18 (2H, m), 4.12 (IH, d), 3.69 (4H, m),
3.52 (IH, d), 1.87 (IH, m), 1.69 (IH, m), 0.89 (IH, m), 0.70 (IH, m).
LCMS (Method C) r/t 3. 18 (M+H) 475.
Example 42: (laRS,7bSR){2[(Z)(Azetidin-l-yl)propyl]fluorobenzenesulfonylamino}-
l ,la,2,7b-tetrahydrocycloprop acid
A solution of (laRS,7bSR){2[(Z)(azetidin-l-yl)prop-l-enyl]
fluorobenzene-sulfonylamino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(Example 40, 0.03g) in methanol was treated, under an atmosphere of nitrogen with palladium
on carbon (10%, O.Olg). The nitrogen was replaced by hydrogen and the mixture was stirred
under an atmosphere of hydrogen overnight. The mixture was filtered and the filtrate was
evaporated to dryness. The residue was purified by HPLC (C18) to give (laRS,7bSR)
{2[(Z)(azetidin- l-yl)propyl]fluorobenzenesulfonylamino }- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.019g) as a white solid.
¾ NMR (DMSO-d ) d : 7.76 (IH, dd), 7.20 (IH, dd), 7.09 (IH, dt), 7.05 (IH, d), 6.99 (IH, d)
4.15 (IH, d), 3.97 (2H, m) 3.56 (IH, d), 3.14 (2H, m), 2.99 (4H, m), 2.29 (2H, m), 1.86 (IH,
m), 1.81-1.64 (3H, m), 0.88 (IH, m), 0.69 (IH, m).
¾ LCMS (Method C) r/t 3.20 (M+H) 461.
Example 43: (laRS,7bSR)[2((Z)Diethylaminobutyl)fluorobenzenesulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 42, starting from
(laRS,7bSR)[2((Z)diethylaminobut-l-enyl)fluorobenzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Example 36) as a white solid.
¾ NMR (DMSO-d ) d : 13.0-1 1.6 (IH, br s), 7.82 (IH, dd), 7.21 (IH, dd), 7.08 (IH, dt), 7.02
(IH, d), 6.96 (IH, d), 4.14 (IH, d), 3.55 (IH, d), 2.99 (8H, m), 1.83 (IH, m), 1.65 (5H, m), 1.14
(6H, t), 0.85 (IH, m), 0.69 (IH, m).
LCMS (Method C) r/t 3.45 (M+H) 491.
Example 44: (laRS,7bSR){2-[N-(4-Dimethylaminobutyl)-N-methylamino]-
benzenesulfonyl-amino}- l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A mixture of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 67, O.lg), N-(4-
dimethylaminobutyl)-N-methylamine (Intermediate 78, 1.07g) and triethylamine (0.42g) in
NMP (6mL) was stirred and heated in a sealed tube at 150°C for 3 days. After cooling, the
mixture was concetrated under vacuum and the residue was purified by chromatogrphy on
silica, eluting with a mixture of methanol and DCM (10%) followed by repurification by HPLC
(C18) to give (laRS,7bSR){2-[N-(4-dimethylaminobutyl)-N-methylamino]-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylic acid (0.03g)
as a white solid.
¾ NMR (DMSO-d ) d : 7.81 (IH, dd), 7.54 (IH, dt), 7.41 (IH, dd), 7.21 (IH, dt), 6.94 (IH, d),
6.85 (IH, d), 4.12 (IH, d), 3.55 (IH, d), 2.96 (2H, t), 2.85 (2H, t), 2.64 (6H, s), 2.49 (3H, s),
1.83 (IH, m), 1.74 (2H, m), 1.63 (3H, m), 0.87 (IH, m), 0.68 (IH, m).
LCMS (Method C) r/t 3.37 (M+H) 474.
Example 45: (laRS,7bSR){2-[((S)-l-Ethylpyrrolidinylcarbamoyl)methyl]fluoro-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylic acid
A mixture of methyl (laRS,7bSR){2-[((S)-l-ethylpyrrolidin
ylcarbamoyl)methyl]fluorobenzenesulfonylamino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 80, 0.148g) and lithium
hydroxide monohydrate (0.168g) in dioxane (3mL) and water (lmL) was irradiated in the
microwave at 130°C for 40 minutes. After cooling, the mixture was diluted with methanol,
acidified with formic acid and evaporated in vacuo. The residue was triturated with 10%
methanol in DCM and filtered. The filtrate was evaporated in vacuo and the residue was
purified by chromatography on silica, eluting with a mixture of methanol and DCM with a
gradient of 0-20%. The resultant solid was triturated with ether and filtered off to give
(laRS,7bSR){2-[((S)- l-ethylpyrrolidinylcarbamoyl)methyl]fluorobenzenesulfonyl-
amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid (0.09 lg) as a white
solid.
¾ NMR (DMSO-d ) d : 9.56 (0.5H, br, d), 9.48 (0.5H, br, d), 7.59 (IH, m), 7.34 (IH, m), 7.16
(2H, m), 7.06 (IH, t), 4.46 (IH, br, q), 4.13 (IH, d), 3.92 (IH, dd), 3.70 (IH, m), 3.65 (IH, d),
3.58 (IH, br, m), 2.95-3.25 (6H, m), 2.40 (IH, m), 1.95 (2H, m), 1.76 (IH, m), 1.20 (3H, t),
0.97 (IH, m), 0.78 (IH, m).
LCMS (Method C) r/t 3.04 (M+H) 5 18.
Example 46: (laRS,7bSR)[2-(l-Ethylazetidinyl)fluorobenzenesulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 45, starting from methyl
(laRS,7bSR)[2-(l-ethylazetidinyl)fluorobenzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylate (Intermediate 86) as a white solid.
¾ NMR (DMSO-d ) d : 7.91 (IH, dd), 7.64 (IH, dd), 7.24 (lH,dt), 6.96 (IH, d),
6.66 (IH, d), 4.79 (IH, m), 4.21 (IH, d), 4.15 (2H, br, t), 3.89 (2H, br, m), 3.62 (IH, d), 3.06
(2H, q), 1.83 (IH, m), 1.70 (IH, m), 1.05 (3H, t), 0.88 (IH, m), 0.72 (IH, m).
LCMS (Method C) r/t 2.99 (M+H) 447.
Example 47: (laRS,7bSR){2-[((R)-l-Ethylpyrrolidinylcarbamoyl)methyl]fluoro-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 45, starting from methyl
(laRS,7bSR){2-[((R)- l-ethylpyrrolidinylcarbamoyl)methyl]
fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 92) as a white solid.
¾ NMR (CDC1 ) d : 10.30 (0.5H, br, s), 10.25 (0.5H, br, s), 9.88 (IH, br, s), 7.52 (IH, m),
7.18-7.41 (3H, m), 6.75 (IH, m), 4.83 (0.5H, m), 4.70 (0.5H, m), 4.17 (1.5H, m), 3.84-4.10
(1.5H, m), 3.60-3.86 (3H, m), 3.45 (0.5H, d), 3.31 (0.5H, m), 3.13 (0.5H, m), 2.98 (0.5H, m),
2.83 (2H, m), 2.46 (IH, m), 2.29 (IH, m), 1.93 (IH, m), 1.67 (IH, q), 1.40 (3H, t), 1.13 (0.5H,
m), 1.07 (0.5H, m), 0.97 (IH, m).
LCMS (Methos C) r/t 3.03 (M+H) 5 18.
Example 48: (laRS,7bSR){2-[2-(Pyrrolidin-l-yl)-ethyl]fluorobenzenesulfonylamino}-
l ,l a,2,7b-tetrahydrocyclopropa[ acid
Prepared by proceeding in a similar manner to Example 39, starting from
(laRS,7bSR)(4-fluorovinylbenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (Intermediate 74) and pyrrolidine as a
white solid.
¾ NMR (DMSO-d ) d : 7.84 (IH, dd), 7.26 (IH, dd), 7.17 (IH, dt), 7.02 (IH, d), 6.74 (IH, d),
4.16 (IH, d), 3.59 (IH, d), 3.36-3.20 (8H, m), 1.91 (4H, m), 1.85 (IH, m), 1.69 (IH, m), 0.89
(IH, m), 0.70 (IH, m).
LCMS (Method C) r/t 3. 12 (M+H) 461.
Example 49: (laRS,7bSR)[2-((R)-l-Ethylpyrrolidinylmethyl)fluorobenzenesulfonyl-
amino] -1,1a,2,7b-tetrahydroc ic acid
Lithium hydroxide (0.1 1lg) was added to a solution of methyl (laRS,7bSR)
[2-((R)-l-ethyl-pyrrolidinylmethyl)fluorobenzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxyl ate (Intermediate 95, 0.13g) in a mixture of
dioxane (4mL) and water (lmL) and the mixture was stirred and heated at 85°C overnight.
After cooling, the mixture was filtered and the filtrate was acidified by addition of 10%
aqueous citric acid (lmL) and then extracted with DCM. The organic extract was dried
(MgSCU) and filtered. The filtrate was evaporated to dryness and the residue was triturated with
diethyl ether and the solid was collected by filtration to give (laRS,7bSR)[2-((R)-l-
ethylpyrrolidinylmethyl)fluorobenzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.085g) as a white solid.
¾ NMR (DMSO-d ) d : 7.81 (IH, dd), 7.28 (IH, dd), 7.16 (IH, dt), 7.1 1 (IH, dd), 6.99 (IH,
dd), 4.20 (IH, dd), 3.60 (IH, t), 3.48-2.98 (9H, br m), 2.25 (IH, m), 1.91 (IH, dt), 1.73 (2H,
m), 1.23 (3H, t), 0.93 (IH, dt), 0.75 (IH, m).
LCMS (Method C) r/t 3.21 (M+H) 475.
Examples 50 and 51: Separation of enantiomers from Example 49.
Sample from Example 49 was subjected to chiral separation using a ChiralPak
IC column, 10mm x 250mm, particle size 5micron. Eluting solvent ferf-butyl methyl ether:
isopropanol : DCM (10: 15:75).
Example 50: First eluting enantiomer: r/t on analytical column (4.6mm x 250mm): 30.0
minutes >99% ee.
¾ NMR (DMSO-d ) d : 7.81 (IH, dd), 7.27 (IH, dd), 7.15 (IH, dt), 7.10 (IH,
d), 7.01 (IH, d), 4.20 (IH, d), 3.58 (IH, d), 3.23-3.1 1 (6H, m), 3.1 1-3.06 (3H, m), 2.25 (IH,
m), 1.91 (IH, dt), 1.73 (2H, m), 1.22 (3H, t), 0.92 (IH, dt), 0.73 (IH, m).
LCMS (Method C) r/t 3.25 (M+H) 475.
Example 51: Second eluting enantiomer: r/t on analytical column 40.0 minutes, >99% ee.
¾ NMR (DMSO-d ) d : 7.80 (IH, dd), 7.27 (IH, dd), 7.15 (IH, dt), 7.10 (IH,
d), 7.03 (IH, d), 4.18 (IH, d), 3.61 (IH, d), 3.48-2.97 (9H, br m), 2.27 (IH, m), 1.91 (IH, dt),
1.71 (2H, m), 1.23 (3H, t), 0.93 (IH, dt), 0.74 (IH, m).
LCMS (Method C) r/t 3.23 (M+H) 475.
Example 52: ( 1aRS,7bSR) {2-[((S)- l-Ethylpyrrolidinyl)cabonylaminomethyl]
fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A mixture of methyl (laRS,7bSR){2-[((S)-l-ethylpyrrolidin
yl)cabonylaminomethyl]fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate (Intermediate 101, 0.212g) and lithium hydroxide (0.05g) in
dioxane (5.5mL) and water (2.5mL) was irradiated in the microwave at 150°C for 30 minutes.
After cooling, the mixture was diluted with water, acidifed with formic acid to pH5 and
extracted with ethyl acetate. The organic layer was washed with water, dried (MgSCU) and
filtered. The filtrate was evaporate to dryness and the residue was purifed by HPLC (CI 8)
eluting with a mixture of methanol and water, containing 0.1% formic acid, with a gradient of
-75% to give (laRS,7bSR){2-[((S)-l-ethylpyrrolidinyl)cabonylaminomethyl]
fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid
(0.064g) as a white solid.
¾ NMR (CDC1 ) d : 10.8-9.6 (IH, br s), 8.90 (IH, br t), 7.71 (IH, m), 7.20 (3H, m), 6.86 (IH,
m), 4.88 (2H, m), 4.37 (IH, dd), 3.85 (IH, dt), 3.61 (IH, m), 3.43 (IH, m), 2.97 (IH, m), 2.77
(2H, m), 2.23 (2H, m), 2.03 (IH, m), 1.91 (2H, m), 1.69 (IH, m), 1.18 (3H, q), 1.01 (2H, m).
LCMS (Method C) r/t 3.09 (M+H) 5 18.
Example 53: (laRS JbSR)[2-(4-Dimethylaminobutyrylamino)fluorobenzenesulfonyl-
amino] -1,1a,2,7b-tetrahydro acid
A mixture of methyl (laRS,7bSR)[2-(4-dimethylaminobutyryl)
fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 108, 0.2g), potassium carbonate (0.22g), lH-pyrazoleamine (0.34g) and
lithium iodide (1.07g) in DMF (lOmL) was irradiated in the microwave at 150°C for 1 hour.
After cooling, the mixture was diluted with methanol and acidified to pH 3 with formic acid
then concentrated under vacuum. The residue was purified by chromatography on silica, eluting
with a mixture of methanol and DCM (5%). The resultant product was purified by HPLC (C18)
to give (laRS,7bSR)[2-(3-dimethylaminobutyryl)fluorobenzenesulfonyl-amino]-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid (0.03g) as a white solid.
¾ NMR (DMSO-d ) d : 7.95 (IH, dd), 7.80 (IH, dd), 6.96 (IH, d), 6.95 (IH, dt), 6.79 (IH, d),
4.13 (IH, d), 3.56 (IH, d), 3.04 (2H, t),2.68 (6H, s), 2.56 (2H, t), 1.94 (2H, m), 1.81 (IH, m),
1.64 (IH, m), 0.84 (IH, m), 0.66 (IH, m).
LCMS (Method C) r/t 3. 12 (M+H) 492.
Example 54: (laRS,7bSR)[2-((S)-l-Ethylpyrrolidinylmethyl)fluorobenzenesulfonyl-
amino] -1,1a,2,7b-tetrahydrocyc acid
Prepared by proceeding in a similar manner to Example 49, starting from methyl
(laRS,7bSR)[2-((S)-l-ethylpyrrolidinylmethyl)fluorobenzenesulfonylamino]-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 113).
¾ NMR (DMSO-d ) d : 7.81 (IH, dd), 7.27 (IH, dd), 7.15 (IH, dt), 7.10 (IH, d), 7.02 (IH, dd),
4.19 (IH, dd), 3.56 (IH, t), 3.23-3.1 1 (6H, m), 3.1 1-3.06 (3H, m), 2.25 (IH, m), 1.91 (IH, dt),
173 (2H, m), 1.22 (3H, t), 0.92 (IH, dt), 0.73 (IH, m).
LCMS (Method C) r/t 3.21 (M+H) 475.
Example 55: (laRS JbSR)[2-(3-Dimethylaminopropylcarbamoyl)benzenesulfonylamino]-
l ,l a,2,7b-tetrahydrocyclopro acid
A solution of terf-butyl (laRS,7bSR){2-[N-(2,4-dimethoxybenzyl)-N-(3-
dimethylamino-propyl)carbamoyl]benzenesulfonylamino }- 1,1a,2,7b-tetrahydro-cyclopropa-
[c]chromenecarboxylate (Intermediate 119, 0.03g) in trifluoroacetic acid (5mL) was stirred
and heated at 30°C overnight. The mixture was evaporated to dryness and the residue was
purified by HPLC (C18) to give (laRS,7bSR)[2-(3-
dimethylaminopropylcarbamoyl)benzenesulfonylamino] -1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.0 13g) as a white solid.
¾ NMR (DMSO-d ) d : 8.61 (IH, br t), 7.73 (IH, d), 7.52 (IH, t), 7.43 (2H, m), 6.97 (IH, d),
6.82 (IH, d), 4.14 (IH, d), 3.58 (IH, d), 3.26 (2H, m), 3.04 (2H, t), 2.60 (6H, s), 1.85 (3H, m),
1.67 (IH, m), 0.87 (IH, m), 0.68 (IH, m).
LCMS (Method C) r/t 2.79 (M+H) 473.
Example 56: (laRS,7bSR)(2-{ [N-((S)-l-Ethylpyrrolidinyl)-N-
methylcarbamoyl]methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
A mixture of methyl (laRS,7bSR)(2-{ [N-((S)- l-ethylpyrrolidinyl)-N-
methylcarbamoyl]-methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 126, 0.047g) and lithium
hydroxide monohydrate (0.168g) in dioxane (3mL) and water (lmL) was irradiated in the
microwave at 130°C for 40 minutes. After cooling, the mixture was diluted with methanol,
acidified with formic acid and evaporated in vacuo. The residue was triturated with 10%
methanol in DCM, filtered and the filtrate was evaporated in vacuo. The residue was purified
by chromatography on silica, eluting with a mixture of methanol and DCM with a gradient of
0-40%. The resultant solid was triturated with ethyl acetate and filtered off to give
(laRS,7bSR)(2-{ [N-((S)-l-ethylpyrrolidinyl)-N-methylcarbamoyl]-methyl}
fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(0.022g) as a white solid.
¾ NMR (DMSO-d at 80°C ) d : 7.83 (1H, t), 7.12 (1H, dt), 7.08 (1H, d), 7.01 (1H, d), 6.84
(1H, m), 4.61 (1H, br, s), 4.19 (1H, d), 4.12 (2H, s), 3.73 (1H, d), 2.71-3.18 (7H, br, m), 2.94
(3H, s), 1.85-2.15 (3H, m), 1.72 (1H, m), 1.17 (3H, t), 0.95 (1H, m), 0.78 (1H, m).
LCMS (Method C) r/t 3.08 (M+H) 532.
Example 57: (laRS,7bSR)(2-{ [N-((R)-l-Ethylpyrrolidinyl)-N-
methylcarbamoyl]methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chro acid
A mixture of methyl (laRS,7bSR)(2-{ [N-((R)- l-ethylpyrrolidin
yl)methylcarbamoyl]-N-methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 131, 0.076g) and lithium
hydroxide monohydrate (0.168g) in dioxane (3mL) and water (lmL) was irradiated in the
microwave at 130°C for 40 minutes. After cooling the mixture was diluted with methanol,
acidified with formic acid and evaporated in vacuo. The residue was triturated with 10%
methanol in DCM, filtered and the filtrate was evaporated in vacuo. The residue was purified
by chromatography on silica, eluting with a mixture of methanol and DCM with a gradient of
0-40%. The resultant solid was triturated with ethyl acetate and filtered off to give
(laRS,7bSR)(2-{ [N-((R)-l-ethylpyrrolidinyl)-N-methylcarbamoyl]-methyl}fluoro-
benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid (0.028g)
as a white solid.
¾ NMR (DMSO-d at 80°C) d : 7.83 (1H, t), 7.12 (1H, dt), 7.08 (1H, d), 7.01 (1H, d), 6.84
(1H, m), 4.61 (1H, br, s), 4.19 (1H, d), 4.12 (2H, s), 3.73 (1H, d), 2.71-3.18 (7H, br, m), 2.94
(3H, s), 1.85-2.15 (3H, m), 1.72 (1H, m), 1.17 (3H, t), 0.95 (1H, m), 0.78 (1H, m).
LCMS (Method C) r/t 3.08 (M+H) 532.
Example 58: (laRS JbSR){2-[2-((S)-l-Emylpyrrolidinyl)emylamino]benzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydroc chromenecarboxylic acid
A mixture of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 67, O.lg), 2-((S)-l-
ethylpyrrolidinyl)ethylamine (Intermediate 136, 0.5g) and triethylamine (0.5mL) was stirred
and heated in a sealed tube at 140°C overnight. After cooloing, the mixture was concentrated
under vacuum and the residue was purified by chromatography on silica, eluting with a mixture
of methanol and DCM (10%). The product was repurified by HPLC (C18) to give
(laRS,7bSR){2-[2-((S)-l-ethylpyrrolidinyl)ethylamino]benzenesulfonylamino}-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid (0.022g) as a white solid.
NMR (DMSO-d ) d : 7.47 (IH, m), 7.25 (IH, t), 6.92 (IH, d), 6.89 (IH, m), 6.72 (IH, d), 6.53
(IH, dt),6.0-5.3 (IH, br s), 4.1 1 (IH, dd), 3.53 (IH, t), 3.33-2.80 (7H, m), 2.19 (2H, m), 1.92
(2H, m), 1.82 (2H, m), 1.64 (2H, m), 1.17 (3H, t), 0.84 (IH, m), 0.67 (IH, m).
LCMS (Method C) r/t 3.34 (M+H) 486.
Example 59: (1aRS ,7bSR) {2-[2-((R)- 1-Ethylpyrrolidinyl)ethylamino]benzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydroc chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 58, starting from
(laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa-[c]chromene-
4-carboxylic acid (Intermediate 67) and 2-((R)-l-ethylpyrrolidinyl)ethylamine (Intermediate
141).
¾ NMR (DMSO-d ) d : 7.47 (IH, m), 7.25 (IH, t), 6.97 (IH, d), 6.90 (IH, m), 6.72 (IH, d),
6.53 (IH, dt), 6.0-5.4 (IH, br s), 4.12 (IH, dd), 3.53 (IH, t), 3.35-2.85 (7H, m), 2.20 (2H, m),
1.93 (2H, m), 1.81 (2H, m), 1.65 (2H, m), 1.18 (3H, t), 0.84 (IH, m), 0.67 (IH, m).
LCMS (Method C) r/t 3.32 (M+H) 486.
Example 60: (laRS JbSR)[2-(3-N,N,-Diethylaminopropylamino)benzenesulfonylamino]-
l ,l a,2,7b-tetrahydrocyclopr acid
3-Diethylaminopropyl amine (0.975g) was added to a solution of (laRS,7bSR)-
-(2-fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic
acid (Intermediate 67, 0.091g) in NMP (3mL) and the mixture was heated at 140°C in a sealed
tube for 36 hours. After cooling, the mixture was diluted with water (2mL) and the solution was
purified by preparative HPLC (CI 8) eluting with a mixture of methanol and water, containing
0.1% formic acid, with a gradient of 10-98% to give (laRS,7bSR)[2-(3-
diethylaminopropylamino)benzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.039g) as a white solid.
¾ NMR (DMSO-d ) d : 7.45 (1H, dd), 7.28 (1H, dt), 7.04 (2H, m), 6.74 (1H, d), 6.5 1 (1H, t),
6.17 (1H, br s), 4.16 (1H, d), 3.57 (1H, d), 3.54-2.97 (8H, br m), 1.87 (1H, dt), 1.81-1.63 (3H,
m), 1.15 (6H, t), 0.89 (1H, m), 0.72 (1H, m).
LCMS (Method C) r/t 3.31 (M+H) 474.
Example 61: (laRS,7bSR)(2-{ [((R)-l-Ethylpyrrolidineyl)carbonylamino]methyl}
fluorobenzenesulfonylamino) romenecarboxylic acid
A mixture of methyl (laRS,7bSR)(2-{ [((R)-l-ethylpyrrolidine
yl)carbonylamino]methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 146, 0.120g) and lithium
hydroxide monohydrate (0.095g) was suspended in dioxane (5mL) and water (lmL) and the
mixture was stirred and heated at 110°C for 22.5 hours. After cooling, the volatiles were
removed in vacuo and the residue was acidified by addition of aqueous citric acid solution
(10%) and extracted with DCM. The organic layer was dried and filtered and the
(Na2SC>4)
filtrate was evaporated to dryness. The residue was purified by preparative HPLC (CI 8) eluting
with a mixture of methanol and water, containing 0.1% formic acid, with a gradient of 10-98%
to give (laRS,7bSR)(2-{ [((R)-l-ethylpyrrolidineyl)carbonylamino] methyl}
fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid
(0.043g) as a white solid.
¾ NMR (DMSO-d ) d : 8.77 (IH, d), 7.83 (IH, dd), 7.22 (IH, td), 7.12 (IH, dd), 7.08 (IH, d),
6.16 (IH, dd), 4.73 (2H, d), 4.24 (IH, d), 3.67 (IH, d), 3.54 (IH, br s), 3.37-3.28 (IH, m), 2.93-
2.80 (IH, m), 2.80-2.61 (2H, m), 2.30-2.20 (IH, m), 1.95-1.70 (5H, m), 1.08 (3H, t), 0.95 (IH,
dt), 0.76 (IH, q).
LCMS (Method C) r/t 3.09 (M+H) 5 18.
Example 62: (laRS,7bSR){2-[(l-Ethylazetidinylmethyl)amino]benzene-sulfonylamino}-
l ,l a,2,7b-tetrahydrocyclopro acid
A mixture of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic (Intermediate 67, 0.07g) and (1-ethylazetidin-
3-yl)methylamine (Intermediate 149, 0.7g) in DMSO (1.4mL) was divided evenly between 7
microwave vials and each was irradiated in the microwave at 130°C for 4 hours. After cooling,
the combined mixture was concentrated under vacuum and the residue was purified by
chromatography on silica, eluting with a mixture of methanol and DCM (10%). The product
was repurified by HPLC (C18) to give (laRS,7bSR){2-[(l-ethylazetidin
ylmethyl)amino]benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid (0.0 12g) as an off-white solid.
¾ NMR (DMSO-d ) d : 7.34 (IH, d), 7.22 (IH, t), 7.04 (IH, d), 6.97 (IH, d), 6.74 (IH, d), 6.49
(IH, t), 6.34 (IH, br s), 4.10 (IH, d), 3.75-3.55 (4H, m), 3.18 (IH, br m), 3.03 (IH, br m), 2.88
(2H, m), 2.32 (IH, m), 1.85 (IH, m), 1.67 (IH, m), 1.19 (IH, m), 0.98 (3H, t), 0.86 (IH, m),
0.69 (IH, m)
LCMS (Method C) r/t 3.21 (M+H) 457.
Examples 63 and 64: (laR,7bS)[2-((Z)Diethylaminoprop-l-enyl)benzenesulfonyl-
amino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid and (laS,7bR)[2-
((Z)diethylaminoprop- 1-enyl)benzenesulfonylamino] -1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid
A mixture of methyl (laRS,7bSR)[2-((Z)diethylaminoprop-l-
enyl)benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 153, 0.495g) and lithium hydroxide monohydrate (0.442g) was suspended in
dioxane (20mL) and water (5mL) and the mixture was stirred and heated at 80°C for 12.5
hours. After cooling, the volatiles were removed in vacuo and the residue was acidified by
addition of aqueous citric acid solution (10%) and extracted with DCM. The organic layer was
dried (Na2SC 4) and filtered. The filtrate was evaporated to dryness and the residue was purified
by preparative HPLC (CI 8) eluting with a mixture of acetonitrile and water, containing 0.1%
formic acid, with a gradient of 35-70% to give (laRS,7bSR)[2-((Z)diethylaminoprop-l-
enyl)benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(0.147g) as a white solid.
This material was subjected to chiral separation using a ChiralPak IC column, 4.6mm x
250mm, particle size 5micron. Eluting solvent absolute ethanol,
Example 63: First eluting enantiomer: retention time on above column: 25.71 minutes, >99%
¾ NMR (DMSO-d ) d : 7.65 (1H, dd), 7.60 (1H, td), 7.44-7.37 (2H, m), 7.28
(1H, d), 7.08 (1H, d), 6.95 (1H, d), 6.15-6.05 (1H, m), 4.16 (1H, d), 3.77-3.67 (2H, m), 3.56
(1H, d), 3.13-3.03 (4H, m), 1.90 (1H, dt), 1.71 (1H, q), 1.12 (6H, t), 0.92 (1H, dt), 0.72 (1H, q).
LCMS (Method C) r/t 3.20 (M+H) 457.
Example 64: Second eluting enantiomer: retention time on above column 35.5 1 minutes, >99%
¾ NMR (DMSO-d ) d : 7.65 (1H, dd), 7.60 (1H, td), 7.43-7.38 (2H, m), 7.28
(1H, d), 7.08 (1H, d), 6.95 (1H, d), 6.16-6.07 (1H, m), 4.16 (1H, d), 3.77-3.67 (2H, m), 3.56
(1H, d), 3..09 (4H, q), 1.91 (1H, dt), 1.71 (1H, q), 1.12 (6H, t), 0.93 (1H, dt), 0.72 (1H, q).
LCMS (Method C) r/t 3.20 (M+H) 457.
Example 65: (laRS,7bSR)(2-{N-[((R)-l-Ethylpyrrolidineyl)carbonyl]-N-methyl
methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
A mixture of methyl (laRS,7bSR)(2-{N-[((R)- l-ethylpyrrolidine
yl)carbonyl]-N-methyl-aminomethyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 155, 0.177g) and lithium
hydroxide monohydrate (0.1 36g) in dioxane (5mL) and water (2mL) was stirred and heated at
100°C for 19.5 hours. After cooling, the mixture was evaporated to dryness and the residue was
acidified by addition of aqueous citric acid solution (10%). The resultant solid was collected by
filtration, washed with water and dried under vacuum at 40°C. The solid was purified by
preparative HPLC (CI 8) eluting with a mixture of methanol and water, containing 0.1% formic
acid, with a gradient of 10-98% to give (laRS,7bSR)(2-{N-[((R)-l-ethylpyrrolidine
yl)carbonyl]-N-methylaminomethyl }fluoro-benzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.053g) as a white solid.
¾ NMR (DMSO-d ) d : 7.93-7.78 (IH, m), 7.17 (IH, m), 6.99 (0.5H, m), 6.95 (0.5H, d), 6.90-
6.76 (1.5H, m), 6.69 (0.5H, dd), 5.02 (1.5H, m), 4.86 (0.5H, dd), 4.61-4.44 (IH, br s), 4.15 (IH,
dd), 3.55 (3H, m), 3.1 1 (2H, m), 2.90 (3H, 2s), 2.06-1.54 (6H, m), 1.18-1.05 (4H, m), 0.84
(IH, m), 0.68 (IH, m).
LCMS (Method C) r/t 3. 14 (M+H) 532.
Example 66: (laRS,7bSR)(2-{N-[((S)-l-Ethylpyrrolidineyl)carbonyl]-N-methyl
methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
Prepared by proceeding in a similar manner to Example 65, starting from methyl
(laRS,7bSR)(2-{N-[((S)-l-ethylpyrrolidineyl)carbonyl]-N-methylaminomethyl}
fluorobenzene-sulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 160) as a white solid.
¾ NMR (DMSO-d ) 7.94-7.76 (IH, m), 7.18 (IH, m), 7.02-6.92 (IH, m), 6.92-6.76 (1.5H, m),
6.68 (0.5H, m), 5.02 (1.5H, m), 4.86 (0.5H, dd), 4.65-4.49 (IH, br s), 4.15 (IH, dd), 3.55 (3H,
m), 3.14 (2H, m), 2.91 (3H, 2s), 2.07-1.59 (6H, m), 1.13 (4H, m), 0.85 (IH, m), 0.68 (IH, m).
LCMS (Method C) r/t 3. 15 (M+H) 532.
Example 67: (laRS,7bSR)[2-(4-Dimethylaminobutylamino)
fluorobenzenesulfonylamino]- chromenecarboxylic acid
A mixture of methyl (laRS,7bSR)[2-(4-dimethylaminobutylamino)
fluorobenzene-sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 161, 0.485g) and lithium hydroxide monohydrate (0.505g) in dioxane (9mL) and
water (3mL) was irradiated in the microwave at 130°C for 45 minutes. After cooling, the
mixture was diluted with methanol, acidified with formic acid and evaporated in vacuo. The
residue was triturated with 20% methanol in DCM, filtered and the filtrate was evaporated in
vacuo. The residue was purified by chromatography on silica, eluting with a mixture of
methanol and DCM with a gradient of 0-20%. The resultant solid was triturated with ethyl
acetate and filtered off to give (laRS,7bSR)[2-(4-dimethylaminobutylamino)
fluorobenzenesulfonylamino] -1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid
(0.215g) as a white solid.
¾ NMR (DMSO-d ) d : 12.52 (2H, br, s), 7.65 (IH, dd), 7.08 (2H, q), 6.56 (IH, dd), 6.39 (IH,
dt), 5.98 (IH, m), 4.20 (IH, d), 3.59 (IH, d), 3.22 (2H, q), 2.98 (2H, m), 2.75 (6H, s), 1.91 (IH,
m), 1.81 (2H, m), 1.72 (IH, m), 1.58 (2H, m), 0.92 (IH, m), 0.76 (IH, m).
LCMS (Method C) r/t 3.43 (M+H) 478.
Example 68: (laRS,7bSR){2-[((R)-l-Ethylpyrrolidinylmethyl)amino]benzene-
sulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A solution of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 67, 0.105g), ((R)-l-
ethylpyrrolidinyl)methyl-amine (Intermediate 163, 0.5g) and triethylamine (0.5g) in DMSO
(lmL) was stirred and heated at 140°C overnight. After cooling, the mixture was concentrated
under vacuum and the residue was purified by chromatogrpahy on silica, eluting with a mixture
of methanol and DCM (5%). The product was purified by HPLC (C18) to give (laRS,7bSR)
{2-[((R)-l-ethylpyrrolidinylmethyl)amino]benzene-sulfonylamino}-l,la,2,7b-
tetrahydrocyclopropa[c]-chromenecarboxylic acid (0.03g) as a white solid,
¾ NMR (DMSO-d ) d : 7.38 (IH, dd), 7.24 (IH, t), 7.06 (2H, s), 6.81 (IH, d), 6.49 (IH, t),
6.14 (IH, br s), 4.13 (IH, dd), 3.54 (2H, m), 3.25 (2H, m) 3.07 (4H, m), 2.82 (IH, m), 2.63
(IH, m), 1.96 (IH, m), 1.86 (IH, m), 1.71-1.46 (2H, m), 1.19 (3H, m), 0.87 (IH, m), 0.70 (IH,
LCMS (Method C) r/t 3.31 (M+H) 472.
Example 69: (laRS,7bSR){2-[((S)-l-Ethylpyrrolidinylmethyl)amino]benzene-
sulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A solution of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic (Intermediate 67, 0.08g), and ((S)-l-
ethylpyrrolidinyl)methylamine (Intermediate 169, 0.8g) in DMSO (0.2mL) was stirred and
heated at 120°C for 24 hours. After cooling, the mixture was diluted with methanol and
concnetrated under vacuum. The residue was purified by HPLC (C18) to give (laRS,7bSR)
{2-[((S)-l-ethylpyrrolidinylmethyl)amino]benzene-sulfonylamino}-l,la,2,7b-
tetrahydrocyclopropa[c]-chromenecarboxylic acid (0.03g) as a white solid.
¾ NMR (DMSO-d ) d : 7.37 (IH, dd), 7.24 (IH, t), 7.05 (2H, s), 6.80 (IH, d), 6.48 (IH, t),
6.13 (IH, br s), 4.13 (IH, dd), 3.54 (2H, m), 3.24 (2H, m), 3.05 (4H, m), 2.82 (IH, m), 2.62
(IH, m), 1.95 (IH, m), 1.85 (IH, m), 1.71-1.46 (2H, m), 1.18 (3H, m), 0.86 (IH, m), 0.69
LCMS (Method C) r/t 3.25 (M+H) 472.
Example 70: (laRS,7bSR)[2-(4-Ethyloxopiperazin-l-ylmethyl)fluorobenzene-
sulfonylamino]- l ,l a,2,7b-tetrah arboxylic acid
A mixture of methyl (laRS,7bSR)[2-(4-ethyloxopiperazin-l-ylmethyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 173, 0.28g) and lithium hydroxide monohydrate (0.126g) in dioxane (9mL) and
water (3mL) was irradiated in the microwave at 130°C for 30 minutes. After cooling, the
mixture was diluted with methanol, acidified with formic acid and evaporated in vacuo. The
residue was triturated with 20% methanol in DCM, filtered and the filtrate was evaporated in
vacuo. The residue was purified by chromatography on silica, eluting with a mixture of
methanol and DCM with a gradient of 0-20%. The resultant solid was triturated with ether and
filtered to give (laRS,7bSR)[2-(4-ethyloxo-piperazin-l-ylmethyl)
fluorobenzenesulfonylamino] -1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid
(0.176g) as a white solid.
¾ NMR (CDC1 ) d : 11.28 (IH, br, s), 8.02 (IH, dd), 7.3 1 (IH, d), 7.23 (IH, d), 6.98 (2H, m),
4.98 (2H, q), 4.57 (IH, d), 4.04 (IH, d), 3.36 (2H, t), 3.30 (2H, s), 2.72 (2H, t), 2.5 1 (2H, q),
1.96 (IH, m), 1.80 (IH, m), 1.1 1 (4H, m), 1.03 (IH, m).
LCMS (Method C) r/t 2.96 (M+H) 504.
Example 71: (laRSJbSR)- 5-[2-(l-Ethylpiperidinylmethyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Methyl (laRS,7bSR)[2-(l-ethylpiperidinylmethyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 177, 0.279g) and lithium hydroxide monohydrate (0.233g) were suspended in
dioxane (7mL) and water (3mL) and the mixture was stirred and heated at 80°C for 25 hours.
Further lithium hydroxide monohydrate (0. 116g) was added and the mixture heating was
continued for 18 hours. After cooling, the volatiles were removed in vacuo, the residue was
acidified by addition of aqueous citric acid solution (10%) and saturated with sodium chloride.
The mixture was extracted with DCM and the organic layer was dried (Na SC>4) and filtered.
The filtrate was evaporated to dryness and the residue was purified by preparative HPLC
(C18), eluting with a mixture of methanol and water, containing 0.1% formic acid, with a
gradient of 10-98% to give (laRS,7bSR)[2-(l-ethylpiperidinylmethyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(0.1 17g) as a white solid.
¾ NMR (DMSO-d ) d : 7.99 (IH, dd), 7.22-7.14 (2H, m), 6.99 (IH, d), 6.76 (IH, d), 4.20 (IH,
d), 3.60 (IH, d), 3.34 (2H, d), 3.02-2.88 (4H, m), 2.71 (2H, br s), 1.99 (IH, br s), 1.84 (IH, dt),
1.74-1.62 (3H, m), 1.56-1.40 (2H, m), 1.18 (3H, t), 0.89 (IH, dt), 0.73 (IH, q).
LCMS (Method C) r/t 3.22 (M+H) 489.
Example 72: (laRS,7bSR){2-[2-(l-Ethylazetidinyl)ethyl]fluorobenzene-
sulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A mixture of methyl (laRS,7bSR){2-[2-(l-ethylazetidinyl)ethyl]
fluorobenzene- sulfonylamino }- 1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(intermediate 183, 0.306g) and lithium hydroxide monohydrate (0.421g) in dioxane (7.5mL)
and water (2.5mL) was irradiated in the microwave at 130°C for 45 minutes. After cooling, the
mixture was diluted with methanol, acidified with formic acid and evaporated in vacuo. The
residue was triturated with 20% methanol in DCM, filtered and the filtrate was evaporated in
vacuo. The residue was purified by chromatography on silica, eluting with a mixture of
methanol and DCM with a gradient of 0-30%. The resultant solid was triturated with ether and
filtered to give (laRS,7bSR){2-[2-(l-ethyl-azetidinyl)ethyl]
fluorbenzenesulfonylamino} l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(0.24 lg) as a white solid.
¾ NMR (DMSO-d ) d : 7.92 (IH, br, s), 7.35 (IH, dd), 7.22 (IH, dt), 7.17 (IH, d), 6.78 (IH,
br, s), 4.27 (IH, d), 4.05 (2H, m), 3.78 (2H, br, s), 3.70 (IH, d), 3.17 (2H, q), 2.86 (2H, br, s),
2.70 (IH, br, s), 1.95 (IH, m), 1.84 (2H, m), 1.75 (IH, m), 1.1 1 (3H, t), 0.98 (IH, m), 0.76
(IH, m).
LCMS (Method C) r/t 3.36 (M+H) 475.
Example 73: (laRS,7bSR){2-[((S)-l-Azabicyclo[2.2.2]octyl)amino]benzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydrocycl chromenecarboxylic acid
A solution of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 67, 0.6g) and (S)-l-
azabicyclo[2.2.2]octylamine (6.0g) in DMSO (6mL) was stirred and heated in a selaed
vessel at 140°C for 22 hours. After cooling, the mixture was diluted with methanol and
concentrated under vacuum. The residue was purified by HPLC (C18) to give (laRS,7bSR)
{2-[((S)-l-azabicyclo[2.2.2]octyl)amino]benzenesulfonylamino}-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.107g) as a white solid.
¾ NMR (DMSO-d ) d : 7.58 (IH, ddd), 7.25 (IH, t), 6.94 (IH, dd), 6.76 (2H, t), 6.62 (2H, m),
6.06 (IH, d), 4.14 (IH, t), 3.86 (IH, br s), 3.57 (3H, m), 3.16-2.87 (4H, m), 2.12 (IH, m), 2.01
(IH, m), 1.82 (3H, m), 1.65 (2H, m), 0.83 (IH, m), 0.67 (IH, m).
LCMS (Method C) r/t 3. 16 (M+H) 470).
Example 74: (laRS,7bSR){2-[((R)-l-Azabicyclo[2.2.2]octyl)amino]benzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 73, starting from
(laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa-[c]chromene-
4-carboxylic acid (Intermediate 67) and (R)-l-azabicyclo[2.2.2]octylamine.
¾ NMR (DMSO-d ) d : 7.58 (IH, ddd), 7.25 (IH, t), 6.94 (IH, dd), 6.76 (2H, t), 6.62 (2H, m),
6.07 (IH, d), 4.13 (IH, t), 3.86 (IH, br s), 3.57 (3H, m), 3.16-2.87 (4H, m), 2.12 (IH, m), 2.01
(IH, m), 1.83 (3H, m), 1.64 (2H, m), 0.83 (IH, m), 0.67 (IH, m).
LCMS (Method C) r/t 3. 15 (M+H) 470
Example 75: (laRS,7bSR)(2-{ [((S)-l-ethylpyrrolidinecarbonyl)amino]methyl}fluoro-
benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Methyl (laRS,7bSR)(2-{ [((S)-l-ethylpyrrolidinecarbonyl)amino]methyl}-
4-fluoro-benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 188, 0.190g) and lithium hydroxide monohydrate (0.150g) were suspended in
dioxane (5mL) and water (5mL) and the mixture was stirred and heated at 100°C for 18.5
hours. After cooling, the volatiles were removed in vacuo and the residue was acidified by
addition of aqueous citric acid solution (10%) and extracted with DCM. The organic layer was
dried (Na2SC 4) and filtered. The filtrate was evaporated to dryness and the residue was purified
by preparative HPLC (CI 8) eluting with a mixture of acetonitrile and water, containing 0.1%
formic acid, with a gradient of 25-60% to give (laRS,7bSR)(2-{ [((S)-l-ethylpyrrolidine
carbonyl)amino]methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.092g) as a white solid.
¾ NMR (DMSO-d ) d : 8.78 (IH, q), 7.89-7.82 (IH, m), 7.19 (IH, td), 7.12 (IH, dt), 7.02 (IH,
dd), 6.75 (IH, dd), 4.74 (2H, d), 4.19 (IH, d), 3.62 (IH, dt), 3.50-3.15 (5H, m), 3.10 (2H, q),
2.35-2.23 (IH, m), 2.10-1.99 (IH, m), 1.86 (IH, dt), 1.75-1.67 (IH, m), 1.20 (3H, t), 0.90 (IH,
dt), 0.73 (IH, q)
LCMS (Method C) r/t 3.01 (M+H) 5 18
Example 76: (laRS,7bSR) {2-[2-((R)- 1-Ethylpyrrolidinylamino)ethyl]fluoro-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylic acid
A solution of (laRS,7bSR)(4-fluorovinylbenzenesulfonylamino)-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid (Intermediate 74, 0.150g) and
(R)-l-ethylpyrrolidinylamine (Intermediate 193, 0.25g) in ethylene glycol (1ml) was
irradiated in the microwave at 200 °C for 30 minutes. After cooling, the mixture was diluted
with water and loaded onto a SCX-2 SPE cartridge then washed with water, methanol and 2M
ammonia in methanol. The basic fractions were combined and evaporated to dryness. The
residue was purified by preparative HPLC (CI 8) eluting with a mixture of methanol and water,
containing 0.1% ammonia, with a gradient of 10-98%. Then further purified by preparative
HPLC (CI 8) eluting with a mixture of acetonitrile and water, containing 0.1% formic acid,
with a gradient of 10-60% to give (laRS,7bSR){2-[2-((R)-l-ethylpyrrolidin
ylamino)ethyl]fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydro-cyclopropa[c] chromene-
4-carboxylic acid (0.005g) as a white solid.
¾ NMR (CDC1 ) d : 7.86 (IH, dd), 7.43 (IH, dd), 7.31 (IH, dt), 7.27 (IH, d), 6.59 (IH, d), 4.31
(IH, d), 4.18-3.97 (1.5H, br), 3.82-3.64 (1.5H, br), 3.79 (IH, d), 3.33-3.20 (8H, br), 2.31 (IH,
br s), 2.04 (IH, m), 1.84 (IH, q), 1.26 (4H, t), 1.07 (IH, m), 0.86 (IH, q).
LCMS (Method C) r/t 2.60 (M+H) 503.9
Example 77: (laRS,7bSR){2-[((R)-l-Ethylpyrrolidinyl)amino]benzenesulfonylamino}-
l ,l a,2,7b-tetrahydrocycloprop acid
A solution of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 67, 0.13g) and (R)-l-
ethylpyrrolidinylamine (Intermediate 193, 1.22g) in DMSO (0.7mL) was stirred and heated
in a selaed vessel at 120°C for 22 hours. After cooling, the mixture was diluted with methanol
and concentrated under vacuum. The residue was purified by HPLC (CI 8) to give
(laRS,7bSR) {2-[((S)- l-ethylpyrrolidinyl)amino]benzenesulfonylamino }- 1,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.107g) as a white solid.
¾ NMR (DMSO-d ) d : 7.32 (2H, m), 7.04 (IH, d), 6.98 (IH, m), 6.72 (IH, d), 6.60 (IH, t),
.55 (IH, br s), 4.18 (IH, br s), 4.1 1 (IH, t), 3.78 (IH, br s), 3.66-3.48 (2H, m), 3.18-2.94 (4H,
m), 2.54 (IH, m), 1.86 (2H, m), 1.66 (IH, m), 1.22 (3H, t), 0.86 (IH, m), 0.68 (IH, m).
LCMS (Method C) r/t 3.40 (M+H) 458.
Example 78: (laRS,7bSR){2-[((S)-l-Ethylpyrrolidinyl)amino]benzenesulfonylamino}-
l ,l a,2,7b-tetrahydrocycloprop acid
Prepared by proceeding in a similar manner to Example 77, starting from
(laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa-[c]chromene-
4-carboxylic acid (Intermediate 67) and (S)-l-ethylpyrrolidinylamine (Intermediate 194).
¾ NMR (DMSO-d ) d : 7.32 (2H, m), 7.05 (IH, d), 6.98 (IH, m), 6.72 (IH, d), 6.60 (IH, t),
.54 (IH, br s), 4.20 (IH, br s), 4.1 1 (IH, t), 3.80 (IH, br s), 3.69-3.48 (2H, m), 3.19-2.96 (4H,
m), 2.56 (IH, m), 1.86 (2H, m), 1.66 (IH, m), 1.22 (3H, t), 0.87 (IH, m), 0.68 (IH, m).
LCMS (Method C) r/t 3.40 (M+H) 458.
Example 79: (laRS,7bSR)(2-{ [((R)-l-Ethylpyrrolidineylcarbonyl)amino]methyl}
fluoro-benzenesulfon romenecarboxylic acid
A mixture of methyl (laRS,7bSR)(2-{ [((R)-l-ethylpyrrolidine
ylcarbonyl)amino]methyl }fluoro-benzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 195, 0.215g) and lithium
hydroxide monohydrate (0.170g) was suspended in dioxane (5mL) and water (5mL) and the
mixture was stirred and heated at 80°C for 2 1 hours. The temperature was raised to 100°C and
the mixture was stirred and heated at that temperature for 2.5 hours. Further lithium hydroxide
monohydrate (0.05g) was added and the mixture was stirred and heated at 100°C for 2 hours.
After cooling, the volatiles were removed in vacuo and the residue was acidified by addition of
aqueous citric acid solution (10%) and extracted with DCM. The organic layer was dried
(Na SC>4) and filtered. The filtrate was evaporated to dryness and the residue was purified by
preparative HPLC (CI 8) eluting with a mixture of acetonitrile and water, containing 0.1%
formic acid, with a gradient of 25-60% to give (laRS,7bSR)(2-{ [((R)-l-ethylpyrrolidine
ylcarbonyl)-amino]methyl}fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.103g) as a white solid.
' H M R (DMSO-d ) d : 8.78 (IH, q), 7.89-7.83 (IH, m), 7.18 (IH, td), 7.1 1 (IH, dt), 7.01 (IH,
dd), 6.76 (IH, dd), 4.74 (2H, d), 4.19 (IH, d), 3.61 (IH, dt), 3.46-3.12 (5H, m), 3.07 (2H, q),
2.34-2.22 (IH, m), 2.10-1.98 (IH, m), 1.86 (IH, dt), 1.70 (IH, q), 1.19 (3H, t), 0.90 (IH, dt),
0.73 (IH, q).
LCMS (Method C) r/t 3.04 (M+H) 5 18.
Example 80: (laRS,7bSR)5-[2-((Z)Diethylaminomethylprop-l-enyl)fluoro-
benzenesulfonylamino]- l ,l a,2, carboxylic acid
A mixture of methyl (laRS,7bSR){N-[2-((Z)diethylaminomethylprop-
l-enyl)fluorobenzenesulfonyl]-N-methoxycarbonylamino]-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate (Intermediate 200, 0.264g) and lithium hydroxide monohydrate
(0.505g) in dioxane (9mL) and water (3mL) was irradiated in the microwave at 130°C for 40
minutes. After cooling, the mixture was diluted with methanol, acidified with formic acid and
evaporated in vacuo then azeotroped with a mixture of ethanol and toluene. The residue was
triturated with 15% methanol in DCM, filtered and the filtrate was evaporated in vacuo. The
residue was purified by chromatography on silica, eluting with a mixture of methanol and
DCM with a gradient of 0-40%. The resultant solid was triturated with ether and filtered to give
(laRS JbSR)[2-((Z)diethylaminomethylprop-l-enyl)fluorobenzene-sulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid (0.202g) as a white solid.
¾ NMR (DMSO-d ) d : 7.95 (IH, dd), 7.28 (IH, dt), 7.14 (IH, dd), 7.06 (IH, d), 6.92 (IH, s),
6.64 (IH, d), 4.25 (IH, d), 3.64 (IH, d), 3.36 (2H, br, s), 2.63 (4H, q), 1.96 (3H, s), 1.90 (IH,
m), 1.74 (IH, m), 0.93 (IH, m), 0.86 (6H, t), 0.75 (IH, m).
LCMS (Method C) r/t 3.27 (M+H) 489
Example 81: (laRS,7bSR){2-[2-((R)-l-Ethylpyrrolidinyl)ethylamino]benzene-
sulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A mixture of (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 67, 0.2g) and 2-((R)-l-
ethylpyrrolidinyl)ethylamine (Intermediate 203, 2.0g) in DMSO (2mL) was divided between
two sealed vials and each was stirred and heated at 130°C for 24 hours. After cooling, the
combined mixture was diluted with methanol and then concentrated under vacuum. The residue
was purified by HPLC (C18) to give (laRS,7bSR){2-[2-((R)-l-ethylpyrrolidin
yl)ethylamino]-benzenesulfonyl-amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid (0.125g) as a white solid.
¾ NMR (DMSO-d ) d : 7.62 (IH, dt), 7.29 (IH, dt), 7.02 (2H, 2s), 6.70 (IH, d), 6.58 (IH, t),
.84 (IH, br m), 4.14 (IH, d), 3.54 (IH, d), 3.36 (IH m), 3.18 (3H, m), 3.06 (4H, m), 2.59 (IH,
m), 2.01 (IH, m), 1.83 (IH, m), 1.80-1.49 (4H, m), 1.19 (3H, q), 0.85 (IH, m), 0.69 (IH, m).
LCMS (Method C) r/t 3.35 (M+H) 486.
Example 82: (laRS,7bSR){2-[2-((S)-l-Ethylpyrrolidinyl)ethylamino]benzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 58, starting from
(laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa-[c]chromene-
4-carboxylic acid (Intermediate 67) and 2-((S)-l-ethylpyrrolidinyl)ethylamine (Intermediate
208).
¾ NMR (DMSO-d ) d : 7.62 (IH, dt), 7.29 (IH, dt), 7.02 (2H, 2s), 6.70 (IH, d), 6.57 (IH, t),
.84 (IH, br m), 4.14 (IH, d), 3.54 (IH, d), 3.36 (IH m), 3.17 (3H, m), 3.06 (4H, m), 2.57 (IH,
m), 2.01 (IH, m), 1.83 (IH, m), 1.80-1.49 (4H, m), 1.19 (3H, q), 0.85 (IH, m), 0.68 (IH, m).
LCMS (Method C) r/t 3.34 (M+H) 486.
Example 83: (laR,7bS)[2-((S)-l-Ethylpyrrolidinyloxymethyl)fluorobenzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
A mixture of methyl (laR,7bS)[2-((S)-l-ethylpyrrolidinyloxymethyl)
fluorobenzene-sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 213, 0.217g) and lithium hydroxide monohydrate (0.168g) in dioxane (3mL) and
water (lmL) was irradiated in the microwave at 130°C for 40 minutes. After cooling, the
mixture was diluted with methanol, acidified with formic acid, evaporated in vacuo and
azeotroped with a mixture of toluene and ethanol. The residue was triturated with 15%
methanol in DCM, filtered and the filtrate was evaporated in vacuo. The residue was purified
by chromatography on silica, eluting with a mixture of methanol and DCM with a gradient of
0-20%. The resultant gum was triturated with ether and ethyl acetate and filtered to give
(laR,7bS)[2-((S)-l-ethylpyrrolidinyloxymethyl)fluorobenzenesulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid (0.136g) as a white solid.
¾ NMR (CDC1 ) d : 7.35 (IH, dd), 7.23 (IH, d), 7.19 (IH, dd), 7.01 (IH, d), 6.83 (IH, dt),
4.87 (IH, br, d), 4.73 (IH, br, d), 4.36 (2H, br, m), 4.19 (IH, d), 3.88 (IH, m), 3.84 (IH, d),
3.38 (IH, m), 2.94 (IH, m), 2.86 (IH, m), 2.75 (IH, m), 2.26-2.45 (2H, m), 1.81 (IH, m), 1.60
(IH, m), 1.39 (3H, t), 0.90 (2H, m).
LCMS (Method C) r/t 3.25 (M+H) 491
Example 84: (laR,7bS)[2-((R)-l-Ethylpyrrolidinyloxymethyl)fluorobenzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Prepared by proceeding in a similar manner to Example 83, starting from methyl
(laR,7bS)[2-((R)-l-ethylpyrrolidinyloxymethyl)fluorobenzenesulfonylamino]-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 217).
¾ NMR (DMSO-d ) d : 7.83 (IH, dd), 7.44 (IH, dd), 7.20 (IH, dt), 7.07 (IH, d), 7.03 (IH, d),
4.99 (IH, d), 4.49 (2H, d), 4.19 (2H, d), 3.57 (2H, d), 2.93-3.30 (4H, m), 2.34 (IH, m), 2.13
(IH, m), 1.88 (IH, m), 1.72 (IH, m), 1.29 (3H, t), 0.92 (IH, m), 0.75 (IH, m).
LCMS (Method C) r/t 3.25 (M+H) 491.
Example 85: (laR,7bS) [2-(l-Ethylpiperidinylmethyl)fluorobenzenesulfonylamino]-
l ,la,2,7b-tetrahydrocycloprop acid
A mixture of methyl (laR,7bS) )[2-(l-ethylpiperidinylmethyl)
fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 221, 0.071g) and lithium hydroxide monohydrate (0.059g) was suspended in
dioxane (5mL) and water (2mL) and the mixture was stirred and heated at 100°C for 25 hours.
Further lithium hydroxide monohydrate (0. 116g) was added and the mixture was heated at
100°C for a further 18 hours. After cooling, the volatiles were removed in vacuo and the
residue was acidified by addition of aqueous citric acid solution (10%) and saturated with
sodium chloride. The mixture was extracted with DCM and the organic layer was dried
(Na2SC 4) and filtered. The filtrate was evaporated to dryness and the residue was purified by
preparative HPLC (CI 8), eluting with a mixture of acetonitrile and water, containing 0.1%
formic acid, with a gradient of 25-60% to give (laR,7bS)[2-(l-ethyl-piperidinylmethyl)-
4-fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid
(0.032g) as a white solid.
¾ NMR (DMSO-d ) d : 8.01-7.91 (IH, m), 7.26-7.18 (2H, m), 7.10-7.00 (2H, m), 4.22-4.17
(IH, m), 3.61 (IH, d), 3.45-2.92 (5H, m), 3.02-2.88 (4H, m), 1.94-1.85 (IH, m), 1.80-1.65
(3H, m), 1.65-1.50 (IH, m), 1.30-1.14 (4H, m), 0.97-0.87 (IH, m), 0.77-0.68 (IH, m).
LCMS (Method C) r/t 3.21 (M+H) 489.
Example 86: (laR,7bS){2-[2-((R)-l-Ethylpyrrolidinyl)ethyl]fluorobenzenesulfonyl-
amino }- 1,1a,2,7b-tetrahydrocy chromenecarboxylic acid
Lithium hydroxide (0.22g) was added to a solution of methyl (laR,7bS){2-
[2-((R)- 1-ethyl-pyrrolidinyl)ethyl]fluorobenzenesulfonylamino }- 1,1a,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylate (Intermediate 229, 0.26g) in a mixture of
dioxane (12mL) and water (4mL) and the mixture was irradiated in a microwave at 150°C for
minutes. After cooling, the mixture was evaporated to dryness and the residue was acidified
by addition of 10% aqueous citric acid (3mL) and then extracted with DCM. The organic layer
was dried (MgSCU) and filtered and the filtrate was evaporated to dryness. The residue was
purified by preparative HPLC (CI 8) eluting with a mixture of acetonitrile and water, containing
0.1% formic acid, with a gradient of 25-35% to give (laR,7bS){2-[2-((R)-l-ethylpyrrolidin-
2-yl)ethyl]fluoro-benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid (0.1 lg) as a white solid.
¾ NMR (DMSO-d ) d : 7.88 (IH, dd), 7.33 (IH, dd), 7.15 (IH, dt), 7.08 (IH, d), 6.98 (IH, d),
4.18 (IH, d), 3.68 (IH, br m), 3.58 (IH, d), 3.56 (IH, m), 3.22-2.96 (5H, m), 2.23 (IH, m), 2.03
(4H, m), 1.87 (2H, m), 1.72 (IH, q), 1.31 (3H, t), 0.91 (IH, m), 0.72 (IH, q).
LCMS (Method C) r/t 3.24 (M+H) 489.
Intermediate 1: Methyl cis-(3aRS,9bRS)(benzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-
furo[2,3-c]chromenecarboxylate
Mixture of cis enantiomers
Formic acid (5mL) was added to methyl cis-(3aRS,9bRS)[&w-(ferf-
butoxycarbonyl)amino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate
(Intermediate 2, 0.15g) and the mixture was stirred at room temperature for 1 hour. The
resultant mixture was evaporated to dryness and the residue was redissolved in toluene and
evaporated to dryness three times. The residue was dissolved in DCM (2mL) and pyridine
(lmL) was added followed by benzenesulfonyl chloride (0.07g). The resultant mixture was
stirred at room temperature for 90 minutes then diluted with DCM and washed with sodium
hydroxide (1M) and brine. The sodium hydroxide washing was saturated with salt and then
extracted with ethyl acetate, dried (MgS0 ) and filtered. The filtrate was evaporated to dryness
to give methyl cis-(3aRS,9bRS)(benzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenecarboxylate (0.082g) as a gum.
¾ NMR (CDC1 ) d : 7.73 (2H, dd), 7.53 (1H, t), 7.42 (2H, t), 7.25 (1H, d), 7.21
(1H, d), 4.29 (1H, m), 4.03 (1H, dd), 3.93 (1H, dd), 3.82 (2H, t), 3.70 (3H, s), 3.45 (1H, m),
2.48 (1H, m), 1.87 (1H, m).
Intermediate 2: Methyl cis-(3aRS,9bRS)[i>w-(½rf-butoxycarbonyl)amino]-l,3a,4,9b-
tetrahydro-2H-furo[2,3-c]chromenecarboxylate
Mixture of cis enantiomers
A solution of methyl 7-[i>w-(½rf-butoxycarbonyl)amino]-4H-furo[2,3-c]-
chromenecarboxylate (Intermediate 3, 0.15g) in a mixture of dioxane (15mL) and acetic acid
(1.5mL) was treated under an atmosphere of nitrogen with palladium on carbon (10%, 0.02g).
The mixture was stirred and the nitrogen was replaced by hydrogen then the mixture was
stirred under an atmosphere of hydrogen for 3 hours. The mixture was filtered through Celite,
the pad was washed thoroughly with dioxane and the filtrate was evaporated to dryness to give
methyl cis-(3aRS,9bRS)[&w-(ferf-butoxycarbonyl)amino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenecarboxylate (0.15g) as a gum.
¾ NMR (CDC1 ) d : 7.22 (1H, dd), 6.80 (1H, d), 4.36 (1H, m), 4.07 (2H, d),
3.86 (2H, t), 3.84 (3H, s), 3.53 (1H, m), 2.50 (1H, m), 1.94 (1H, m), 1.40 (18H, s).
Intermediate 3: Methyl 7-[i>w-(ferf-butoxycarbonyl)amino]-4H-furo[2,3-c]-chromene
carboxylate
Carbon tetrabromide (2.66g) was added to a solution of methyl 6-[bis-(tert-
butoxycarbonyl)amino]hydroxy(2-hydroxymethylfuranyl)-benzoate (Intermediate 4,
2.65g) and triphenyl phosphine (2.1g) in DCM (40mL) and the resultant solution was stirred at
room temperature for 1 hour. The mixture was evaporated to dryness and DMF (60mL) and
cesium carbonate (5.59g) were added to the residue. The resultant mixture was stirred for 1
hour, then partitioned between ethyl acetate and water. The organic layer was separated, dried
and filtered. The filtrate was evaporated to dryness and the residue was purified by
(Na2SC 4)
chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 5-25% to give methyl 7-[i>w-(½rf-butoxycarbonyl)amino]-4H-furo[2,3-c]-
chromenecarboxylate (0.735g) as a gum which crystallised on standing.
¾ NMR d : 7.45 (1H, m), 7.26 (1H, s), 6.79 (1H, d), 6.65 (1H, d), 5.44
(CDCI3)
(2H, s), 3.87 (3H, s), 1.42 (18H, s).
Intermediate 4: Methyl 6-[i>w-(ferf-butoxycarbonyl)amino]hydroxy(2-
hydroxymethylf
1M aqueous sodium hydroxide (50mL) was added to a solution of methyl 6-[i>w-
(½rf-butoxycarbonyl)amino](2-hydroxymethylfuranyl)(4-methylbenzene-
sulfonyloxy)benzoate (Intermediate 5, 3.82g) in methanol (lOOmL) and the mixture was stirred
and heated at 45°C for 1.5 hours. The mixture was evaporated to dryness and the residue was
dissolved in ethyl acetate and acidified with acetic acid. The organic layer was separated, dried
and filtered. The filtrate was evaporated to dryness and the residue was purified by
(Na2SC 4)
chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 10-50% to give methyl 6-[i>w-(½rf-butoxycarbonyl)amino]hydroxy(2-
hydroxymethylfuranyl)benzoate (2.65g) as a white foam.
¾ NMR (CDC1 ) d : 11.91 (1H, s), 7.50 (2H, m), 6.80 (1H, d), 6.57 (1H, d), 4.58
(2H, s), 3.97 (3H, s), 1.43 (18H, s).
Intermediate 5: Methyl 6-[i>w-(ferf-butoxycarbonyl)amino](2-hydroxymethyl-furanyl)-
2-(4-methylbenzenesulfonyloxy)benzoate
Sodium borohydride (0.304g) was added to a solution of methyl 6-[bis-(tert-
butoxycarbonyl)amino](2-formylfuranyl)(4-methylbenzenesulfonyloxy)-benzoate
(Intermediate 6, 3.9g) in ethanol (50mL) and the mixture was stirred for 15 minutes. The
mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and
water. The organic layer was separated, dried and filtered. The filtrate was
(Na2SC 4)
evaporated to dryness to give methyl 6-[i>w-(½rf-butoxycarbonyl)amino](2-
hydroxymethylfuranyl)(4-methylbenzene-sulfonyloxy)benzoate (3.82g) as a white solid.
¾ NMR (CDC1 ) d : 7.40 (1H, d), 7.38 (2H, d), 7.30 (1H, d), 7.18 (1H, d), 7.1 1
(2H, d), 6.28 (1H, d), 4.33 (2H, s), 3.82 (3H, s), 2.40 (3H, s), 1.42 (18H, s).
Intermediate 6: Methyl 6-[i>w-(ferf-butoxycarbonyl)amino](2-formylfuranyl)(4-
methylbenzenesulfonyloxy)benzoate
Triethylamine (0.848g) was added to a stirred solution of methyl 6-amino(2-
formylfuranyl)hydroxybenzoate (Intermediate 7, 1.72g), 4-methylbenzenesulfonyl
chloride (1.25g) and DMAP (0.804g) in DCM (30mL) and the resultant mixture was stirred for
1 hour. The mixture was diluted with water and the organic layer was separated, dried
and filtered. The filtrate was evaporated to dryness and the residue was dissolved in
(Na2SC>4)
acetonitrile (30mL) and DMAP (0.804g) and di-ferf-butyl dicarboante (3.16g) were added. The
mixture was stirred for 2 hours then diluted with ethyl acetate and water. The organic layer was
separated, dried and filtered. The filtrate was evaporated to dryness and the residue
(Na2SC>4)
was purified by chromatography on silica, eluting with a mixture of ethyl acetate and
cyclohexane with a gradient of 10-50% to give methyl 6-[i>w-(½rf-butoxycarbonyl)amino]
(2-formylfuranyl)(4-methylbenzenesulfonyloxy)-benzoate (3.9 lg) as a white foam.
¾ NMR (CDC1 ) d : 9.13 (1H, d), 7.54 (1H, dd), 7.38 (1H, d), 7.31 (2H, d), 7.23
(1H, d), 7.05 (2H, d), 6.75 (1H, d), 3.94 (3H, s), 2.37 (3H, s), 1.45 (18H, s).
Intermediate 7: Methyl 6-amino(2-formylfuranyl)hydroxybenzoate
A mixture of methyl 6-aminobromohydroxybenzoate (prepared according
to Wang et al, Bioorg Med Chem Let,t 2007, 17, 2817; 1.84g), 2-formylfuranboronic acid
pinacol ester (1.99g), tri-ferf-butylphosphonium tetrafluoroborate (0.2 18g), cesium carbonate
(7.33g) and frw-(dibenzylideneacetone)dipalladium (0.343g) in dioxane (75mL) and water
(9.4mL) was heated at 65°C, under nitrogen, for 1 hour. After cooling, the mixture was diluted
with ethyl acetate and water and the organic layer was separated, dried and filtered.
(Na2SC>4)
The filtrate was evaporated to dryness and the residue was purified by chromatography on
silica, eluting with a mixture of ethyl acetate and cyclohexane with a gradient of 10-50% to
give methyl 6-amino(2-formylfuranyl)hydroxybenzoate (1.72g) as a yellow solid. The
material was used without further characterisation.
Intermediate 8: 7-[2-((Z)Diethylaminoprop-l-enyl)fluorobenzene-sulfonylamino]-4H-
furo[2,3-c]chro
Methyl 7-[2-((Z)diethylaminoprop- l-enyl)fluorobenzenesulfonylamino]-
4H-furo[2,3-c]chromenecarboxylate (Intermediate 9, 0.129g) was added to a solution of
lithium hydroxide monohydrate (0.42g) in water (2mL) and dioxane (8mL), and the mixture
was irradiated in the microwave at 130°C for 1 hour. After cooling, the mixture was acidified
with formic acid, and evaporated to dryness. The residue was triturated with 10% methanol in
DCM, filtered and the filtrate was evaporated to dryness. The residue was purified by
chromatography on silica, eluting with a mixture of methanol and DCM with a gradient of 0-
%. The isolated product was triturated with ethyl acetate and the solid was collected by
filtration and dried in vacuo to give 7-[2-((Z)diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-4H-furo[2,3-c]chromenecarboxylic acid (0.056 g) as a white
solid.
¾ NMR (DMSO-d ) d : 7.71 (1H, d), 7.68 (1H, d), 7.38 (1H, d), 7.28 (1H, dd),
7.26-7.19 (2H, m), 7.02 (1H, d), 6.86 (1H, d), 6.20-6.1 1 (1H, m), 5.28 (2H, s), 3.79 (2H, d),
3.12 (4H, q), 1.14 (6H, t).
LCMS (Method C) r/t 3.48 (M+H) 501.
Intermediate 9: Methyl 7-[2-((Z)Diethylaminoprop-l-enyl)fluorobenzene-
sulfonylamino]-4H-furo[2,3-c]chromenecarboxylate
A mixture of methyl 7-(2-bromofluorobenzenesulfonylamino)-4H-furo[2,3-
c]chromenecarboxylate (Intermediate 10, 2.04g), N,N-diethyl-N-((Z)-l-
tributylstannanylprop-l-enyl)amine (Intermediate 11, 3.4g), tri-ferf-butylphosphonium
tetrafluoroborate (0.246g), frw-(dibenzylideneacetone)dipalladium (0.0.388g) in dioxane
(35mL) was degassed and purged with argon then heated at 100°C for 3.5 hours. After cooling,
the mixture was diluted with ethyl acetate and filtered. The filtrate was washed with water,
dried and filtered. The filtrate was evaporated to dryness and the residue was purified
(Na2SC 4)
by chromatography on silica, eluting with a mixture of ammonia in methanol (2M) and DCM
with a gradient of 0-10%. The product was triturated with ether and the solid was collected by
filtration to give methyl 7-[2-((Z)diethylaminoprop- 1-en- l-yl)fluorobenzenesulfonyl-
amino]-4H-furo[2,3-c]chromenecarboxylate (1.47g) as a pale orange solid.
¾ NMR (CDC1 ) d : 8.06 (1H, dd), 7.40 (1H, m), 7.17 (1H, d), 7.14-6.98 (2H,
m), 7.0-6.9 (2H, m), 6.56 (1H, d), 6.06 (1H, m), 5.37 (2H, s), 3.87 (3H, s), 3.17 (2H, m), 2.55
(4H, m), 0.97 (6H, t).
Intermediate 10: Methyl 7-(2-bromofluorobenzenesulfonylamino)-4H-furo[2,3-
c]chromene
Methyl 7-[i>w-(½rf-butoxycarbonyl)amino]-4H-furo[2,3-c]-chromene
carboxylate (Intermediate 3, 2.66g) was dissolved in formic acid (50mL) and the mixture was
stirred at room temperature for 90 minutes. The mixture was evaporated to dryness and the
crude residue was partitioned between ethyl acetate and aqueous potassium carbonate solution
(10%). The organic layer was separated, dried (MgSCU) and filtered. The filtrate was
evaporated to dryness and the residue was dissolved in DCM (20mL) and pyridine (lOmL) and
2-bromofluorobenzenesulfonyl chloride (1.95g) was added. The resultant mixture was
stirred for 3.5 hours then evaporated to dryness. The residue was dissolved in DCM washed
with water and filtered through a phase separator. The filtrate was evaporated to dryness and
the residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate
and cyclohexane with a gradient of 0-60% to give methyl 7-(2-bromofluorobenzenesulfonyl-
amino)-4H-furo[2,3-c]chromenecarboxylate (0.47g) as a pale yellow solid.
¾ NMR (CDC1 ) d : 9.25 (1H, br s), 8.14 (1H, dd), 7.40 (2H, m), 7.16 (2H, m),
7.12 (1H, m), 6.55 (1H, d), 5.36 (2H, s), 3.92 (3H, s).
Intermediate 11: N,N-Diethyl-N-((Z)- 1-tributylstannanylprop- l-enyl)-amine
Diethylamine (19mL) was added to a solution of ((Z)bromoprop-l-enyl)-
tributyl-stannane (Intermediate 12, 7.52g) in THF (60mL) and the mixture was stirred for 3
hours. The reaction mixture was evaporated to dryness and the residue was purified by
chromatography on a silica column which had been pre-washed with 20% triethylamine in
acetonitrile. The column was eluted with a mixture of ethyl acetate and pentane with a gradient
of 0-10% to give N,N-diethyl-N-((Z)- 1-tributylstannanylprop- l-enyl)amine (4.75 g) as an
orange oil.
¾ NMR (CDC1 ) d : 6.59 (1H, dt), 5.97 (1H, dt), 3.08 (2H, dd), 2.53 (4H, q),
1.49 (6H, m), 1.37-1.24 (6H, m), 1.04 (6H, t), 0.92-0.89 (15H, m).
Intermediate 12: ((Z)Bromoprop-l-enyl)-tributylstannane
A solution of triphenylphosphine (5.32g) in DCM (60mL) was added to a
solution of (Z)tributylstannanylpropen-l-ol (Intermediate 13, 6.4g) and carbon
tetrabromide (9. 18g) in DCM (60mL) and the mixture was stirred for 2.5 hours. The mixture
was evaporated to low volume and pentane was added. The solids were removed by filtration
and the filtrate was evaporated to dryness. Pentane was added and the solids were again
removed by filtration and the filtrate was evaporated to dryness to give ((Z)bromoprop-l-
enyl)-tributylstannane (12.14 g) as an oil.
¾ NMR (CDC1 ) d : 6.71 (1H, dt), 6.1 1 (1H, d), 3.88 (2H, d), 1.52-1.50 (6H, m),
1.37-1.27 (6H, m), 0.99-0.97 (6H, m), 0.90 (9H, t).
Intermediate 13: (Z)Tributylstannanylpropen-l-ol
Propargyl alcohol (5mL) was added to a solution of lithium aluminium hydride
(1M in THF, 43mL) in THF (70mL) at -78°C. The resultant mixture was warmed to room
temperature and stirred for 18 hours. It was re-cooled to -78°C and a solution of tri-n-butyl tin
chloride (8.32mL) in diethyl ether (50mL) was added and the mixture was stirred for 3 hours
whilst gradually warming to room temperature. The reaction mixture was cooled to -5°C and
quenched by addition of water and 15% aqueous sodium hydroxide solution then warmed to
room temperature. Ethyl acetate was added and the mixture was stirred for 1 hour. The mixture
was filtered through Celite and the filtrate was evaporated to dryness. The residue was purified
by chromatography on a silica column which had been pre-washed with 20% triethylamine in
acetonitrile. The column was eluted with a mixture of ethyl acetate and pentane with a gradient
of 0-10% to give (Z)tributylstannanyl-propen-l-ol (5.06 g) as a clear oil.
¾ NMR (CDC1 ) d : 6.70 (1H, dt), 6.08 (1H, dt), 4.12 (2H, dd), 1.49 (6H, m),
1.31 (6H, m), 0.98-0.84 (15H, m).
Intermediate 14: Methyl cis-(3aRS,9bRS)[2-(3-{pyrrolidin-l-yl}propyl)
fluorobenzenesul -furo[2,3-c]chromenecarboxylate
A solution of methyl 7-[2-((Z){pyrrolidin-l-yl}prop-l-enyl)
fluorobenzene-sulfonylamino]-4H-furo[2,3-c]chromenecarboxylate (Intermediate 15, 0.06g)
in IMS (4mL) and formic acid (2 drops) was treated under an atmosphere of nitrogen with
palladium hydroxide on carbon (10%, 0.02g). The nitrogen was replaced by hydrogen and the
mixture was stirred under an atmosphere of hydrogen for 1 hour. The mixture was filtered
through Celite and the filtrate was evaporated to dryness to give methyl cis-(3aRS,9bRS)[2-
(3- {pyrrolidin- 1-yl }propyl)fluorobenzene-sulfonylamino]- 1,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenecarboxylate (0.06g) which was used without further characterisation.
Intermediate 15: Methyl 7-[2-((Z){pyrrolidin- l-yl}prop-l-enyl)fluorobenzene-
sulfonylamino]-4H-furo[2,3-c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 9, starting from
methyl 7-(2-bromofluorobenzenesulfonylamino)-4H-furo[2,3-c]chromenecarboxylate
(Intermediate 10) and l-((Z)tributylstannanylallyl)pyrrolidine (Intermediate 16).
¾ NMR (CD OD) d : 8.02 (IH, dd), 7.5 1 (lH, m), 7.16 (2H, d), 7.1 1-7.01
(2H, m), 6.76 (lH, d), 6.69 (IH, d), 5.93-5.83 (IH, m), 5.31 (2H, s), 3.80 (3H, s), 3.37-3.33
(2H, m), 2.69 (4H, m), 1.78 (4H, m).
Intermediate 16: l-((Z)tributylstannanylallyl)pyrrolidine
Prepared by proceeding in a similar manner to Intermediate 11 starting from
((Z)bromoprop-l-enyl)tributylstannane (Intermediate 12) and pyrrolidine.
¾ NMR (CDCI ) d : 6.64 (IH, dt), 5.96 (IH, dt), 3.10 (2H, dd), 2.5 1 (4H, m),
1.79-1.78 (4H, m), 1.54-1.45 (6H, m), 1.36-1.26 (6H, m), 0.91-0.88 (15H, t).
Intermediate 17: Methyl cis-(3aRS,9bRS)[2-((Z)diethylaminoprop-l-enyl)
fluorobenzenesul -furo[2,3-c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 9, starting from
methyl cis-(3aRS,9bRS)(2-bromofluorobenzenesulfonylamino)- 1,3a,4,9b-tetrahydro-2H-
furo[2,3-c]chromenecarboxylate (Intermediate 18) and N,N-diethyl-N-((Z)-l-
tributylstannanylprop-l-enyl)-amine (Intermediate 11) and heating at 80°C for 2 hours.
LCMS (Method A) r/t 2.25 (M+H) 5 19.
Intermediate 18: Methyl cis-(3aRS,9bRS)(2-bromofluorobenzenesulfonyl-amino)-
l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate
Mixture of cis enantiomers
2-Bromofluorobenzenesulfonyl chloride (0.335g) was added to a solution of
methyl cis-(3aRS,9bRS)amino- 1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate
(Intermediate 19, 0.255g) in DCM (4mL) and pyridine (2mL) and the resultant mixture was
stirred at room temperature overnight. The mixture was evaporated to dryness and the residue
was purified by chromatography on silica eluting with a mixture of ethyl acetate and
cyclohexane with a gradient of 0-100% to give methyl cis-(3aRS,9bRS)(2-bromo
fluorobenzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate
(0.486g) as a yellow gum.
¾ NMR (CDC1 ) d : 9.47 (1H, s), 8.17 (1H, m), 7.42 (1H, dd), 7.12 (1H, dt),
7.1 1 (2H, s), 4.28 (1H, m), 4.06 (1H, dd), 3.96 (1H, dd), 3.91 (3H, s), 3.82 (2H, m), 3.41 (1H,
m), 2.45 (1H, m), 1.84 (1H, m).
Intermediate 19: Methyl cis-(3aRS,9bRS)amino-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenec
Mixture of cis enantiomers
Trifluoroacetic acid (7mL) was added to a solution of methyl cis-(3aRS,9bRS)-
7-[i>w-(½rf-butoxycarbonyl)amino]-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene
carboxylate (Intermediate 2, 0.66g) in DCM (15mL) and the mixture was stirred at room
temperature for 1 hour. The mixture was evaporated to dryness and the residue was treated with
aqueous sodium bicarbonate and extracted with DCM, dried (MgSC^) and filtered. The filtrate
was evaporated to dryness to give methyl cis-(3aRS,9bRS)amino-l,3a,4,9b-tetrahydro-2H-
furo[2,3-c]chromenecarboxylate (0.255g) as a gum.
¾ NMR (CDC1 ) d : 7.0 (1H, dd), 6.31 (1H, d), 4.32 (1H, m), 4.01 (2H, m), 3.88
(3H, s), 3.84 (2H, m), 3.39 (1H, m), 2.41 (1H, m), 1.86 (1H, m).
Intermediate 20: Methyl 7-[N-{2-((Z)Diethylaminoprop-l-enyl)fluoro-
benzenesulfonyl rof ro[2,3-c]quinolinecarboxylate
Prepared by proceeding in a similar manner to Intermediate 9, starting from
methyl 7-[N-(2-bromofluorobenzenesulfonyl)-N-(methoxycarbonyl)amino]-l,2-dihydro-
furo[2,3-c]quinolinecarboxylate (Intermediate 21) and N,N-diethyl-N-((Z)-l-
tributylstannanylprop-l-enyl)amine (Intermediate 11) and heating at 60°C for 1 hour.
¾ NMR (CDC1 ) d : 8.72 (1H, s), 8.32 (1H, dd), 7.76 (1H, d), 7.62 (1H, d),
7.22-7.08 (3H, m), 6.03 (1H, m), 4.87 (2H, t), 3.93 (3H, s), 3.62 (3H, s), 3.56 (2H, t), 3.20 (2H,
m), 2.52 (4H, m), 0.97 (6H, t).
Intermediate 21: Methyl 7-[N-(2-bromofluorobenzenesulfonyl)-N-(methoxy-
carbonyl)amino]- linecarboxylate
A solution of methyl 7-(2-bromofluorobenzenesulfonylamino)- 1,2-dihydro-
furo[2,3-c]quinolinecarboxylate (Intermediate 22, 0.29g) in THF (5mL) was added slowly to
a suspension of sodium hydride (40% oil dispersion, 0.048g) in THF (15mL). Once the
evolution of hydrogen had ceased, methyl chloroformate (0.147g) was added and the mixture
was stirred at room temperature for 1 hour. The mixture was diluted with ethyl acetate, washed
with saturated sodium bicarbonate solution, dried (MgSCU) and filtered. The filtrate was
evaporated to dryness and the residue was triturated with a mixture of ether and cyclohexane
(1: 1) and the solid was collected by filtration to give methyl 7-[N-(2-bromo
fluorobenzenesulfonyl)-N-(methoxy-carbonyl)amino]-l,2-dihydrofuro -c]quinoline
carboxylate (0.3g) as a pale orange solid.
¾ NMR (CDC1 ) d : 8.73 (1H, s), 8.48 (1H, dd), 7.76 (2H, s), 7.5 1 (1H, dd),
7.25 (1H, m), 4.86 (2H, t), 4.01 (3H, s), 3.66 (3H, s), 3.56 (2H, t).
Intermediate 22: Methyl 7-(2-bromofluorobenzenesulfonylamino)-l,2-dihydro-furo[2,3-
c]quinoline
Prepared by proceeding in a similar manner to Intermediate 18, starting from
methyl 7-amino-l,2-dihydrofuro[2,3-c]quinolinecarboxylate (Intermediate 23) and 2-bromo-
4-fluorobenzenesulfonyl chloride and stirring at room temperature for 3 days.
¾ NMR (CDC1 ) d : 8.60 (1H, s), 8.07 (1H, dd), 7.84 (1H, d), 7.62 (1H, d), 7.43
(1H, dd), 7.06 (1H, m), 4.79 (2H, t), 4.02 (3H, s), 3.48 (2H, t).
Intermediate 23: Methyl 7-amino-l,2-dihydrofuro[2,3-c]quinolinecarboxylate
A solution of methyl 7-aminofuro[2,3-c]quinolinecarboxylate (Intermediate
24, 1.1 3g) in a mixture of dioxane (5mL) and acetic acid (5mL) was treated under an
atmosphere of nitrogen with palladium hydroxide on carbon (10%, O.lg). The nitrogen was
replaced by hydrogen and the mixture was stirred under an atmosphere of hydrogen for 24
hours. The mixture was diluted with ethyl acetate and filtered through Celite and the filtrate
was washed with 1M aqueous sodium hydroxide solution, dried (MgSCU) and filtered. The
filtrate was evaporated to dryness and the residue was purified by chromatography on silica
eluting with a mixture of methanol and ethyl acetate with a gradient of 0-10%. The isolated
product was triturated with a mixture of ether and cyclohexane and the solid was collected by
filtration to give methyl 7-amino-l,2-dihydrofuro[2,3-c]quinolinecarboxylate (0.666g) as a
yellow solid.
¾ NMR (CDC1 ) d : 8.56 (1H, s), 7.5 1 (1H, d), 6.95 (1H, d), 5.16 (2H, br s),
4.74 (2H, t), 4.05 (3H, s), 3.46 (2H, t).
Intermediate 24: Methyl 7-aminofuro[2.3-c]quinolinecarboxylate
A mixture of methyl 3-bromo-2,6-diaminobenzoate (Intermediate 25, 1.34g), 2-
formylfuranboronic acid pinacol ester (1.46g), tri-ferf-butylphosphonium tetrafluoroborate
(0.305g), cesium carbonate (5.15g) and frw-(dibenzylideneacetone)dipalladium (0.49g) in a
mixture of dioxane (80mL) and water (30mL) was degassed and purged with argon then heated
at 60°C for 1 hour. After cooling, the mixture was filtered through Celite and the pad was
washed thoroughly with ethyl acetate. The filtrate was washed with water, dried (MgSC^) and
filtered. The filtrate was evaporated to dryness and the residue was purified by chromatography
on silica eluting with a mixture of ethyl acetate and cyclohexane with a gradient of 0-100% to
give methyl 7-aminofuro[2,3-c]quinolinecarboxylate (1.13g) as a brown gum.
¾ NMR (CDC1 ) d : 9.1 1 (1H, s), 7.95 (1H, d), 7.82 (1H, d), 7.14 (1H, dd), 7.05
(1H, d), 5.05 (2H, br s), 4.08 (3H, s).
Intermediate 25: Methyl 3-bromo-2,6-diaminobenzoate
Iron powder (4.07g) was added slowly with stirring and cooling to a solution of
methyl 6-aminobromonitrobenzoate (prepared according to Brock et al, Tetrahedron,
1963, 19, 191 1; 2.0g) in a mixture of absolute ethanol (49mL), acetic acid (5mL), formic acid
(0.7mL) and water (15mL). On completion of the addition, the mixture was stirred at room
temperature for 2 hours . The mixture was diluted with DCM and water (1:1) then filtered
through Celite. The layers were separated and the aqueous layer was extracted with DCM. The
combined organic layers were washed with 1M aqueous sodium hydroxide solution, dried
(MgSCU) and filtered. The filtrate was evaporated to dryness and the residue was triturated with
ether and cyclohexane (1: 1) and the solid was collected by filtration to give methyl 3-bromo-
2,6-diaminobenzoate (1.34g) as a pale yellow solid.
¾ NMR (CDC1 ) d : 7.21 (1H, d), 6.1 1 (2H, br s), 5.88 (1H, d), 5.46 (2H, br s),
3.93 (3H, s).
Intermediate 26: Methyl 7-(benzenesulfonylamino)-l,2-dihydro[furo[2,3-c]quinoline
carboxylate
Prepared by proceeding in a similar manner to Intermediate 18, starting from
methyl 7-amino-l,2-dihydrofuro[2,3-c]quinolinecarboxylate (Intermediate 23) and
benzenesulfonyl chloride and stirring at room temperature overnight.
¾ NMR (CDC1 ) d : 8.59 (1H, s), 7.94 (1H, d), 7.70 (1H, d), 7.50 (1H, m), 7.40
(2H, t), 7.21 (2H, m), 4.81 (2H, t), 3.75 (3H, s), 3.5 1 (2H, t).
Intermediate 27: Methyl cis-(3aRS,9bRS)acetyl[2-((Z)diethylaminoprop- l-enyl)
fluorobenzenesul rofuro[2,3-c]quinolinecarboxylate
Mixture of cis enantiomers
Prepared by proceeding in a similar manner to Intermediate 9, starting from
methyl cis-(3aRS,9bRS)acetyl(2-bromofluorobenzenesulfonylamino)-l,2,3a,4,5,9b-
hexahydrofuro[2,3-c]quinolinecarboxylate (Intermediate 28) and heating at 80°C for 2
hours.
LCMS (Method B) r/t 2.29 (M+H) 560.
Intermediate 28: Methyl cis-(3aRS,9bRS)acetyl(2-bromofluorobenzene-
sulfonylamino)-l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinolinecarboxylate
Mixture of cis enantiomers
Prepared by proceeding in a similar manner to Intermediate 18, starting from
methyl cis-(3aRS,9bRS)acetylamino-l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinoline
carboxylate (Intermediate 29) and 2-bromofluorobenzenesulfonyl chloride.
¾ NMR (CDC1 ) d : 9.5 1 (IH, br s), 8.16 (IH, m), 7.42 (IH, dd), 7.34 (IH, d),
7.18 (IH, d), 7.12 (IH, dt), 4.46 (IH, d), 3.84 (2H, m), 3.81 (3H, s), 3.67 (IH, m), 3.49 (IH,
m), 3.38-3.19 (IH, m), 2.41-2.30 (IH, m), 2.25 (3H, s), 1.57 (IH, m).
Intermediate 29: Methyl cis-(3aRS,9bRS)acetylamino-l,2,3a,4,5,9b-hexahydrofuro[2,3-
c]quinolineca
Mixture of cis enantiomers
Concentrated sulfuric acid (5 drops) was added to a solution of methyl cis
(3aRS,9bRS)acetyl(2,2-dimethylpropionylamino)-l,2,3a,4,5,9b-hexahydro-furo[2,3-
c]quinolinecarboxylate (Intermediate 30, 0.15g) in methanol (5mL) and the solution was
stirred and heated at reflux for 48 hours. After cooling, the mixture was evaporated to low
volume and the residue was dissolved in ethyl acetate and carefully washed with saturated
aqueous sodium bicarbonate solution. The organic layer was filtered through a phase separator
and the filtrate was evaporated to dryness to give methyl cis-(3aRS,9bRS)acetylamino-
l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinolinecarboxylate (0.09g) as a brown gum.
¾ NMR (CDC1 ) d : 7.04 (IH, d), 6.53 (IH, d), 4.97 (2H, br s), 4.47 (IH, m),
3.90 (2H, m), 3.79 (3H, s), 3.67 (IH, m), 3.45 (IH, m), 3.30 (IH, m), 2.4-2.32 (IH, m), 2.27
(3H, s), 1.68-1.54 (IH, m).
Intermediate 30: Methyl cis-(3aRS,9bRS)acetyl(2,2-dimethylpropionylamino)-
l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinolinecarboxylate
Mixture of cis enantiomers
Sodium hydride (60% oil dispersion, 0.02g) was added to a solution of methyl
2-acetylamino(2,2-dimethylpropionylamino)[cis-(2RS,3RS)(methanesulfonyl-
oxymethyl)tetrahydrofuranyl]benzoate (Intermediate 31, 0.166g) in THF (3mL) and the
mixture was stirred at room temperature for 20 minutes. A saturated aqueous solution of
ammonium chloride was added and the mixture was extracted with DCM, dried (MgSCU) and
filtered. The filtrate was evaporated to dryness to give methyl cis-(3aRS,9bRS)acetyl(2,2-
dimethylpropionylamino)-l,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinolinecarboxylate (0.15g)
as a tan coloured solid.
¾ NMR (CDC1 ) d : 9.92 (IH, s), 8.29 (IH, d), 7.30 (IH, d), 4.5 1 (IH, d), 3.82
(3H, s), 3.75 (2H, m), 3.69 (IH, m), 3.56 (IH, m), 3.37-3.27 (IH, br m), 2.44-2.34 (IH, br m),
2.29 (3H, s), 1.68-1.58 (IH, br m), 1.29 (9H, s).
Intermediate 31: Methyl 2-acetylamino(2,2-dimethylpropionylamino)[cis-(2RS,3RS)
(methanesulfon 3-yl]benzoate
Mixture of cis enantiomers
Methanesulfonyl chloride (0.042mL) was added to a mixture of methyl 2-
acetylamino(2,2-dimethylpropionylamino)[cis-(2RS,3RS)(hydroxymethyl)-
tetrahydrofuranyl]benzoate (Intermediate 32, 0.14g) and triethylamine (0.15mL) in DCM
(5mL) and the resultant mixture was stirred at room temperature for 30 minutes. The mixture
was washed with 1M hydrochloric acid, dried (MgSCU) and filtered. The filtrate was
evaporated to dryness to give methyl 2-acetylamino(2,2-dimethylpropionylamino)[cis-
(2RS,3RS)(methanesulfonyloxymethyl)-tetrahydrofuranyl]benzoate (0.166g) as a gum.
LCMS (Method B) r/t 2.57 (M+Na) 493.
Intermediate 32: Methyl 2-acetylamino(2,2-dimethylpropionylamino)[cis-(2RS,3RS)
(hydroxymethyl) oate
Mixture of cis enantiomers
A solution of methyl 2-acetylamino(2,2-dimethylpropionylamino)(2-
hydroxymethylfuranyl)benzoate (Intermediate 38, 0.2g) in dioxane (4mL) and acetic acid
(ImL) was treated under an atmosphere of nitrogen with palladium hydroxide on carbon (10%,
0.03g). The nitrogen was replaced by hydrogen and the mixture was stirred under an
atmosphere of hydrogen overnight. The mixture was filtered through Celite and the pad was
washed thoroughly with ethyl acetate. The filtrate was evaporated to dryness and the residue
was purified by chromatography on silica eluting with a mixture of methanol and ethyl acetate
with a gradient of 0-10% to give methyl 2-acetylamino(2,2-dimethylpropionylamino)[cis-
(2RS,3RS)(hydroxymethyl)tetrahydrofuranyl]benzoate (0.14g) as a white solid.
¾ NMR (CDC1 ) d : 9.70 (1H, br s), 8.29 (1H, d), 8.25 (1H, br s), 7.36 (1H, d),
4.22 (1H, m), 4.10 (1H, m), 3.91 (1H, m), 3.90 (3H, s), 3.64 (2H, m), 3.24 (1H, m), 2.41 (1H,
m), 2.16 (3H, s), 2.1 1 (1H, m), 1.30 (9H, s).
Intermediate 33: Methyl 2-acetylamino(2,2-dimethylpropionylamino)(2-
hydroxymethylf
Tetrabutylammonium fluoride (1M solution in THF, l.lmL) was added to a
stirred, cooled solution of methyl 2-acetylamino[2-(½rf-butyldimethylsilanyloxymethyl)-
furanyl](2,2-dimethylpropionylamino)benzoate (Intermediate 34, 0.43g) in THF (lOmL)
at 0°C and the mixture was stirred at 0°C for 40 minutes then evaporated to dryness. The
residue was partitioned between ethyl acetate and water and the organic layer was washed with
brine, dried (MgSCU) and filtered. The filtrate was evaporated to dryness and the residue was
purified by chromatography on silica eluting with a mixture of methanol and ethyl acetate with
a gradient of 0-2% to give methyl 2-acetylamino(2,2-dimethylpropionylamino)(2-
hydroxymethylfuranyl)benzoate (0.2g) as a gum.
¾ NMR (CDC1 ) d : 9.95 (1H, br s), 8.36 (1H, d), 8.00 (1H, br s), 7.46 (1H, s),
7.36 (1H, d), 6.32 (1H, s), 4.54 (2H, d), 3.90 (3H, s), 2.45 (1H, t), 1.99 (3H, s), 1.32 (9H, s).
Intermediate 34: Methyl 2-acetylamino[2-(½rf-butyldimethylsilanyloxymethyl)-furan
yl](2,2-
Acetyl chloride (0.09mL) was added to a stirred solution of methyl 2-amino
[2-(½rf-butyldimethylsilanyloxymethyl)furanyl](2,2-dimethylpropionylamino)-benzoate
(Intermediate 35, 0.47g) in DCM (5mL) and pyridine (0.16mL) and the mixture was stirred at
room temperature for 1 hour. The mixture was diluted with DCM and washed with water and
brine, dried (MgSCU) and filtered. The filtrate was evaporated to dryness and the residue was
purified by chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane
with a gradient of 20-50% to give methyl 2-acetylamino[2-(½rf-
butyldimethylsilanyloxymethyl)-furanyl](2,2-dimethylpropionylamino)benzoate (0.442g)
as a colourless foam.
¾ NMR (CDC1 ) d : 10.08 (1H, br s), 8.34 (1H, d), 8.15 (1H, br s), 7.46 (1H, s),
7.36 (1H, d), 6.32 (1H, s), 4.5 1 (2H, s), 3.93 (3H, s), 1.98 (3H, s), 1.32 (9H, s), 0.93 (9H, s),
0.13 (6H, s).
Intermediate 35: Methyl 2-amino[2-(½rf-butyldimethylsilanyloxymethyl)furan-:
(2,2-dimeth
Pivaloyl chloride (0.353g) was added to a stirred, cooled mixture of methyl 2,6-
diamino[2-(½rf-butyldimethylsilanyloxymethyl)furanyl]benzoate (Intermediate 36, l.Og)
and sodium bicarbonate (0.268g) in ethyl acetate (20mL) and water (7mL) at 0°C. The mixture
was allowed to warm to room temperature and stirred for 1.5 hours. Further pivaloyl chloride
(0.048g) was added and the mixture was stirred for 1 hour. Ethyl acetate was added and the
layers were separated. The organic layer was washed with aqueous sodium bicarbonate solution
dried (MgSCU) and filtered. The filtrate was evaporated to dryness and the residue was purified
by chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 5-20% to give methyl 2-amino[2-(½rf-butyldimethylsilanyloxymethyl)furan
yl](2,2-dimethylpropionylamino)benzoate (0.744g) as an oil.
¾ NMR (CDC1 ) d : 10.81 (1H, br s), 7.97 (1H, d), 7.48 (1H, s), 7.18 (1H, d),
6.41 (1H, s), 5.67 (2H, s), 4.5 1 (2H, s), 3.98 (3H, s), 1.33 (9H, s), 0.87 (9H, s), 0.05 (6H, s).
Intermediate 36: Methyl 2,6-diamino[2-(½rf-butyldimethylsilanyloxymethyl)-furan
yl]benzoate
A mixture of methyl 3-bromo-2,6-diaminobenzoate (Intermediate 25, 2.6g), 2-
(½rf-butyldimethylsilanyloxymethyl)furanboronic acid (Intermediate 37, 3.5g), cesium
carbonate ( 11.35g), tri-ferf-butylphosphonium tetrafluoroborate (0.334g) and tris-
(dibenzylideneacetone)dipalladium (0.529g) in dioxane (72mL) and water (18mL) was
degassed and purged with nitrogen then heated at 70°C for 75 minutes. After cooling, ethyl
acetate and water were added and the mixture was filtered through Celite. The filtrate was
separated and the organic layer was washed with brine, dried (MgSC^) and filtered. The filtrate
was evaporated to dryness and the residue was purified by chromatography on silica eluting
with a mixture of ethyl acetate and cyclohexane with a gradient of 5-20% to give methyl 2,6-
diamino[2-(½rf-butyldimethylsilanyloxymethyl)furanyl]benzoate (2.39g) as a viscous oil
which was used without further characterization.
Intermediate 37: 2-(½rf-Butyldimethylsilanyloxymethyl)furanboronic acid
OH O -
n-Butyllithium (2.5M in hexanes, 11.25mL) was added slowly to a stirred,
cooled solution of 3-bromo(½rf-butyldimethylsilanyloxymethyl)furan (Intermediate 38,
7.5g) in dry ether (150mL) while maintaining the temperature below -70°C. The mixture was
stirred at -78°C for 2.5 hours. Tri-isopropyl borate (6.75g) was added and the mixture was
allowed to warm to room temperature and stirred for 1.75 hours. Ethyl acetate and aqueous
ammonium chloride solution were added and the layers were separated. The organic layer was
washed with aqueous ammonium chloride solution, dried (MgSCU) and filtered. The filtrate
was evaporated to dryness and the residue was purified by chromatography on silica eluting
with a mixture of ethyl acetate and cyclohexane with a gradient of 10-35% to give 2-(tert-
butyldimethylsilanyloxymethyl)furanboronic acid (3.6g) which was used directly without
further characterization.
Intermediate 38: 3-Bromo(½rf-butyldimethylsilanyloxymethyl)furan
ferf-Butyldimethylsilanyl triflate (17.13g) was added slowly to a stirred, cooled
solution of 3-bromohydroxymethylfuran (Intermediate 39, 10. lg) in DCM (160mL) and
pyridine (9.57g) while maintaining the temperature at 0°C. The mixture was allowed to warm
to room temperature and stirred for 1 hour. The mixture was washed with aqueous citric acid
solution, brine, dried and filtered. The filtrate was evaporated to dryness to give 3-
(Na2SC>4)
bromo(½rf-butyldimethylsilanyloxymethyl)furan (17. lg).
¾ NMR (CDC1 ) d : 7.35 (1H, d), 6.38 (1H, d), 4.65 (2H, s), 0.90 (9H, s), 0.09
(6H, s).
Intermediate 39: 3-Bromohydroxymethylfuran
Sodium borohydride (1.14g) was added slowly to a stirred, cooled solution of 3-
bromoformylfuran (5g) in a mixture of THF (50mL) and methanol (25mL) while
maintaining the temperature around 0°C. The mixture was allowed to warm to room
temperature and stirred for 1 hour. The mixture was evaporated to dryness and the residue was
partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate
and the combined organic layers were washed with brine, dried and filtered. The
(Na2SC>4)
filtrate was evaporated to dryness to give 3-bromohydroxymethylfuran (5.3 lg) as a
colourless oil.
¾ NMR (CDC1 ) d : 7.37 (1H, d), 6.42 (1H, d), 4.65 (2H, d), 1.71 (1H, t).
Intermediate 40: Methyl (laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)
f l uorobenzene- yclopropa[c]chromenecarboxylate
A solution of methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 41, 0.208g) and N,N-
diethyl-N-((Z)-l-tributylstannanylprop-l-enyl)-amine (Intermediate 11, 0.367g) in dioxane
(5mL) and DMSO (0.5mL) was de-gassed and flushed with nitrogen. Tris-
(dibenzylideneacetone)-dipalladium (0.02 lg) and tri-ferf-butylphosphonium tetrafluoroborate
(0.0 13g) were added and the mixture was again de-gassed and flushed with nitrogen. The
resultant mixture was heated at 95°C for 45 minutes. After cooling, the mixture was partitioned
between ethyl acetate and water and the organic layer was dried (MgS0 ) and filtered. The
filtrate was concentrated in vacuo and the residue was purified by chromatography on silica,
eluting with a mixture of methanol and DCM, with a gradient of 0-12% to give methyl
(laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)fluorobenzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.1 88g) as a yellow/brown oil.
¾ NMR (CDC1 ) d : 8.06 (1H, dd), 7.16 (1H, d), 7.09-7.03 (2H, m), 6.94 (1H,
d), 6.86 (1H, d), 6.10-6.02 (1H, m), 4.33 (1H, d), 3.84 (3H, s), 3.78 (1H, d), 3.13 (2H, br, d),
2.54 (4H, br, q), 1.88 (1H, m), 1.71 (1H, m), 1.03-0.92 (8H, m).
Intermediate 41: Methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate
Methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 42, 0.120g) was suspended in DCM (5mL). Pyridine (0.885mL) and
2-bromofluorobenzenesufonyl chloride (0.1 80g) were added. The mixture was stirred at
room temperature for 5 hours then concentrated in vacuo. The residue was dissolved in ethyl
acetate and washed with 0.5M aqueous hydrochloric acid solution, dried (MgSCU) and filtered.
The filtrate was concentrated in vacuo and the residue was purified by chromatography on
silica, eluting with a mixture of ethyl acetate and cyclohexane, with a gradient of 5-10% to give
methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.208g) as a colourless oil.
¾ NMR (CDC1 ) d : 9.31 (1H, br, s), 8.14 (1H, dd), 7.41 (1H, dd), 7.17 (1H, d),
7.1 1 (1H, ddd), 7.06 (1H, d), 4.34 (1H, dd), 3.90 (3H, s), 3.80 (1H, dd), 1.94-1.85 (1H, m),
1.75-1.67 (1H, m), 1.01 (2H, m).
Intermediate 42: Methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromene-
4-carboxylate
Methyl (laRS,7bSR)(2,2-dimethylpropionylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 43, 0.3 lOg) was suspended in
methanol (7.5mL) and concentrated sulphuric acid (4 drops) was added. The reaction mixture
was heated to reflux, under an atmosphere of nitrogen, for 36 hours. A further 2 drops of
concentrated sulphuric acid was added and heating was continued for a further 24 hours. After
cooling, the mixture was concentrated in vacuo and the residue was partitioned between ethyl
acetate and saturated aqueous potassium carbonate solution. The aqueous layer was extracted
with ethyl acetate and the combined organic layers were dried and filtered. The
(Na2SC 4)
filtrate was concentrated in vacuo and the residue was purified by chromatography on silica,
eluting with a mixture of ethyl acetate and cyclohexane, with a gradient of 5-20% to give
methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(0.120g) as an off-white solid.
¾ NMR (CDC1 ) d : 7.06 (1H, d), 6.26 (1H, d), 4.33 (1H, d), 3.87 (3H, s), 3.85
(1H, d), 1.83 (1H, td), 1.64 (1H, m), 0.99-0.89 (2H, m).
Intermediate 42A: Methyl (laR,7bS)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
Sample from Intermediate 42 was subjected to chiral SFC separation using a
Lux C-3 column, 50mm x 250mm, particle size 5micron. Eluting with 5% methanol (+0.1%
diethylamine) in C(¾
Absolute configuration of Intermediate 42A was confirmed by conversion of a sample to
Example 12 and comparison with the analytical chiral HPLC.
Intermediate 43: Methyl (laRS,7bSR)(2,2-dimethylpropionylamino)-l,la,2,7b-
tetrahydrocyclop oxylate
Methyl (laRS,7bSR)-l,l-dibromo(2,2-dimethylpropionylamino)-l,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 44, 1.1 3g) was suspended in
ethanol (30mL). Zinc dust (1.17g), followed by ammonium chloride (1.31g) were added and
the reaction mixture was heated to reflux, under an atmosphere of nitrogen, for 6 hours. After
cooling, the solid was filtered off and washed with ethyl acetate. The filtrate was concentrated
in vacuo and the residue was purified by chromatography on silica, eluting with a mixture of
ether and cyclohexane, with a gradient of 5-12.5% to give methyl (laRS,7bSR)(2,2-
dimethylpropionylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0.3 lOg)
as a colourless oil.
¾ NMR (CDC1 ) d : 9.72 (1H, br, s), 7.98 (1H, d), 7.30 (1H, d), 4.36 (1H, dd),
3.91 (3H, s), 3.84 (1H, dd), 1.95 (1H, td), 1.73 (1H, m), 1.28 (9H, s), 1.03 (2H, m).
Intermediate 44: Methyl (laRS,7bSR)-l,l-dibromo(2,2-dimethylpropionylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Methyl 7-(2,2-dimethylpropionylamino)-2H-chromenecarboxylate
(Intermediate 45, 2.372g) and benzyl triethyl ammonium chloride (0.373g) were suspended in
bromoform (6.45mL) and aqueous sodium hydroxide solution (50%, 3.64mL) was added
dropwise. The resultant black suspension was heated to 60°C for 2 hours. After cooling, the
mixture was partitioned between water and ethyl acetate. The emulsion formed was filtered
through a pad of Celite and the organic layer was decanted off. The aqueous was re-extracted
with ethyl acetate and the combined organic layers were dried (MgSCU) and filtered. The
filtrate was concentrated in vacuo and the residue was purified by chromatography on silica,
eluting with a mixture of ethyl acetate and cyclohexane, with a gradient of 2.5-15% to give
methyl l,l-dibromo(2,2-dimethylpropionylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (1.557g) as an off-white solid.
¾ NMR (CDC1 ) d : 9.89 (1H, br, s), 8.13 (1H, d), 7.43 (1H, d), 4.47 (1H, dd),
4.32 (1H, dd), 3.91 (3H, s), 2.89 (1H, d), 2.45 (1H, ddd), 1.30 (9H, s).
Intermediate 45: Methyl 7-(2,2-dimethylpropionylamino)-2H-chromenecarboxylate
A solution of methyl 2-(2,2-dimethylpropionylamino)(prop
ynyloxy)benzoate (Intermediate 46, 4.74g) and [fc(trifluoromethanesulfonyl)imidate]-
(triphenylphosphine)gold (2: 1) toluene adduct (0.060g) in toluene (70mL) was heated to 85°C,
under an atmosphere of nitrogen for 3 hours. After cooling, the mixture was concentrated in
vacuo and the residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and cyclohexane, with a gradient of 0-20% to give methyl 7-(2,2-
dimethylpropionylamino)-2H-chromenecarboxylate (3.59g) as a colourless oil.
¾ NMR (CDC1 ) d : 10.02 (1H, br, s), 8.05 (1H, d), 7.05 (1H, d), 6.39 (1H,
ddd), 5.76 (1H, dt), 4.83 (2H, dd), 3.93 (3H, s), 1.30 (9H, s).
Intermediate 46: Methyl 2-(2,2-dimethylpropionylamino)(propynyloxy)benzoate
A mixture of methyl 2-(2,2-dimethylpropionylamino)hydoxybenzoate
(Intermediate 47, 4.57g), propargyl bromide (80% solution in toluene, 2.03mL) and potassium
carbonate (3.74g) in acetone (35mL) was heated at reflux for 8 hours. After cooling, the
mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by
chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane, with a
gradient of 5-20% to give methyl 2-(2,2-dimethylpropionylamino)(propynyloxy)benzoate
(4.74g) as an oil which crystallised on standing to give a white solid.
¾ NMR (CDC1 ) d : 9.89 (1H, br, s), 8.16 (1H, dd), 7.41 (1H, t), 6.83 (1H, dd),
4.74 (2H, d), 3.95 (3H, s), 2.53 (1H, t), 1.31 (9H, s).
Intermediate 47: Methyl 2-(2,2-dimethylpropionylamino)hydoxybenzoate
Trimethylacetyl chloride (3.69g) was added to a mixture of methyl 2-amino
hydoxybenzoate (prepared according to Comess et al, US2004 0167128, 3.99g) and sodium
bicarbonate (2.57g) in ethyl acetate (77mL) and water (18mL). The reaction mixture was
stirred at room temperature for 1 hour. A further amount of trimethylacetyl chloride (1.85g)
was added and the mixture was stirred for 1 hour. A further amount of trimethylacetyl chloride
(0.920g) was added and the mixture was stirred for 30 minutes. The mixture was diluted with
ethyl acetate, the layers were separated and the organic layer was dried and filtered.
(Na2SC 4)
The filtrate was concentrated in vacuo and the residue was purified by chromatography on
silica, eluting with a mixture of ethyl acetate and cyclohexane, with a gradient of 5-25% to give
methyl 2-(2,2-dimethylpropionylamino)hydoxybenzoate (5.79g) as a white solid.
¾ NMR (CDC1 ) d : 10.32 (1H, br, s), 8.22 (1H, dd), 7.41 (1H, t), 6.71 (1H, dd),
4.08 (3H, s), 1.33 (9H, s).
Intermediate 48: Methyl (laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-7b-methyl-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
Prepared by proceeding in a similar manner to Intermediate 40, starting from
methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-7b-methyl-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 49) and N,N-diethyl-N-((Z)-l-
tributylstannanylprop-l-enyl)amine (Intermediate 11).
¾ NMR (CDC1 ) d : 8.07 (IH, dd), 7.28 (IH, d), 7.05 (2H, m), 6.95 (IH, d), 6.88 (IH, d), 6.06
(IH, m), 4.28 (IH, d), 3.85 (3H, s), 3.83 (IH, d), 3.14 (2H, br d), 2.53 (4H, q), 1.41 (3H, s),
1.12 (IH, m), 1.07 (IH, t), 0.93 (6H, t), 0.84 (IH, dd).
Intermediate 49: Methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-7b-
methyl- l ,l a,2,7b-tetrahydroc ylate
Prepared by proceeding in a similar manner to Intermediate 41, starting from
methyl (laRS,7bSR)amino-7b-methyl-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 50) and 2-bromofluorobenzenesulfonyl chloride.
¾ NMR (CDCI ) d : 9.18 (IH, br s), 8.14 (IH, dd), 7.41 (IH, dd), 7.29 (IH, d), 7.1 1 (IH, m),
7.08 (IH, d), 4.28 (IH, d), 3.89 (3H, s), 3.84 (IH, d), 1.44 (IH, m), 1.42 (3H, s), 1.10 (IH, t),
0.83 (IH, dd).
Intermediate 50: Methyl (laRS,7bSR)amino-7b-methyl-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
Trifluoroacetic acid (4mL) was added to a solution of methyl (laRS,7bSR)
(½rf-butoxycarbonylamino)-7b-methyl-l,la,2,7b-tetrahydrocyclopropa-[c]chromene
carboxylate (Intermediate 5 1, 0.6g) in dichloromethane (4mL) and the resultant dark solution
was stirred at room temperature for 1 hour. The solution was evaporated to dryness and the
residue was partitioned between water and ethyl acetate and treated with a small amount of
solid sodium bicarbonate until the pH of the aqueous layer was >7. The layers were separated
and the aqueous layer was extracted with ethyl acetate. The combined organic layers were
washed with water, dried (MgSCU) and filtered. The filtrate was evaporated to dryness to give
methyl (laRS,7bSR)amino-7b-methyl-l,la,2,7b-tetrahydrocyclopropa-[c]chromene
carboxylate (0.402g) as a red/orange solid.
¾ NMR (CDC1 ) d : 7.20 (IH, d), 6.30 (IH, d), 4.27 (IH, d), 3.90 (IH, d), 3.88 (3H, s), 1.42
(3H, s), 1.37 (IH, m), 1.06 (IH, t), 0.78 (IH, dd).
Intermediate 51: Methyl (laRS,7bSR)(ferf-butoxycarbonylamino)-7b-methyl-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 43, starting from
methyl (laRS,7bSR)(½rf-butoxycarbonylamino)-l,l-dibromo-7b-methyl-l,la,2,7b-
tetrahydro-cyclopropa-[c]chromenecarboxylate (Intermediate 52).
¾ NMR (CDCI ) d : 8.27 (IH, br s), 7.72 (IH, d), 7.38 (IH, d), 4.29 (IH, d), 3.91 (3H, s), 3.88
(IH, d), 1.50 (9H, s), 1.46 (3H, s), 1.44 (IH, m), 1.13 (IH, t), 0.84 (IH, dd).
Intermediate 52: Methyl (laRS,7bSR)-l,l-dibromo(ferf-butoxycarbonylamino)-7b-methyl-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 44, starting from
methyl 4-methyl(½rf-butoxycarbonylamino)-2H-chromenecarboxylate (Intermediate 53).
¾ NMR (CDC1 ) d : 8.55 (IH, br s), 7.87 (IH, d), 7.42 (IH, d), 4.75 (IH, dd), 4.13 (IH, dd),
3.92 (3H, s), 2.05 (IH, dd), 1.79 (3H, s), 1.50 (9H, s).
Intermediate 53: Methyl 4-methyl(½rf-butoxycarbonylamino)-2H-chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 45, starting from
methyl 2-[i>w-(½rf-butyoxycarbonyl)amino](butynyloxy)benzoate (Intermediate 54).
¾ NMR (CDCI ) d : 8.66 (IH, br s), 7.77 (IH, d), 7.18 (IH, dd), 5.53 (IH, m), 4.73 (2H, m),
3.93 (3H, s), 1.99 (3H, q), 1.5 1 (9H, s).
Intermediate 54: Methyl 2-[i>w-(ferf-butyoxycarbonyl)amino](butynyloxy)benzoate
Prepared by proceeding in a similar manner to Intermediate 46, starting from
methyl 2-[i>w-(½rf-butyoxycarbonyl)amino]hydroxybenzoate (Intermediate 55) and 1-
bromobutyne
¾ NMR (CDCI ) d : 7.36 (IH, t), 7.08 (IH, dd), 6.82 (IH, dd), 4.70 (2H, q), 3.84 (3H, s), 1.84
(3H, t), 1.39 (18H, s).
Intermediate 55: Methyl 2-[i>w-(ferf-butyoxycarbonyl)amino]hydroxybenzoate
Prepared by proceeding in a similar manner to Intermediate 4, starting from methyl 2-[bis-(tert-
butoxycarbonyl)amino](4-methylbenzenesulfonyloxy)benzoate (Intermediate 56)
¾ NMR (CDC1 ) & 11.17 (IH, s), 7.40 (IH, t), 6.99 (IH, dd), 6.69 (IH, dd), 3.92 (3H, s), 1.37
(18H, s).
Intermediate 56: Methyl 2-[i>w-(½rf-butoxycarbonyl)amino](4-
methylbenzenesulfonyloxy)-benzoate
Prepared by proceeding in a similar manner to Intermediate 6, starting from
methyl 2-aminohydroxybenzoate (prepared according to Comess et al, US2004 0167128)
¾ NMR (CDCI ) d : 7.72 (2H, d), 7.40 (IH, t), 7.31 (2H, d), 7.22 (IH, dd), 7.1 1 (IH, dd), 3.71
(3H, s), 2.44 (3H, s), 1.33 (18H, s).
Intermeidate 57: Cis-(3aRS,9bRS)(2-fluorobenzenesulfonylamino)-l,3a,4,9b-tetrahydro-
2H-furo[2,3-c]chromenecarbox
Mixture of cis enantiomers
A mixture of lithium hydroxide (0.5g) and methyl cis-(3aRS,9bRS)(2-
fluorobenzenesulfonyl-amino)- 1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate
(Intermediate 58, 0.217g) in a mixture of dioxane (13mL) and water (4mL) was divided
between two microwave vials and the mixtures were irradiated in the microwave at 150°C for
minutes. After cooling, the combined mixture was acidified by addition of 10% aqueous
citric acid (2mL), extracted with DCM, dried (MgSC^) and filtered. The filtrate was evaporated
to dryness to give cis-(3aRS,9bRS)(2-fluorobenzenesulfonylamino)-l,3a,4,9b-tetrahydro-
2H-furo[2,3-c]chromenecarboxylic acid (0.5 18g) as a glass.
¾ NMR (CDC1 ) d : 12.00 (IH, br s), 11.57 (IH, br s), 7.97 (IH, dt), 7.55 (IH, m), 7.43 (IH,
d), 7.26 (2H, m), 7.15 (IH, t), 4.43 (IH, dd), 4.37 (IH, m), 4.14 (IH, dd), 3.83 (2H, m), 3.50
(IH, m), 2.50 (IH, m), 1.87 (IH, m).
Intermediate 58: Methyl cis-(3aRS,9bRS)(2-fluorobenzenesulfonylamino)-l,3a,4,9b-
tetrahydro-2H-furo[2,3-c]chromene
Mixture of cis enantiomers
2-Fluorobenzenesulfonyl chloride (0.5g) was added to a solution of methyl cis-
(3aRS,9bRS)amino-l,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylate
(Intermediate 19, 0.53g) in DCM (lOmL) and pyridine (20mL) and the resultant mixture was
stirred at room temperature for 48 hours. The mixture was evaporated to dryness and the
residue was treated with water, extracted with DCM, dried (MgSCU) and filtered. The filtrate
was evaporated to dryness and the residue was purified by chromatography on silica, eluting
with a mixture of ethyl acetate and cyclohexane with a gradient of 0-60% to give methyl cis-
(3aRS,9bRS)(2-fluorobenzenesulfonylamino)-l,3a,4,9b-tetrahydro-2H-furo[2,3-
c]chromenecarboxylate (0.574g) as a pale yellow solid.
¾ NMR (CDCI ) d : 9.1 1 (IH, s), 7.85 (IH, dt), 7.53 (IH, m), 7.23 (IH, d), 7.21 (IH, dt), 7.15
(IH, d), 7.13 (IH, dd), 4.28 (IH, m), 4.04 (IH, dd), 3.95 (IH, dd), 3.87 (3H, s), 3.82 (2H, m),
3.41 (IH, m), 2.45 (IH, m), 1.84 (IH, m).
Intermediate 59: Methyl (laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino] -1,1-difluoro- 1,1a,2,7b-tetrahydro-cyclopropa[c] chromene
carboxylate
Prepared by proceeding in a similar manner to Intermediate 9, starting from
methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-l,l-difluoro-l,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 60) and N,N-diethyl-N-((Z)-l-
tributylstannanylprop-l-enyl)amine (Intermediate 11) as a pale yellow gum.
H NMR (CDC1 ) & 8.1 1 (IH, dd), 7.18 (IH, d), 7.13-7.04 (2H, m), 6.98 (IH, d), 6.93 (IH, d),
6.08 (IH, m), 4.38 (IH, d), 4.02 (IH, m), 3.87 (3H, s), 3.23-3.04 (2H, br s), 2.67 (IH, t), 2.60-
2.43 (4H, br s), 3.32 (IH, m), 0.94 (6H, t).
Intermediate 60: Methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-l,l-
difluoro-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 18, starting from
methyl (laRS,7bSR)amino-l,l-difluoro-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 61) and 2-bromofluorobenzene sulfonyl chloride, as a colourless
foam.
¾ NMR (CDCI ) d : 9.58 (IH, s), 8.18 (IH, dd), 7.42 (IH, dd), 7.20 (IH, d), 7.13 (IH, d), 7.16-
7.08 (IH, m), 4.38 (IH, d), 4.03 (IH, m), 3.91 (3H, s), 2.67 (IH, t), 2.32 (IH, m).
Intermediate 61: Methyl (laRS,7bSR)amino-l,l-difluoro-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 42, starting from
methyl (laRS,7bSR)(2,2-dimethylpropionylamino)-l,l-difluoro-l,la,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylate (Intermediate 62) as an off white solid.
¾ NMR (CDC1 ) d : 7.07 (IH, d), 6.30 (IH, d), 5.19-4.95 (2H, br s), 4.32 (IH, d), 4.1 1 (IH,
m), 3.87 (3H, s), 2.60 (IH, t), 2.27 (IH, m).
Intermediate 62: Methyl (laRS,7bSR)(2,2-dimethylpropionylamino)-l,l-difluoro-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Methyl 7-(2,2-dimethylpropionylamino)-2H-chromenecarboxylate
(intermediate 45, l.Og) was dissolved in diglyme (30mL) and the solution was heated to 160°C.
Sodium chlorodifluoroacetate (4.27g) was added in portions over 15 minutes with the final
portion being washed in with diglyme (15mL). On completion of the addition the mixture was
heated at 180°C for 15 minutes. After cooling, the mixture was poured into water and extracted
with ethyl acetate, washed with water, dried (MgSCU) and filtered. The filtrate was evaporated
to dryness and the residue was purified by chromatography on silica, eluting with a mixture of
ethyl acetate and pentane with a gradient of 2.5-15% to give methyl (laRS,7bSR)(2,2-
dimethylpropionylamino)- 1,1-difluoro- 1,1a,2,7b-tetrahydro-cyclopropa[c]chromene
carboxylate (0.66g) as a colourless oil.
'NMR (CDCI ) d : 9.86 (IH, br s), 8.12 (IH, d), 7.33 (IH, d), 4.41 (IH, d), 4.07 (IH, m), 3.92
(3H, s), 2.74 (IH, t), 2.34 (IH, m), 1.29 (9H, s).
Intermediate 63: Methyl (laRS,7bSR)[2-((Z)ethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Methane sulfonic anhydride (0.09g) was added to a stirred, cooled mixture of
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzenesulfonyl]amino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 64, 0.17g) and N,N-di-isopropyl-N-ethylamine (0. 134g) in DCM (1OmL) at 0°C.
The temperature was allowed to rise to room temperature and the mixture was stirred for 2
hours. A solution of ethylamine (2M in toluene, 2mL) was added and the resultant mixture was
stirred at room temperature for 3 hours then diluted with water. The organic layer was
separated, dried and filtered. The filtrate was evaporated to dryness to give methyl
(Na2SC 4)
(laRS,7bSR)[2((Z)ethylaminoprop-l-enyl)fluorobenzenesulfonyl-amino]-l,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylate (0.09g) as a white solid.
¾ NMR (DMSO-d ) d : 7.89 (IH, dd), 7.35 (IH, d), 7.16 (IH, m), 7.08 (IH, d), 6.83 (IH, d),
6.58 (IH, d), 5.69 (IH, m), 4.17 (IH, d), 3.84-3.04 (2H, br s), 3.67 (3H, s), 3.58 (IH, d), 2.78
(2H, m), 1.83 (IH, m), 1.66 (IH, m), 1.04 (3H, t), 0.88 (IH, m), 0.64 (IH, m).
Intermediate 64: Methyl (laRS,7bSR){N-[2-((Z)hydroxyprop-l-enyl)fluorobenzene-
sulfonyl]-N-[methoxycarbonyl]amino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromene
carboxylate
A mixture of methyl (laRS,7bSR)[N-(2-bromofluorobenzenesulfonyl)-N-
(methoxycarbonyl)amino]-l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate
(Intermediate 65, 0.6g), (Z)tributylstannanylpropen-l-ol (Intermediate 12, 0.8 lg), tris-
(dibenzylideneacetone)dipalladium (O.lg) and tri-ferf-butylphosphonium tetrafluoroborate
(0.07g) in dioxane (18mL) and DMSO (2mL) was stirred at room temperature for 30 minutes.
The resultant mixture was diluted with ethyl acetate and washed with water, dried
(Na2SC 4)
and filtered. The filtrate was evaporated to dryness and the residue was purified by
chromatography on silica, eluting with a mixture of ethyl acetate and petroleum ether with a
gradient of 30-50% to give methyl (laRS,7bSR){N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzenesulfonyl]-N-[methoxycarbonyl]amino}-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate (0.55g) as an off-white solid.
¾ NMR (CDC1 ) d : 8.19 (IH, m), 7.39 (IH, d), 7.16 (IH, m), 7.02 (IH, m), 6.96 (2H, m), 6.03
(IH, m), 4.41 (IH, m), 4.23 (2H, m), 3.88 (IH, dd), 3.71 (3H, 2s), 3.65 (3H, 2s), 2.06 (IH, m),
1.82 (IH, m), 1.25 (IH, m), 1.14 (IH, m).
Intermediate 65: Methyl (laRS,7bSR)[N-(2-bromofluorobenzenesulfonyl)-N-
(methoxycarbonyl)amino]- l ,l a,2, chromenecarboxylate
A solution of methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 41, 1.7g) in THF
(20mL) was added to a suspension of sodium hydride (70% oil dispersion, 0.2g) in THF
(lOmL). The resultant solution was stirred for 30 minutes then methyl chloroformate (0.53g)
was added. The resultant mixture was stirred at room temperature overnight. Saturated aqueous
sodium bicarbonate was added and the mixture was extracted with ethyl acetate, dried
(Na SC>4) and filtered. The filtrate was evaporated to dryness and the residue was purified by
chromatography on silica, eluting with a mixture of ethyl acetate and petroleum ether (30%) to
give methyl (laRS,7bSR)[N-(2-bromofluorobenzenesulfonyl)-N-
(methoxycarbonyl)amino]-l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (1.6g) as
a white solid.
¾ NMR (CDCI ) d : 8.42 (IH, m), 7.48 (IH, dd), 7.37 (IH, d), 7.19 (2H, m), 4.42 (IH, m),
3.95 (IH, dd), 3.86 (3H, s,), 3.69 (3H, s), 2.06 (IH, m), 1.84 (IH, m), 1.16 (2H, m).
Intermediate 66: Methyl (laRS,7bSR){2[(Z)(pyrrolidin-l-yl)prop-l-enyl]
fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 63, starting from
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzenesulfonyl]amino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 64) and pyrrolidine as a brown oil.
LCMS (Method D) r/t 1.28 (M+H) 487
Intermediate 67: (laRS,7bSR)(2-Fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydro-
cyclopropa[c]chr acid
A mixture of methyl (laRS,7bSR)(2-Fluorobenzenesulfonylamino)
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 68, 0.6g) and lithium
hydroxide monohydrate (1.5g) in dioxane (45mL) and water (13.8mL) was stirred and heated at
100°C overnight. After cooling, the mixture was concentrated under vacuum and the residue
was diluted with water and acidified to pH3 with 1M hydrochloric acid. The precipitated solid
was collected by filtration to give (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid (0.58g) as a white solid.
¾ NMR (DMSO-d ) d : 13.05 (IH, br s), 9.96 (IH, s), 7.73 (2H, m), 7.45-7.31 (2H, m), 7.23
(IH, d), 6.64 (IH, d), 4.29 (IH, d), 3.74 (IH, d), 2.01 (IH, m), 1.80 (IH, m), 1.02 (IH, m), 0.81
(IH, m).
Intermediate 68: Methyl (laRS,7bSR)(2-fluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 41, starting from
methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 42) and 2-fluorobenzenesulfonyl chloride.
¾ NMR (CDC1 ) d : 8.90 (IH, s), 7.84 (IH, dt), 7.53 (IH, m), 7.24-7.1 1 (4H, m), 4.34 (IH, d),
3.88 (3H, s), 3.80 (IH, dd), 1.91 (IH, m), 1.74 (IH, m), 1.02 (2H, m).
Intermediate 69: Methyl (laRS,7bSR){2[(Z)(propanyl)aminoprop-l-enyl]
fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 63, starting from
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzene-sulfonyl] amino }- 1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 64) and 2-aminopropane.
LCMS (Method D) r/t 1.17 (M+H) 475 .
Intermediate 70: Methyl (laRS,7bSR){2[(Z)((S)hydroxypyrrolidin-l-yl)aminoprop-
l-enyl]fluorobenzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
Prepared by proceeding in a similar manner to Intermediate 63, starting from
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzene-sulfonyl] amino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 64) and (S)hydroxypyrrolidine.
LCMS (Method D) r/t 1.14 (M+H) 503.
Intermediate 71: Methyl (laRS,7bSR){2[(Z)((R)hydroxypyrrolidin-l-yl)aminoprop-
1-enyl]fluorobenzenesulfonylamino }-1,1a,2,7b-tetrahydro 1cyclopropa[c]chromene
carboxylate
Prepared by proceeding in a similar manner to Intermediate 63, starting from
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzene-sulfonyl] amino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 64) and (R)hydroxypyrrolidine and used without further characterisation.
Intermediate 72: Methyl (laRS,7bSR){N-(methoxycarbonly)-N-[2((Z)diethylaminobut-
l-enyl)fluorobenzenesulfonyl]amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate.
Methyl sulfonic anhydride (0.062g) was added to a stirred, cooled mixture of
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxybut-l-enyl)
fluorobenzene-sulfonyl] amino }-1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 73, 0.12g) and N,N-di-isopropyl-N-ethylamine (0.046g) in DCM (15mL) at 0°C.
The resultant mixture was stirred at 0°C for 20 minutes. Diethylamine (0.026g) was added and
the mixture was then stirred at room temperature for 24 hours. The mixture was diluted with
water and extracted with DCM, dried and filtered. The filtrate was evaporated to
(Na2SC 4)
dryness and the residue was purified by chromatography on silica, eluting with a mixture of
methanol and DCM with a gradient of 2-10% to give methyl (laRS,7bSR){N-
(methoxycarbonly)-N-[2((Z)diethylaminobut-l-enyl)fluorobenzenesulfonyl]amino}-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (0.08g) as alight yellow solid.
LCMS (Method D) r/tl.22 (M+H) 561.
Intermediate 73: Methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxybut-l-
enyl)iluorobenzenesulfonyl]amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
Prepared by proceeding in a similar manner to Intermediate 64, starting from
methyl (laRS,7bSR)[N-(2-bromofluorobenzenesulfonyl)-N-(methoxycarbonyl)amino]-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (Intermediate 65) and (Z)
tributylstannanylpropen-l-ol (prepared according to Miura et al, Organic Letters, 2005, 7(3)
503).
¾ NMR (CDC1 ) d : 8.18 (IH, m), 7.38 (IH, d), 7.13 (3H, m), 6.96 (IH, d), 5.91 (IH, m), 4.44
(IH, m), 3.98 (IH, dd), 3.79 (3H, s), 3.75 (2H, m), 3.65 (3H, s), 2.49 (2H, m), 2.07 (IH, m),
1.81 (IH, m), 1.27 (IH, m), 1.15 (IH, m).
Intermediate 74: (laRS,7bSR)(4-Fluorovinylbenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromene- acid
Lithium hydroxide (O.lOlg) was added to a solution of methyl (laRS,7bSR)
(4-fluorovinylbenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 75, 0.150g) in a mixture of dioxane (3mL) and water (0.6mL) and
the mixture was irradiated in the microwave at 130°C for 30 minutes. After cooling, the
mixture evaporated to dryness and the residue was acidified by addition of 10% aqueous citric
acid (2mL), extracted with DCM, dried (MgS0 ) and filtered. The filtrate was evaporated to
dryness and the residue was purified by chromatography on silica eluting with a mixture of
methanol and DCM with a gradient of 0-10% to give (laRS,7bSR)(4-fluoro
vinylbenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(0.0.35g) as a glass.
¾ NMR (CDCI ) d : 11.69 (IH, br s), 8.10 (IH, dd), 7.50 (IH, dd), 7.31-7.17 (3H, m), 7.03
(IH, dt), 5.60 (IH, d), 5.50 (IH, d), 4.60 (IH, d), 4.04 (IH, d), 1.97 (IH, m), 1.81 (IH, m),
1.20 (IH, m), 0.99 (IH, m).
Intermediate 75: Methyl (laRS,7bSR)(4-fluorovinylbenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromene-
A mixture of methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 41, O.lg), vinyl
boronic acid pinacol ester (0.073g), i>w(triphenylphospine)palladium (II) chloride (0.034g) and
cesium carbonate (0.215g) in dioxane (5mL) and water (1ml) was degassed and purged with
argon then irradiated in a microwave at 130°C for 20 minutes. After cooling, the mixture was
partitioned between 1M hydrochloric acid and ethyl acetate. The organic layer was dried
(MgSCU) and filtered and the filtrate evaporated to dryness to give methyl (laRS,7bSR)(4-
fluorovinylbenzenesulfonyl-amino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (0.15g) as a yellow glass.
¾ NMR (CDCI ) d : 8.99 (IH, br s), 7.97 (IH, dd), 7.38 (IH, dd), 7.21 (IH, dd), 7.18 (IH, d),
7.05 (IH, d), 7.00 (IH, m), 5.59 (IH, d), 5.38 (IH, d), 4.32 (IH, d), 3.77 (4H, m), 1.90 (IH, dt),
1.71 (IH, m), 1.00 (2H, m).
Intermediate 76: Methyl (laRS,7bSR){2-[(Z)(azetidin-l-yl)prop-l-enyl]fluoro-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 63, starting from
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzene-sulfonyl] amino }- 1,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 64) and azetidine as a yellow oil.
LCMS (Method D) r/t 1.17 (M+H) 473.
Intermediate 77: Methyl (laRS,7bSR){2-[(Z)(3-hydroxyazetidin-l-yl)prop-l-enyl]
fluorobenzenesulfonylamino 4-carboxylate
Prepared by proceeding in a similar manner to Intermediate 63, starting from
methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-((Z)hydroxyprop-l-enyl)
fluorobenzene-sulfonyl]amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 64) and 3-hydroxyazetidine as a yellow oil.
LCMS (Method D) r/t 1.15 (M+H) 489.
Intermediate 78: N-(4-Dimethylaminobutyl)-N-methylamine
A solution of lithium aluminium hydride in THF ( 1M, 28mL) was added
dropwise to a stirred, cooled solution of N-(4-dimethylaminobutyl)formamide (Intermediate 79,
2.7g) in THF (60mL) while maintaining the temperature at 0°C under an atmosphere of
nitrogen. On completion of the addition, the mixture was stirred and heated at 75°C for 2 hours.
The reaction mixture was cooled to 0°C and ethanol was added then the mixture was
evaporated to dryness. The residue was diluted with a mixture of diethyl ether and DCM (30%)
and the solid was filtered off. The filtrate was evaporated to dryness to give N-(4-
dimethylaminobutyl)-N-methylamine (1.5g) as a yellow oil.
¾ NMR (CDC1 ) d : 2.56 (2H, m), 2.41 (3H, s), 2.25 (2H, m), 2.20 (6H, s), 1.47 (4H, m).
Intermediate 79: N-(4-Dimethylaminobutyl)formamide
A solution of 4-dimethylaminobutylamine (3.0g) in ethyl formate (30mL) was
stirred and heated at reflux under an atmosphere of nitrogen for 3 hours. After cooling, the
mixture was evaporated to dryness and the residue was purified by chromatography on silica,
eluting with a mixture of methanol and DCM (20%) to give N-(4-
dimethylaminobutyl)formamide (2.7g) as a pale yellow oil.
¾ NMR (CDC1 ) d : 8.14 (IH, s), 6.80 (IH, s), 3.50 (2H, m), 2.28 (2H, m), 2.20 (6H, s), 1.61
(4H, m).
Intermediate 80: Methyl (laRS,7bSR){2-[((S)-l-ethylpyrrolidinylcarbamoyl)methyl]
fluorobenzenesulfonylamino romenecarboxylate
A solution of methyl (laRS,7bSR)(2-carboxymethyl
fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 83, 0.180g), (S)-l-ethylpyrrolidinylamine ditrifluoroacetic acid salt
(Intermediate 81, 0.171g), EDAC (0.144g) and triethylamine (0.202g) in DCM (5mL) was
allowed to stand at room temperature for 6 days then washed with water and filtered through a
phase separator. The filtrate was directly purified by chromatography on silica, eluting with a
mixture of methanol and DCM with a gradient of 0-20% to give methyl (laRS,7bSR){2-
[((S)-l-ethylpyrrolidinylcarbamoyl)methyl]fluorobenzenesulfonylamino}-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.178g) as an off-white foam.
LCMS (Method E) r/t 2.57 (M+H) 532
Intermediate 81: (S)-l-Ethylpyrrolidinylamine ditrifluoroacetic acid salt
A solution of ferf-butyl ((S)-l-ethylpyrrolidinyl)carbamate (Intermediate 82,
0.107g) in a solution of trifluoroacetic acid (2mL) and DCM (2mL) was left to stand at room
temperature for 30 minutes then concentrated in vacuo. The residue was azeotroped with
toluene to give (S)-l-ethylpyrrolidinylamine ditrifluoroacetic acid salt (0.23 lg) as a light
brown gum which was used without further characterisation.
Intermediate 82: ferf-Butyl ((S)- l -eth arbamate
A mixture of te butyl (S)-pyrrolidinylcarbamate (1.048g), iodoethane
(0.90g) and potassium carbonate (1.55g) in acetonitrile (15mL) was stirred at room temperature
for 17 hours then filtered. The filtrate was concentrated in vacuo and the residue was triturated
with DCM and filtered. The filtrate was concentrated in vacuo and the residue was purified by
chromatography on silica, eluting with a mixture of methanol and DCM with a gradient of 0-
% to give ferf-butyl ((S)-l-ethylpyrrolidinyl)carbamate (0.891g) as a light coloured gum.
¾ NMR (CDC1 ) d : 5.1 1 (1H, br, s), 4.29 (1H, br, s), 3.88 (1H, br, s), 3.18 (1H, br, s), 2.90
(2H, br, m), 2.76 (2H, br, m), 2.62 (1H, br, q), 2.38 (1H, m), 1.44 (9H, s), 1.28 (3H, t).
Intermediate 83: Methyl (laRS,7bSR)(2-carboxymethylfluorobenzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
1M Sodium hydroxide solution (3mL) was added to a solution of methyl
(laRS,7bSR)(4-fluoromethoxycarbonylmethylbenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylate (Intermediate 84, 0.438g) in methanol (6mL)
and the mixture was heated at 50°C for 2 hours. After cooling, the mixture was evaporated to
dryness and the residue was dissolved in ethyl acetate and water and acidified with
concentrated hydrochloric acid. The organic layer was dried and filtered and the
(Na2SC>4)
filtrate was concentrated in vacuo, the residue was dissolved in touene and re-evaporated to
give methyl (laRS,7bSR)(2-carboxymethylfluorobenzene-sulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.422g) as a white solid.
¾ NMR (CDCI ) d : 8.83 (IH, br, s), 7.86 (IH, dd), 7.22 (IH, d), 7.01 (3H, m), 4.32 (IH, d),
4.00 (2H, m), 3.76 (IH, d), 3.73 (3H, s), 1.94 (IH, m), 1.73 (IH, m), 1.02 (2H, m).
Intermediate 84: Methyl (laRS,7bSR)[4-fluoro(methoxycarbonylmethyl)benzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
A solution of methyl (2-chlorosulfonylfluorophenyl)acetate (Intermediate 85,
0.293g) and methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydro-cyclopropa[c]chromene
carboxylate (Intermediate 42, 0.2 19g) in pyridine (ImL) and DCM (3mL) was left to stand at
room temperature for 4 days. The mixture was diluted with DCM, washed with 2M
hydrochloric acid and filtered through a phase separator. The filtrate was concentrated in vacuo
and the residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and cyclohexane with a gradient of 0-40% to give methyl (laRS,7bSR)[4-fluoro
(methoxycarbonylmethyl)-benzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.438g) as a colourless gum.
¾ NMR (CDCI ) d : 8.77 (IH, br, s), 7.84 (IH, dd), 7.22 (IH, d), 7.01 (3H, m), 4.33 (IH, d),
4.01 (2H, s), 3.79 (IH, d), 3.76 (3H, s), 3.69 (3H, s), 1.93 (IH, m), 1.73 (IH, m), 1.03 (2H, m).
Intermediate 85: Methyl (2-Chlorosulfonylfluorophenyl)acetate
Methyl (3-fluorophenyl)acetate (1.5 lg) was added dropwise to chlorosulphonic
acid (7mL) with stirring and ice cooling. The cooling bath was removed and the mixture was
allowed to stand at room temperature for 16 hours before being carefully added to a mixture of
ice and ethyl acetate. The organic layer was separated, washed with water, dried (MgSCU) and
filtered. The filtrate was concentrated in vacuo and the residue was purified by chromatography
on silica, eluting with a mixture of ethyl acetate and cyclohexane with a gradient of 0-20% to
give methyl (2-chlorosulfonylfluorophenyl)acetate (1.42g) as a white solid.
¾ NMR (CDC1 ) d : 8.16 (IH, dd), 7.21 (2H, m), 4.19 (2H, s), 3.76 (3H, s).
Intermediate 86: Methyl (laRS,7bSR)[2-(l-ethylazetidinyl)fluorobenzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
A mixture of methyl (laRS,7bSR)[2-(azetidinyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 87, 0.216g), iodoethane (0.078g) and potassium carbonate (0.138g) in acetonitrile
(5mL) was stirred at room temperature for 18 hours. The mixture was evaporated to dryness
and the residue was purified by chromatography on silica, eluting with a mixture of methanol
and DCM with a gradient of 0-15% to give methyl (laRS,7bSR)[2-(l-ethylazetidinyl)
fluorobenzenesulfonylamino] -1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylate
(0.05 lg).
¾ NMR (CDCI ) d : 7.97 (IH, dd), 7.62 (IH, dd), 7.24 (lH,d), 6.99 (IH, dt), 6.96 (IH, d),
4.35 (IH, d), 4.31 (IH, m), 3.79 (3H, s), 3.77 (IH, d), 3.58 (2H, m), 3.22 (2H, br, m), 2.53 (2H,
q), 1.93 (IH, m), 1.74 (IH, q), 0.99 (5H, m).
Intermediate 87: Methyl (laRS,7bSR)[2-(azetidinyl)fluorobenzenesulfonylamino]-
l ,l a,2,7b-tetrahydrocyclopropa[c]
A mixture of methyl (laRS,7bSR){4-fluoro[l-(2,2,2-
trifluoroacetyl)azetidinyl]benzene-sulfonylamino}-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 88, 0.294g) and potassium
carbonate (0.155g) in methanol (5mL) and water (0.5mL) was stirred at room temperature for
45 minutes. The mixture was concentrated in vacuo and the residue was triturated with 10%
methanol in DCM and filtered. The filtrate was concentrated in vacuo and the residue was
purified by chromatography on silica, eluting with a mixture of methanol and DCM with a
gradient of 0-40% to give methyl (laRS,7bSR)[2-(azetidinyl)fluoro-
benzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0.216g) as
a pale yellow foam.
¾ NMR (CDC1 ) d : d : 7.94 (IH, dd), 7.54 (IH, dd), 7.27 (lH,d), 7.09 (IH, dt), 6.99 (IH, d),
4.87 (IH, m), 4.32 (3H, m), 4.12 (2H, t), 3.78 (IH, m), 3.73 (3H, s), 1.94 (IH, m), 1.73 (IH,
m), 0.99 (2H, m).
Intermediate 88: Methyl (laRS,7bSR){4-fluoro[l-(2,2,2-trifluoroacetyl)azetidin
yl]benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
A solution of methyl 4-fluoro[l-(2,2,2-trifluoroacetyl)azetidin
yl]benzenesulfonyl chloride (Intermediate 89, 0.192g) and methyl (laRS,7bSR)amino-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (Intermediate 42, 0.122g) in
pyridine (lmL) and DCM (3mL) was left to stand at room temperature for 18 hours. The
mixture was diluted with DCM, washed with 1M hydrochloric acid and filtered through a phase
separator. The filtrate was concentrated in vacuo and the residue was purified by
chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 0-30% to give methyl (laRS,7bSR){4-fluoro[l-(2,2,2-trifluoro-
acetyl)azetidinyl]benzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromene
carboxylate (0.294g) as a colourless gum.
(CDCI )
¾ NMR d : 8.99 (IH, br, s), 7.99 (IH, m), 7.81 (2H, m), 7.06 (2H, m), 4.68 (2H, m),
4.41 (IH, m), 4.34 (IH, d), 4.19 (IH, m), 4.08 (IH, m), 3.79 (IH, m), 3.72 (3H, s), 1.94 (IH,
m), 1.75 (IH, m), 1.02 (2H, m).
Intermediate 89: 4-Fluoro[l -(2,2,2- azetidinyl]benzenesulfonyl chloride
Chlorosulphonic acid (5mL) was added to 2,2,2-trifluoro- l-[3-(3-
fluorophenyl)azetidin-l-yl]ethanone (Intermediate 90, 1.15g) with stirring and ice cooling. The
mixture was stirred for 1 hour then poured carefully onto a mixture of ice and ethyl acetate. The
organic layer was washed with water and concentrated in vacuo. The residue was purified by
chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 0-20% to give 4-fluoro[l-(2,2,2-trifluoroacetyl)azetidinyl]benzenesulfonyl
chloride (0.9 lOg) as a white solid.
¾ NMR (CDC1 ) d : 8.22 (1H, m), 7.5 1 (1H, dd), 7.26 (1H, m), 4.95 (2H, m), 4.70 (1H, t),
4.42 (1H, m), 4.31 (1H, m).
Intermediate 90: 2,2,2-Trifluoro- l-[3-(3-fluorophenyl)azetidin- l-yl]ethanone
A solution of ferf-butyl 3-(3-fluorophenyl)azetidine-l-carboxylate (Intermediate
92, 2.5 lg) in trifluoroacetic acid (15mL) and DCM (15mL) was left to stand at room
temperature for 30 minutes. The mixture was concentrated in vacuo and the residue was
azeotroped with toluene. The residue was dissolved in DCM (15mL) and pyridine (5mL) and
trifluoroacetic anhydride (3.15g) was added. The mixture was left to stand at room temperature
for 30 minutes, then washed with 1M hydrochloric acid and filtered through a phase separator.
The filtrate was concentrated in vacuo and the residue was purified by chromatography on
silica, eluting with a mixture of ethyl acetate and cyclohexane with a gradient of 0-20% to give
2,2,2-trifluoro- l-[3-(3-fluorophenyl)azetidin-l-yl]ethanone (2.31g) as a light brown oil.
¾ NMR (CDCI ) d : 7.36 (1H, m), 7.10 (1H, d), 7.02 (2H, m), 4.81 (1H, t), 4.57 (1H, t), 4.44
(1H, dd), 4.20 (1H, dd), 3.96 (1H, m).
Intermediate 91: ferf-Butyl 3-(3-fluoroph l -carboxylate
A solution of 1,2-dibromoethane (0.30g) in anhydrous DMF (25ml) was stirred
with zinc dust (1.39g) at 70°C for 10 minutes then cooled to room temperature and
chlorotrimethylsilane was (0.155g) added. The resultant mixture was stirred at room
temperature for 45 minutes. ferf-Butyl 3-iodoazetidine-l-carboxylate (5g) added and stirring
was continued at 40°C for 45 minutes then a solution of 3-fluoroiodobenzene (4.08g),
f i(dibenzylideneacetone)dipalladium(0) (0.325g) and frw(2-furyl)phosphine (0.165g) in DMF
(15mL) was added and the mixture was stirred at 70°C for 3 hours. After cooling, the mixture
was diluted with water and ethyl acetate and filtered through celite. The organic layer was
washed twice with water, dried and filtered. The filtrate was concentrated in vacuo
(Na2SC>4)
and the residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and cyclohexane with a gradient of 0-10%. The crude product was further purified by
chromatography on silica, eluting with a mixture of DCM and cyclohexane with a gradient of
0-100% to give ferf-butyl 3-(3-fluorophenyl)azetidine-l-carboxylate (2.52g) as a colourless oil.
¾ NMR (CDC1 ) d : 7.32 (1H, m), 6.90-7.1 1 (3H, m), 4.34 (2H, t), 3.95 (2H, dd), 3.72 (1H,
m), 1.48 (9H, s).
Intermediate 92: Methyl (laRS,7bSR){2-[((R)-l-ethylpyrrolidinylcarbamoyl)methyl]
fluorobenzenesulfonylamino romenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 80, starting from
methyl (laRS,7bSR)(2-carboxymethylfluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 83) and (R)-l-ethylpyrrolidin-
3-ylamine ditrifluoroacetic acid salt (Intermediate 93) as a light brown foam.
LCMS (Method E) r/t 2.57 (M+H) 532.
Intermediate 93: (R)-l-Ethylpyrrolidinylamine ditrifluoroacetic acid salt
Prepared by proceeding in a similar manner to Intermediate 81, starting from
tert-butyl ((R)-l-ethylpyrrolidinyl)carbamate as a light brown gum which was used without
further characterisation.
Intermediate 94: ferf-Butyl ((R)-l-ethylpyrrolidinyl)carbamate
Prepared by proceeding in a similar manner to Intermediate 82, starting from
te butyl (R)-pyrrolidinyl-carbamate and iodoethane as a light coloured gum.
¾ NMR (CDC1 ) d : 5.09 (2H, br, s), 4.25 (1H, br, s), 3.08 (1H, br, s), 2.82 (2H, br, m), 2.69
(2H, br, q), 2.52 (1H, br, q), 2.35 (1H, m), 1.44 (9H, s), 1.21 (3H, t).
Intermediate 95: Methyl (laS,7bR)[2-((R)-l-ethylpyrrolidinylmethyl)fluoro-
benzenesulfonylamino]- l ,l a,2, -carboxylate
A solution of methyl (laRS,7bSR)amino-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 42, 0.257g) in DCM (lOmL)
and pyridine (5mL) was treated with a solution of 2-((R)-l-ethylpyrrolidinylmethyl)
fluorobenzenesulfonyl chloride (Intermediate 96, 0.36g) in DCM (lOmL) and the mixture was
stirred at room temperature overnight. The resultant mixture was evaporated to dryness and the
residue was re-dissolved in DCM, washed with water, dried (MgSCU) and filtered. The filtrate
was evaporated to dryness and the residue was purified by chromatography on silica, eluting
with a mixture of methanol and DCM with a gradient of 0-10%, then flushed with 100%
methanol to give methyl (laS,7bR)[2-((R)-l-ethylpyrrolidinylmethyl)
fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(0.1 3g) as a gum.
H MR d : 7.88 (IH, br t), 7.23 (IH, d), 7.13(1H, br d), 6.98 (2H, m), 4.33 (IH, d),
(CDCI3)
3.79 (IH, d), 3.77 (3H, s), 3.20-2.90 (6H, m) 2.24 (IH, br s), 2.04-1.18 (3H, br s), 1.93 (2H, dt),
1.74 (IH, q), 1.45 (3H, t), 1.02 (2H, m).
Intermediate 96: 2-((R)- l -Ethylp fluorobenzenesulfonyl chloride
A solution of (R)-l-ethyl(3-fluorobenzyl)pyrrolidine (Intermediate 97, 0.24g)
in DCE (1.2mL) was added carefully to chlorosulfonic acid and the mixture was stirred at room
temperature for 2 hours. The mixture was carefully poured into iced water and extracted with
DCM, dried (MgSCU) and filtered. The filtrate was evaporated to dryness to give 2-((R)-l-
ethyl-pyrrolidinylmethyl)fluorobenzenesulfonyl chloride (0.36g) as an oil which was
used without further charactersiation.
Intermediate 97: (R)- l -Ethyl(3-fluo
Ethyl bromide (0.22g) was added to a suspension of 3-(R)-(3-
fluorobenzyl)pyrrolidine (Intermediate 98, 0.36g) and potassium carbonate (0.55g) in
acetonitrile and the mixture was stirred at room temperature for 2.5 hours. The mixture was
diluted with ethyl acetate, filtered and the filtrate was evaporated to dryness. The residue was
triturated with DCM, the solvent was decanted off and evaporated to dryness to give (R)-l-
ethyl(3-fluorobenzyl)pyrrolidine (0.24g) as an oil.
¾ NMR d : 7.22 (1H, m), 6.95 (1H, d), 6.88 (2H, m), 2.73-2.60 (4H, m), 2.52-2.38
(CDCI3)
(4H, m), 2.17 (1H, dd), 1.97 (1H, m), 1.49 (1H, m), 1.09 (3H, t).
Intermediate 98: 3-(R)-(3-Fluorobenzyl)
Trifluoroacetic acid (lOmL) was added to a solution of ten butyl (R)(3-
fluorobenzyl)-pyrrolidine-l-carboxylate (Intermediate 99, 0.5 15g) in DCM (lOmL) and the
mixture was stirred for 1 hour at room temperature. The mixture was evaporated to dryness and
the residue was partitioned between DCM and saturated aqueous NaHCC The organic extract
was separated, dried (MgSCU) and filtered. The filtrate was evaporated to dryness to give 3-(R)-
(3-fluoro-benzyl)pyrrolidine (0.402g) as an oil.
¾ NMR (CDCI ) d : 7.30-7.23 (2H, m), 6.94 (1H, d), 6.88 (1H, dt), 3.45-3.16 (3H, br m), 2.90
(1H, m), 2.76 (2H, d), 2.63 (1H, m), 2.12 (1H, m), 1.74 (1H, m).
Intermediate 99: ferf-Butyl (R)(3-fluorobenzyl)pyrrolidine-l-carboxylate
Nickel Iodide (0. 147g), transaminocyclohexanol HC1 salt (0.74g), 3-
fluorobenzene boronic acid (0.78g) and sodium hexamethyldisilazide (0.208g) were placed in a
sealed tube and degassed and purged with argon. Isopropanol (8mL) was added and the mixture
was stirred at 40°C for 5 minutes. A solution of ferf-butyl (R)iodomethylpyrrolidine-l-
carboxylate (Intermediate 100, 1.44g) in isopropanol (8mL) was added and the mixture was
stirred and heated at 70°C overnight. After cooling, the mixture was diluted with ethyl acetate,
filtered through Celite and the filtrate was evaporated to dryness. The residue was purified by
chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 0-60% to give ferf-butyl (R)(3-fluorobenzyl)pyrrolidine-l-carboxylate (0.5 15g)
as an oil.
¾ NMR (CDC1 ) d : 7.27-7.21 (2H, m), 6.95-6.84 (2H, m), 3.46 (2H, m), 3.26 (IH, m), 2.98
(IH, dd), 2.67 (2H, m), 2.40 (IH, m), 1.92 (IH, m), 1.58 (IH, m), 1.46 (9H, s).
Intermediate 100: ferf-Butyl (R)iodo dine- l -carboxylate
Iodine (1.91g) was added in portions to a vigorously stirred, ice cooled
suspension of imidazole (0.681g) and triphenylphosphine (1.97g) in diethyl ether (12mL). The
mixture was then stirred for 10 minutes before a solution of te butyl (R)
hydroxymethylpyrrolidine-l-carboxylate (lg) in dioxane (6mL) was added dropwise. The
resulting mixture was stirred at room temperature overnight, then diluted with diethyl ether and
filtered. The solid was washed with diethyl ether and the combined filtrate was evaporated to
dryness. The residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and pentane with a gradient of 0-20% to give ferf-butyl (R)iodomethylpyrrolidine-l-
carboxylate (1.44 g) as an oil.
¾ NMR (CDCI ). d : 3.64-3.46 (2H, m), 3.33 (IH, m), 3.19 (2H, d), 3.02 (IH, dd), 2.49 (IH,
m), 2.07 (IH, m), 1.65 (IH, m), 1.46 (9H, s).
Intermediate 101: Methyl (laRS,7bSR){2-[((S)-l-ethylpyrrolidinyl)cabonyl-
aminomethyl]fluorobenzenesulfonylamino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromene
carboxylate
A mixture of methyl (laRS,7bSR)(2-aminomethyl
fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 102, 0.5 15g), HATU (0.483g), (S)-N-ethylpyrrolidinecarboxylic acid
(Intermediate 106, 0.182g) and N,N-di-isopropyl-N-ethylamine (0.328g) in dry DMF (25mL)
was stirred at room temperature for 2 hours. The mixture was concentrated under vacuum and
the residue was diluted with water and extracted with ethyl acetate, washed with water, dried
(MgSCU) and filtered. The filtrate was evaporated to dryness and the residue was purified by
chromatography on silica, eluting with a mixture of methanol and DCM, with a graident of 1-
2% to give methyl (laRS,7bSR){2-[((S)-l-ethylpyrrolidinyl)cabonyl-aminomethyl]
fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylate
(0.505g) as a glassy solid.
¾ NMR (CDC1 ) d : 9.2-8.9 (IH, br s), 7.82 (2H, m), 7.24 (2H, m), 7.00 (IH, dt), 6.95 (IH,
dd), 4.75 (2H, m), 4.33 (IH, d), 3.99 (IH, br s), 3.79 (IH, m), 3.77 (3H, s), 3.67 (IH, m), 3.15-
2.87 (3H, m), 2.48 (IH, m), 2.02 (2H, m), 1.93 (2H, m), 1.74 (IH, m), 1.20 (3H, m), 1.02 (2H,
Intermediate 102: Methyl (laRS,7bSR)(2-aminomethyl)fluorobenzenesulfonylamino)-
l ,l a,2,7b-tetrahydrocyclopropa[c]
A solution of potassium carbonate (2. lg) in water was added to a solution of
methyl (laRS,7bSR)(4-fluorotrifluoroacetylaminomethyl)benzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 103, 1.53g) in
methanol (50mL) and the resultant mixture was stirred and heated at 45°C for 4 hours. After
cooling, the mixture was concentrated under vacuum and the residue was diluted with water
and saturated with salt. The resultant solid was collected by filtration, washed with water and
ethyl acetate then dried under vacuum at 50°C to give methyl (laRS,7bSR)(2-aminomethyl)-
4-fluoro-benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(1.06g) as a white solid.
¾ NMR (DMSO-d ) d : 8.52 (IH, br s), 7.99 (IH, dd), 7.32 (2H, m), 6.89 (IH, d), 6.74 (IH, d),
4.32 (2H, s), 4.17 (IH, d), 3.70 (3H, s), 3.64 (IH, d), 1.82 (IH, m), 1.65 (IH, m), 0.89 (IH, m),
0.61 (IH, m).
Intermediate 103: Methyl (laRS,7bSR)(4-fluorotrifluoroacetylaminomethyl)
benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Methyl (laRS,7bSR)-5amino-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 42, 0.972g) was added to a solution of 4-fluoro
(trifluoroacetylaminomethyl)-benzenesulfonyl chloride (Intermediate 104, 1.53g) in DCM
(25mL) and pyridine (6mL). The resultant mixture was stirred at room temperature for 2 hours.
The mixture was diluted with DCM, washed with water, H (1M), water, dried (MgSCU) and
filtered. The filtrate was evaporated to dryness and the residue was purified by chromatography
on silica, eluting with a mixture of ethyl acetate and pentane with a gradient of 5-30% to give
methyl (laRS,7bSR)(2-trifluoroacetylaminomethyl)fluorobenzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (1.76g) as a glassy foam.
¾ NMR (CDC1 ) d : 9.04 (IH, br s), 7.83 (IH, dd), 7.49 (IH, br t), 7.30 (IH, dd), 7.29 (IH, d),
7.09 (IH, d), 7.06 (IH, dt), 4.61 (2H, d), 4.34 (IH, d), 3.78 (IH, dd), 3.73 (3H, s), 1.95 (IH,
m), 1.75 (IH, m), 1.04 (2H, m).
Intermediate 104: 4-Fluoro(trifluoroacetylaminomethyl)benzenesulfonyl chloride
3-Fluoro-N-trifluoroacetylbenzylamine (Intermediate 105, 1.1 lg) was added
portionwise to chlorosulfonic acid (5mL), while stirring and cooling in an ice bath. On
completion of the addition, the ice bath was removed and the mixture was allowed to come to
room temperature then heated to 70°C for 3 hours. After cooling, the mixture was slowly added
to ice and the resultant suspension was extracted with ethyl acetate, washed with water, dried
(MgSCU) and filtered. The filtrate was evaporated to dryness to give 4-fluoro
(trifluoroacetylaminomethyl)benzenesulfonyl chloride (1.53g) as a brown solid.
¾ NMR (CDCI ) d : 8.18 (IH, dd), 7.47 (IH, m), 7.29 (IH, m), 7.18 (IH, br s), 4.92 (2H, d).
Intermediate 105: 3-Fluoro-N-trifluoroacetylbenzylamine
Trifluoroacetic anhydride (5.05g) was added dropwise to an ice-cooled solution
of 3-fluorobenzylamine (2.5g) and triethylamine (2.22g) in ethyl acetate (75mL) while
maintaining the temperature below 10°C. The mixture was stirred at 0-5°C for 1 hour then
allowed to warm to room temperature and stirred for 2 hours. Water was added and the layers
were separated. The organic layer was washed with water, dried (MgS0 ) and filtered. The
filtrate was evaporated to dryness to give 3-fluoro-N-trifluoroacetylbenzylamine (4.58g) as an
oil which crystallised on standing to a white solid.
¾ NMR (CDC1 ) d : 7.34 (IH, m), 7.03 (3H, m), 6.72 (IH, br s), 4.53 (2H, d).
Intermediate 106: (S)-N-Ethylpyrrolid acid
Palladium on carbon (10%, 0.2g) was added to a solution of benzyl (S)-N-
ethylpyrrolidinecarboxylate (Intermediate 107, 0.603g) under an atmosphere of nitrogen.
The mixture was then hydrogenated at 4Bar for 3 hours. The mixture was filtered through
Celite and the filtrate was evaporated to dryness to give (S)-N-ethylpyrrolidinecarboxylic
acid (0.378g) as a straw coloured gummy solid.
¾ NMR (CDCI ) d : 4.01 (IH, m), 3.78 (IH, m), 3.31 (IH, m), 3.18 (IH, m), 2.87 (IH, m),
2.38 (IH, m), 2.27 (IH, m), 2.02 (2H m), 1.39 (3H, t).
Intermediate 107: Benzyl (S)-N-ethylpyrrolidinecarboxylate hydrochloride
Iodoethane (1.34g) was added to a mixture of benzyl (S)-pyrrolidine
carboxylate (l.Og) and potassium carbonate (1.77g) in dry DMF (7mL) and the resultant
mixture was stirred at room temperature for 3 days. The mixture was diluted with water,
extracted with ethyl acetate, washed with water, dried (MgSC^) and filtered. The filtrate was
evaporated to dryness and the residue was purified by chromatography on silica, eluting with a
mixture of ethyl acetate and pentane with a gradient of 10-20% to give benzyl (S)-N-
ethylpyrrolidinecarboxylate (0.643g) as a pale straw coloured oil.
¾ NMR (CDC1 ) d : 7.35 (5H, m), 5.17 (2H, s), 3.19 (2H, m), 2.74 (IH, m), 2.45 (IH, m), 2.34
(IH, m), 2.12 (IH, m) 1.93 (2H, m), 1.81 (IH, m), 1.10 (3H, t).
Intermediate 108: Methyl (laRS,7bSR)[2-(4-dimethylaminobutyrylamino)
fluorobenzene-sulfonyl 4-carboxylate
A mixture of methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-(4-
chlorobutyryl-amino)fluorobenzenesulfonyl]amino }-1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate (Intermediate 109, 0.15g) and dimethylamine (30% aqueous
solution, 5mL) in acetonitrile (lOmL) was stirred and heated at 40°C for 10 hours. After
cooling, the mixture was concentrated under vacuum and the residue was extracted with a
mixture of ethyl acetate and THF (50%), dried and filtered. The filtrate was
(Na2SC 4)
evaporated to dryness and the residue was purified by thick layer chromatography on silica,
eluting with a mixture of methanol and DCM (10%) to give methyl (laRS,7bSR)[2-(4-
dimethylaminobutyrylamino)fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate (0.14g) as a yellow oil.
LCMS (Method D) r/t 1.24 (M+H) 506.
Intermediate 109: Methyl (laRS,7bSR){N-[methoxycarbonyl]-N-[2-(4-chlorobutyryl-
amino)fluorobenzenesulfonyl]amino}-l,la,2,7b-tetrahydrocyclopropa-[c]chromene
carboxylate
4-Chlorobutyryl chloride (3.0g) was added to a stirred, cooled solution of
methyl (laRS,7bSR)[N-(methoxycarbonyl)-N-(2-aminofluorobenzenesulfonyl]amino}-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (Intermediate 110, 0.135g) and
triethylamine (l.Og) in THF (lOmL) at 0°C. On completion of the addition, the mixture was
stirred at room temperature for 4 hours.Saturated aqueous sodium bicarbonate was added and
the mixture was extracted with ethyl acetate, dried and filtered. The filtrate was
(Na2SC 4)
evaporated to dryness and the residue was purified by chromatography on silica, eluting with a
mixture of ethyl acetate and petroleum ether, with a gradient of 20-25% to give methyl
(laRS,7bSR){N-[methoxycarbonyl]-N-[2-(4-chlorobutyrylamino)fluoro-
benzenesulfonyl]amino}- l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (0.15g) as
a yellow oil.
LCMS (Method D) r/t 1.72 (M+H) 555.
Intermediate 110: Methyl (laRS,7bSR)[N-(methoxycarbonyl)-N-(2-amino
fluorobenzene-sulfonyl)amino]- l , a[c]chromenecarboxylate
A mixture of methyl (laRS,7bSR)[N-(methoxycarbonyl)-N-(4-fluoro
nitrobenzene-sulfonyl)amino]-l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate
(Intermediate 111, 0.2g), zinc (0.54g) and acetic acid (0.5g) in ethanol (20mL) was stirred and
heated at reflux for 1 hour. After cooling, the solid was filtered off and the filtrate was
evaporated to dryness. The residue was treated with saturated aqueous sodium bicarbonate and
extracted with ethyl acetate, dried and filtered. The filtrate was evaporated to dryness
(Na2SC 4)
and the residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and petroleum ether with a gradient of 30-50% to give methyl (laRS,7bSR)[N-
(methoxycarbonyl)-N-(2-aminofluorobenzenesulfonyl)amino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.15g) as a white solid.
¾ NMR (CDC1 ) d : 7.74 (IH, m), 7.36 (IH, d), 6.95 (IH, d), 6.47 (IH, m), 6.39 (IH, d), 5.37
(2H, m), 4.42 (IH, m), 3.91 (IH, d), 3.74 (3H, 2s), 3.70 (3H, 2s), 2.06 (IH, m), 1.84 (IH, m),
1.28 (lH, m), 1.15 (IH, m).
Intermediate 111: Methyl (laRS,7bSR)[N-(methoxycarbonyl)-N-(4-fluoronitrobenzene-
sulfonyl)amino] -1,1a,2,7b-tetrah -carboxylate
A solution of methyl (laRS,7bSR)(4-fluoronitrobenzenesulfonylamino)-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 112, 0.25g) in THF
(lOmL) was added dropwise with stirring to a cooled suspension of sodium hydride (O.lg) in
THF (5mL) at 0°C. On completion of the addition, the mixture was stirred at room temperature
for 30 minutes. Methyl chloroformate (0.3g) was added dropwise and the mixture was stirred at
room temperature for 1.5 hours. Saturated aqueous sodium bicarbonate was added and the
mixture was extracted with ethyl acetate, dried and filtered. The filtrate was
(Na2SC 4)
evaporated to dryness and the residue was purified by chromatography on silica, eluting with a
mixture of ethyl acetate and petroleum ether to give methyl (laRS,7bSR)[N-
(methoxycarbonyl)-N-(4-fluoronitrobenzenesulfonyl)amino]-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylate (0.2g) as a white solid.
LCMS (Method D) r/t 1.58 (M+H) 481.
Intermediate 112: Methyl (laRS,7bSR)(4-fluoronitrobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromene
A mixture of methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate (Intermediate 42, O.lg), 4-fluoronitrobenzenesulfonyl chloride
(0.1 15g) and pyridine (2mL) in DCM (5mL) was stirred at room temperature overnight. The
mixture was concentrated under vacuum and the residue was partitioned between ethyl acetate
and water. The organic layer was dried and filtered and the filtrate was evaporated to
(Na2SC 4)
dryness. The residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and petroleum ether (20%) to give methyl (laRS,7bSR)(4-fluoro
nitrobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0. 11g)
as a yellow oil.
¾ NMR (CDC1 ) d : 8.56 (IH, br s), 7.92 (IH, m), 7.55 (IH, dd), 7.31 (2H, m), 7.24 (IH, m),
4.34 (IH, d), 3.85 (3H, s), 3.82 (IH, d), 1.98 (IH, m), 1.74 (IH, m), 1.08 (2H, m).
Intermediate 113: Methyl (laS,7bR)[2-((S)-l-ethyl-pyrrolidinylmethyl)fluoro-
benzenesulfonylamino]- l ,l a,2,7 carboxylate
A solution of methyl 5-amino-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 42, 0.19g) in DCM (lOmL) and pyridine (3.5mL) was treated with a
solution of 2-((S)-l-ethylpyrrolidinylmethyl)fluorobenzenesulfonyl chloride
(Intermediate 114, 0.26g) in DCM (5mL) and the mixture was stirred and heated at 40°C for 1
hour. The resultant mixture was evaporated to dryness and the residue was purified by
chromatography on silica, eluting with a mixture of DCM and methanol with a gradient of 0-
25%, then flushed with 100% methanol to give methyl (laS,7bR)[2-((S)-l-ethylpyrrolidin-
3-ylmethyl)fluoro-benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (0.107g) as a gum.
LCMS (Method A) r/t 2.29 (M+H) 489.
Intermediate 114: 2-((S)- l -Ethylp fluorobenzenesulfonyl chloride
Prepared by proceeding in a similar manner to Intermediate 96, starting from
(S)-l-ethyl(3-fluorobenzyl)pyrrolidine (Intermediate 115).
LCMS (Method A) r/t 1.95 (M+H) 308.
Intermediate 115: (S)-l-Ethyl(3-fluorobenzyl)pyrrolidine
Prepared by proceeding in a similar manner to Intermediate 97 starting with 3-
(S)-(3-fluoro-benzyl)pyrrolidine (Intermediate 116).
¾ NMR (CDC1 ) d : 7.22 (IH, m), 6.95 (IH, d), 6.88 (2H, m), 2.81-2.62 (4H, br m), 2.61-2.39
(4H, br m), 2.21 (lH. br s), 1.99 (IH, m), 1.52 (IH, m), 1.1 1 (3H, t).
Intermediate 116: 3-(S)-(3-Fluorobenzy
Prepared by proceeding in a similar manner to Intermediate 98 starting with tert-
butyl (S)(3-fluorobenzyl)-pyrrolidine-l-carboxylate (intermediate 117).
¾ NMR (CDCI ) d : 7.27 (IH, m), 6.96-6.84 (3H, m), 3.32 (IH, m), 3.25 (IH, dd), 3.16 (IH,
m), 2.83 (IH, m), 2.73 (2H, d), 2.58 (IH, m), 2.08 (IH, m), 1.68 (IH, m).
Intermediate 117: ferf-Butyl (S)(3-fluorobenzyl)-pyrrolidine-l-carboxylate
Prepared by proceeding in a similar manner to Intermediate 99 starting with tert-
butyl (S)iodomethylpyrrolidine-l-carboxylate (Intermediate 118).
¾ NMR (CDCI ) d : 7.27 (IH, m), 6.97-6.83 (3H, m), 3.46 (2H, m), 3.25 (IH, m), 2.98 (IH,
m), 2.67 (2H, m), 2.40 (IH, m), 1.91 (IH, m), 1.58 (IH, m), 1.45 (9H, s).
Intermediate 118: ferf-Butyl (S)iodomethylpyrrolidine-l-carboxylate
Prepared by proceeding in a similar manner to Intermediate 100 starting with
ferf-butyl (S)hydroxymethylpyrrolidine- 1-carboxylate.
¾ NMR d : 3.59 (1H, dd), 3.5 1 (1H, m), 3.33 (1H, m), 3.19 (2H, d), 3.02 (1H, dd),
(CDCI3)
2.49 (1H, m), 2.07 (1H, m), 1.65 (1H, m), 1.46 (9H, s).
Intermediate 119: ferf-Butyl (laRS,7bSR){2-[N-(2,4-dimethoxybenzyl)-N-(3-dimethyl-
aminopropyl)carbamoyl]benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromene-
4-carboxylate
A solution of N-(2,4-dimethoxybenzyl)-N-(3-dimethylaminopropyl)amine
(Intermediate 120, 0.179g) in DCM (2mL) was added dropwise with stirring to a cooled
solution of 2-chlorosulfonylbenzoyl chloride (Intermediate 121, 0.17g) in DCM (20mL) at 0°C.
The mixture was stirred at 0°C for 1 hour then a solution of ferf-butyl (laRS,7bSR)amino-
l,la,2,7b-tetrahydro-cyclopropa-[c]chromenecarboxylate (Intermediate 122, 0.185g) in
DCM (2mL) was added. The resultant mixture was stirred and heated at 30-35°C overnight.
After cooling, the mixture was concentrated under vacuum and the residue was purified by
HPLC (C18) to give ferf-butyl (laRS,7bSR){2-[N-(2,4-dimethoxybenzyl)-N-(3-
dimethylaminopropyl)carbamoyl]-benzenesulfonylamino }- 1,1a,2,7b-tetrahydro-cyclopropa-
[c]chromenecarboxylate (0.03g) as a yellow oil.
LCMS (Method D) r/t 3.16 (M+H) 680.
Intermediate 120: N-(2,4-Dimethoxybenzyl)-N-(3-dimethylaminopropyl)amine
A mixture of 3-dimethylaminopropylamine (3.06g), 2,4-dimethoxybenzaldehyde
(6.0g) and sodium triacetoxyborohydride (9.54g) in methanol (20mL) was stirred at room
temperature for 10 hours. The mixture was concentrated under vacuum and the residue was
dissolved in ethyl acetate and washed with water and brine, dried and filtered. The
(Na2SC 4)
filtrate was evaporated to dryness to give N-(2,4-dimethoxybenzyl)-N-(3-
dimethylaminopropyl)amine (7.2g) as a brown oil which was used directly without further
characterisation.
Intermediate 121: 2-Chlorosulfonylben chloride
A mixture of l,l-dioxo-lH-llambda*6*benzo[c][l,2]oxathiolone (4.5g) and
phosphorous pentachloride (15g) was stirred and heated at 60°C overnight. After cooling, a
mixture of ice and water was added and the solution was extracted with DCM, dried
(Na2SC 4)
and filtered. The filtrate was evaporated to dryness to give 2-chlorosulfonylbenzoyl chloride
(5g) as a yellow solid which was used without further characterisation.
Intermediate 122: ferf-Butyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
Sodium borohydride (0.32g) was added in portions to a stirred solution of tert-
butyl (laRS,7bSR)(trifluoroacetylamino)-l,la,2,7b-tetrahydro-cyclopropa-[c]chromene
carboxylate (Intemediate 123, 0.5g) in ethanol (20mL). The resultant mixture was stirred at
room temperature for 1 hour then concentrated under vacuum. The residue was purified by
chromatography on silica, eluting with a mixture of ethyl acetate and petroleum ether with a
gradient of 2-4% to give ferf-butyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate (0.2g) as a white solid.
¾ NMR (CDCI ) d : 7.04 (IH, d), 6.25 (IH, d), 4.57 (2H, br s), 4.32 (IH, d), 3.87 (IH, d), 1.86
(IH, m), 1.65 (IH, m), 1.60 (9H, s), 0.95 (2H, m).
Intermediate 123: ferf-Butyl (laRS,7bSR)(trifluoroacetylamino)-l,la,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylate
A mixture of (laRS,7bSR)(trifluoroacetylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (Intermediate 124, 0.97g), DMAP (0.2g),
dicyclohexyl carbodiimide (1.33g) and di-ferf-butyl dicarbonate (3.5 lg) in ferf-butanol (20mL)
was stirred and heated at reflux for 7 hours. After cooling, the mixture was concentrated under
vacuum and the residue was purified by chromatography on silica, eluting with a mixture of
ethyl acetate and petroleum ether (2%) to give ferf-butyl (laRS,7bSR)
(trifluoroacetylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0.5g) as a
yellow oil.
¾ NMR (CDCI ) d : 10.47 (IH, br s), 7.89 (IH, d), 7.34 (IH, d), 4.39 (IH, d), 3.88 (IH, d),
2.02 (IH, m), 1.77 (IH, m), 1.60 (9H, s), 1.09 (2H, m).
Intermediate 124: (laRS,7bSR)(Trifluoroacetylamino)- 1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid
Trifluoroacetic anhydride (2.98g) was added dropwise to a stirred, cooled
solution of (1aRS ,7bSR)amino- 1,1a,2,7b-tetrahydro-cyclopropa- [c]chromenecarboxylic
acid (Intermediate 125, 0.97g) and triethylamine (2.39g) in THF (20mL). The resultant mixture
was stirred at room temperature for 30 minutes. Water was added and the mixture was
extracted with ethyl acetate, dried and filtered. The filtrate was evaporated to dryness
(Na2SC 4)
and the residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and petroleum ether (2%) to give (laRS,7bSR)(trifluoroacetylamino)-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylic acid (0.97g) as a white solid.
¾ NMR (DMSO-d ) d : 7.92 (IH, d), 7.28 (IH, d), 4.54 (IH, d), 3.94 (IH, d), 2.27 (IH, m),
2.02 (IH, m), 1.21 (IH, m), 0.95 (IH, m).
Intermediate 125: (laRS,7bSR)Amino-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
A mixture of methyl (laRS,7bSR)amino-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermedaite 42, l.Og) and lithium hydroxide
monohydrate (0.96g) in dioxane (16mL) and water (14mL) was stirred and heated at 90°C for 1
hour. After cooling, the mixture was concentrated under vacuum and the residue was diluted
with water and neutralised to pH7 with formic acid. The mixture was then extracted with ethyl
acetate, dried and filtered and the filtrate was evaporated to dryness to give
(Na2SC 4)
(laRS,7bSR)amino-l, la,2,7b-tetrahydro-cyclopropa-[c]chromenecarboxylic acid (0.97g)
as a yellow oil.
LCMS (Method D) r/t 2.13 (M+H) 206.
Intermediate 126: Methyl (laRS,7bSR)(2-{ [N-((S)-l-ethylpyrrolidinyl)-N-methyl-
carbamoyl]-methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chro
EDAC (0.058g) was added to a stirred solution of methyl (laRS,7bSR)(2-
carboxymethylfluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 83, 0.109g) in DCM (3mL) and the mixture was stirred at room
temperature for 10 minutes. A solution of N-((S)-l-ethylpyrrolidinyl)-N-methylamine
dihydrochloride (Intermediate 127, 0.102g) and triethylamine (0. 15 lg) in DCM (3mL) was
added and the mixture stirred for 17 hours. The mixture was evaporated in vacuo and the
residue was dissolved in dioxane (4mL) and the mixture was heated at 75°C for 20 hours. After
cooling, the mixture was diluted with DCM and water and filtered through a phase separator.
The filtrate was evaporated in vacuo and the residue was combined with an identical reaction
carried out earlier. The material was purified by chromatography on silica, eluting with a
mixture of methanol and DCM with a gradient of 0-50% to give methyl (laRS,7bSR)(2-
{[((S)-l-ethylpyrrolidinyl)methylcarbamoyl]methyl}fluoro-benzenesulfonylamino)-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate (0.48g) as a light brown foam.
LCMS (Method E) r/t 2.65 (M+H) 546.
Intermediate 127: N-((S)-l-Ethylpyrrolidinyl)-N-methylamine dihydrochloride
A mixture of benzyl N-((S)-l-ethylpyrrolidinyl)-N-methylcarbamate
(Intermediate 128, 0.682g) and 10% palladium on carbon (0.10g) in ethanol (20mL) was stirred
at room temperature under an atmosphere of hydrogen for 3 hours. The mixture was filtered,
and concentrated hydrochloric acid (2mL) was added. The solution was evaporated in vacuo
then redissolved in a mixture of toluene and ethanol then re-evaporated to give N-((S)
ethylpyrrolidinyl)-N-methylamine dihydrochloride (0.53 lg) as a light coloured, viscous oil
which was used without further characterisation.
Intermediate 128: Benzyl N-((S)-l-ethylpyrrolidinyl)-N-methylcarbamate
A mixture of benzyl N-methyl-(S)-pyrrolidinylcarbamate (Intermediate 129,
1.28g), iodoethane (0.853g), and potassium carbonate (1.5 lg) in acetonitrile (12mL) was stirred
at room temperature for 4 hours. The mixture was evaporated in vacuo and the residue was
basified with 5M sodium hydroxide and filtered through a phase separator. The filtrate was
concentrated in vacuo and the residue was purified by chromatography on silica, eluting with a
mixture of methanol and DCM with a gradient of 0-30% to give benzyl N-((S)
ethylpyrrolidinyl)-N-methylcarbamate (0.686g) as a colourless oil.
¾ NMR (CDC1 ) d : 7.35 (5H, m), 5.13 (2H, s), 4.84 (1H, br, s), 2.91 (3H, s), 2.30-2.82 (6H,
m), 2.12 (1H, br, m), 1.79 (1H, m), 1.10 (3H, t).
Intermediate 129: Benzyl N-methyl-(S)-pyrrolidinylcarbamate
A solution of ferf-butyl (S)(N-benzyloxycarbonyl-N-
methylamino)pyrrolidine-l-carboxylate (Intermediate 130, 1.8 lg) in trifluoroacetic acid (8mL)
and DCM (8mL) was left to stand at room temperature for 30 minutes. The resultant mixture
was concentrated in vacuo and the residue was dissolved in DCM and brine, basified with 2M
sodium hydroxide and filtered through a phase separator. The filtrate was concentrated in vacuo
to give benzyl N-methyl-(S)-pyrrolidinylcarbamate (1.46g) as a light coloured oil.
¾ NMR (CDCI ) d : 7.35 (5H, m), 5.14 (2H, s), 4.68 (1H, br, m), 3.08 (2H, m), 2.88 (3H, s),
2.76-2.95 (3H, m), 2.01 (1H, m), 1.75 (1H, m).
Intermediate 130: ferf-Butyl (S)(N-benzyloxycarbonyl-N-methylamino)pyrrolidine-l-
carboxylate
Sodium hydride (60% oil dispersion, 0.32g) was added to a stirred solution of
ferf-butyl (S)benzyloxycarbonylaminopyrrolidine-l-carboxylate (prepared according to
Cheng et al, WO2007 142585, 1.73g) in THF (20mL) and the mixture was stirred for 15
minutes. lodomethane (1.85g) was added and the mixture was stirred at room temperature for 1
hour. Methanol was carefully added to destroy the excess sodium hydride then ethyl acetate
and water were added and the organic layer was washed with brine, dried (Na2SC 4), filtered.
The filtrate was concentrated in vacuo to give ferf-butyl (S)(N-benzyloxycarbonyl-N-
methylamino)pyrrolidine-l-carboxylate (1.66g) as a pale coloured oil.
¾ NMR (CDCI3) d : 7.36 (5H, m), 5.15 (2H, s), 4.79 (1H, br, s), 3.54 (2H, br, m), 3.1 1-3.38
(2H, br, m), 2.86 (3H, s), 1.98 (2H, m), 1.46 (9H, s).
Intermediate 131: Methyl (laRS,7bSR)(2-{ [N-((R)-l-ethylpyrrolidinyl)-N-methyl-
carbamoyl]methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 126, starting from
methyl (laRS,7bSR)(2-carboxymethylfluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 83) and N-((R)
ethylpyrrolidinyl)-N-methylamine dihydrochloride (Intermediate 132) as a light brown
foam.
LCMS (Method E) r/t 2.63 (M+H) 546
Intermediate 132: N-((R)- l-Ethylpyrrolid methylamine dihydrochloride
Prepared by proceeding in a similar manner to Intermediate 127, starting from
benzyl N-((R)-l-ethylpyrrolidinyl)-N-methylcarbamate (Intermediate 133) as a light
coloured viscous oil, which was used without further characterization.
Intermediate 133: Benzyl N-((R)-l-ethylpyrrolidinyl)-N-methylcarbamate
Prepared by proceeding in a similar manner to Intermediate 128, starting from
benzyl N-methyl-(R)-pyrrolidinylcarbamate (I including bridged or fused rings, and
ntermediate 134) and iodoethane, as a light coloured oil.
¾ NMR (CDC1 ) d : 7.35 (5H, m), 5.13 (2H, s), 4.84 (IH, br, s), 2.91 (3H, s), 2.30-2.87 (6H,
m), 2.12 (IH, br, m), 1.80 (IH, m), 1.10 (3H, t).
Intermediate 134: Benzyl N-methyl-(R)-pyrrolidinylcarbamate
Prepared by proceeding in a similar manner to Intermdiate 129, starting from
ferf-butyl (R)(N-benzyloxycarbonyl-N-methylamino)-pyrrolidine- 1-carboxylate
(Intermediate 135) as a plae coloured oil.
¾ NMR (CDCI ) d : 7.35 (5H, m), 5.14 (2H, s), 4.79 (IH, br, s), 3.08 (2H, m), 2.88 (3H, s),
2.76-2.95 (3H, m), 2.01 (IH, m), 1.75 (IH, m).
Intermediate 135: ferf-Butyl (R)(N-benzyloxycarbonyl-N-methylamino)pyrrolidine-l-
carboxylate
Prepared by proceeding in a similar manner to Intermediate 130, starting from
ferf-butyl (R)benzyloxycarbonylaminopyrrolidine-l-carboxylate (prepared according to
Zhou et al, US 2008 0293771) and iodomethane, as a pale coloured oil.
¾ NMR (CDCI ) d : 7.35 (5H, m), 5.15 (2H, s), 4.69 (1H, br, s), 3.54 (2H, br, m), 3.1 1-3.38
(2H, br, m), 2.86 (3H, s), 1.98 (2H, m), 1.46 (9H, s).
Intermediate 136: 2((S)- l -Ethylpyrrol
((S)-l-Acetylpyrrolidinyl)acetonitrile (Intermediate 137, l.Og) was added
potionwise to a stirred, cooled solution of lithium aluminium hydride (0.36g) in THF (30mL)
under an atmosphere of nitrogen while maintaining the temperature at 0°C. The mixture was
allowed to warm to room temperature then heated at reflux for 2 hours. After cooling, ethanol
(4mL) was added dropwise and the resultant solid was filtered off. The filtrate was evaporated
to dryness to give 2((S)-l-ethylpyrrolidinyl)ethylamine (0.6g) as a colourless oil.
¾ NMR (D 0 ) d : 3.59 (1H, m), 3.37 (2H, m), 3.01 (4H, m), 2.24 (2H, m), 1.98 (3H, m), 1.65
(1H, m), 1.21 (3H, t).
Intermediate 137: ((S)- l -Acetylpyrrolid trile
Acetyl chloride (8.6g) was added dropwise to a stirred, cooled solution of ((S)-
pyrrolidinyl)acetonitrile hydrochloride (Intermediate 138, 8.0g) and triethylamine (16.5g) in
DCM (80mL) while maintaining the temperature at 0°C. The resultant solution was stirred at
0°C for 30 minutes. Water was added and the layers were separated. The aqueous layer was
further extracted with DCM and the combined organic layers were washed with brine, dried
and filtered. The filtrate was evaporated to dryness and the residue was purified by
(Na2SC 4)
HPLC (CI 8) to give ((S)-l-acetylpyrrolidinyl)acetonitrile (5.0g) as a light yellow oil which
was used directly without further characterisation.
Intermediate 138: ((S)-Pyrrolidinyl)a hydrochloride
A solution of ferf-butyl (S)cyanomethylpyrrolidine-l-carboxylate
(Intermediate 139, 13.0g) in methanol (130mL) and concentrated hydrochloric acid (13mL)
was stirred and heated at 40°C overnight. After cooling, the mixture was concentrated under
vacuum and the residue was diluted with toluene and reconcentrated. Ethanol (20mL) was
added and the resultant solid was collected by filtration and washed with hexane to give ((S)-
pyrrolidinyl)acetonitrile hydrochloride (8.0g) as a white solid.
LCMS (Method D) r/t 0.50 (M+H) 111.
Intermediate 139: ferf-Butyl (S)cyanomethylpyrrolidine-l-carboxylate
Sodium cyanide (8.2g) was added to a solution of ferf-butyl (S)(4-
methylbenzenesulfonyloxymethyl)pyrrolidine-l-carboxylate (Intermediate 140, 29.6g) in
DMSO (300mL) and the resultant mixture was stirred and heated at 90°C for 5.5 hours. After
cooling, the mixture was treated with saturated aqueous iron (II) sulphate solution and the
mixture was stirred for a further 5 hours then extracted with ethyl acetate. The organic layer
was washed with brine, dried and filtered. The filtrate was evaporated to dryness and
(Na2SC 4)
the residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate
and petroleum ether (5%) to give ferf-butyl (S)cyanomethylpyrrolidine-l-carboxylate
(13.0g) as a light yellow oil which was used without further characterisation.
Intermediate 140: ferf-Butyl (S)(4-methylbenzenesulfonyloxymethyl)pyrrolidine-l-
carboxylate
4-Methylbenzenesulfonyl chloride (22.7g) was added portionwise to a stirred,
cooled solution of ferf-butyl (S)hydroxyoxymethylpyrrolidine-l-carboxylate (20.0g) in
pyridine (70mL) while maintaining the temperature at 0°C. The resultant mixture was stirred at
room temperature overnight. The mixture was concentrated under vacuum and the residue was
dissolved in DCM and washed with saturated aqueous sodium bicarbonate solution and brine,
dried and filtered. The filtrate was evaporated to dryness to give ferf-butyl (S)(4-
(Na2SC 4)
methylbenzenesulfonyl-oxymethyl)pyrrolidine-l-carboxylate (34g) as a yellow oil which was
used without further characterisation.
Intermediate 141: 2-((R)- l-Ethylp
Prepared by proceeding in a similar manner to Intermediate 136, starting from
((S)-l-acetylpyrrolidinyl)acetonitrile (Intermediate 142) and used without further
characterisation.
Intermediate 142: ((R)- l-Acetylpyrroli trile
Prepared by proceeding in a similar manner to Intermediate 137, starting from
((R)-pyrrolidinyl)acetonitrile hydrochloride (Intermediate 143) and used without further
characterisation.
Intermediate 143: ((R)-Pyrrolidinyl)a hydrochloride
Prepared by proceeding in a similar manner to Intermediate 138, starting from
ferf-butyl (R)cyanomethylpyrrolidine-l-carboxylate (Intermediate 144) and used without
further characterisation.
Intermediate 144: ferf-Butyl (R)cyanomethylpyrrolidine-l-carboxylate
Prepared by proceeding in a similar manner to Intermediate 139, starting from
ferf-butyl (R)(4-methylbenzenesulfonyloxymethyl)pyrrolidine- 1-carboxylate (Intermediate
145) and used without further characterisation.
Intermediate 145: ferf-Butyl (R)(4-methylbenzenesulfonyloxymethyl)pyrrolidine-l-
carboxylate
Prepared by proceeding in a similar manner to Intermediate 140, starting from
ferf-butyl (R)hydroxymethylpyrrolidine- 1-carboxylate and used without further
characterisation.
Intermediate 146: Methyl (laRS,7bSR)(2-{ [((R)-l-ethylpyrrolidineyl)carbonylamino]-
methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
Prepared by proceeding in a similar manner to Intermediate 101, starting from
methyl (laRS,7bSR)(2-aminomethylfluorobenzenesulfonylamino)-l,la,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylate (Intermediate 102) and (R)-l-ethylpyrrolidine
carboxylic acid (Intermediate 147) as a solid.
LCMS (Method B) r/t 2.37 (M+H) 532
Intermediate 147: (R)- l-Ethyl-pyrrolidinecarboxylic acid
Prepared by proceeding in a similar manner to Intermediate 106, starting from
ferf-butyl (R)-l-ethylpyrrolidinecarboxylate (Intermediate 148) as a solid.
¾ NMR (CDC1 ) d : 3.99 (IH, m), 3.76 (IH, dd), 3.37-3.23 (IH, m), 3.21-3.08 (IH, m), 2.84
(IH, dt), 2.45-2.21 (2H, m), 2.07-1.94 (2H, m), 1.39 (3H, t).
Intermediate 148: Benzyl (R)-l-ethylpyrrolidine carboxylate
Prepared by proceeding in a similar manner to Intermediate 107, starting from
benzyl (R)-pyrrolidinecarboxylate as a colourless oil.
¾ NMR (CDCI ) d : 7.34 (5H, m), 5.17 (2H, s), 3.19 (2H, m), 2.75 (IH, m), 2.45 (IH, m), 2.33
(IH, m), 2.12 (IH, m), 1.93 (2H, m), 1.81 (IH, m), 1.09 (3H, t).
Intermediate 149: (l -Ethylazetidin
A solution of 3-[i>w-(ferf-butoxycarbonylamino)methyl]- 1-ethylazetidine
(intermediate 150, 0.83g) in a mixture of methanol (6mL) and concentrated hydrochloric acid
(ImL) was stirred and heated at 50°C for 3 hours. After cooling, the mixture was concentrated
under vacuum and the residue was dissolved in isopropanol and treated with potassium
carbonate (3g). The mixture was stirred at room temperature for 48 hours, then the solid was
filtered off and the filtrate was evaporated to dryness to give (l-ethylazetidinyl)methylamine
(0.1 8g) as a light sticky gum which was used without further characterisation.
Intermediate 150: 3-[i>w-(½rf-Butoxycarbonylamino)methyl]- 1-ethylazetidine
A mixture of acetaldehyde (1.5g) and 3-[£>«-(¾rf-butoxycarbonyl-
amino)methyl]azetidine (Intermediate 15 1, l.Og) in ethanol (20mL) was stirred at room
temperature for 30 minutes and then 10% palladium on carbon (0.3g) was added. The mixture
was stirred under an atmosphere of hydrogen overnight. The solid was filtered off and the
filtrate was evaporated to dryness. The residue was purified by chromatography on silica,
eluting with a mixture of methanol and DCM (10%) to give 3-[bis-(tert-
butoxycarbonylamino)methyl]-l-ethylazetidine (0.83g) as a colourless liquid, which was used
without further characterization.
Intermediate 151: 3-[i -( rf-Butox azetidine
A mixture of 3-[i>w-(ferf-butoxycarbonylamino)methyl]-l
(diphenylmethyl)azetidine (Intermediate 152, 6.4g) and 10% palladium on carbon (3g) in
ethanol (lOOmL) and acetic acid (2mL) was stirred under an atmosphere of hydrogen overnight.
The solid was filtered off and the filtrate was evaporated to dryness. The residue was dissolved
in ethyl acetate and washed with saturated aqueous sodium carbonate, dried and
(Na2SC 4)
filtered. The filtrate was evaporated to dryness and the residue was purified by chromatography
on silica, eluting with a mixture of methanol and DCM (10%) to give 3-[bis-(tert-
butoxycarbonylamino)methyl]azetidine (4.0g) as a colourless liquid, which was used without
further characterisation.
Intermediate 152: 3-[i>w-(½rf-Butoxycarbonylamino)methyl]- l-(diphenylmethyl)-azetidine
Di-tert-butyl dicarbonate (22g) was added to a solution of 1-
(diphenylmethyl)azetidinylmethylamine (5g), DMAP (0.5g) and triethylamine (12g) in THF
(150mL) and the resultant solution was stirred and heated at 60°C for 5 hours. After cooling,
the mixture was added to brine solution and extracted with ethyl acetate, washed with brine,
dried and filtered. The filtrate was evaporated to dryness and the residue was purified
(Na2SC 4)
by chromatography on silica, eluting with a mixture of ethyl acetate and petroleum ether (10%)
to give 3-[i>w-(½rf-butoxycarbonylamino)methyl]-l-(diphenylmethyl)azetidine (6.4g) as a
white solid, which was used without further characterisation.
Intermediate 153: Methyl (laRS,7bSR)[2-((Z)diethylaminoprop-l-enyl)benzene-
sulfonylamino]- l ,la,2,7b-te oxylate
A mixture of methyl (laRS,7bSR)(2-bromobenzenesulfonylamino)-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate (Intermeidate 154, 0.612g), N,N-
diethyl-N-((Z)-l-tributylstannanylprop-l-enyl)amine (Intermediate 11, 1.13g), tn-tert-
butylphosphonium tetrafluoroborate (0.041g), frw-(dibenzylideneacetone)dipalladium (0.064g)
in dioxane (12mL) and DMSO (0.4mL) was degassed and purged with nitrogen then heated at
100°C for 1.5 hours. After cooling, the mixture was diluted with brine and extracted with ethyl
acetate. The organic layer was washed with water, dried and filtered. The filtrate was
(Na2SC 4)
evaporated to dryness and the residue was purified by chromatography on silica, eluting with a
mixture of methanol and DCM with a gradient of 0-15% to give methyl (laRS,7bSR)[2-
((Z)diethylamino-prop- 1-enyl)benzenesulfonylamino] -1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.495g) as a solid.
¾ NMR (CDCI ) d : 8.06 (IH, dd), 7.52 (IH, m), 7.40 (IH, m), 7.30 (IH, m), 7.14 (IH, d),
7.01 (IH, m), 6.86 (IH, d), 6.02 (IH, m), 4.33 (IH, d), 3.84 (3H, s), 3.77 (IH, d), 3.12 (2H, br
s), 2.5 1 (4H, br s), 1.87 (IH, m), 1.70 (IH, m), 1.05-0.85 (8H, m).
Intermediate 154: Methyl (laRS,7bSR)(2-bromobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromene-
2- Bromobenzenesulfonyl chloride (0.559g) was added to a solution of methyl
(laRS,7bSR)amino-l, la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 42, 0.40g) in DCM (12mL) and pyridine (4mL) and the resultant mixture was
stirred at room temperature for 1 hour. The mixture was evaporated to dryness and the residue
was dissolved in DCM and washed with 2N HC1, dried and filtered. The filtrate was
(Na2SC 4)
evaporated to dryness and the residue was purified by chromatography on silica, eluting with a
mixture of ethyl acetate and cyclohexane with a gradient of 0-35% to give methyl
(laRS,7bSR)(2-bromo-benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene-
4-carboxylate (0.6 12g) as a solid.
¾ NMR (CDCI ) d : 9.85 (IH, s), 7.89 (IH, dd), 7.85 (IH, dd), 7.57-7.49 (2H, m), 7.26 (IH, d),
6.64 (IH, d), 4.27 (IH, d), 3.72 (IH, d), 3.66 (3H, s), 2.05-1.95 (IH, m), 1.86-1.76 (IH, m),
1.08-0.98 (IH, m), 0.84-0.76 (IH, m).
Intermediate 155: Methyl (laRS,7bSR)(2-{N-[((R)-l-ethylpyrrolidineyl)carbonyl]-N-
methylaminomethyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
HATU (0.136g) was added to a mixture of methyl (laRS,7bSR)(4-fluoro
methylaminomethylbenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 156, 0.150g), (R)-l-ethylpyrrolidinecarboxylic acid (Intermediate
147, 0.061g) and N,N-diisopropyl-N-ethylamine (0.124mL) in DMF (5mL) and the mixture
was stirred for 3 days at room temperature. The volatiles were removed in vacuo and the
residue was extracted with ethyl acetate (50mL). The organic layer was washed with water
(50mL), brine, dried and filtered. The filtrate was evaporated to dryness and the
(Na2SC>4)
residue was purified by chromatography on silica eluting with a mixture of methanol and DCM
with a gradient of 0-10% to give methyl (laRS,7bSR)(2-{N-[((R)-l-ethylpyrrolidine
yl)carbonyl]methylamino] -methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.177g) as a solid.
LCMS (Method F) r/t 2.33 (M+H) 546.
Intermediate 156: Methyl (laRS,7bSR)(4-fluoromethylaminomethylbenzenesulfonyl-
amino)- l ,la,2,7b-tetrahydroc ylate
A solution of potassium carbonate (0.345g) in water (2mL) was added to a
solution of methyl (laRS,7bSR)(4-fluoro[N-methyl-N-(2,2,2-trifluoroacetyl)-
aminomethyl]-benzenesulfonyl-amino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 157, 0.257g) in methanol (12mL) and the mixture was heated at
45°C for 3 hours. After cooling, the volatiles were removed in vacuo and the residue was
treated with water (30mL) and saturated with sodium chloride and extracted with ethyl acetate
(50mL). The organic layer was dried and filtered and the filtrate was evaporated to
(Na2SC>4)
dryness to give methyl (laRS,7bSR)(4-fluoromethylaminomethylbenzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0.156g) as a solid.
LCMS (Method B) r/t 2. 14 (M+H) 421.
Intermediate 157: Methyl (laRS,7bSR)(4-fluoro[N-methyl-N-(2,2,2-trifluoroacetyl)-
aminomethyl]benzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
A mixture of 4- fluoro[N-methyl-N-(2,2,2-
trifluoroacetyl)aminomethyl]benzenesulfonyl chloride (Intermediate 158, 0.182g) was added to
a solution of methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (Intermediate 42, 0.1 OOg) in DCM (3mL) and pyridine (lmL) and the resultant
mixture was stirred at room temperature for 1 hour. The mixture was evaporated to dryness and
the residue was purified by chromatography on silica eluting with a mixture of ethyl acetate
and cyclohexane with a gradient of 0-40% to give methyl (laRS,7bSR)(4-fluoro[N-
methyl-N-(2,2,2-trifluoroacetyl)aminomethyl]benzenesulfonyl-amino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.257g) as a solid.
LCMS (Method F) r/t 3.77 (M+H) 5 17.
Intermediate 158: 4- Fluoro[N-methyl-N-(2,2,2-trifluoroacetyl)aminomethyl]benzene-
sulfonyl chloride
A solution of 3-fluoro-N-methyl-N-(trifluoroacetyl)benzylamine (Intermediate
159, 0.497g) in DCE (0.5mL) was added to stirred, cooled chlorosulfonic acid (3mL). The
mixture was allowed to come up to room temperature and then heated at 70°C for 3 hours.
After cooling, the mixture was added carefully to a mixture of ice and water, then extracted
with ethyl acetate, washed with water, dried (MgSCU) and filtered. The filtrate was evaporated
to dryness and the residue was purified by chromatography on silica, eluting with a mixture of
ethyl acetate and pentane with a gradient of 2.5-10% to give 4-fluoro[N-methyl-N-(2,2,2-
trifluoroacetyl)aminomethyl]-benzenesulfonyl chloride (0.21g) as a clear oil.
¾ NMR (CDC1 ) d : 8.20 (IH, m), 7.24 (IH, m), 7.01 (IH, d), 5.21 (2H, s), 3.24 (2H, s), 3.13
(IH, s).
Intermediate 159: 3-Fluoro-N-methyl-N-(trifluoroacetyl)benzylamine
A solution of 3-fluoro-N-(trifluoroacetyl)benzylamine (Intermediate 105,
0.508g) in THF (5mL) was added to a stirred suspension of sodium hydride (60% oil
dispersion, 0.096g) in THF (5mL). The resultant mixture was stirred at room temperature for
minutes. lodomethane (0.653g) was added and the mixture was stirred at room temperature
overnight. The mixture was poured into water and extracted with ethyl acetate, washed with
water, dried (MgSCU) and filtered. The filtrate was evaporated to dryness to give 3-fluoro-N-
methyl-N-(trifluoroacetyl)benzylamine (0.497g) as a white solid.
¾ NMR (CDC1 ) d : 7.34 (IH, m), 7.10-6.90 (3H, m), 4.63 (2H, s), 3.07 (2H, q), 2.94 (IH, s).
Intermediate 160: Methyl (laRS,7bSR)(2-[N-((S)-l-ethylpyrrolidineyl)carbonyl-N-
methylaminomethyl]fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 155, starting from
methyl (laRS,7bSR)(4-fluoromethylaminomethylbenzenesulfonylamino)-l,la,2,7b-
tetrahydro-cyclopropa[c]chromenecarboxylate (intermediate 156) and (S)-l-
ethylpyrrolidinecarboxylic acid (Intermediate 106) as a solid/
LCMS (Method B) r/t 2.47 (M+H) 546.
Intermediate 161: Methyl (laRS,7bSR)[2-(4-dimethylaminobutylamino)fluoro-
benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene-4carboxylate
A solution of methyl (laRS,7bSR)(2,4-difluorobenzenesulfonylamino)-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylate (Intermediate 162, 0.675g) and
N ,N -dimethylbutane-diamine (0.496g) in dioxane (20mL) was stirred and heated at 80°C for 17
hours then left at room temperature for 3 days. The solution was diluted with ethyl acetate,
washed with potassium carbonate solution and water then dried (Na SC>4) and filtered. The
filtrate was concentrated in vacuo and the residue was purified by chromatography on silica,
eluting with a mixture of methanol and DCM with a gradient of 0-40% to give methyl
(laRS,7bSR)[2-(4-dimethyl-aminobutylamino)fluorobenzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa-[c]chromene-4carboxylate (0.499g) as a colourless gum.
¾ NMR (CDC1 ) d : 7.5 1 (IH, dd), 7.26 (IH, d), 7.12 (IH, d), 6.29 (2H, m), 6.00 (IH, br, s),
4.31 (IH, d), 3.75 (IH, d), 3.50 (3H, s), 3.01 (2H, m), 2.25 (6H, s), 2.1 1 (2H, t), 1.94 (IH, m),
1.73 (IH, m), 1.58 (4H, m), 1.03 (2H, m).
Intermediate 162: Methyl (laRS,7bSR)(2,4-difluorobenzenesulfonylamino)-l,la,2,7b-
tetrahydrocyclopropa[c]chromene
2,4-Difluorobenzenesulphonyl chloride (0.468g) was added to a solution of
methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylater
(Intermediate 42, 0.438g) in pyridine (2mL) and DCM (4mL) and the solution was left at room
temperature for 2 hours. The mixture was diluted with DCM, washed with 2M hydrochloric
acid, dried (Na S0 )and filtered. The filtrate was concentrated in vacuo and the residue was
purified by chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane
with a gradient of 0-30% to give methyl (laRS,7bSR)(2,4-difluorobenzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0.761g) as a light coloured gum.
¾ NMR (CDCI ) d : 8.90 (IH, br, s), 7.82 (IH, m), 7.22 (IH, d), 7.13 (IH, d), 6.88 (2H, m),
4.32 (IH, d), 3.89 (3H, s), 3.79 (IH, d), 1.90 (IH, m), 1.71 (IH, m), 1.01 (2H, m).
Intermediate 163: ((R)-l-Ethylpyrrolidinylmethyl)amine
Lithium aluminium hydride was added to a stirred solution of ((R)-l-
acetylpyrrolidinylmethyl)amine (Intermediate 164, 1.5g) in THF (50mL) and the resulting
mixture was stirred and heated at reflux for 2 hours. After cooling, ethanol was slowly added
and the mixture was concentrated under vacuum. The residue was diluted with DCM and the
solid was filtered off. The filtrate was evaporated to dryness to give ((R)-l-ethylpyrrolidin
ylmethyl)amine (0.9g) as a yellow solid.
LCMS (Method D) r/t 0.396 (M+H) 129.
Intermediate 164: ((R)-l-Acetylpyrrolidinylmethyl)amine
A mixture of benzyl N-((S)-l-acetylpyrrolidinylmethyl)-N-benzylcarbamate
(Intermediate 165, 4.2g) and palladium hydroxide on carbon (0.4g) in methanol (42mL) was
stirred under an atmosphere of hydrogen at 60°C for 48 hours. The mixture was filtered and the
filtrate was evaporated to dryness to give ((R)-l-acetylpyrrolidinylmethyl)amine (1.5g) as a
light yellow oil.
LCMS (Method D) r/t 0.49 (M+H) 143.
Intermediate 165: Benzyl N-((S)-l-acetylpyrrolidinylmethyl)-N-benzylcarbamate
Acetyl chloride (2.86g) was added to a stirred solution of benzyl N-((S)-
pyrrolidinylmethyl)-N-benzylcarbamate (Intermediate 166, 5.9g) and triethylamine (3.68g)
in DCM (80mL) with ice cooling. The resultant mixture was stirred at room temperature for 2
hours then concentrated under vacuum. The residue was treated with saturated aqueous sodium
bicarbonate and extracted with ethyl acetate, dried and filtered. The filtrate was
(Na2SC 4)
evaporated to dryness and the residue was purified by chromatography on silica, eluting with
ethyl acetate to give benzyl N-((S)-l-acetylpyrrolidinylmethyl)-N-benzylcarbamate (4.2g) as
a yellow oil.
LCMS (Method D) r/t 1.65 (M+H) 367.
Intermediate 166: Benzyl N-((S)-pyrrolidinylmethyl)-N-benzylcarbamate
ferf-Butyl (S)[N-benzyl-N-(benzyloxycarbonyl)aminomethyl]pyrrolidine-l-carboxylate
(Intermediate 167, l lg) was added dropwise to a solution of acetyl chloride (15g) in methanol
(50mL) and the resultant mixture was stirred at room temperature overnight. The mixture was
concentrated under vacuum and the residue was purified by HPLC (CI 8) to give benzyl N-((S)-
pyrrolidinylmethyl)-N-benzylcarbamate (8.0g) as an off white solid which was used without
further characterisation.
Intermediate 167: ferf-Butyl (S)[N-benzyl-N-(benzyloxycarbonyl)aminomethyl]-
pyrrolidine- 1-carboxylate
A solution of ferf-butyl (R)(N-benzyloxycarbonyl)aminomethylpyrrolidine-l
carboxylate (Intermediate 168, 19g) in DMF (90mL) was added dropwise to a suspension of
sodium hydride (60%, 4.55g) in DMF (lOOmL) After stirring for 30 minutes, benzyl bromide
( 11.7g) was added dropwise. The resultant mixture was stirred and heated at 70°C overnight.
After cooling, saturated aqueous sodium bicarbonate was added and the mixture was extracted
with eithyl acetate, dried and filtered. The filtrate was purified by chromatography on
(Na2SC 4)
silica, eluting with a mixture of ethyl acetate and petroleum ether (10%) to give ferf-butyl (S)-
3-[N-benzyl-N-(benzyloxycarbonyl)aminomethyl]-pyrrolidine-l-carboxylate ( 1l.Og) as a light
yellow oil, which was used without further characterisation.
Intermediate 168: ferf-Butyl (R)(N-benzyloxycarbonyl)aminomethylpyrrolidine-l-
carboxylate
Benzyl chloroformate (14. lg) was added dropwise to a cooled solution of tert-
butyl (R)aminomethylpyrrolidine-l-carboxylate (15g) in THF (150mL) while maintaining
the temperature below 0°C. On completion of the addition, triethylamine (15.2g) was added
dropwise. The resultant mixture was stirred at -5°C for 30 minutes then at room temperature
overnight. Brine was added and the mixture was extracted with ethyl acetate, washed with
brine, dried and filtered. The filtrate was evaporated to dryness to give ferf-butyl (R)-
(Na2SC 4)
3-(N-benzyloxycarbonyl)aminomethylpyrrolidine-l-carboxylate (23g) as a colourless sticky
gum, which was used without further characterisation.
Intermediate 169: ((S)- l-Ethylpyrroli
Palladium on carbon (10%, 0.3g) was added to a solution of benzyl N-((S)
ethylpyrrolidinylmethyl)carbamate (Intermediate 170, 1.8g) in methanol (20mL) and the
resultant mixture was stirred under an atmosphere of hydrogen for 24 hours. The mixture was
filtered and the filtrate was evaporated to dryness to give ((S)-l-ethylpyrrolidin
yl)methylamine (0.8g) as a colourless oil, which was used without further characterisation.
Intermediate 170: Benzyl N-((S)-l-ethylpyrrolidinylmethyl)carbamate
Iodoethane (4.1g) was added to a cooled mixture of benzyl N-((R)-pyrrolidin
ylmethyl)carbamate trifluoroacetate salt (Intermediate 171, 7.6g) and potassium carbonate
(12.2g) in DMF (lOmL) while maintaining the temperature at 0°C. The mixture was then stirred
at room temperature for 4 hours. Water was added and the mixture was extracted with ethyl
acetate, washed with brine, dried and filtered. The filtrate was evaporated to dryness
(Na2SC 4)
to give benzyl N-((S)-l-ethylpyrrolidinylmethyl)carbamate (1.8g) as a colourless oil, which
was used without further characterisation.
Intermediate 171: Benzyl N-((R)-pyrrolidinylmethyl)carbamate trifluoroacetate salt
A mixture of ferf-butyl (S)(N-benzyloxycarbonyl)aminomethylpyrrolidine-l-
carboxylate (Intermediate 172, 8.0g) in trifluoroacetic acid (lOmL) was stirred at room
temperature for 5 hours. The mixture was concentrated under vacuum to give crude benzyl N-
((R)-pyrrolidinylmethyl)carbamate trifluoroacetate salt (7.6g) as a light brown oil which was
used without further purification or characterisation.
Intermediate 172: ferf-Butyl (S)(N-benzyloxycaibonyl)aminomethylpyrrolidine-l-
carboxylate
Prepared by proceeding in a similar manner to Intermediate 168, starting form
ferf-butyl (S)aminomethylpyrrolidine-l-carboxylate and used without further
characterisation.
Intermediate 173: Methyl (laRS,7bSR)[2-(4-Ethyloxopiperazin-l-ylmethyl)
fluorobenzene-sulfonylamino]- l , chromenecarboxylate
A solution of 2-(4-ethyloxopiperazin-l-ylmethyl)fluorobenzenesulfonyl
chloride (Intermediate 174, 0.368g) and methyl (laRS,7bSR)amino-l,la,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylate (Intermediate 42, 0.219g) in pyridine (3mL) and DCM
(3mL) was left to stand at room temperature for 17 hours. The mixture was evaporated in vacuo
and the residue was dissolved in water and DCM and the organic layer was dried (Na SC>4) and
filtered. The filtrate was concentrated in vacuo and the residue was purified by chromatography
on silica, eluting with a mixture of ethyl acetate and cyclohexane with a gradient of 50-100% to
give a gum which was triturated with ether and filtered to give methyl (laRS,7bSR)[2-(4-
ethyloxopiperazin-l-ylmethyl)fluorobenzenesulfonylamino]-l,la,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylate (0.3 12g) as a white solid.
¾ NMR (DMSO-d ) d : 9.95 (1H, br, s), 7.81 (1H, dd), 7.26 (2H, m), 6.89 (1H, dd), 6.59 (1H,
d), 4.75 (2H, s), 4.29 (1H, d), 3.71 (1H, d), 3.62 (3H, s), 3.15 (4H, m), 2.70 (2H, t), 2.45 (2H,
q), 2.02 (1H, m), 1.72 (1H, m), 1.06 (1H, m), 1.02 (3H, t), 0.80 (1H, q).
Intermediate 174: 2-(4-Eth yl )fluorobenzenesulfonyl chloride
Chlorosulphonic acid (2mL) was added to 4-ethyl-l-(3-fluorobenzyl)-piperazin-
2-one (Intermediate 175, 0.59g) with stirring and cooling in ice. The cooling was removed and
the solution was stirred at room temperature for 4 hours before being carefully added to a
mixture of ethyl acetate, ice and sodium bicarbonate. The organic layer was dried (Na S0 ) and
filtered and the filtrate was concentrated in vacuo to give 2-(4-ethyloxopiperazin-l-
ylmethyl)fluoro-benzenesulfonyl chloride (0.37g) as a colourless gum.
LCMS (Method E) r/t 1.99 (M-H) 335, 337
Intermediate 175: 4-Ethyl- l -(3-fluoro-b inone
Sodium hydride (60% oil dispersion, 0.176g) was added to a stirred solution of
4-ethyl-piperazinone (Intermediate 176, 0.5 12g) in anhydrous THF (lOmL) and the mixture
was stirred at room temperature for 10 minutes. 3-Fluorobenzyl bromide (0.827g) was added
and stirring was continued for 2 hours. The solution was diluted with water and ethyl acetate
and the organic layer was dried (Na SC>4) and filtered. The filtrate was concentrated in vacuo
and the residue was purified by chromatography on silica, eluting with a mixture of methanol
and DCM with a gradient of 0-5% to give 4-ethyl-l-(3-fluorobenzyl)piperazinone (0.595g)
as a colourless oil.
¾ NMR (CDC1 ) d : 7.26 (1H, m), 6.91- 7.10 (3H, m), 4.61 (2H, s), 3.27 (2H, t), 3.23 (2H, s),
2.65 (2H, t), 2.48 (2H, q), 1.09 (3H, t).
Intermediate 176: 4-Ethylpiperazinone
A mixture of 2-oxopiperazine (1.07g), iodoethane (1.72g) and potassium
carbonate (2.76g) in acetonitrile (50mL) was stirred at 55°C for 3 hours. After cooling, the
mixture was filtered and the filtrate was concentrated in vacuo. The residue was triturated with
DCM and filtered and the filtrate was concentrated in vacuo. The residue was purified by
chromatography on silica, eluting with a mixture of methanol and DCM with a gradient of 0-
40% to give 4-ethylpiperazinone (0.991g) as a colourless oil.
¾ NMR (CDCI ) d : 6.81 (1H, br, s), 3.37 (2H, m), 3.14 (2H, s), 2.66 (2H, t), 2.50 (2H, q), 1.1 1
(3H, t).
Intermediate 177: Methyl (laRS,7bSR)[2-(l-ethylpiperidinylmethyl)fluorobenzene-
sulfonylamino]- l ,l a,2,7b- ylate
2-(l-Ethylpiperidineylmethyl)fluorobenzenesulfonyl chloride
(Intermediate 178, 0.165g) was added to a solution of methyl (laRS,7bSR)amino-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylate (Intermediate 42, 0.290g) in DCM (5mL) and
pyridine (lmL) and the resultant mixture was stirred at room temperature for 2 1 hours. The
mixture was evaporated to dryness and the residue was purified by chromatography on silica
eluting with a mixture of 2M N¾ in methanol and DCM with a gradient of 0-20% to give
methyl (laRS,7bSR)[2-(l-ethyl-piperidinylmethyl)fluorobenzenesulfonylamino]-
l,la,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylate (0.200g) as a solid.
LCMS (Method F) r/t 2.34 (M+H) 503
Intermediate 178: 2-(l -Ethylpiper i d enzenesulfonyl chloride
A solution of l-ethyl(3-fluorobenzyl)piperidine (Intermediate 179, 0.21 Og) in
DCE (ImL) was added to chlorosulfonic acid (2mL) at 0°C. The mixture was allowed to warm
to room temperature and stirred for 2 hours. The resultant mixture was added caefully to
ice/water and extracted with DCM. The organic layer was dried and filtered and the
(Na2SC 4)
filtrate was evaporated to dryness to give 2-(l-ethylpiperidinylmethyl)
fluorobenzenesulfonyl chloride (0.290g) as a solid.
¾ NMR (CDC1 ) d : 8.17 (IH, dd), 7.17 (IH, m), 7.08 (IH, dd), 3.59 (2H, d), 3.13-2.99 (4H,
m), 2.57 (2H, m), 2.24 (2H, m), 1.95-1.77 (3H, m), 1.47 (3H, t).
Intermediate 179: l -Ethyl(3-fluoro
Bromoethane (O.lmL) was added to a mixture of 4-(3-fluorobenzyl)piperidine
(Intermediate 180, 0.259g) and potassium carbonate (0.204g) in acetonitrile (lOmL). The
mixture was stirred for 20 hours then filtered. The filtrate acidified by addition of few drops of
2M H and the solution was passed through a SCX-2 column (lOg). The product was eluted
with 2M ammonia in methanol and the residue after evaporation was triturated with diethyl
ether. The solid was filtered off and the filtrated was concentrated in vacuo to give l-ethyl
(3-fluorobenzyl)piperidine (0.21 Og)
¾ NMR (CDCI ) d : 7.24-7.16 (IH, m), 6.94-6.79 (3H, m), 2.91 (2H, dt), 2.52 (2H, d), 2.36
(2H, q), 1.82 (2H, td), 1.68-1.57 (2H, m), 1.56-1.44 (IH, m), 1.30 (2H, m), 1.06 (3H, t).
Intermediate 180: 4-(3-Fluorobenzyl)piperidine
A mixture of benzyl 4-(3-fluorobenzylidene)piperidine-l-carboxylate
(Intermediate 181, 1.05g), 20% palladium hydroxide on carbon (0.227g), IMS (30mL) and
acetic acid (lOmL) was degassed b y nitrogen/vacuum purging. The mixture was placed under
an atmosphere of hydrogen with rapid stirring. After 2 hours the mixture was filtered and the
filtrate was diluted with water (40mL) and neutralized with Na CC>3. The solution was
saturated with sodium chloride, extracted with ethyl acetate dried (MgSCU) and filtered. The
filtrate was concentrated in vacuo and the residue was dissolved in a mixture of methanol and
water (20mL, 1: 1) and passed down a SCX-2 column. The product was eluted with 2M
ammonia to give 4-(3-fluorobenzyl)piperidine (0.532g)
¾ NMR (CDC1 ) d : 7.24-7.16 (IH, m), 6.95-6.77 (3H, m), 3.04 (2H, dt), 2.56 (2H, dd), 2.5 1
(2H, d), 1.71-1.54 (3H, m), 1.42 (IH, s), 1.14 (2H, m)
Intermediate 181: Benzyl 4-(3-fluorobenzylidene)piperidine-l-carboxylate
Sodium hydride (0.245g) was added portionwise to a solution of diethyl (3-
fluorobenzyl)phosphonate (Intermediate 182, lg) in THF (40mL) at 0°C. The mixture was
stirred for 30 minutes then benzyl 4-oxopiperidine-l-carboxylate (0.947g) was added at 0°C.
The mixture was allowed to warm to room temperature and stirred for 21.5 hours. The mixture
was partitioned between water and ethyl acetate and the organic layer was washed with brine,
dried (Na SC>4) and filtered. The filtrate was evaporated to dryness and the residue was purified
b y chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 0-25% to give benzyl 4-(3-fluorobenzylidene)piperidine-l-carboxylate (1.05g)
¾ NMR d : 7.39-7.22 (6H, m), 6.98-6.83 (3H, m), 6.33 (IH, s), 5.15 (2H, s), 3.54 (4H,
(CDCI3)
dt), 2.41 (4H, dt).
Intermediate 182: Diethyl (3- fluorobenzyl)phosphonate
A mixture of 3-fluorobenzyl bromide (2g) and triethyl phosphite (2.2mL) was
heated at 160°C under nitrogen for 4 hours. After cooling, the were volatiles removed in vacuo
and the residue was purified by chromatography on silica eluting with a mixture of ethyl
acetate and cyclohexane with a gradient of 0-100% to give diethyl (3-
fluorobenzyl)phosphonate (2.46g)
¾ NMR (CDC1 ) d : 7.31-7.22 (1H, m), 7.1 1-6.89 (3H, m), 4.09-3.97 (4H, m), 3.13 (2H, d),
1.25 (6H, t).
Intermediate 183: Methyl (laRS,7bSR){2-[2-(l-ethylazetidinyl)ethyl]fluorobenzene-
sulfonylamino }- 1,1a,2,7b-tetrah carboxylate
A solution of terf-butyl (laRS,7bSR){2-[5-fluoro(4-methoxycarbonyl-
l,la,2,7b-tetrahydrocyclopropa[c]chromenylsulfamoyl)phenyl]ethyl}azetidine-l-
carboxylate (Intermediate 184, 0.397g) in DCM (5mL) and trifluoroacetic acid (5mL) was left
at room temperature for 30 minutes then evaporated in vacuo and the residue was dissolved in
toluene and re-evaporated. The residue was dissolved in DCM (15mL) and acetaldehyde
(0.063g) was added followed by sodium triacetoxyborohydride (0.301g). The mixture was
stirred at room temperature for 2 hours then diluted with ethyl acetate and water and the
organic layer was dried (Na SC>4) and filtered. The filtrate was concentrated in vacuo and the
residue was purified by chromatography on silica, eluting with a mixture of methanol and
DCM with a gradient of 0-25% to give methyl (laRS,7bSR){2-[2-(l-ethylazetidin
yl)ethyl]fluorobenzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromene
carboxylate (0.3 12g) as a white foam.
LCMS (Method E) r/t 2.75 (M+H) 489.
Intermediate 184: ferf-butyl (laRS,7bSR){2-[5-fluoro(4-methoxycarbonyl-l,la,2,7b-
tetrahydro-cyclopropa[c]chro }azetidine- 1-carboxylate
A mixture of terf-butyl (laRS,7bSR){ (E/Z)[5-fluoro(4-
methoxycarbonyl-l,la,2,7b-tetrahydrocyclopropa[c]chromen
ylsulfamoyl)phenyl]vinyl}azetidine-l-carboxylate (Intermediate 185, 0.502g) and 10%
palladium on carbon (0.05g) in ethanol (25mL) was stirred under an atmosphere of hydrogen
for 30 minutes. The suspension was filtered and the filtrate was concentrated in vacuo. The
residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate and
cyclohexane with a gradient of 0-40% to give ferf-butyl (laRS,7bSR){2-[5-fluoro(4-
methoxycarbonyl-l,la,2,7b-tetrahydrocyclopropa[c]chromenylsulfamoyl)phenyl]-
ethyl}azetidine- 1-carboxylate (0.401g) as a colourless gum.
¾ NMR (CDC1 ) d : 9.01 (1H, br, s), 7.90 (1H, dd), 7.21 (1H, d), 7.02 (1H, d), 6.94 (2H, m),
4.32 (1H, d), 4.00 (2H, t), 3.79 (1H, d), 3.77 (3H, s), 3.56 (2H, dd), 2.79 (2H, dd), 2.56 (1H,
m), 1.89 (3H, m), 1.72 (1H, m), 1.45 (9H, s), 0.99 (2H, m).
Intermediate 185: tert-Butyl (laRS,7bSR){(E/Z)[5-fluoro(4-methoxycarbonyl-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenylsulfamoyl)phenyl] vinyl }azetidine-l-
carboxylate
A mixture of methyl (laRS,7bSR)(2-bromofluorobenzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 41, 0.456g), ferf-butyl
3-((E/Z)trimethylstannanylvinyl)azetidine-l-carboxylate (Intermediate 186, 0.433g),
f i(dibenzylideneacetone)dipalladium(0) (0.046g) and tri-ferf-butylphosphonium
tetrafluoroborate (0.029g) in dioxane (15mL) and DMSO (1.5mL) was stirred and heated at
90°C under nitrogen for 1 hour. After cooling, the solution was diluted with ethyl acetate,
washed with water, dried (Na SC>4) and filtered. The filtrate was concentrated in vacuo and the
residue was purified b y chromatography on silica, eluting with a mixture of ethyl acetate and
cyclohexane with a gradient of 0-40% to give ferf-butyl (laRS,7bSR){(E/Z)[5-fluoro
(4-methoxycarbonyl-l,la,2,7b-tetrahydrocyclopropa[c]chromenylsulfamoyl)phenyl] vinyl }-
azetidine-l-carboxylate (0.508g) as a colourless gum.
LCMS (Method E) r/t 4.47 (M-H) 557
Intermediate 186: ferf-Butyl 3-((E/Z)trimethylstannanylvinyl)azetidine-l-carboxylate
A solution of terf-butyl 3-((E/Z)iodovinyl)azetidine-l-carboxylate
(Intermediate 187, 1.39g), hexamethylditin (2.95g), and
½fra£iXtriphenylphosphine)palladium(0) (0.52g) in anhydrous THF (40mL) was stirred and
heated at 50°C under nitrogen for 2 hours. After cooling, the mixture was evaporated in vacuo
and the residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and cyclohexane with a gradient of 0-10% to give ferf-butyl 3-((E/Z)
trimethylstannanylvinyl)azetidine-l-carboxylate (0.60 lg) as a pale yellow oil.
¾ NMR (CDC1 ) d : 5.79-6.5 (2H, m), 3.95 (2H, m), 3.62 (2H, m), 2.88-3.12 (1H, m), 1.32
(9H, s), 0.0 (9H, s).
Intermediate 187: ferf-Butyl 3-((E/Z)iodovinyl)azetidine-l-carboxylate
A solution of ferf-butyl 3-formylazetidine-l-carboxylate (1.97g) and iodoform
(8.37g) in anhydrous THF (25mL) was added to a stirred suspension of anhydrous
chromium(II) chloride in anhydrous THF (lOOmL) under nitrogen and the mixture was stirred
at room temperature for 4 hours. The resulting mixture was diluted with water and ethyl acetate
and the organic layer was dried (Na SC>4) and filtered. The filtrate was concentrated in vacuo
and the residue was purified by chromatography on silica, eluting with a mixture of ethyl
acetate and cyclohexane with a gradient of 0-15% to give ferf-butyl 3-((E/Z)
iodovinyl)azetidine-l-carboxylate (2.0 lg) as a pale yellow oil.
¾ NMR (CDCI ) d : 6.71 (0.8H, dd), 6.55 (0.2H, t), 6.33 (0.2H, d), 6.18 (0.8H, d), 4.20 (0.4H,
t), 4.08 (1.6H, t), 3.76 (2H, m), 3.45 (0.2H, m), 3.19 (0.8H, m), 1.44 (9H, s).
Intermediate 188: Methyl (laRS,7bSR)(2-{ [((S)-l-ethylpyrrolidinecarbonyl)amino]-
methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
HATU (0.234g) was added to a mixture of (S)-l-ethylpyrrolidinecarboxylic
acid (Intermediate 189, 0.089g) and NMM (0.068mL) in DMF (4mL) and the mixture was
stirred for 15 minutes. Methyl (laRS,7bSR)(2-aminomethyl
fluorobenzenesulfonylamino)-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 102, 0.250g) was added and the mixture was stirred for 20 hours. The mixture
was diluted with water and extracted with ethyl acetate. The organic layer was washed with
saturated NaHC0 solution, dried and filtered. The filtrate was evaporated to dryness
(Na2SC 4)
and the residue was purified by chromatography on silica eluting with a mixture of 2M
ammonia in methanol and DCM with a gradient of 0-15% to give methyl (laRS,7bSR)(2-
{[((S)-l-ethylpyrrolidinecarbonyl)amino]methyl}fluoro-benzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0.190g) as a solid.
¾ NMR (CDCI ) d : 7.81 (IH, dd), 7.46-7.38 (IH, m), 7.30-7.20 (3H, m), 7.06-6.93 (2H, m),
4.58 (2H, d), 4.32 (IH, dd), 3.79 (IH, dd), 3.76 (3H, s), 2.93-2.78 (3H, m), 2.70-2.49 (4H, m),
2.24-2.08 (IH, m), 2.00-1.87 (2H, m), 1.78-1.68 (IH, m), 1.15 (3H, t), 1.06-0.98 (2H, m)
Intermediate 189: (S)- l -Ethyl-pyrroli acid
A mixture of benzyl (S)-l-ethylpyrrolidinecarboxylate (Intermediate 190,
0.563g), 20%palladium hydroxide on carbon (0.056g), ethyl acetate (9mL) and IMS (lmL) was
degassed and hydrogenated for 4 hours. The catalyst was removed by filtration, washed with
ethyl acetate and the filtrate was concentrated in vacuo to give (S)-l-ethylpyrrolidine
carboxylic acid (0.3 18g) as a solid.
¾ NMR (CDC1 ) d : 12.46-10.55 (1H, br s), 3.84-3.57 (1H, br s), 3.49-3.26 (1H, br s), 3.26-
2.93 (5H, m), 2.50-2.33 (1H, m), 2.28-2.1 1 (1H, m), 1.35 (3H, t).
Intermediate 190: Benzyl (S)-l-ethylpyrrolidinecarboxylate
Ethyl bromide (0.21mL) was added to a mixture of benzyl (S)-pyrrolidine-3
carboxylate trifluoroacetic acid salt (Intermediate 191, 0.897g), potassium carbonate (0.971g)
and DMF (lOmL) at room tempertaure and the mixture was stirred for 25 hours. Further ethyl
bromide (0.1 lmL) was added and stirring was continued for 24 hours. Further ethyl bromide
(0.05mL) was added and stirring was continued for 22 hours. The resultant mixture was diluted
with water and extracted with diethyl ether, washed with brine, dried (Na SC>4) and filtered.
The filtrate was concentrated in vacuo to give benzyl (S)-l-ethylpyrrolidinecarboxylate
(0.563g).
¾ NMR (CDCI ) d : 7.38-7.30 (5H, m), 5.13 (2H, s), 3.09 (1H, m), 2.93 (1H, t), 2.76-2.66 (1H,
m), 2.63 (1H, dd), 2.56-2.41 (3H, m), 2.16-2.05 (2H, m), 1.10 (3H, t).
Intermediate 191: Benzyl (S)-pyrrolidinecarboxylate trifluoroacetic acid salt
Trifluoroacetic acid (2.5mL) was added to a solution of benzyl (S)-l-ferf-
butoxycarbonylpyrrolidinecarboxylate (Intermediate 192, 0.859g) and DCM (lOmL) at room
tempertaure. The mixture was stirred for 4 hours then concentrated in vacuo. The residue was
azetroped with toluene then ethyl acetate to give benzyl (S)-pyrrolidinecarboxylate
trifluoroacetic acid salt (lg).
¾ NMR (CDCI ) d : 7.41-7.29 (5H, m), 5.16 (2H, dd), 3.64-3.45 (2H, m), 3.44-3.23 (3H, m),
2.42-2.20 (2H, m).
Intermediate 192; Benzyl (S)-l-½rf-butoxycarbonylpyrrolidinecarboxylate
DBU (0.764mL) was added to a mixture of benzyl bromide (0.61mL), (S)-l
¾rf-butoxycarbonyl-pyrrolidinecarboxylic acid (lg) in anhydrous toluene (lOmL) and the
mixture was stirred at room temperature for 24 hours. The mixture was filtered and the filtrate
was concentrated in vacuo. The residue was purified by chromatography on silica eluting with
a mixture of ethyl acetate and cyclohexane with a gradient of 0-35% to give benzyl (S)-l-ferf-
butoxycarbonylpyrrolidinecarboxylate (0.859g)
¾ NMR (CDC1 ) d : 7.39-7.29 (5H, m), 5.14 (2H, s), 3.70-3.41 (3H, m), 3.41-3.27 (1H, m),
3.08 (1H, m), 2.13 (2H, q), 1.45 (9H, s).
Intermediate 193: (R)-l-Ethylpyrrolidinylamine
Acetyl chloride (15mL) was added to methanol (120mL) and the resultant
solution was stirred for 20 minutes. A solution of ferf-butyl N-((R)-l-ethylpyrrolidin
yl)carbamate (Intermediate 94, 8.4g) in methanol (30mL) was then added and the mixture was
stirred and heated at 80°C overnight. After cooling, the mixture was concentrated under
vacuum and the residue was redissolved in methanol (150mL) and potassium carbonate (25.8g)
was added. The mixture was stirred and heated at 30°C for 30 hours. After cooling, the solid
was filtered off and the filtrate was distilled, collecting the product at 100°C to give (R)-l-
ethylpyrrolidinylamine (2.10g) as a yellow oil, which was used without further
characterisation.
Intermediate 194: (S)-l-Ethylpyrrolidinylamine
Prepared by proceeding in a similar manner to Intermediate 193, starting from ferf-butyl N-
((S)-l-ethylpyrrolidinyl)carbamate (Intermediate 82) and used without further
characterisation.
Intermediate 195: Methyl (laRS,7bSR)(2-{ [((R)-l-ethylpyrrolidinecarbonyl)amino]-
methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate
Prepared by proceeding in a similar manner to Intermediate 188, starting from
methyl (laRS,7bSR)(2-aminomethylfluorobenzenesulfonylamino)-l,la,2,7b-tetrahydro-
cyclopropa[c]chromenecarboxylate (intermediate 102) and (R)-l-ethylpyrrolidine
carboxylic acid (Intermediate 196).
¾ NMR (CDC1 ) d : 7.81 (IH, dd), 7.43-7.34 (IH, m), 7.30-7.20 (3H, m), 7.05-6.93 (2H, m),
4.59 (2H, d), 4.32 (IH, dd), 3.79 (IH, dd), 3.76 (3H, s), 2.99-2.84 (3H, m), 2.81-2.73 (IH, m),
2.73-2.60 (3H, m), 2.27-2.12 (IH, m), 2.01-1.88 (2H, m), 1.78-1.67 (IH, m), 1.17 (3H, s), 1.08-
0.98 (2H, m).
Intermediate 196: (R)- l -Ethylpyrrolid acid
Prepared by proceeding in a similar manner to Intermediate 189, starting from
benzyl (R)-l-ethylpyrrolidinecarboxylate (Intermediate 197).
¾ NMR (CDCI ) d : 11.05-9.55 (IH, br s), 3.71 (IH, br s), 3.37 (IH, br s), 3.27-2.94 (5H, m),
2.49-2.32 (IH, m), 2.29-2. 13 (IH, m), 1.35 (3H, t).
Intermediate 197: Benzyl (R)-l-ethylpyrrolidinecarboxylate
Prepared by proceeding in a simialr manner to Intermedaite 190, starting from benzyl (R)-
pyrrolidinecarboxylate trifluoroacetic acid salt (Intermediate 198).
¾ NMR (CDCI ) d : 7.38-7.30 (5H, m), 5.13 (2H, s), 3.09 (1H, m), 2.93 (1H, t), 2.76-2.66 (1H,
m), 2.63 (1H, dd), 2.52-2.42 (3H, m), 2.16-2.06 (2H, m), 1.1 1 (3H, t).
Intermediate 198: Benzyl (R)-pyrrolidinecarboxylic trifluoroacetic acid salt
Prepared by proceeding in a similar manner to Intermediate 191, starting from
benzyl (R)-l-½rf-butoxycarbonylpyrrolidinecarboxylate (Intermediate 199).
¾ NMR (CDCI ) d : 7.41-7.29 (5H, m), 5.16 (2H, dd), 3.64-3.45 (2H, m), 3.42-3.23 (3H, m),
2.41-2.20 (2H, m).
Intermediate 199: Benzyl (R)-l-½rf-butoxycarbonylpyrrolidinecarboxylate
Prepared by proceeding in a similar manner to Intermediate 192, starting from
(R)- l-½rf-butoxycarbonyl-pyrrolidinecarboxylic acid.
¾ NMR (CDCI ) d : 7.42-7.29 (5H, m), 5.15 (2H, s), 3.72-3.42 (3H, m), 3.42-3.26 (1H, m),
3.08 (1H, m), 2.13 (2H, q), 1.45 (9H, s).
Intermediate 200: Methyl (laRS,7bSR){N-[2-((Z)diethylaminomethylprop-l-enyl)-
4-fluorobenzenesulfonyl]-N-(methoxycarbonyl)amino }-1,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
Methanesulphonic anhydride (0.159g) was added to a solution of methyl
(laRS,7bSR){N-[4-fluoro((Z)hydroxymethylprop-l-enyl)benzenesulfonyl]-N-
(methoxycarbonyl)amino }- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 201, 0.310g) and N,N-diisopropyl-N-ethylamine (0.1 18g) in DCM (lOmL) and
the mixture was left at room temperature for 1 hour. Diethylamine (lmL) was added and the
solution was left for a further 16 hours. The mixture was washed with water and filtered
through a phase separator. The filtrate was concentrated in vacuo and the residue was purified
by chromatography on silica, eluting with a mixture of methanol and DCM with a gradient of
0-8% to give methyl (laRS,7bSR){N-[2-((Z)diethylaminomethylprop-l-enyl)
fluorobenzene-sulfonyl]-N-methoxy-carbonylamino }- 1,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.268g) as a white foam.
LCMS (Method E) r/t 2.79 (M+H) 561.
Intermediate 201: Methyl (laRS,7bSR){N-[4-fluoro((Z)hydroxymethylprop-l-
enyl)benzenesulfonyl]-N-(methoxycarbonyl)amino}-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylate
Concentrated hydrochloric acid (lmL) was added to a solution of methyl
(laRS,7bSR)(N-{2-[(Z)(ferf-butyldimethylsilanyloxy)methylprop- l-enyl]
fluorobenzenesulfonyl]-N-methoxycarbonyl-amino }- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 202, 0.385g) in methanol
(20mL) and the mixture was left at room temperature for 45 minutes. The solution was
concentrated in vacuo and the residue was purified by chromatography on silica, eluting with a
mixture of ethyl acetate and cyclohexane with a gradient of 0-60% to give methyl
(laRS,7bSR){N-[4-fluoro((Z)hydroxymethylprop-l-enyl)benzenesulfonyl]-N-
methoxycarbonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylate (0.3 14g)
as a white foam.
¾ NMR (CDC1 ) d : 8.18 (IH, dd), 7.35 (IH, d), 7.11 (IH, dt), 6.94 (IH, d), 6.89 (IH, d), 6.74
(IH, s), 4.39 (IH, d), 3.82-4.17 (3H, m), 3.76 (1.5H, s), 3.72 (1.5H, s), 3.64 (3H, s), 1.98 (4H,
m), 1.82 (IH, q), 1.14 (2H, m).
Intermediate 202: Methyl (laRS,7bSR)(N-{2-[(Z)(ferf-butyldimethylsilanyloxy)
methylprop-l-enyl]fluorobenzenesulfonyl]-N-(methoxycarbonyl)amino}-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenecarboxylate
A mixture of methyl (laRS,7bSR)[N-(2-bromofluorobenzenesulfonyl)-N-
(methoxy-carbonyl)amino] -1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylate
(Intermediate 65, 0.257g), ½rf-butyl-dimethyl-((Z)methyltributylstannanylallyloxy)silane
(0.475g), frw(dibenzylideneacetone)dipalladium(0) (0.023g) and tri-ferf-butylphosphonium
tetrafluoroborate (0.015g) in dioxane (8mL) and DMSO (0.8mL) was stirred and heated at
90°C under nitrogen for 1hour. Further frw(dibenzylideneacetone)dipalladium(0) (0.023g) and
tri-ferf-butylphosphonium tetrafluoroborate (0.015g) were added and heating was continued for
a further 40 minutes. After cooling, the mixture was diluted with ethyl acetate, washed with
water, dried (Na2SC 4) and filtered. The filtrate was concentrated in vacuo and the residue was
purified by chromatography on silica, eluting with a mixture of ethyl acetate and cyclohexane
with a gradient of 0-20% to give methyl (laRS,7bSR)(N-{2-[(Z)(ferf-
butyldimethylsilanyloxy)methylprop-l-enyl]fluorobenzenesulfonyl]-N-methoxycarbonyl-
amino}-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (0.231g) as a colourless
gum.
LCMS (Method E) r/t 5.22 (M+Na) 642.
Intermediate 203: 2-((R)-l-Ethylp
Lithium aluminium hydride (l.Og) was added in portions to a stirred, cooled
solution of 2-((S)-l-ethylpyrrolidinyl)acetonitrile (Intermediate 204, 3.8g) in THF (20mL) at
0°C. On completion of the addition, the mixture was stirred at room temperature for 4 hours.
Water was added cautiously, followed by addition of 15% aqueous sodium hydroxide solution
and more water. The solid was filtered off and the filtrate was evaporated to dryness. The
residue was dissolved in DCM, dried (Na2SC 4) and filtered. The filtrate was evaporated to
dryness to give 2-((R)-l-ethylpyrrolidinyl)ethylamine (2.0g) as a colourless oil, which was
used without further characterisation.
Intermediate 204: 2-((S)-l-Ethylpyrrolidinyl)acetonitrile
Iodoethane (10. lg) was added to a mixture of 2-((S)-pyrrolidinyl)acetonitrile
hydrochloride (Intermediate 205, 7.9g) and potassium carbonate (29.7g) in DMF (20mL) and
the resultant mixture was stirred at room temperature for 5 hours. Water was added and the
mixture was extracted with ethyl acetate, washed with brine, dried and filtered. The
(Na2SC
filtrate was evaporated to dryness to give 2-((S)-l-ethylpyrrolidinyl)acetonitrile (3.8g) as a
yellow oil which was used without further characterisation.
Intermediate 205: 2-((S)-Pyrrolidinyl) hydrochloride
A solution of ferf-butyl (S)cyanomethylpyrrolidine-l-carboxylate
(Intermediate 206, 12.3g) in methanol (150mL) and concentrated hydrochloric acid (12mL)
was stirred and heated at 50°C overnight. After cooling, the mixture was concentrated under
vacuum to give crude 2-((S)-pyrrolidinyl)acetonitrile hydrochloride (9.0g) as a white solid
which was used without further characterisation.
Intermediate 206: ferf-Butyl (S)cyanomethylpyrrolidine-l-carboxylate
A mixture of ferf-butyl ((R)(4-methylbenzenesulfonyloxymethyl)pyrrolidine-
1-carboxylate (Intermediate 207, 22.3g) and sodium cyanide (6.13g) in DMSO (lOOmL) was
stirred and heated at 100°C for 4 hours. After cooling, a saturated aqueous solution of iron (II)
sulphate was added and the mixture was stirred at room temperature for 8 hours. The resultant
mixture was extracted with ethyl acetate, washed with brine, dried and filtered. The
(Na2SC
filtrate was evaporated to dryness and the residue was purified by chromatography on silica,
eluting with an mixture of ethyl acetate and petroleum ether (20%) to give ferf-butyl (S)
cyanomethylpyrrolidine-l-carboxylate (12.3g) as a white solid which was used without further
characterisation.
Intermediate 207: ferf-Butyl ((R)(4-methylbenzenesulfonyloxymethyl)-pyrrolidine-l-
carboxylate
Prepared by proceeding in a similar manner to Intermediate 140, starting from ferf-butyl (R)
hydroxymethylpyrrolidine-l-carboxylate and 4-methylbenzenesulfonyl chloride and used
without further characterisation.
Intermediate 208: 2-((S)-l-Ethylpyrrolidinyl)ethylamine
Prepared by proceeding in a similar manner to Intermediate 203, starting from 2-
((R)-l-ethylpyrrolidinyl)acetonitrile (Intermediate 209) and used without further
characterisation.
Intermediate 209: 2-((R)-l-Ethylpyrrolidinyl)acetonitrile
Iodoethane (6.46g) was added in portions to a cooled mixture of 2-((R)-
pyrrolidinyl)acetonitrile (Intermediate 210, 4.6g) and potassium carbonate (8.6g) in
acetonitrile (30mL) at 0°C. The mixture was stirred for 3 hours at 0°C then concentrated under
vacuum. The residue was partitioned between water and DCM. The organic layer was washed
with brine, dried and filtered. The filtrate was evaporated to dryness to give 2-((R)-l-
(Na2SC 4)
ethylpyrrolidinyl)acetonitrile (2.1g) as a colourless liquid which was used without further
characterisation.
Intermediate 210: 2-((R)-Pyrrolidinyl)acetonitrile hydrochloride
Prepared by proceeding in a similar manner to Intermediate 205, starting from
ferf-butyl (R)cyanomethylpyrrolidine-l-carboxylate (Intermediate 2 11) and used without
further characterisation.
Intermediate 211: ferf-Butyl (R)cyanomethylpyrrolidine-l-carboxylate
Prepared by proceeding in a similar manner to Intermediate 206, sarting from
ferf-butyl ((S)(4-methylbenzenesulfonyloxymethyl)pyrrolidine- 1-caiboxylate (Intermediate
212) and used without further characterisation.
Intermediate 212: ferf-Butyl ((S)(4-methylbenzenesulfonyloxymethyl)-pyrrolidine-l-
carboxylate
Prepared by proceeding in a similar manner to Intermediate 140, starting from
ferf-butyl (S)hydroxymethylpyrrolidine-l-carboxylate and 4-methylbenzenesulfonyl
chloride and used without further characterisation.
Intermediate 213: Methyl (laR,7bS)[2-((S)-l-ethylpyrrolidinyloxymethyl)fluoro-
benzenesulfonylamino]- l ,l a,2,7 -carboxylate
A solution of ferf-butyl (S)[(laR,7bS)fluoro(4-methoxycarbonyl-
l,la,2,7b-tetrahydro-cyclopropa[c]chromenylsulfamoyl)benzyloxy]pyrrolidine-l-
carboxylate (Intermediate 214, 0.284g) in trifluoroacetic acid (4mL) and DCM (4mL) was left
at room temperature for 30 minutes. The mixture was evaporated in vacuo and the residue was
azeotroped with toluene. The residue was dissolved in DCM (4mL) and acetaldehyde (0.044g)
was added followed by sodium triacetoxyborohydride (0.212g). The mixture was stirred at
room temperature for 1 hour. The resulting solution was diluted with DCM and 1M sodium
hydroxide solution and the organic layer was dried ( SC ) and filtered. The filtrate was
evaporated in vacuo and the residue was purified by chromatography on silica, eluting with a
mixture of methanol and DCM with a gradient of 0-20% to give methyl (laR,7bS)[2-((S)-l-
ethylpyrrolidinyloxymethyl)fluorobenzenesulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (0.221g) as a white foam.
¾ NMR (CDC1 ) d : 7.76 (IH, dd), 7.32 (IH, dd), 7.16 (IH, d), 6.94 (IH, dt), 6.87 (IH, d),
4.86 (IH, d), 4.68 (IH, d), 4.32 (IH, d), 4.19 (IH, m), 3.79 (IH, d), 3.73 (3H, s), 3.13 (IH, d),
2.92 (IH, q), 2.35-2.75 (4H, m), 2.10 (2H, m), 1.92 (IH, m), 1.72 (IH, m), 1.14 (3H, t), 1.03
(2H, m).
Intermediate 214: ferf-Butyl (S)[(laR,7bS)- 5-fluoro(4-methoxycarbonyl-l,la,2,7b-
tetrahydrocyclopropa[c]chromenylsulfamoyl)benzyloxy]pyrrolidine-l-carboxylate
A solution of ferf-butyl (S)(2-chlorosulfonylfluorobenzyloxy)pyrrolidine-
1-carboxylate (Intermediate 215, 0.295g) in DCM (2mL) was added to a solution of methyl
(laR,7bS)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate
42A, 0.1lg) in DCM (2mL) and the mixture was left at room temperature for 5 days. The
mixture was diluted with DCM, washed with 1M hydrochloric acid and filtered through a phase
separator. The filtrate was evaporated in vacuo and the residue was purified by chromatography
on silica, eluting with a mixture of ethyl acetate and cyclohexane with a gradient of 0-30% to
give ferf-butyl (S)[5-fluoro((laR,7bS)methoxycarbonyl-l,la,2,7b-
tetrahydrocyclopropa-[c]chromenylsulfamoyl)benzyloxy]pyrrolidine- 1-carboxylate (0.288g)
as a white foam.
¾ NMR (CDC1 ) d : 8.86 (IH, br, s), 7.76 (IH, dd), 7.41 (IH, dd), 7.25 (IH, d), 7.07 (IH, d),
6.95 (IH, dt), 4.69-4.91 (2H, br, q), 4.32 (IH, d), 4.19 (IH, m), 3.77 (IH, d), 3.71 (3H, s), 3.49
(4H, br, m), 1.89-2.18 (3H, m), 1.73 (IH, m), 1.47 (9H, s), 1.00 (2H, m).
Intermediate 215: ferf-Butyl (S)(2-chlorosulfonylfluorobenzyloxy)pyrrolidine-l-
carboxylate
n-Butyllithium (1.6M in hexanes, 3.3mL) was added to a solution of ferf-butyl
(S)(2-bromofluorobenzyloxy)pyrrolidine-l-carboxylate (Intermediate 216, 1.87g), in
anhydrous THF (20mL) at -78°C under an atmosphere of nitrogen and the mixture was stirred
for 30 minutes. Sulphur dioxide was passed through the resulting solution for 30 minutes, then
the cooling bath was removed and the mixture was allowed to warm to room temperature and
stirred for 15 minutes. The solution was evaporated in vacuo and the residue was dissolve in
DCM (20mL) and N-chlorosuccinimide (0.668g) was added. The mixture was stirred for 30
minutes then diluted with ether and water. The organic layer was dried (MgSCU) and filtered
and the filtrate was evaporated in vacuo. The residue was purified by chromatography on silica,
eluting with a mixture of ethyl acetate and cyclohexane with a gradient of 0-25% to give tert-
butyl (S)(2-chlorosulfonylfluorobenzyloxy)pyrrolidine-l-carboxylate (l.Olg) as a
colourless, viscous oil.
¾ NMR (CDC1 ) d : 8.09 (1H, dd), 7.58 (1H, dd), 7.18 (1H, dt), 4.98 (2H, q), 4.28 (1H, m),
3.40-3.61 (4H, m), 1.92-2.20 (2H, m), 1.47 (9H, s).
Intermediate 216: ferf-Butyl (S)(2-bromofluorobenzyloxy)pyrrolidine-l-carboxylate
Sodium hydride (60% oil dispersion, 0.24g) was added to a stirred solution of
ferf-butyl (S)hydroxypyrrolidine-l-carboxylate (0.935g) in THF (15mL) and the mixture
was stirred for 5 minutes. 2-Bromofluorobenzyl bromide (1.608g) was added and stirring
was continued for 20 hours. The resultant suspension was filtered and the filtrate was
evaporated to dryness. The residue was purified by chromatography on silica, eluting with a
mixture of ethyl acetate and cyclohexane with a gradient of 0-15% to give ferf-butyl (S)(2-
bromofluorobenzyloxy)-pyrrolidine-l-carboxylate (1.88g) as a colourless oil.
(CDCI )
¾ NMR d : 7.46 (1H, dd), 7.22 (1H, dd), 6.88 (1H, dt), 4.52 (2H, s), 4.19 (1H, m),
3.40-3.65 (4H, br, m), 1.91-2.18 (2H, m), 1.49 (9H, s).
Intermediate 217: Methyl (laR,7bS)[2-((R)-l-ethylpyrrolidinyloxymethyl)fluoro-
benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 213, starting from
ferf-butyl (R)[(laR,7bS)fluoro(4-methoxycarbonyl-l,la,2,7b-
tetrahydrocyclopropa[c]chromenylsulfamoyl)benzyloxy]-pyrrolidine- 1-carboxylate
(Intermediate 218).
¾ NMR (CDC1 ) d : 7.76 (IH, dd), 7.32 (IH, dd), 7.17 (IH, d), 6.95 (IH, dt), 6.88 (IH, d),
4.85 (IH, d), 4.68 (IH, d), 4.32 (IH, d), 4.18 (IH, m), 3.81 (IH, d), 3.72 (3H, s), 3.1 1 (IH, d),
2.92 (IH, q), 2.25-2.75 (4H, m), 2.09 (2H, m), 1.91 (IH, m), 1.72 (IH, m), 1.14 (3H, t), 1.03
(2H, m).
Intermediate 218: ferf-Butyl (R)[(laR,7bS)fluoro(4-methoxycarbonyl-l,la,2,7b-
tetrahydrocyclopropa[c] lidine- 1-carboxylate
Prepared by proceeding in a similar manner to Intermediate 214, starting from
ferf-butyl (R)(2-chlorosulfonylfluorobenzyloxy)pyrrolidine- 1-carboxylate (Intermediate
219) and methyl (laR,7bS)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 42A).
¾ NMR (CDCI ) d : 8.86 (IH, br, s), 7.76 (IH, dd), 7.41 (IH, dd), 7.25 (IH, d), 7.07 (IH, d),
6.95 (IH, dt), 4.78 (2H, br, s), 4.32 (IH, d), 4.19 (IH, m), 3.77 (IH, d), 3.71 (3H, s), 3.49 (4H,
br, m), 1.89-2.18 (3H, m), 1.73 (IH, m), 1.47 (9H, s), 1.00 (2H, m).
Intermediate 219: ferf-Butyl (R)(2-chlorosulfonylfluorobenzyloxy)pyrrolidine-l-
carboxylate
Prepared by proceeding in a similar manner to Intermediate 215, starting from ferf-butyl (R)
(2-bromofluorobenzyloxy)pyrrolidine-l-carboxylate (Intermediate 220).
¾ NMR (CDC1 ) d : 8.10 (IH, dd), 7.58 (IH, dd), 7.17 (IH, dt), 4.99 (2H, q), 4.28 (IH, m),
3.40-3.61 (4H, m), 1.92-2.20 (2H, m), 1.48 (9H, s).
Intermediate 220: ferf-Butyl (R)(2-bromofluorobenzyloxy)pyrrolidine-l-carboxylate
Prepared by proceeding in a similar manner to Intermediate 216, starting from
½rf-butyl(R)hydroxy-pyrrolidine-l-carboxylate.
¾ NMR (CDCI ) d : 7.46 (IH, dd), 7.22 (IH, dd), 6.88 (IH, dt), 4.52 (2H, s), 4.19 (IH, m),
3.40-3.65 (4H, br, m), 1.91-2.18 (2H, m), 1.49 (9H, s).
Intermediate 221: Methyl (laR,7bS)[2-(l-ethylpiperidinylmethyl)fluorobenzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
2-(l-Ethylpiperidinylmethyl)fluorobenzenesulfonyl chloride (Intermediate
222, 0.21g) was added to a solution of methyl (laR,7bS)amino-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylate (Intermediate 42A 0.290g) in DCM (lOmL)
and pyridine (2mL) and the resultant mixture was stirred at room temperature for 4 hours. The
mixture was evaporated to dryness and the residue was partitioned between DCM and water.
The organic layer was dried (Na2SC 4), filtered and the filtrate was concentrated in vacuo. The
residue was purified by chromatography on silica eluting with a mixture of 2M ammonia in
methanol and DCM with a gradient of 0-15% to give methyl (laR,7bS)[2-(l-ethylpiperidin-
3-ylmethyl)fluoro-benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylate (0.071g).
¾ NMR (CDC1 ) d : 7.95-7.88 (IH, m), 7.21-7.15 (IH, m), 7.03-6.86 (3H, m), 4.31 (IH, d),
3.81-3.73 (4H, m), 2.89-2.63 (4H, m), 2.39-2.28 (2H, m), 2.09-2.08-1.95 (IH, m), 1.94-1.44
(8H, m), 1.06-0.94 (6H, m).
Intermediate 222: 2-(l -Ethylpiper i -benzenesulfonyl chloride
A solution of l-ethyl(3-fluorobenzyl)piperidine (Intermediate 223, 0.214g) in
DCE (ImL) was added to chlorosulfonic acid (2mL) at 0°C. The mixture was allowed to warm
to room temperature and stirred for 2 hours. The mixture was added dropwise to a mixture of
ice and brine and extracted with DCM. The organic layer was dried (Na2SC 4) and filtered and
the filtrate was evaporated to dryness to give 2-(l-ethylpiperidinylmethyl)fluorobenzene-
sulfonyl chloride (0.44g) as a solid.
(CDCI )
¾ NMR d : 8.17-8.1 1 (IH, m), 7.43-7.37 (IH, m), 7.19-7.12 (IH, m), 3.62-3.52 (IH,
m), 3.42-3.32 (IH, m), 3.16 (2H, d), 3.1 1-2.92 (3H, m), 2.64-2.29 (3H, m), 1.91 (2H, d), 1.43
(3H, t), 1.39-1.23 (lH, m).
Intermediate 223: l-Ethyl(3-fluorobenzyl)-piperidine
A solution of lithium aluminium hydride (2M in THF, 2.8mL) was added
dropwise to a solution of l-[3-(3-fluorobenzyl)piperidin-l-yl]ethanone (Intermediate 224,
0.66g) in anhydrous THF (20mL) at 0°C under argon. The mixture was stirred for 30 minutes
then allowed to warm to room temperature and stirred for 2 hours. The mixture was recooled to
0°C and water was added. The mixture was extracted with ether, washed with brine, dried
and filtered. The filtrate was evaporated to dryness to give l-ethyl(3-
(Na2SC 4)
fluorobenzyl)piperidine (0.535g).
¾ NMR (CDC1 ) d : 7.25-7.17 (IH, m), 6.95-6.80 (3H, m), 2.92-2.73 (2H, m), 2.58-2.42 (2H,
m), 2.42-2.26 (2H, m), 1.96-1.76 (2H, m), 1.74-1.48 (4H, m), 1.04 (3H, t), 1.00-0.84 (IH, m).
Intermediate 224: l -[3-(3-Fluorobenzyl) yl]ethanone
A mixture of l-{ 3-[l-(3-fluorophenyl)methylidene]piperidin-l-yl}ethanone
(Intermediate 225, 0.7g), palladium hydroxide (20% on carbon, 0.07g) in ethyl acetate (20mL)
and IMS (lmL) was degassed by nitrogen/vacuum purging. The mixture was stirred under an
atmosphere of hydrogen for 21.5 hours. The mixture was filtered the filtrate was evaporated to
dryness to give l-[3-(3-fluorobenzyl)piperidin-l-yl]ethanone (0.66g).
¾ NMR (CDCI ) d : 7.31-7.17 (IH, m), 6.97-6.80 (3H, m), 4.52-4.43 (0.5H, m), 4.41-4.31
(0.5H, m), 3.76-3.65 (0.5H, m), 3.65-3.55 (0.5H, m), 3.07-2.95 (0.5H, m), 2.82-2.62 (1.5H, m),
2.60-2.49 (IH, m), 2.45-2.33 (IH, m), 2.08 (1.5H, s), 1.95 (1.5H, s), 1.83-1.63 (3H, m), 1.50-
1.32 (IH, m), 1.29-1.09 (IH, m).
Intermediate 225: 1-{3-[1-(3-Fluorophenyl)methylidene]piperidin- 1-yl }ethanone
Acetyl chloride (0.5 15mL) was added to a mixture of 3-[l-(3-
fluorophenyl)methylidene]-piperidine hydrochloride (Intermediate 226, 1.5g) and N,N-di-
isopropyl-N-ethylamine (2.52mL) in anhydrous THF (50mL) at 0°C under nitrogen. The
mixture was allowed to warm to room temperature and was stirred for 2 hours. The mixture
was diluted with water (lOOmL) and extracted with ether, washed with brine, dried
(Na2SC 4)
and filtered. The filtrate was evaporated to dryness and the residue was purified by
chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane with a
gradient of 75-100% to give l-{3-[l-(3-fluorophenyl)-methylidene]piperidin-l-yl}ethanone
(1.38g).
¾ NMR (CDC1 ) d : 7.37-7.21 (IH, m), 7.04-6.82 (3H, m), 6.48-6.26 (IH, 4s), 4.39-4.00 (2H,
m), 3.72-3.48 (2H, m), 2.61-2.41 (2H, m), 2.18-2.02 (3H, 4s), 1.83-1.61 (2H, m).
Intermediate 226: 3-[l -(3-Fluorophenyl) piper i dine hydrochloride
A solution of HCI in dioxane (4M, 30mL) was added to a solution of ferf-butyl
3-[l-(3-fluorophenyl)methylidene]piperidine-l-carboxylate (Intermediate 227, 2.38g) in ether
(30mL) and the mixture was stirred at room temperature for 5 hours. The mixture was
concentrated in vacuo and the residue was treated with ether. The solid was collected by
filtration, washed with ether and dried under vacuum to give 3-[l-(3-
fluorophenyl)methylidene]piperidine hydrochloride (1.64g).
¾ NMR (CDCI ) 3:2 ratio of E and Z isomers d : 9.34 (2H, br s), 7.48-7.37 (IH, m), 7.22-7.00
(3H, m), 6.59 (IH, s), 3.78-3.68 (2H, m), 3.13 (2H, m), 2.52 (1.2H, m), 2.43 (0.8H, m), 1.84
(1.2H, m), 1.76 (0.8H, m).
Intermediate 227: ferf-Butyl 3-[l-(3-fluorophenyl)methylidene]piperidine-l-carboxylate
(3-Fluorobenzyltriphenylphosphonium bromide (Intermediate 228, 5.3g) was
added in portions to a solution of sodium ferf-butoxide (1.06g) in anhydrous THF (20mL) at
room temperature and the mixture was stirred for 30 minutes. A solution of ferf-butyl 3-
oxopiperidine-l-carboxylate (2g) in anhydrous THF (lOmL) was added dropwise at room
temperature and the mixture was stirred for 24 hours. The mixture was diluted with water
(lOOmL) and extracted with ether (lOOmL), washed with brine, dried and filtered.
(Na2SC>4)
The filtrate was concentrated in vacuo and the residue was purified by chromatography on
silica eluting with a mixture of ethyl acetate and cyclohexxane with a gradient of 0-20% to give
ferf-butyl 3-[l-(3-fluorophenyl)-methylidene]piperidine-l-carboxylate (1.42g).
¾ NMR (CDC1 ) 3:2 ratio of E and Z isomers d : 7.33-7.21 (IH, m), 7.05-6.85 (3H, m), 6.37
(0.6H, s), 6.28 (0.4H, s), 4.16 (0.8H, s), 4.00 (1.2H, s), 3.50 (2H, t), 2.50 (1.2H, m), 2.39 (0.8H,
m), 1.72 (0.8H, m), 1.62 (1.2H, m), 1.48 (5.4H, s), 1.34 (3.6H, br s).
Intermediate 228: (3-Fluorobenzyl)tr bromide
A mixture of 3-fluorobenzyl bromide (5g) and triphenyl phosphine (6.94g) in
toluene (50mL) was heated at reflux for 3 hours. After cooling, the solid was collected by
filtration, washed with toluene and dried under vacuum at 50°C to give (3-
fluorobenzyl)triphenylphosphonium bromide (lO.lg).
¾ NMR (DMSO-d ) d : 7.96-7.87 (3H, m), 7.81-7.64 (12H, m), 7.35-7.26 (IH, m), 7.20-7.1 1
(IH, m), 6.88-6.82 (IH, m), 6.78-6.70 (IH, m), 5.21 (2H, d).
Intermediate 229: Methyl (laR,7bS){2-[2-((R)-l-ethylpyrrolidinyl)ethyl]fluoro-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa[c] chromenecarboxylate
Prepared by proceeding in a similar manner to Intermediate 95, starting from 2-
[2-((R)-l-ethyl-pyrrolidinyl)-ethyl]fluorobenzenesulfonyl chloride (intermediate 230) and
methyl (laR,7bS)amino-l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylate
(Intermediate 42A).
LCMS (Method A) r/t 2.30 (M+H) 503.
Intermediate 230: 2-[2-((R)-l-Ethylpyrrolidinyl)ethyl]fluorobenzenesulfonyl chloride
Prepared by proceeding in a similar manner to intermediate 96, starting from
(R)- l-ethyl[2-(3-fluorophenyl)ethyl]pyrrolidine (intermediate 23 1).
¾ NMR (CDC1 ) d : 8.1 1 (1H, dd), 7.42 (1H, dd), 7.14 (1H, t), 3.93 (1H, m), 3.46-3.21 (2H,
m), 3.13 (1H, m), 2.91 (2H, m), 2.43 (2H, m), 2.32 (2H, m), 2.1 1 (3H, m), 1.50 (3H, t).
Intermediate 231: (R)- l-Ethyl[2-(3- yl]pyrrolidine
A solution of l-{ (R)[2-(3-fluorophenyl)ethyl]pyrrolidin-l-yl}ethanone
(Intermediate 232, 0.48g) in THF (20mL) was cooled to 0°C and treated with a solution of
lithium aluminum hydride (2M in THF, 3.6mL) under an atmosphere of nitrogen. The resultant
mixture was allowed to warm to room temperature before heating to 60°C overnight. The
mixture was cooled to 0°C and treated with water (0.35ml), 4N sodium hydroxide solution
(0.35ml) and further water (0.9ml). Sodium bisulphate powder was added to the suspension and
the slurry was filtered through Celite and the filtrate was evaporated to dryness to give (R)-l-
ethyl[2-(3-fluoro-phenyl)ethyl]pyrrolidine (0.41g) as an oil.
¾ NMR (CDC1 ) d : 7.22 (IH, m), 6.96 (IH, d), 6.87 (2H, m), 3.18 (IH, dd), 2.87 (IH, m),
2.69 (IH, m), 2.55 (IH, m), 2.20 (IH, dq), 2.12-1.91 (4H, m), 1.75 (2H, m), 1.54 (2H, m), 1.10
(3H, t). HNMR 205205
Intermediate 232: 1-{(R) [2-(3-Fluorophenyl)ethyl] pyrrolidin- 1-yl }ethanone
Acetyl chloride (0.29ml) was added to a solution of N,N-diisopropyl-N-ethylamine (0.71ml)
and (R)[2-(3-fluorophenyl)ethyl]-pyrrolidine (Intermediate 233, 0.39g) in DCM (30ml) and
the mixture was stirred for 1.5 hours. The mixture was washed with 1M HC1, dried (MgSCU)
and filtered. The filtrate was evaporated to dryness to give l-{(R)[2-(3-fluorophenyl)ethyl]-
pyrrolidin-l-yl}ethanone (0.48g) as an oil.
¾ NMR (d -DMSO, 80°C) d : 7.28 (IH, q), 7.02 (2H, t), 6.92 (IH, t), 3.93 (IH, br s), 3.41 (2H,
m), 2.60 (2H, m), 2.05-1.54 (6H, m), 1.90 (3H, t).
Intermediate 233: (R)[2-(3-Fluoroph lidine
Trifluoroacetic acid (5mL) was added to a solution of ferf-butyl (R)[2-(3-
fluorophenyl)ethyl]-pyrrolidine-l-carboxylate (Intermediate 234, 0.55g) in DCM (5mL) and
the mixture was stirred at room temperature for 1.5 hours. The mixture was evaporated to
dryness and the residue was dissolved in a small amount of methanol and loaded onto a 20g
SCX-2 SPE cartridge, washed with methanol then eluted with 2M ammonia in methanol to give
(R)[2-(3-fluorophenyl)-ethyl]pyrrolidine (0.39g).
¾ NMR (CDCI ) d : 7.23 (IH, q), 6.97 (IH, d), 6.88 (2H, m), 2.99 (2H, m), 2.85 (lH,m), 2.69
(2H, m), 1.91 (IH, m), 1.75 (3H, m), 1.61 (IH, br s), 1.28 (IH, m).
Intermediate 234: ferf-Butyl (R)[2-(3-fluorophenyl)ethyl]pyrrolidine-l-carboxylate
A solution of ferf-butyl (S)(3-fluorophenylethynyl)pyrrolidine-l-carboxylate
(Intermediate 235, 1.26g) in IMS (70mL) was carefully added to 20% palladium on carbon
(0.6g) under a carbon dioxide atmosphere. The mixture was degassed under vacuum and placed
under an atmosphere of hydrogen. This was repeated three times then the mixture was stirred
under an atmosphere of hydrogen for 18 hours. The mixture was filtered through Celite and the
filtrate was evaporated to dryness. The residue was purified by chromatography on silica,
eluting with a mixture of DCM and pentane with a gradient of 0-100% to give ferf-butyl (R)
[2-(3-fluoro-phenyl)ethyl]pyrrolidine-l-carboxylate (0.55g) as an oil.
¾ NMR (CDC1 ) d : 7.21 (IH, br m), 6.99-6.81 (3H, br m), 3.80 (IH, br d), 3.37 (2H, br d),
2.61 (2H, br m), 1.97 (2H, br m), 1.83 (2H, m), 1.65 (2H, br m), 1.45 (9H, s).
Intermediate 235: ferf-Butyl (S)(3-fluorophenylethynyl)pyrrolidine-l-carboxylate
A suspension of 3-fluorobromobenzene (0.62ml), frw(dibenzylideneacetone)
dipalladium(O) (0.276g), tri-ferf-butylphosphonium tetrafluoroborate (0.165g) and tert-butyl
(S)tributyl-stannanylethynylpyrrolidine-l-carboxylate (Intermediate 236, 2.94g) in
anhydrous toluene (40ml) was degassed under nitrogen and stirred at room temperature for 1.5
hours. The mixture was evaporated to dyrness and the residue was purified by chromatogrphy
on silica, eluting with a mixture of DCM and pentane with a gradient of 0-100% to give tert-
butyl (S)(3-fluoro-phenylethynyl)pyrrolidine-l-carboxylate (1.26g) as an oil.
¾ NMR (CDCI ) d : 7.25 (IH, m), 7.16 (IH, br d), 7.08 (IH, br d), 6.99 (IH, br t), 4.69 (IH, br
d), 3.5 1 (IH, br s), 3.37 (IH, br s), 2.11 (3H, br m), 1.94 (IH, br s), 1.49 (9H, s).
Intermediate 236: ½rf-Butyl(S)tributylstannanylethynylpyrrolidine- 1-carboxylate
n-Butyl lithium (2.5M solution in hexanes. 1lmL) was added dropwise to a
cooled solution of ferf-butyl (S)ethynylpyrrolidine-l-carboxylate (prepared according A
Paul et al, Tetrahedron, 2006, 62, 8919, 4.49g) in dry THF (230ml) under an atmosphere of
nitrogen while maintaining the temperature below -65°C. When the addition was completed,
the mixture was stirred at -78°C for 15 minutes then allowed to warm to 0°C and stirred for 2.5
hours. Tributyl tin chloride (7.7mL) was added dropwise over five minutes and the mixture was
stirred at room temperature for 1.5 hours. The mixture was cooled to 0°C and saturated sodium
bicarbonate was added while maintaining the temperature below 15°C. The layers were
separated and the aqueous layer was extracted with ethyl acetate, washed with saturated sodium
bicarbonate, water, dried (MgSCU) and filtered. The filtrate was evaporated to dryness and the
residue was purified by chromatography on silica, eluting with a mixture of pentane and ethyl
acetate with a gradient of 0-7.5% to give tert-butyl (S)tributylstannanylethynylpyrrolidine-l-
carboxylate (0.39g) as an oil.
¾ NMR (CDC1 ) d : 4.41 (1H, br s), 3.45 (1H, br m), 3.28 (1H, br s), 2.03 (3H, br m), 1.86
(1H, br s), 1.54 (6H, m), 1.48 (9H, s), 1.33 (6H, q), 0.95 (6H, t), 0.90 (9H, t).
Biological Example:
Compounds are tested for their capacity to inhibit recombinant human MetAP2
activity using the following assay.
Human recombinant MetAP2 expressed in Sf9 cells followed by affinity
purification and EDTA treatment to remove endogenous active site cation was dialysed against
Mn ¾ to produce the manganese enzyme used in the assay. The assay was carried out for 30
minutes at 25°C in 50mM HEPES buffer containing lOOmM NaCl, pH 7.5 the presence of
0.75mM Methionine-Alanine-Serine (MAS) substrate and 50 g ml amino acid oxidase using a
dilution of purified MetAP2 giving > 3-fold signal : noise. Cleavage of the substrate by
MetAP2 and oxidation of free methionine by amino acid oxidase was detected and quantified
using fluorescence generated by Amplex red (10-acetyl-3,7-dihydroxyphenoxazine) in
combination with horseradish peroxidase which detects released during the oxidation
H2O2
step. The fluorescent signal was detected using a multiwell fluorimeter. Compounds were
diluted in DMSO prior to addition to assay buffer, the final DMSO concentration in the assay
being 1%.
The is defined as the concentration at which a given compound achieves
IC50
50% inhibition of control. values are calculated using the XLfit software package (version
IC50
2.0.5).
Compounds of the invention demonstrated activity in the assay of this Example
as indicated in the following table, wherein A represents < 0.05m M , B represents between
IC50
0.05m M and 0.5m M , and C represents IC > 0.5m M .
Compound name Activity
Cis-(3aRS,9bRS)(Benzenesulfonylamino)-l,3a,4,9b-
tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid
Cis-(3aRS,9bRS)[2-(3-Diethylaminopropyl)
fluorobenzenesulfonyl-amino]- 1,3a,4,9b-tetrahydro-2H-furo[2,3- B
c]chromenecarboxylic acid
Cis-(3aRS,9bRS)[2-(3-{Pyrrolidin-l-yl}propyl)
fluorobenzene-sulfonylamino]- 1,3a,4,9b-tetrahydro-2H-furo[2,3- A
c]chromenecarboxylic acid
Cis-(3aRS,9bRS)[2-((Z)Diethylaminoprop-l-enyl)
fluoro-benzenesulfonylamino]- 1,3a,4,9b-tetrahydro-2H-furo[2,3- A
c]chromenecarboxylic acid
First eluting enantiomer of cis-(3aRS,9bRS)[2-((Z)
Diethylaminoprop-l-enyl)fluoro-benzenesulfonylamino]- A
1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid
Second eluting enantiomer of cis-(3aRS,9bRS)[2-((Z)
Diethylaminoprop-l-enyl)fluoro-benzenesulfonylamino]- B
1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid
7-[2-((Z)Diethylaminoprop-l-enyl)fluorobenzenesulfonyl-
amino]-l,2-dihydrofuro[2,3-c]quinolinecarboxylic acid A
formate salt
7-(Benzenesulfonylamino))-l,2-dihydrofuro[2,3-c]quinoline
carboxylic acid formate salt
Cis-(3aRS,9bRS)[2-((Z)Diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino]-l,2,3a,4,5,9b-hexahydrofuro[2,3- A
c]quinolinecarboxylic acid
-[2-((Z)Diethylaminoprop-l-enyl)fluorobenzenesulfonyl-
amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecaiboxylic A
acid
(laSJbR) 5-[2-((Z)Diethylaminoprop-l-enyl)
fluorobenzenesulfonyl-amino]- 1,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRJbS) 5-[2-((Z)Diethylaminoprop-l-enyl)
fluorobenzenesulfonyl-amino]- 1,la,2,7b- A
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2-((Z)Diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino] -7b-methyl- 1,1a,2,7b- A
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2-((E)Diethylaminoprop-l-enyl)
fluorobenzenesulfonylamino] -7b-methyl- 1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
Cis-(3aRS,9bRS)[2-(4-dimethylamino-butylamino)-
benzenesulfonylamino]- 1,3a,4,9b-tetrahydro-2H-furo[2,3- B
c]chromenecarboxylic acid
(laR,7bS)[2-(3-Diethylaminopropyl)fluorobenzenesulfonyl-
amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecaiboxylic A
acid
(laRS,7bSR)[2-((Z)Diethylaminoprop-l-enyl)
fluorobenzene-sulfonylamino]- 1,1-difluoro- 1,la,2,7b- A
tetrahydrocyclopropa[c]chromenecarboxylic acid
First eluting enantiomer of (laRS,7bSR)[2-((Z)
diethylaminoprop- l-enyl)fluorobenzene-sulfonylamino]- 1, 1-
difluoro-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
Second eluting enantiomer of (laRS,7bSR)[2-((Z)
diethylaminoprop- l-enyl)fluorobenzene-sulfonylamino]- 1, 1-
difluoro-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
(laRS,7bSR)[2((Z)Ethylaminoprop-l-enyl)fluoro-
benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid
First eluting enantiomer of (laRS,7bSR)[2((Z)
ethylaminoprop- 1-enyl)fluorobenzenesulfonylamino]- A
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Second eluting enantiomer of (laRS,7bSR)[2((Z)
ethylaminoprop-l-enyl)fluorobenzene-sulfonylamino]- B
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2[(Z)(Pyrrolidin-l-yl)prop-l-enyl]
fluorobenzenesulfonylamino }-1,1a,2,7b-tetrahydro- A
cyclopropa[c]chromenecarboxylic acid
First eluting enantiomer of (laRS,7bSR){2[(Z)(pyrrolidin-
1-yl)prop- 1-enyl]fluorobenzenesulfonylamino }-1,1a,2,7b- B
tetrahydro-cyclopropa[c]chromenecarboxylic acid
Second eluting enantiomer of (laRS,7bSR){2[(Z)
(pyrrolidin-l-yl)prop-l-enyl]fluorobenzenesulfonylamino}- B
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2-(3-Dimethylaminopropylamino)benzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene A
carboxylic acid
First eluting enantiomer of (laRS,7bSR)[2-(3-
dimethylaminopropylamino)benzene-sulfonylamino]-1,1a,2,7b- C
tetrahydrocyclopropa[c]chromenecarboxylic acid
Second eluting enantiomer of (laRS,7bSR)[2-(3-
dimethylaminopropylamino)benzene-sulfonylamino]-1,1a,2,7b- A
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2-(4-Dimethylaminobutylamino)benzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene A
carboxylic acid
First eluting enantiomer of (laRS,7bSR)[2-(4- B
dimethylaminobutylamino)benzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
Second eluting enantiomer of (laRS,7bSR)[2-(4-
dimethylaminobutylamino)benzene-sulfonylamino]-l,la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS JbSR^S-P-CS-DimethylaminopentylamuKObenzene-
sulfonylamino]-! Ja,2Jb-tetrahydrocyclopropa[c]chromene A
carboxylic acid
(laRS,7bSR){2[(Z)(propanyl)aminoprop-l-enyl]
fluorobenzene-sulfonylamino }-1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2[(Z)((S)hydroxypyrrolidin-l-
yl)aminoprop- 1-enyl]fluorobenzenesulfonylamino }-1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2[(Z)((R)Hydroxypyrrolidin-l-
yl)aminoprop- 1-enyl]fluorobenzene-sulfonylamino }-1,1a,2,7b- B
tetrahydro-cyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2((Z)Diethylaminobut-l-enyl)
fluorobenzenesulfonyl-amino]- 1,la,2,7b- A
tetrahydrocyclopropa[c]chromenecarboxylic acid
First eluting enantiomer of (laRS,7bSR)[2((Z)
diethylaminobut-l-enyl)fluorobenzenesulfonyl-amino]- B
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
Second eluting enantiomer of (laRS,7bSR)[2((Z)
diethylaminobut-l-enyl)fluorobenzenesulfonyl-amino]- B
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-(4-Ethylpiperazin-l-yl)-ethyl]
fluorobenzenesulfonylamino }-1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2[(Z)(Azetidin-l-yl)prop-l-enyl]
fluorobenzene-sulfonylamino }-1,1a,2,7b-tetrahydro- B
cyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2[(Z)(3-Hydroxyazetidin-l-yl)prop-l-enyl]- A
4-fluorobenzene-sulfonylamino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRSJbSR){2[(Z)(Azetidin-l-yl)propyl]
fluorobenzenesulfonylamino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2((Z)Diethylaminobutyl)
fluorobenzenesulfonylamino]-1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2-[N-(4-Dimethylaminobutyl)-N-methylamino]-
benzenesulfonyl-amino }- 1,1a,2,7b-tetrahydrocyclopropa- C
[c]chromenecarboxylic acid
(laRS,7bSR){2-[((S)- l-Ethylpyrrolidinylcarbamoyl)-
methyl]fluoro-benzenesulfonyl-amino}-l,la,2,7b- B
tetrahydrocyclopropa-[c]chromenecarboxylic acid
(laRSJbSR)[2-(l-Ethylazetidinyl)fluorobenzene-
sulfonylamino]- 1,1a,2,7b-tetrahydro-cyclopropa[c]chromene B
carboxylic acid
(laRS,7bSR){2-[((R)- l-Ethylpyrrolidinylcarbamoyl)-
methyl]fluorobenzenesulfonyl-amino }-1,1a,2,7b-tetrahydro- B
cyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-(Pyrrolidin-l-yl)-ethyl]fluorobenzene-
sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene B
carboxylic acid
(laRS,7bSR)[2-((R)-l-Ethylpyrrolidinylmethyl)
fluorobenzenesulfonyl-amino]-l,la,2,7b-tetrahydro- A
cyclopropa[c]chromenecarboxylic acid
First eluting enantiomer of (laRS,7bSR)[2-((R)-l-ethyl-
pyrrolidinylmethyl)fluorobenzenesulfonylamino]-l,la,2,7b- B
tetrahydro-cyclopropa[c]chromenecarboxylic acid
Second eluting enantiomer of (laRS,7bSR)[2-((R)-l-
Ethylpyrrolidinylmethyl)fluorobenzenesulfonyl-amino]- A
l,la,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2-[((S)- l-Ethylpyrrolidinyl)cabonyl- A
aminomethyl]fluorobenzenesulfonylamino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2-(4-Dimethylaminobutyrylamino)
fluorobenzenesulfonyl-amino]-l ,la,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid
(laRS,7bSR)[2-((S )-l -Ethyl-pyrrolidinylmethyl)
fluorobenzenesulfonyl-amino]- 1,la,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS bSR -P -CS-Dimethylaminopropylcarbamoy^benzene-
sulfonylamino]-! Ja,2Jb-tetrahydrocyclopropa[c]chromene B
carboxylic acid
(laRS,7bSR)(2-{ [N-((S)-l -Ethyl-pyrrolidinyl)-N-methyl-
carbamoyl]methyl }fluoro-benzenesulfonylamino)- 1,1a,2,7b- B
tetrahydrocyclopropa-[c]chromenecarboxylic acid
(laRS,7bSR)(2-{ [N-((R)-l -Ethylpyrrolidinyl)-N-methyl-
carbamoyl]methyl }fluoro-benzenesulfonylamino)- 1,1a,2,7b- B
tetrahydrocyclopropa-[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-((S)-l-Ethylpyrrolidinyl)ethylamino]-
benzenesulfonyl-amino }- 1,1a,2,7b-tetrahydrocyclopropa- A
[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-((R)-l-Ethylpyrrolidinyl)ethylamino]-
benzenesulfonyl-amino }- 1,1a,2,7b-tetrahydrocyclopropa- A
[c]chromenecarboxylic acid
(laRS,7bSR)[2-(3-N,N,-Diethylaminopropylamino)benzene-
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene A
carboxylic acid
(laRS,7bSR)(2-{ [((R)-l-Ethylpyrrolidineyl)carbonyl-
amino]methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2-[(l-Ethylazetidinylmethyl)amino]benzene-
sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene B
carboxylic acid
First eluting enantiomer of (laRS,7bSR)[2-((Z) B
diethylaminoprop- l-enyl)benzenesulfonylamino]- 1, la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
Second eluting enantiomer of (laRS,7bSR)[2-((Z)
diethylaminoprop- l-enyl)benzenesulfonylamino]- 1, la,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)(2-{N-[((R)-l-Ethylpyrrolidineyl)carbonyl]-N-
methylaminomethyl }fluorobenzenesulfonylamino)- 1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)(2-{N-[((S)-l-Ethylpyrrolidineyl)carbonyl]-N- B
methylamino-methyl }fluorobenzenesulfonylamino)- 1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2-(4-Dimethylaminobutylamino)fluoro-
benzenesulfonyl-amino]-l,la,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR){2-[((R)- l-Ethylpyrrolidinylmethyl)amino]-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR){2-[((S)- l-Ethylpyrrolidinylmethyl)amino]-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR)[2-(4-Ethyloxopiperazin-l-ylmethyl)
fluorobenzene-sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR)[2-(l-Ethylpiperidinylmethyl)fluoro-
benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa- A
[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-(l-Ethylazetidinyl)ethyl]fluoro-
benzenesulfonyl-amino }- 1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR){2-[((S)- l-Azabicyclo[2.2.2]oct
yl)amino]benzenesulfonyl-amino }-1,1a,2,7b- B
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2-[((R)- l-Azabicyclo[2.2.2]oct A
yl)amino]benzenesulfonyl-amino }-1,1a,2,7b-
tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)(2-{ [((S)-l-ethylpyrrolidine
carbonyl)amino]methyl}fluoro-benzenesulfonylamino)-
l,la,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-((R)-l-Ethylpyrrolidinylamino)ethyl]
fluoro-benzenesulfonylamino }-1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR){2-[((R)- l-Ethylpyrrolidinyl)amino]-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR){2-[((S)- l-Ethylpyrrolidinyl)amino]-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR)(2-{ [((R)-l-Ethylpyrrolidinecarbonyl)amino]-
methyl }fluoro-benzenesulfonylamino)- 1,1a,2,7b-tetrahydro- B
cyclopropa[c]chromenecarboxylic acid
(laRS,7bSR)[2-((Z)Diethylaminomethylprop-l-enyl)
fluorobenzene-sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa- A
[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-((R)-l-Ethylpyrrolidinyl)ethylamino]-
benzenesulfonylamino }- 1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laRS,7bSR){2-[2-((S)-l-Ethylpyrrolidinyl)ethylamino]-
benzenesulfonyl-amino }- 1,1a,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laR,7bS)[2-((S)-l-Ethylpyrrolidinyloxymethyl)fluoro-
benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laR,7bS)[2-((R)-l-Ethylpyrrolidinyloxymethyl)fluoro-
benzenesulfonylamino]-l,la,2,7b-tetrahydrocyclopropa- B
[c]chromenecarboxylic acid
(laR,7bS) [2-(l-Ethylpiperidinylmethyl)fluorobenzene- B
sulfonylamino]-l,la,2,7b-tetrahydrocyclopropa[c]chromene
carboxylic acid
(laR,7bS) {2-[2-((R)- 1-Ethylpyrrolidinyl)ethyl]
fluorobenzenesulfonyl-amino }-1,1a,2,7b-tetrahydrocyclopropa-
[c]chromenecarboxylic acid
INCORPORATION BY REFERENCE
All publications and patents mentioned herein, including those items listed
below, are hereby incorporated by reference in their entirety for all purposes as if each
individual publication or patent was specifically and individually incorporated by reference. In
case of conflict, the present application, including any definitions herein, will control.
EQUIVALENTS
While specific embodiments of the subject invention have been discussed, the
above specification is illustrative and not restrictive. Many variations of the invention will
become apparent to those skilled in the art upon review of this specification. The full scope of
the invention should be determined by reference to the claims, along with their full scope of
equivalents, and the specification, along with such variations.
Unless otherwise indicated, all numbers expressing quantities of ingredients,
reaction conditions, and so forth used in the specification and claims are to be understood as
being modified in all instances by the term "about." Accordingly, unless indicated to the
contrary, the numerical parameters set forth in this specification and attached claims are
approximations that may vary depending upon the desired properties sought to be obtained by
the present invention.
Claims (46)
1. A tricyclic compound represented by: # B1 A2 B A2 B R O O O O 2 A1 A N A1 A N (R ) (R ) CO H CO H Formula I or Formula II wherein: B is a 3-6 membered saturated or partially unsaturated heterocyclic or carbocyclic ring; B is a 3-6 membered saturated heterocyclic or carbocyclic ring; wherein the ring B or B is optionally substituted by one or more fluorine atoms on any of the available carbon atoms; D is a 5-7 membered heterocyclic, carbocyclic, heteroaromatic or aromatic ring; D is a 5-7 membered heterocyclic or carbocyclic ring; 1 1 1 1 wherein B is fused to D such that the two atoms shared by B and D are both carbon 2 2 2 2 and B is fused to D such that the two atoms shared by B and D are both carbon; and wherein for Formula I the bond common to both the B and D rings is a single or double bond; 1 + D1 D2 + 1 + D1 D2 X is selected from the group consisting of: -C(R R )-*, -W -*, -C(R R )- D5 D6 + C1 C2 + 2 D5 D6 + 2 + D1 D2 4 + C(R R )-*, -C(R )=C(R )-*, -W -C(R R )-*, -W -C(O)-*, -C(R R )-W -*, - C2 + C1 + D1 D2 D3 D4 D5 D6 + 2 D3 D4 N=C(R )-*, -C(R )=N-*, -C(R R )-C(R R )-C(R R )-*, -W -C(R R )- D5 D6 + 2 D5 D6 + D1 D2 3 D5 D6 + D1 D2 3 C(R R )-*, -W -C(O)-C(R R )-*, -C(R R )-W -C(R R )-*, -C(R R )-W -C(O)- + D1 D2 D3 D4 4 + D1 D2 4 + *, -C(R R )-C(R R )-W -* and -C(R R )-C(O)-W -*; wherein the and * indicate the attachment points of X as indicated in Formula I; 2 + D1 D2 + 1 + D1 D2 X is selected from the group consisting of: -C(R R )-*, -W -*, -C(R R )- D5 D6 + 2 D5 D6 + 2 + D1 D2 4 + D1 D2 D3 D4 C(R R )-*, -W -C(R R )-*, -W -C(O)-*, -C(R R )-W -*, -C(R R )-C(R R )- D5 D6 + 2 D3 D4 D5 D6 + 2 D5 D6 + D1 D2 3 C(R R )-*, -W -C(R R )-C(R R )-*, -W -C(O)-C(R R )-*, -C(R R )-W - D5 D6 + D1 D2 3 + D1 D2 D3 D4 4 + D1 D2 C(R R )-*, -C(R R )-W -C(O)-*, -C(R R )-C(R R )-W -* and -C(R R )-C(O)- 4 + 2 W -*; wherein the and * indicate the attachment points of X as indicated in Formula II; # # # Y is selected from the group consisting of: a bond, *-CH - , *-O- , *-CH -CH - , *-O- 2 2 2 # # # # # # CH - , *-CH -O- , *-CH -CH -CH - , *-O-CH -CH - and *-CH -O-CH - ; wherein the * and 2 2 2 2 2 2 2 2 2 indicate the attachment points of Y as indicated in Formula I or Formula II; 1 N1 W is selected from the group consisting of O, S or N(R ); 2 N2 W is selected from the group consisting of O or N(R ); 3 N3 W is selected from the group consisting of O or N(R ); 4 N4 W is selected from the group consisting of O or N(R ); A is a ring selected from the group consisting of phenyl, a 5-6 membered heteroaryl having 1, 2 or 3 heteroatoms each selected from S, N or O, and a 4-7 membered heterocycle having 1, 2 or 3 heteroatoms each selected from N or O; B1 B2 R and R are independently selected from the group consisting of H, F, OH, CN, C alkoxy or C alkyl; wherein C alkyl and C alkoxy are optionally substituted by a group 1-2 1-3 1-3 1-2 selected from OH, C alkoxy, CN or one or more fluorine atoms; R is selected, independently for each occurrence, from the group consisting of hydrogen, hydroxyl, cyano, halogen, C alkyl or C alkoxy; wherein C alkyl, or C alkoxy 1-4 1-3 1-4 1-3 may be optionally substituted by oneor more fluorines; n is 0, 1, or 2; A2 i j R is selected from the group consisting of hydrogen, R R N-, heterocyclyl, heterocyclyloxy and heterocyclyl-(NR )-; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R ; R is selected from the group consisting of: C alkyl, C alkenyl, C alkynyl, C 1-6 2-6 2-6 3- cycloalkyl, C alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) - 6 1-6 3-6 3-6 3-6 1-6 w a a a (wherein w is 0, 1 or 2), C alkyl-N(R )-, C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-, 1-6 1-6 1-6 a a a a C alkyl-N(R )-carbonyl-N(R )-, C alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C 1-6 1-6 2 1-6 2 1- a a a alkoxycarbonyl-N(R )-, C alkylcarbonyl-N(R )-C alkyl-, C alkyl-N(R )-carbonyl-C 6 1-6 1-6 1-6 1- alkyl-, C alkoxyC alkyl-; wherein C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C 6 1-6 1-6 1-6 2-6 2-6 3-6 1- alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) -, C alkyl-N(R )-, 6 3-6 3-6 3-6 1-6 w 1-6 a a a a C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-, C alkyl-N(R )-carbonyl-N(R )-, C 1-6 1-6 1-6 1- a a a alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C alkoxycarbonyl-N(R )-, C alkylcarbonyl- 6 2 1-6 2 1-6 1-6 N(R )C alkyl-, C alkyl-N(R )-carbonyl-C alkyl-, C alkoxy-C alkyl may optionally be 1-6 1-6 1-6 1-6 1-6 substituted by R , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR )-, heterocyclyl, heterocyclyloxy or heterocyclyl-N(R )-; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from R ; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R ; and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R ; D1 D2 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-2 1-2 1-2 1-2 optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl; D3 D4 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-3 1-3 1-3 1-3 optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); D5 D6 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-2 1-2 1-2 1-2 optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorine atoms,cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen, halogen, C alkyl or C alkoxy; 1-2 1-2 wherein the C alkyl or C alkoxy may optionally be substituted by one or more fluorine 1-2 1-2 atoms; R is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may optionally be substituted by one 2 1-2 1-2 1-2 or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen or C alkyl; R is selected from the group consisting of hydrogen or C alkyl; R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl; 1-3 1-2 wherein the C alkyl and C alkylcarbonyl may optionally be substituted by a substituent or 1-3 1-2 substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl; 1-3 1-2 wherein the C alkyl and C alkylcarbonyl may optionally be substituted by a substituent or 1-3 1-2 substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or N(R R ); R and R are independently selected, for each occurrence, from the group consisting of hydrogen and C alkyl; wherein C alkyl may optionally be substituted by one or more 1-3 1-3 substituents selected from fluorine, cyano, oxo and hydroxyl; or R and R , together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl; R is independently selected, for each occurrence, from the group consisting of R , hydrogen, C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -, 1-6 3-6 2-6 2-6 1-6 1-6 w (wherein wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-; 1-6 1-6 wherein C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -, C 1-6 3-6 2-6 2-6 1-6 1-6 w 1- alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or 6 1-6 more substituents selected from R ; R is independently selected for each occurrence from the group consisting of R , hydrogen, oxo, C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -, 1-6 2-6 2-6 3-6 1-6 1-6 w (wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-; wherein C 1-6 1-6 1- alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -, C 6 2-6 2-6 3-6 1-6 1-6 w 1- alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or 6 1-6 more substituents selected from R ; R is independently selected for each occurrence from the group consisting of hydrogen, C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) -, C alkoxycarbonyl-, 1-6 3-6 3-6 3-6 1-6 2 1-6 i j i j R R N-carbonyl- and R R N-SO -; wherein C alkyl, C alkenyl, C alkynyl C cycloalkyl 2 1-6 3-6 3-6 3-6 and C alkyl-S(O) -, C alkylcarbonyl- may optionally be substituted by one or more 1-6 2 1-6 substituents selected from R ; R and R are selected independently for each occurrence from the group consisting of hydrogen, C alkyl C cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein C alkyl 1-4 3-6 1-4 and C cycloalkyl may be optionally substituted by one or more substituents selected from a b a b fluorine, hydroxyl, cyano, R R N-, R R N-carbonyl- and C alkoxy and wherein heterocyclyl and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected from C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, halo-C -alkyl, hydroxyl- 1-6 2-6 2-6 3-6 1-6 1-6 C -alkyl, R R N-C alkyl- and C -alkoxy-C -alkyl group; and wherein if said heterocyclyl 1-6 1-6 1-6 1-6 or heterocyclylcarbonyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) - and C 1-6 3-6 3-6 3-6 1-6 2 1- -alkylcarbonyl; or R and R taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, a b a b a b C alkyl, C alkoxy, R R N-, R R N-SO - and R R N-carbonyl-; wherein said C alkyl or C 1-6 1-6 2 1-6 1- alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7 membered heterocyclic ring may be optionally substituted on nitrogen by one or more substituents selected from the group consisting of C alkyl and R R N-carbonyl-; and wherein said C alkyl may be optionally substituted by one or more substituents selected from the group consisting of fluorine, hydroxyl, cyano; R is independently selected, for each occurrence, from the group consisting of halogen, i j i j i j i j a hydroxyl, cyano, C alkoxy, R R N-, R R N-carbonyl-, R R N-SO - and R R N-carbonyl-N(R )-; 1-6 2 and pharmaceutically acceptable salts, stereoisomers and esters thereof.
2. The tricyclic compound of claim 1, wherein X is selected from the group consisting of: + + N1 + D1 D2 D5 D6 + C1 C2 + D5 D6 -O-*, -N(R )-*, -C(R R )-C(R R )-*, -C(R )=C(R )-*, -O-C(R R )-*, + N2 D5 D6 + + N2 + C2 -N(R )-C(R R )-*, -O-C(O)-*, -N(R )-C(O)-*, -N=C(R )-* and + D3 D4 D5 D6 -O-C(R R )-C(R R )-*; wherein the and * indicate the attachment points of X as indicated in Formula I.
3. The tricyclic compound of any one of claims 1-2, wherein X is selected from the group + + + + + consisting of: -NH-*, -O-CH -*, -NH-CH -*, -N=CH-* and -CH=CH-*; wherein the and * indicate the attachment points of X as indicated in Formula I.
4. The tricyclic compound of claim 1, wherein X is selected from the group consisting of: + + N1 + D1 D2 D5 D6 + D5 D6 + N2 D5 D6 -O-*, -N(R )-*, -C(R R )-C(R R )-*, -O-C(R R )-*, -N(R )-C(R R )-*, + + N2 + D3 D4 D5 D6 + -O-C(O)-*, -N(R )-C(O)-*, and -O-C(R R )-C(R R )-*; wherein the and * indicate the attachment points of X as indicated in Formula II.
5. The tricyclic compound of claim 1 or 4, wherein X is selected from the group consisting of: + + + 2 -O-CH -* and -NH-CH -*; wherein the and * indicate the attachment points of X as indicated in Formula II. D1 D2 C1 N1 N2
6. The tricyclic compound of any one of claims 1-5, wherein R , R , R , R and R are independently selected for each occurrence from the group consisting of hydrogen and methyl. D1 D2 C1 N1 N2
7. The tricyclic compound of any one of claims 1-5, wherein R , R , R , R and R are hydrogen. D3 D4 D5 D6
8. The tricyclic compound of any one of claims 1-7, wherein R , R , R and R are independently selected for each occurrence from the group consisting of hydrogen, fluorine, cyano and C alkyl. D3 D4 D5 D6
9. The tricyclic compound of any one of claims 1-7, wherein R , R , R and R are hydrogen.
10. The tricyclic compound of any one of claims 1-9, wherein R is selected from the group consisting of hydrogen, halogen, cyano and C alkyl.
11. The tricyclic compound of any one of claims 1-9, wherein R is hydrogen.
12. The tricyclic compound of any one of claims 1-11, wherein R is H, F or C alkyl.
13. The tricyclic compound of any one of claims 1-11, wherein R is H or methyl.
14. The tricyclic compound of any one of claims 1-13, wherein R is H.
15. The tricyclic compound of any one of claims 1-14, wherein D is selected from the group consisting of: wherein the *, # and + indicate the points of attachment to the phenyl ring and the B ring as indicated in Formula I.
16. The tricyclic compound of any one of claims 1-15, wherein D is selected from the group consisting of: wherein the *, # and + indicate the points of attachment to the phenyl ring and the B ring as indicated in Formula I.
17. The tricyclic compound of any one of claims 1-14, wherein D may be selected from the group consisting of: wherein the *, # and + indicate the points of attachment to the phenyl ring and the B ring as indicated in Formula II.
18. The tricyclic compound of any one of claims 1-17, wherein Y is selected from the group consisting of a bond, *-O-CH - and *-CH -O-CH - . 2 2 2
19. The tricyclic compound of any one of claims 1-18, wherein Y is a bond or *-O-CH - .
20. The tricyclic compound of claim any one of claims 1-19, wherein B or B is selected from the group consisting of: 1 * * # B1 wherein the * and # indicate the points of attachment to Y as indicated in Formulas I and II.
21. The tricyclic compound of any one of claims 1-20 , wherein B or B is selected from the group consisting of: R B1 B2 * R B2 wherein the * and # indicate the points of attachment to Y as indicated in Formulas I and II.
22. The tricyclic compound of claim 1, wherein the compound is represented by: O O O O A2 A2 A N O A N O N A1 H A1 H H H (R ) (R ) (R ) n CO H n CO H 2 CO H 2 Ia, Ib, 2 Ic, O O R A2 A2 S S S A N A N N A1 H (R ) n CO H A1 H A1 H 2 (R ) (R ) n CO H n CO H Id, Ie, If or R O O A1 A N O (R ) CO H
23. The tricyclic compound of claim 22, wherein A is phenyl.
24. A tricyclic compound represented by: A2 B A1 + X (R ) CO H Formula III; wherein: B is a 3-6 membered saturated or partially unsaturated heterocyclic or carbocyclic ring; wherein the ring B is optionally substituted by one or more fluorine atoms on any of the available carbon atoms; D is a 5-7 membered heterocyclic, carbocyclic, heteroaromatic or aromatic ring; 1 1 1 1 wherein B is fused to D such that the two atoms shared by B and D are both carbon; and wherein the bond common to both the B and D rings is a single or double bond; 1 + D1 D2 + 1 + D1 D2 X is selected from the group consisting of: -C(R R )-*, -W -*, -C(R R )- D5 D6 + C1 C2 + 2 D5 D6 + 2 + D1 D2 4 + C(R R )-*, -C(R )=C(R )-*, -W -C(R R )-*, -W -C(O)-*, -C(R R )-W -*, - C2 + C1 + D1 D2 D3 D4 D5 D6 + 2 D3 D4 N=C(R )-*, -C(R )=N-*, -C(R R )-C(R R )-C(R R )-*, -W -C(R R )- D5 D6 + 2 D5 D6 + D1 D2 3 D5 D6 + D1 D2 3 C(R R )-*, -W -C(O)-C(R R )-*, -C(R R )-W -C(R R )-*, -C(R R )-W -C(O)- + D1 D2 D3 D4 4 + D1 D2 4 + *, -C(R R )-C(R R )-W -* and -C(R R )-C(O)-W -*; wherein the and * indicate the attachment points of X as indicated in Formula III; # # # Y is selected from the group consisting of: a bond, *-CH - , *-O- , *-CH -CH - , *-O- 2 2 2 # # # # # # CH - , *-CH -O- , *-CH -CH -CH - , *-O-CH -CH - and *-CH -O-CH - ; wherein the * and 2 2 2 2 2 2 2 2 2 indicate the attachment points of Y as indicated in Formula III; 1 N1 W is selected from the group consisting of O, S or N(R ); 2 N2 W is selected from the group consisting of O or N(R ); 3 N3 W is selected from the group consisting of O or N(R ); 4 N4 W is selected from the group consisting of O or N(R ); R is selected, independently for each occurrence, from the group consisting of hydrogen, hydroxyl, cyano, halogen, C alkyl or C alkoxy; wherein C alkyl, or C alkoxy 1-4 1-3 1-4 1-3 may be optionally substituted by one or more fluorines; n is 1 or 2; A2 i j R is selected from the group consisting of hydrogen, R R N-, heterocyclyl, heterocyclyloxy and heterocyclyl-(NR )-; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R ; R is selected from the group consisting of: C alkyl, C alkenyl, C alkynyl, C 1-6 2-6 2-6 3- cycloalkyl, C alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) - 6 1-6 3-6 3-6 3-6 1-6 w a a a (wherein w is 0, 1 or 2), C alkyl-N(R )-, C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-, 1-6 1-6 1-6 a a a a C alkyl-N(R )-carbonyl-N(R )-, C alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C 1-6 1-6 2 1-6 2 1- a a a alkoxycarbonyl-N(R )-, C alkylcarbonyl-N(R )-C alkyl-, C alkyl-N(R )-carbonyl-C 6 1-6 1-6 1-6 1- alkyl-, C alkoxyC alkyl-; wherein C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C 6 1-6 1-6 1-6 2-6 2-6 3-6 1- alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) -, C alkyl-N(R )-, 6 3-6 3-6 3-6 1-6 w 1-6 a a a a C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-, C alkyl-N(R )-carbonyl-N(R )-, C 1-6 1-6 1-6 1- a a a alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C alkoxycarbonyl-N(R )-, C alkylcarbonyl- 6 2 1-6 2 1-6 1-6 N(R )C alkyl-, C alkyl-N(R )-carbonyl-C alkyl-, C alkoxy-C alkyl may optionally be 1-6 1-6 1-6 1-6 1-6 substituted by R , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR )-, heterocyclyl, heterocyclyloxy or heterocyclyl-N(R )-; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from R ; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R ; and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R ; D1 D2 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-2 1-2 1-2 1-2 optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl; D3 D4 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-3 1-3 1-3 1-3 optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); D5 D6 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-2 1-2 1-2 1-2 optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen, halogen, C alkyl or C alkoxy; 1-2 1-2 wherein the C alkyl or C alkoxy may optionally be substituted by one or more fluorine 1-2 1-2 atoms; R is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may optionally be substituted by one 2 1-2 1-2 1-2 or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen or C alkyl; R is selected from the group consisting of hydrogen or C alkyl; R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl; 1-3 1-2 wherein the C alkyl and C alkylcarbonyl may optionally be substituted by one or more 1-3 1-2 fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl; 1-3 1-2 wherein the C alkyl and C alkylcarbonyl may optionally be substituted by one or more 1-3 1-2 fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); R and R are independently selected, for each occurrence, from the group consisting of hydrogen and C alkyl; wherein C alkyl may optionally be substituted by one or more 1-3 1-3 substituents selected from fluorine, cyano, oxo and hydroxyl; or R and R , together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl; R is independently selected, for each occurrence, from the group consisting of R , hydrogen, C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -, 1-6 3-6 2-6 2-6 1-6 1-6 w (wherein wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-; 1-6 1-6 wherein C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -, C 1-6 3-6 2-6 2-6 1-6 1-6 w 1- alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or 6 1-6 more substituents selected from R ; R is independently selected for each occurrence from the group consisting of R , hydrogen, oxo, C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -, 1-6 2-6 2-6 3-6 1-6 1-6 w (wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-; wherein C 1-6 1-6 1- alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -, C 6 2-6 2-6 3-6 1-6 1-6 w 1- alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or 6 1-6 more substituents selected from R ; R is independently selected for each occurrence from the group consisting of hydrogen, C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) -, C alkoxycarbonyl-, 1-6 3-6 3-6 3-6 1-6 2 1-6 i j i j R R N-carbonyl- and R R N-SO -; wherein C alkyl, C alkenyl, C alkynyl C cycloalkyl 2 1-6 3-6 3-6 3-6 and C alkyl-S(O) -, C alkylcarbonyl- may optionally be substituted by one or more 1-6 2 1-6 substituents selected from R ; R and R are selected independently for each occurrence from the group consisting of hydrogen, C alkyl C cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein C alkyl 1-4 3-6 1-4 and C cycloalkyl may be optionally substituted by one or more substituents selected from a b a b fluorine, hydroxyl, cyano, R R N-, R R N-carbonyl- and C alkoxy and wherein heterocyclyl and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected from C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, halo-C -alkyl, hydroxyl- 1-6 2-6 2-6 3-6 1-6 1-6 C -alkyl, R R N-C alkyl- and C -alkoxy-C -alkyl group; and wherein if said heterocyclyl 1-6 1-6 1-6 1-6 or heterocyclylcarbonyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) - and C 1-6 3-6 3-6 3-6 1-6 2 1- -alkylcarbonyl; or R and R taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, C a b a b a b alkyl, C alkoxy, R R N-, R R N-SO - and R R N-carbonyl-; wherein said C alkyl or C 6 1-6 2 1-6 1- alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7 membered heterocyclic ring may be optionally substituted on nitrogen by one or more substituents selected from the group consisting of C alkyl and R R N-carbonyl-; and wherein said C alkyl may be optionally substituted by fluorine, hydroxyl, cyano; R is independently selected, for each occurrence, from the group consisting of halogen, i j i j i j i j a hydroxyl, cyano, C alkoxy, R R N-, R R N-carbonyl-, R R N-SO - and R R N-carbonyl-N(R )-; 1-6 2 and pharmaceutically acceptable salts, stereoisomers and esters thereof.
25. The tricyclic compound of claim 24, wherein R is selected from the group consisting of hydrogen, halogen, C alkyl and C alkoxy; wherein C alkyl may optionally be substituted 1-2 1-2 1-2 by one or more fluorines.
26. The tricyclic compound of claim 24, wherein R is selected from hydrogen or fluorine.
27. The tricyclic compound of any one of claims 24-26, wherein R is selected from the group consisting of hydrogen, R R N, heterocyclyl, C alkyl, C alkenyl, C cycloalkyl, C alkoxy; 1-6 3-6 3-6 1-6 wherein said heterocyclyl may optionally be substituted by one or more groups R ; and wherein if said heterocyclyl contains a –NH moiety, that nitrogen may optionally be substituted by on or more groups R ; and wherein said C alkyl, C alkenyl, C cycloalkyl and C alkoxy may 1-6 3-6 3-6 1-6 optionally be substituted by one or more groups R .
28. The tricyclic compound of any one of claims 24-27, wherein R is selected from the group consisting of 3-(N,N-diethylamino)propyl, 3-(pyrrolidinyl)propyl, (Z)(N,N- diethylamino)propenyl, (Z)(azetidinyl)propenyl and (Z)(pyrrolidinyl)prop enyl.
29. The tricyclic compound represented by: A1 + (R ) CO H Formula IV D is a 5-7 membered partially unsaturated heterocyclic or carbocyclic ring; 2 + D1 D2 + 1 X is selected from the group consisting of: -C(R R )-*, -W -*, + D1 D2 D5 D6 + 2 D5 D6 + 2 + D1 D2 4 + D1 D2 -C(R R )-C(R R )-*, -W -C(R R )-*, -W -C(O)-*, -C(R R )-W -*, -C(R R )- D3 D4 D5 D6 + 2 D3 D4 D5 D6 + 2 D5 D6 + C(R R )-C(R R )-*, -W -C(R R )-C(R R )-*, -W -C(O)-C(R R )-*, - D1 D2 3 D5 D6 + D1 D2 3 + D1 D2 D3 D4 4 + C(R R )-W -C(R R )-*, -C(R R )-W -C(O)-*, -C(R R )-C(R R )-W -* and - D1 D2 4 + 2 C(R R )-C(O)-W -*; wherein the and * indicate the attachment points of X as indicated in Formula IV; 1 N1 W is selected from the group consisting of O, S or N(R ); 2 N2 W is selected from the group consisting of O or N(R ); 3 N3 W is selected from the group consisting of O or N(R ); 4 N4 W is selected from the group consisting of O or N(R ); R is selected from the group consisting of H, F, OH, CN, C alkoxy or C alkyl; 1-2 1-3 wherein C alkyl and C alkoxy are optionally substituted by a group selected from OH, 1-3 1-2 C alkoxy, CN or one or more fluorine atoms; R is selected, independently for each occurrence, from the group consisting of hydrogen, hydroxyl, cyano, halogen, C alkyl or C alkoxy; wherein C alkyl, or C alkoxy 1-4 1-3 1-4 1-3 may be optionally substituted by one or more fluorines; n is 0, 1, or 2; A2 i j R is selected from the group consisting of hydrogen, R R N-, heterocyclyl, heterocyclyloxy and heterocyclyl-(NR )-; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R ; R is selected from the group consisting of: C alkyl, C alkenyl, C alkynyl, C 1-6 2-6 2-6 3- cycloalkyl, C alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) - 6 1-6 3-6 3-6 3-6 1-6 w a a a (wherein w is 0, 1 or 2), C alkyl-N(R )-, C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-, 1-6 1-6 1-6 a a a a C alkyl-N(R )-carbonyl-N(R )-, C alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C 1-6 1-6 2 1-6 2 1- a a a alkoxycarbonyl-N(R )-, C alkylcarbonyl-N(R )-C alkyl-, C alkyl-N(R )-carbonyl-C 6 1-6 1-6 1-6 1- alkyl-, C alkoxyC alkyl-; wherein C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C 6 1-6 1-6 1-6 2-6 2-6 3-6 1- alkoxy, C alkenyloxy, C alkynyloxy, C cycloalkoxy, C alkyl-S(O) -, C alkyl-N(R )-, 6 3-6 3-6 3-6 1-6 w 1-6 a a a a C alkyl-N(R )-carbonyl-, C alkylcarbonyl-N(R )-, C alkyl-N(R )-carbonyl-N(R )-, C 1-6 1-6 1-6 1- a a a alkyl-N(R )-SO -, C alkyl-SO -N(R )-, C alkoxycarbonyl-N(R )-, C alkylcarbonyl- 6 2 1-6 2 1-6 1-6 N(R )C alkyl-, C alkyl-N(R )-carbonyl-C alkyl-, C alkoxy-C alkyl may optionally be 1-6 1-6 1-6 1-6 1-6 substituted by R , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR )-, heterocyclyl, heterocyclyloxy or heterocyclyl-N(R )-; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from R ; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R ; and wherein if said heterocyclyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups R ; D1 D2 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-2 1-2 1-2 1-2 optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl; D3 D4 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-3 1-3 1-3 1-3 optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); D5 D6 R and R are each independently selected from the group consisting of hydrogen, fluorine, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may 1-2 1-2 1-2 1-2 optionally be substituted by a substituent or substituents selected from the group consisting of: one or more fluorine atoms,cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen, halogen, C alkyl or C alkoxy; 1-2 1-2 wherein the C alkyl or C alkoxy may optionally be substituted by one or more fluorine 1-2 1-2 atoms; R is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, C alkyl or C alkoxy; wherein the C alkyl and C alkoxy may optionally be substituted by one 2 1-2 1-2 1-2 or more fluorine atoms or a group selected from cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen or C alkyl; R is selected from the group consisting of hydrogen or C alkyl; R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl; 1-3 1-2 wherein the C alkyl and C alkylcarbonyl may optionally be substituted by a substituent or 1-3 1-2 substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or N(R R ); R is selected from the group consisting of hydrogen, C alkyl or C alkylcarbonyl; 1-3 1-2 wherein the C alkyl and C alkylcarbonyl may optionally be substituted by a substituent or 1-3 1-2 substituents selected from the group consisting of: one or more fluorines, cyano, hydroxyl or N(R R ); R and R are independently selected, for each occurrence, from the group consisting of hydrogen and C alkyl; wherein C alkyl may optionally be substituted by one or more 1-3 1-3 substituents selected from fluorine, cyano, oxo and hydroxyl; or R and R , together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of fluorine, cyano, oxo or hydroxyl; R is independently selected, for each occurrence, from the group consisting of R , hydrogen, C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -, 1-6 3-6 2-6 2-6 1-6 1-6 w (wherein wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-; 1-6 1-6 wherein C alkyl, C cycloalkyl, C alkenyl, C alkynyl, C alkoxy, C alkyl-S(O) -, C 1-6 3-6 2-6 2-6 1-6 1-6 w 1- alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or 6 1-6 more substituents selected from R ; R is independently selected for each occurrence from the group consisting of R , hydrogen, oxo, C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -, 1-6 2-6 2-6 3-6 1-6 1-6 w (wherein w is 0, 1 or 2), C alkylcarbonyl-N(R )- and C alkoxycarbonyl-N(R )-; wherein C 1-6 1-6 1- alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, C alkyl-S(O) -, C 6 2-6 2-6 3-6 1-6 1-6 w 1- alkylcarbonyl-N(R )-, C alkoxycarbonyl-N(R )- may be optionally substituted by one or 6 1-6 more substituents selected from R ; R is independently selected for each occurrence from the group consisting of hydrogen, C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) -, C alkoxycarbonyl-, 1-6 3-6 3-6 3-6 1-6 2 1-6 i j i j R R N-carbonyl- and R R N-SO -; wherein C alkyl, C alkenyl, C alkynyl C cycloalkyl 2 1-6 3-6 3-6 3-6 and C alkyl-S(O) -, C alkylcarbonyl- may optionally be substituted by one or more 1-6 2 1-6 substituents selected from R ; R and R are selected independently for each occurrence from the group consisting of hydrogen, C alkyl, C cycloalkyl, heterocyclyl and heterocyclylcarbonyl; wherein C alkyl 1-4 3-6 1-4 and C cycloalkyl may be optionally substituted by one or more substituents selected from a b a b fluorine, hydroxyl, cyano, R R N-, R R N-carbonyl- and C alkoxy and wherein heterocyclyl and heterocyclylcarbonyl may be optionally substituted by one or more substituents selected from C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkoxy, halo-C -alkyl, hydroxyl- 1-6 2-6 2-6 3-6 1-6 1-6 C -alkyl, R R N-C alkyl- and C -alkoxy-C -alkyl group; and wherein if said heterocyclyl 1-6 1-6 1-6 1-6 or heterocyclylcarbonyl contains a –NH moiety that nitrogen may optionally be substituted by one or more groups C alkyl, C alkenyl, C alkynyl, C cycloalkyl, C alkyl-S(O) - and C 1-6 3-6 3-6 3-6 1-6 2 1- -alkylcarbonyl;or R and R taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may have an additional heteroatom selected from O, S, or N; wherein the 4-7 membered heterocyclic ring may be optionally substituted on carbon by one or more substituents selected from the group consisting of fluorine, hydroxyl, oxo, cyano, a b a b a b C alkyl, C alkoxy, R R N-, R R N-SO - and R R N-carbonyl-; wherein said C alkyl or C 1-6 1-6 2 1-6 1- alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and wherein the 4-7 membered heterocyclic ring may be optionally substituted on nitrogen by one or more substituents selected from the group consisting of C alkyl and R R N-carbonyl-; and wherein said C alkyl may be optionally substituted by one or more substituents selected from the group consisting of fluorine, hydroxyl, cyano; R is independently selected, for each occurrence, from the group consisting of halogen, i j i j i j i j a hydroxyl, cyano, C alkoxy, R R N-, R R N-carbonyl-, R R N-SO - and R R N-carbonyl-N(R )-; 1-6 2 and pharmaceutically acceptable salts, stereoisomers and esters thereof.
30. The tricyclic compound of claim 29, wherein R is selected from hydrogen or fluorine.
31. The tricyclic compound of any one of claims 29-30, wherein R is selected from the group consisting of hydrogen, R R N, heterocyclyl, C alkyl, C alkenyl, C cycloalkyl, C alkoxy; 1-6 3-6 3-6 1-6 wherein said heterocyclyl may optionally be substituted by one or more groups R ; and wherein if said heterocyclyl contains a –NH moiety, that nitrogen may optionally be substituted by on or more groups R ; and wherein said C alkyl, C alkenyl, C cycloalkyl and C alkoxy may 1-6 3-6 3-6 1-6 optionally be substituted by one or more groups R .
32. A compound selected from the group consisting of: cis-(3aRS,9bRS) (benzenesulfonylamino)-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid; cis- (3aRS,9bRS)[2-(3-diethylaminopropyl)fluorobenzenesulfonyl-amino]-1,3a,4,9b- tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid; cis-(3aRS,9bRS)[2-(3-{pyrrolidin yl}propyl)fluorobenzene-sulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene carboxylic acid; cis-(3aRS,9bRS)[2-((Z)diethylaminopropenyl)fluoro- benzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid; cis- (3aR,9bR)[2-((Z)diethylaminopropenyl)fluorobenzenesulfonylamino]-1,3a,4,9b- tetrahydro-2H-furo[2,3-c]chromenecarboxylic acid; cis-(3aS,9bS)[2-((Z) diethylaminopropenyl)fluorobenzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3- c]chromenecarboxylic acid; 7-[2-((Z)diethylaminopropenyl)fluorobenzenesulfonyl- amino]-1,2-dihydrofuro[2,3-c]quinolinecarboxylic acid formate salt; 7- (benzenesulfonylamino))-1,2-dihydrofuro[2,3-c]quinolinecarboxylic acid formate salt; cis- (3aRS,9bRS)[2-((Z)diethylaminopropenyl)fluorobenzenesulfonylamino]- 1,2,3a,4,5,9b-hexahydrofuro[2,3-c]quinolinecarboxylic acid; (1aRS,7bSR)[2-((Z) diethylaminopropenyl)fluorobenzenesulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aR,7bS)- 5-[2-((Z)diethylaminoprop- 1-enyl)fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene carboxylic acid; (1aS,7bR)[2-((Z)diethylaminopropenyl) fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-((Z)diethylaminopropenyl)fluorobenzenesulfonylamino]-7b- methyl-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-((E)- 3-diethylaminopropenyl)fluorobenzenesulfonylamino]-7b-methyl-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; cis-(3aRS,9bRS)[2-(4-dimethylamino- butylamino)-benzenesulfonylamino]-1,3a,4,9b-tetrahydro-2H-furo[2,3-c]chromene carboxylic acid; (1aR,7bS)[2-(3-diethylaminopropyl)fluorobenzenesulfonyl-amino]- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-((Z) diethylaminopropenyl)fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aR,7bS)[2-((Z)diethylaminoprop- 1-enyl)fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aS,7bR)[2-((Z)diethylaminoprop- 1-enyl)fluorobenzene-sulfonylamino]-1,1-difluoro-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2((Z)ethylaminoprop- 1-enyl)fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene carboxylic acid; (1aR,7bS)[2((Z)ethylaminopropenyl) fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aS,7bR)[2((Z)ethylaminopropenyl)fluorobenzene-sulfonylamino]-1,1a,2,7b- tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2[(Z)(pyrrolidin yl)propenyl]fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene- 4-carboxylic acid; (1aR,7bS){2[(Z)(pyrrolidinyl)propenyl] fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aS,7bR){2[(Z)(pyrrolidinyl)propenyl]fluorobenzenesulfonylamino}-1,1a,2,7b- tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(3-dimethylamino- propylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene carboxylic acid; (1aR,7bS)[2-(3-dimethylaminopropylamino)benzene-sulfonylamino]- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aS,7bR)[2-(3- dimethylamino-propylamino)benzene-sulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(4- dimethylaminobutylamino)benzene-sulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aR,7bS)[2-(4-dimethylaminobutyl- amino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aS,7bR)[2-(4-dimethylaminobutylamino)benzene-sulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(5-dimethylamino- pentylamino)benzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene carboxylic acid; (1aRS,7bSR){2[(Z)(propanyl)aminopropenyl]fluorobenzene- sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)- 5-{2[(Z)((S)hydroxypyrrolidinyl)aminopropenyl]fluorobenzenesulfonylamino}- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2[(Z)((R)- 3-hydroxypyrrolidinyl)aminopropenyl]fluorobenzene-sulfonylamino}-1,1a,2,7b- tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2((Z) diethylaminobutenyl)fluorobenzenesulfonyl-amino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aR,7bS)[2((Z)diethylaminobut enyl)fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene carboxylic acid; (1aS,7bR)[2((Z)diethylaminobutenyl)fluorobenzenesulfonyl- amino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR){2-[2- (4-ethylpiperazinyl)-ethyl]fluorobenzenesulfonylamino}-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2[(Z)(azetidin yl)propenyl]fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromene- 4-carboxylic acid; (1aRS,7bSR){2[(Z)(3-hydroxyazetidinyl)propenyl] fluorobenzene-sulfonylamino}-1,1a,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2[(Z)(azetidinyl)propyl]fluorobenzenesulfonylamino}-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2((Z) diethylaminobutyl)fluorobenzenesulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2-[N-(4-dimethylamino- butyl)-N-methylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene- 4-carboxylic acid; (1aRS,7bSR){2-[((S)ethylpyrrolidinylcarbamoyl)methyl]fluoro- benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(1-ethylazetidinyl)fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydro- cyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2-[((R)ethylpyrrolidin ylcarbamoyl)methyl]fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydro-cyclopropa- [c]chromenecarboxylic acid; (1aRS,7bSR){2-[2-(pyrrolidinyl)-ethyl] fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-((R)ethylpyrrolidinylmethyl)fluorobenzenesulfonyl-amino]- 1,1a,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aR,7bS)[2-((R) ethylpyrrolidinylmethyl)fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydro- cyclopropa[c]chromenecarboxylic acid; (1aS,7bR)[2-((R)ethylpyrrolidinylmethyl)- 4-fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2-[((S)ethylpyrrolidinyl)cabonyl-aminomethyl] fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(4-dimethylaminobutyrylamino)fluorobenzenesulfonyl-amino]-1,1a,2,7b- tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR)[2-((S)ethyl- pyrrolidinylmethyl)fluorobenzenesulfonyl-amino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(3- dimethylaminopropylcarbamoyl)benzene-sulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)(2-{[N-((S)ethyl- pyrrolidinyl)-N-methylcarbamoyl]methyl}fluoro-benzenesulfonylamino)-1,1a,2,7b- tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR)(2-{[N-((R) ethylpyrrolidinyl)-N-methylcarbamoyl]methyl}fluoro-benzenesulfonylamino)-1,1a,2,7b- tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR){2-[2-((S) ethylpyrrolidinyl)ethylamino]-benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid; (1aRS,7bSR){2-[2-((R)ethylpyrrolidinyl)ethylamino]- benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(3-N,N,-diethylaminopropylamino)benzene-sulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)(2-{[((R) ethylpyrrolidineyl)carbonyl-amino]methyl}fluorobenzenesulfonylamino)-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2-[(1-ethylazetidin ylmethyl)amino]benzene-sulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene carboxylic acid; (1aR,7bS)[2-((Z)diethylaminopropenyl)benzenesulfonylamino]- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aS,7bR)[2-((Z) diethylaminopropenyl)benzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene- 4-carboxylic acid; (1aRS,7bSR)(2-{N-[((R)ethylpyrrolidineyl)carbonyl]-N- methylaminomethyl}fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid; (1aRS,7bSR)(2-{N-[((S)ethylpyrrolidineyl)carbonyl]- N-methylamino-methyl}fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid; (1aRS,7bSR)[2-(4-dimethylaminobutylamino) fluorobenzenesulfonyl-amino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2-[((R)ethylpyrrolidinylmethyl)amino]-benzenesulfonylamino}- 1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR){2-[((S) ethylpyrrolidinylmethyl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid; (1aRS,7bSR)[2-(4-ethyloxopiperazinylmethyl) fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-(1-ethylpiperidinylmethyl)fluoro-benzenesulfonylamino]-1,1a,2,7b- tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR){2-[2-(1-ethylazetidin yl)ethyl]fluorobenzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene carboxylic acid; (1aRS,7bSR){2-[((S)azabicyclo[2.2.2]octyl)amino]benzenesulfonyl- amino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2- [((R)azabicyclo[2.2.2]octyl)amino]benzenesulfonyl-amino}-1,1a,2,7b- tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR)(2-{[((S) ethylpyrrolidinecarbonyl)-amino]methyl}fluoro-benzenesulfonylamino)-1,1a,2,7b- tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2-[2-((R) ethylpyrrolidinylamino)ethyl]fluoro-benzenesulfonylamino}-1,1a,2,7b- tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR){2-[((R) ethylpyrrolidinyl)amino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid; (1aRS,7bSR){2-[((S)ethylpyrrolidinyl)amino]- benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aRS,7bSR)(2-{[((R)ethylpyrrolidinecarbonyl)amino]-methyl}fluoro- benzenesulfonylamino)-1,1a,2,7b-tetrahydro-cyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR)[2-((Z)diethylaminomethylpropenyl)fluorobenzene-sulfonylamino]- 1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aRS,7bSR){2-[2-((R) ethylpyrrolidinyl)ethylamino]-benzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa- [c]chromenecarboxylic acid; (1aRS,7bSR){2-[2-((S)ethylpyrrolidinyl)ethylamino]- benzenesulfonyl-amino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aR,7bS)[2-((S)ethylpyrrolidinyloxymethyl)fluoro-benzenesulfonylamino]- 1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; (1aR,7bS)[2-((R) ethylpyrrolidinyloxymethyl)fluoro-benzenesulfonylamino]-1,1a,2,7b-tetrahydro- cyclopropa-[c]chromenecarboxylic acid; (1aR,7bS) [2-(1-ethylpiperidinylmethyl) fluorobenzene-sulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromenecarboxylic acid; (1aR,7bS){2-[2-((R)ethylpyrrolidinyl)ethyl]fluorobenzenesulfonyl-amino}- 1,1a,2,7b-tetrahydrocyclopropa-[c]chromenecarboxylic acid; and pharmaceutically acceptable salts, stereoisomers and esters thereof.
33. A pharmaceutically acceptable composition comprising a compound of any one of claims 1-32 and a pharmaceutically acceptable excipient.
34. A method of treating and/or controlling obesity, comprising administering to a non-human patient in need thereof an effective amount of a compound of any one of claims 1-32.
35. A method of inducing weight loss in a non-human patient in need thereof, comprising administering to said patient an effective amount of a compound of any one of claims 1-32.
36. The method of claim 34 or 35, wherein the patient is a cat or dog.
37. The method of any one of claims 34-36, wherein the compound is administered orally.
38. The composition of claim 33, wherein the composition is formulated as a unit dose.
39. The composition of claim 33, wherein the composition is formulated for oral administration.
40. The composition of claim 33, wherein the composition is formulated for intravenous or subcutaneous administration.
41. The method of any one of claims 34-36, comprising administering said compound in an amount sufficient to establish inhibition of intracellular MetAP2 effective to increase thioredoxin production in the patient and to induce multi organ stimulation of anti-obesity processes in the subject.
42. The method of claim 41, comprising administering said compound in an amount insufficient to reduce angiogenesis in the patient.
43. The use of a compound of any one of claims 1 to 32 in the manufacture of a medicament for treating or preventing obesity.
44. The use of a compound of any one of claims 1 to 32 in the manufacture of a medicament for inducing weight loss.
45. The use according to claim 43 or claim 44 where the medicament is for oral administration.
46. The use according to any one of claims 43 to 45 wherein the medicament is formulated as a unit dose.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483257P | 2011-05-06 | 2011-05-06 | |
US61/483,257 | 2011-05-06 | ||
US201161559856P | 2011-11-15 | 2011-11-15 | |
US61/559,856 | 2011-11-15 | ||
PCT/US2012/036789 WO2012154676A1 (en) | 2011-05-06 | 2012-05-07 | Partially saturated tricyclic compounds and methods of making and using same |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617388A NZ617388A (en) | 2015-11-27 |
NZ617388B2 true NZ617388B2 (en) | 2016-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012253757B2 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
EP2705036B1 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
EP2705035B1 (en) | Tricyclic pyrazole sulfonamide compounds and methods of making and using same | |
EP2804866B1 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
EP2917197B1 (en) | Tricyclic compounds and methods of making and using same | |
EP2925737B1 (en) | Tricyclic compounds for use in the treatment and/or control of obesity | |
NZ617388B2 (en) | Partially saturated tricyclic compounds and methods of making and using same |